,"Trade_Name
",Chemical,Manufacturer,Top_15_Brand_Corporation,Biologic_(by_Product),Biosimilar,NAS,Oncology,Rare_Disease_(FDA),Rare_Disease_(EMA),Rare_Disease_(FDA_or_EMA),HC-HTA_Aligned_Review,Health_Canada_Submission_Date,NOC_Date,Health_Canada_Review_Time,HTA_Agency,CADTH_Submission_Date,CADTH_Timing_of__Submission,CADTH_Submission_Type_-_Agency_Specific,CADTH_Indication,CADTH_Review_Status,CADTH_Final_Recommendation/Withdrawn_Date,CADTH_Recommended_-_Agency_Specific,CADTH_Decision_Type_-_Standardized,INESSS_Submission_Date,INESSS_Timing_of__Submission,INESSS_Submission_Type_-_Agency_Specific,INESSS_Indication,INESSS_Review_Status,INESSS_Final_Recommendation/Withdrawn_Date,INESSS_Recommended_-_Agency_Specific,INESSS_Decision_Type_-_Standardized,pCPA_Negotiation,pCPA_First_Date,pCPA_Final_Date,pCPA_Type,pCPA_Negotiation_Outcome,BC_Status,AB_Status,SK_Status,MB_Status,ON_Status,NB_Status,NS_Status,PEI_Status,NL_Status,QC_Status,Listing_BC_Date,Listing_AB_Date,Listing_SK_Date,Listing_MB_Date,Listing_ON_Date,Listing_NB_Date,Listing_NS_Date,Listing_PEI_Date,Listing_NL_Date,Listing_QC_Date,First_Prov_Listing_(excl_QC),First_Prov_Listing_(inc_QC),Rank_BC_Listing_Date,Rank_AB_Listing_Date,Rank_SK_Listing_Date,Rank_MB_Listing_Date,Rank_ON_Listing_Date,Rank_NB_Listing_Date,Rank_NS_Listing_Date,Rank_PEI_Listing_Date,Rank_NL_Listing_Date,Rank_QC_Listing_Date,Rank_1,Rank_2,Rank_3,Rank_4,Rank_5,Rank_6,Rank_7,Rank_8,Rank_9,Rank_10,Total_population_coverage_(incl_QC),Date_>_50%_Cumulative_Ranking,Date_>_80%_Cumulative_Ranking,NOC_to_CADTH_Submission,NOC_to_INESSS_Submission,CADTH_Duration,INESSS_Duration,CADTH_to_pCPA_Initiation,INESSS_to_pCPA_Initiation,pCPA_LOI_to_LOE,pCPA_to_Listing_BC_Date,pCPA_to_Listing_AB_Date,pCPA_to_Listing_SK_Date,pCPA_to_Listing_MB_Date,pCPA_to_Listing_ON_Date,pCPA_to_Listing_NB_Date,pCPA_to_Listing_NS_Date,pCPA_to_Listing_PEI_Date,pCPA_to_Listing_NL_Date,pCPA_to_Listing_QC_Date,pCPA_to_Listing_Nat_Avg_(excl_QC),pCPA_Completion_to_1st_Listing_(excl_QC),pCPA_to_Listing_Nat_Avg_(incl_QC),pCPA_Completion_to_1st_Listing_(incl_QC),pCPA_Completion_to_80%_Listing,NOC_to_Listing_BC_Date,NOC_to_Listing_AB_Date,NOC_to_Listing_SK_Date,NOC_to_Listing_MB_Date,NOC_to_Listing_ON_Date,NOC_to_Listing_NB_Date,NOC_to_Listing_NS_Date,NOC_to_Listing_PEI_Date,NOC_to_Listing_NL_Date,NOC_to_Listing_QC_Date,NOC_to_Listing_Nat_Avg_(excl_QC),NOC_to_Listing_Nat_Avg_(inc_QC),"NOC_to_1st_Provincial_Listing
(unique_at_product/indication_level)_exc_QC","CADTH_Submission_to_1st_Provincial_Listing
exc_QC",CADTH_Recommendation_to_1st_Provincial_Listing_exc_QC,HTA_Rec_to_BC_Listing_Date,HTA_Rec_to_AB_Listing_Date,HTA_Rec_to_SK_Listing_Date,HTA_Rec_to_MB_Listing_Date,HTA_Rec_to_ON_Listing_Date,HTA_Rec_to_NB_Listing_Date,HTA_Rec_to_NS_Listing_Date,HTA_Rec_to_PEI_Listing_Date,HTA_Rec_to_NL_Listing_Date,HTA_Rec_to_QC_Listing_Date,Nat`l_Avg_(excl_QC),NOC_to_CADTH_Rec,NOC_to_INESSS_Rec,CADTH_Rec_to_pCPA_Decision,INESSS_Rec_to_pCPA_Decision,NOC_to_80%_Listing,First_Provincial_Listing_to_80%_Listing_(incl_QC),First_Provincial_Listing_to_80%_Listing_(excl_QC),First_Provincial_Listing_to_50%_Listing_(incl_QC),50%_Listing_to_80%_Listing,HC_Sub_to_CADTH_Rec
1,Abilify (MDD),aripiprazole,Bristol-Myers Squibb ,Y,N,N,N,N,N,N,N,N,,29-May-13,,CADTH,01-Oct-13,post-NOC,Initial,"Depression, Major Depressive Disorder (MDD)",Completed,22-Oct-14,Do not list ,Negative,,,,,,,,,none,02-Dec-14,,Do Not Negotiate,,NR,FB/RB,NR,FB,NR,FB,FB,NR,NR,NR,,2012-01-01,,2012-05-24,,2020-06-18,2021-08-01,,,,01-Jan-12,2012-01-01,,1.0,,2.0,,3.0,4.0,,,,4.50%,10.00%,10.90%,12.20%,,,,,,,12.20%,,,125.0,,386.0,,41.0,,,,,,,,,,,,,,,,,,,-514.0,,-370.0,,2577.0,2986.0,,,,1170.0,1170.0,-514.0,-639.0,-1025.0,,-1025.0,,-881.0,,2066.0,2475.0,,,,659.0,511.0,,,,,,,,,41934
2,Abilify Maintena,aripiprazole,Otsuka Pharmaceutical & Lundbeck,N,N,N,N,N,N,N,N,N,,10-Feb-14,,CADTH & INESSS,06-Jan-14,pre-NOC,Initial,Schizophrenia,Completed,19-Dec-14,List with criteria/condition,Conditional,22-Mar-14,post-NOC,New Drug,Schizophrenia,Completed,01-Oct-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,29-Jan-15,14-Jun-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,FB,FB,SA,SA,FB,2015-08-11,2015-09-01,2015-07-01,2015-10-22,2015-07-29,2015-10-14,2015-09-01,2016-04-25,2015-08-01,2014-10-01,01-Jul-15,2014-10-01,5.0,6.0,2.0,9.0,3.0,8.0,7.0,10.0,4.0,1.0,28.60%,34.30%,66.50%,67.20%,87.50%,91.90%,93.20%,94.10%,99.60%,100.00%,100.00%,29-Jul-15,11-Aug-15,-35.0,40.0,347.0,193.0,41.0,120.0,136.0,58.0,79.0,17.0,130.0,45.0,122.0,79.0,316.0,48.0,-256.0,99.0,17.0,64.0,-256.0,58.0,547.0,568.0,506.0,619.0,534.0,611.0,568.0,805.0,537.0,233.0,588.0,553.0,506.0,541.0,194.0,235.0,256.0,194.0,307.0,222.0,299.0,256.0,493.0,225.0,0.0,276.0,312.0,233.0,177.0,256.0,547.0,314.0,41.0,301.0,13.0,41992
3,Abraxane,nab paclitaxel,Celgene ,N,N,N,N,Y,Y,N,Y,N,,16-Jul-14,,CADTH & INESSS,14-Feb-14,pre-NOC,New indication,GI: Metastatic Pancreatic Cancer,Completed,23-Sep-14,Cond'l on Cost,Conditional,04-Aug-14,post-NOC,New Indication,Metastatic Pancreatic Cancer,Completed,02-Feb-15,Ajout dune indication reconnue à la Liste Établissements  Médicament dexception  Avis de refus  À moins que le rapport entre le coût et lefficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,29-Oct-14,02-Mar-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2014-11-01,2015-03-30,2015-05-01,2015-04-20,2015-04-17,2015-07-15,2015-04-01,2018-08-01,2015-09-01,2015-11-20,01-Nov-14,2014-11-01,1.0,2.0,6.0,5.0,4.0,7.0,3.0,10.0,8.0,9.0,20.30%,24.70%,26.00%,58.30%,63.80%,69.50%,70.40%,71.10%,99.60%,100.00%,100.00%,17-Apr-15,20-Nov-15,-152.0,19.0,221.0,182.0,36.0,-96.0,124.0,-121.0,28.0,60.0,49.0,46.0,135.0,30.0,1248.0,183.0,263.0,184.0,-121.0,192.0,-121.0,263.0,108.0,257.0,289.0,278.0,275.0,364.0,259.0,1477.0,412.0,492.0,413.0,421.0,108.0,260.0,39.0,39.0,188.0,220.0,209.0,206.0,295.0,190.0,1408.0,343.0,291.0,344.0,69.0,201.0,160.0,28.0,492.0,384.0,384.0,167.0,217.0,41905
4,Actemra ,tocilizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,N,N,N,N,01-May-17,27-Oct-17,179.0,CADTH & INESSS,25-Sep-17,pre-NOC,Initial,Giant cell arteritis (GCA),Completed,27-Mar-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Arteritis,Completed,06-Jun-18,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,26-Jul-18,06-Dec-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,NR,SA,SA,EM,2019-03-12,2019-03-01,2019-05-01,2019-05-31,2019-04-17,2020-10-22,,2022-02-28,2020-06-15,2019-10-02,01-Mar-19,2019-03-01,2.0,1.0,4.0,5.0,3.0,8.0,,9.0,7.0,6.0,4.50%,24.70%,56.90%,62.70%,68.20%,96.80%,97.40%,98.30%,98.70%,,98.70%,17-Apr-19,02-Oct-19,-32.0,,183.0,,121.0,50.0,133.0,96.0,85.0,146.0,176.0,132.0,686.0,,1180.0,557.0,300.0,382.0,85.0,373.0,85.0,300.0,501.0,490.0,551.0,581.0,537.0,1091.0,,1585.0,962.0,705.0,787.0,778.0,490.0,522.0,339.0,350.0,339.0,400.0,430.0,386.0,940.0,,1434.0,811.0,483.0,636.0,151.0,222.0,254.0,183.0,705.0,215.0,215.0,47.0,168.0,330
5,Actemra (JIA),tocilizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,Y,N,Y,N,,19-Jan-12,,CADTH & INESSS,30-Jan-12,post-NOC,Initial,"Arthritis, juvenile idiopathic ",Completed,19-Jul-12,List with clinical criteria and/or conditions,Conditional,,,New Indication,JIA,Completed,01-Oct-12,Ajout d'une indication reconnue par l'INESSS - Médicament d'exception,Conditional,none,,,,,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2013-04-11,2012-11-01,2013-01-01,2013-07-17,,2013-02-14,2013-02-01,2013-10-01,2016-07-01,2012-10-01,01-Nov-12,2012-10-01,6.0,2.0,3.0,7.0,,5.0,4.0,8.0,9.0,1.0,28.60%,33.00%,38.80%,40.10%,41.00%,61.20%,66.70%,67.10%,67.80%,,67.80%,11-Apr-13,,11.0,,171.0,,,,,,,,,,,,,,,,,,,,448.0,287.0,348.0,545.0,,392.0,379.0,621.0,1625.0,256.0,581.0,545.0,287.0,276.0,105.0,266.0,105.0,166.0,363.0,,210.0,197.0,439.0,1443.0,0.0,399.0,182.0,256.0,,,,,,192.0,,41109
6,Actemra (pJIA),tocilizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,Y,N,Y,N,,17-Oct-13,,CADTH & INESSS,29-Jul-13,pre-NOC,Initial,Polyarticular juvenile idiopathic arthritis,Completed,19-Mar-14,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Indication,pJIA,Completed,02-Feb-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,none,31-May-14,,Negotiation by Province,,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2014-12-09,2015-05-01,2014-11-01,2015-01-19,2014-04-09,2016-04-12,2016-06-01,2016-04-25,2016-07-01,2015-02-02,09-Apr-14,2014-04-09,3.0,6.0,2.0,4.0,1.0,7.0,9.0,8.0,10.0,5.0,32.20%,38.00%,58.20%,63.70%,92.30%,96.80%,97.70%,98.00%,99.30%,100.00%,100.00%,09-Dec-14,02-Feb-15,-80.0,291.0,233.0,182.0,73.0,-247.0,,,,,,,,,,,,,,,,,418.0,561.0,380.0,459.0,174.0,908.0,958.0,921.0,988.0,473.0,641.0,624.0,174.0,254.0,21.0,265.0,408.0,227.0,306.0,21.0,755.0,805.0,768.0,835.0,0.0,488.0,153.0,473.0,,,473.0,299.0,299.0,244.0,55.0,41717
7,Actemra SC (RA),tocilizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,N,N,N,N,,06-May-14,,CADTH & INESSS,03-Mar-14,pre-NOC,Initial,"Arthritis, Rheumatoid",Completed,19-Feb-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Form,"Arthritis, Rheumatoid",Completed,02-Feb-15,Avis de refus,Negative,1st,01-May-15,16-Dec-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2016-02-19,2016-03-01,2016-05-01,2016-04-18,,2016-04-12,2016-06-01,2016-04-25,2016-07-01,2016-06-15,19-Feb-16,2016-02-19,1.0,2.0,6.0,4.0,,3.0,7.0,5.0,9.0,8.0,20.30%,24.70%,25.60%,31.10%,31.50%,37.20%,38.50%,67.10%,67.80%,,67.80%,15-Jun-16,,-64.0,90.0,353.0,182.0,71.0,88.0,229.0,65.0,76.0,137.0,124.0,,118.0,168.0,131.0,198.0,182.0,127.0,65.0,133.0,65.0,,654.0,665.0,726.0,713.0,,707.0,757.0,720.0,787.0,771.0,716.0,722.0,654.0,718.0,365.0,365.0,376.0,437.0,424.0,,418.0,468.0,431.0,498.0,499.0,427.0,289.0,272.0,300.0,317.0,,,,117.0,,42054
8,Actikerall,fluorouracil and Salicylic Acid,Cipher Pharmaceuticals ,N,N,N,N,N,N,N,N,N,,28-Aug-15,,CADTH,31-Aug-16,post-NOC,Initial,Hyperkeratotic actinic keratosis,Completed,22-Mar-17,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,23-Feb-18,22-Aug-18,Negotiation,Completed with Agreements,NR,FB,FB,FB,FB,FB,FB,FB,SA,NR,,2018-12-01,2019-01-01,2019-01-24,2018-10-31,2018-11-08,2019-04-01,2018-12-24,2018-12-20,,31-Oct-18,2018-10-31,,3.0,6.0,7.0,1.0,2.0,8.0,5.0,4.0,,32.20%,33.10%,37.60%,38.30%,38.60%,44.30%,49.90%,51.20%,,,51.20%,01-Apr-19,,369.0,,203.0,,338.0,,180.0,,101.0,132.0,155.0,70.0,78.0,222.0,124.0,120.0,,125.0,70.0,125.0,70.0,,,1191.0,1222.0,1245.0,1160.0,1168.0,1312.0,1214.0,1210.0,,1215.0,1215.0,1160.0,791.0,588.0,,619.0,650.0,673.0,588.0,596.0,740.0,642.0,638.0,,643.0,572.0,,518.0,,,,,152.0,,42816
9,Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,Y,Y,Y,Y,Y,N,,01-Feb-13,,CADTH & INESSS,14-Mar-13,post-NOC,New drug,Hodgkin Lymphoma (HL):For HL patients after failure of ASCT or after failure of at least two prior therapies in patients who are not ASCT candidates,Completed,29-Aug-13,Cond'l on Cost,Conditional,01-Oct-13,post-NOC,New Drug,Hodgkin Lymphoma (HL):For HL patients after failure of ASCT or after failure of at least two prior therapies in patients who are not ASCT candidates,Completed,02-Jun-14,Ajout dune indication reconnue à la Liste Établissements  Médicament dexception  Avec linstauration dun suivi clinique,Conditional,1st,,31-Jan-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2014-06-01,2014-05-01,2014-02-04,2014-03-01,2014-02-19,2014-10-01,2015-01-01,,2018-06-25,2014-06-02,04-Feb-14,2014-02-04,5.0,4.0,1.0,3.0,2.0,7.0,8.0,,9.0,6.0,5.70%,38.00%,43.50%,47.90%,68.20%,96.80%,97.70%,99.00%,99.60%,,99.60%,01-Jun-14,02-Jun-14,41.0,242.0,168.0,244.0,,,,121.0,90.0,4.0,29.0,19.0,243.0,335.0,,1606.0,122.0,306.0,4.0,285.0,4.0,122.0,485.0,454.0,368.0,393.0,383.0,607.0,699.0,,1970.0,486.0,670.0,649.0,368.0,327.0,159.0,276.0,245.0,159.0,184.0,174.0,398.0,490.0,,1761.0,0.0,461.0,209.0,486.0,155.0,-122.0,486.0,118.0,118.0,117.0,1.0,41515
10,Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,Y,Y,Y,Y,Y,N,,01-Feb-13,,CADTH & INESSS,15-Mar-13,post-NOC,New drug,Systemic Anaplastic Large Cell Lymphoma (sALC),Completed,05-Dec-13,Cond'l on Cost,Conditional,02-Aug-13,post-NOC,New Drug,Systemic Anaplastic Large Cell Lymphoma (sALC),Completed,03-Feb-14,Ajout à la Liste Établissements - Médicament d'exception - Conditionnel à ce que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable et à l'instauration d'un suivi,Conditional,1st,04-Sep-13,31-Jan-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2014-06-01,2014-05-01,2014-02-04,2014-03-01,2014-02-19,2015-10-01,2015-01-01,,2018-06-25,2014-02-03,04-Feb-14,2014-02-03,6.0,5.0,2.0,4.0,3.0,8.0,7.0,,9.0,1.0,28.60%,34.30%,66.50%,72.10%,76.50%,96.80%,98.10%,99.00%,99.60%,,99.60%,19-Feb-14,01-Jun-14,42.0,182.0,265.0,185.0,-92.0,-152.0,149.0,121.0,90.0,4.0,29.0,19.0,608.0,335.0,,1606.0,3.0,352.0,4.0,313.0,3.0,121.0,485.0,454.0,368.0,393.0,383.0,972.0,699.0,,1970.0,367.0,716.0,677.0,368.0,326.0,61.0,178.0,147.0,61.0,86.0,76.0,665.0,392.0,,1663.0,0.0,409.0,307.0,367.0,57.0,-3.0,485.0,118.0,117.0,16.0,102.0,41613
12,Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,N,Y,Y,Y,Y,N,,20-Jul-17,,CADTH,10-Aug-17,post-NOC,Resubmission,Hodgkins Lymphoma at high risk of relapse or progression post-ASCT,Completed,21-Feb-18,Cond'l on Cost,Conditional,,,,,,,,,1st,22-Jun-18,13-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,2019-02-01,2020-04-10,2019-05-01,2019-04-01,2019-12-17,2019-07-25,2019-07-01,,2019-07-29,2019-04-11,01-Feb-19,2019-02-01,1.0,9.0,4.0,2.0,8.0,6.0,5.0,,7.0,3.0,20.30%,25.80%,54.40%,60.10%,61.40%,62.30%,63.00%,95.20%,99.60%,,99.60%,11-Apr-19,17-Dec-19,21.0,,195.0,,121.0,,264.0,-40.0,394.0,49.0,19.0,279.0,134.0,110.0,,138.0,29.0,135.0,-40.0,124.0,-40.0,279.0,561.0,995.0,650.0,620.0,880.0,735.0,711.0,,739.0,630.0,736.0,725.0,561.0,540.0,345.0,345.0,779.0,434.0,404.0,664.0,519.0,495.0,,523.0,,520.0,216.0,,385.0,,880.0,319.0,319.0,69.0,250.0,43152
13,Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,N,Y,Y,Y,Y,N,01-May-19,22-Nov-19,205.0,CADTH & INESSS,08-Oct-19,pre-NOC,New indication,"Peripheral T-Cell Lymphoma (PTCL): For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",Completed,04-Jun-20,Fund,Positive,25-Oct-19,pre-NOC,New Indication,"Peripheral T-Cell Lymphoma (PTCL): For the treatment of previously untreated adult patients with systemic anaplastic large cell lymphoma (sALCL), peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) or angioimmunoblastic T-cell lymphoma (AITL), whose tumours express CD30, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP).",Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,03-Jul-20,21-Sep-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,2020-12-01,2021-02-28,2021-01-01,2022-08-25,2022-01-31,,,,,2020-11-11,01-Dec-20,2020-11-11,2.0,4.0,3.0,6.0,5.0,,,,,1.0,28.60%,48.80%,54.60%,59.00%,91.20%,96.80%,,,,,96.80%,01-Jan-21,31-Jan-22,-45.0,-28.0,240.0,229.0,29.0,23.0,80.0,71.0,160.0,102.0,703.0,497.0,,,,,51.0,307.0,71.0,264.0,51.0,497.0,375.0,464.0,406.0,1007.0,801.0,,,,,355.0,611.0,568.0,375.0,420.0,180.0,180.0,269.0,211.0,812.0,606.0,,,,,154.0,416.0,195.0,201.0,109.0,103.0,801.0,446.0,426.0,51.0,395.0,400
14,Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,N,Y,Y,Y,Y,N,01-Apr-18,21-Dec-18,264.0,CADTH & INESSS,30-Mar-20,post-NOC,New indication,Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides,Completed,03-Dec-20,Cond'l on Cost,Conditional,08-May-20,post-NOC,New Indication,Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides,Completed,14-Oct-20,Inscription - Avec conditions,Conditional,1st,05-Feb-21,28-Apr-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,2021-08-01,2021-07-01,2021-08-01,2022-03-07,2022-01-31,,,,,2021-08-18,01-Jul-21,2021-07-01,2.0,1.0,3.0,6.0,5.0,,,,,4.0,4.50%,24.70%,30.40%,59.00%,91.20%,96.80%,,,,,96.80%,18-Aug-21,31-Jan-22,465.0,504.0,248.0,159.0,64.0,114.0,82.0,95.0,64.0,95.0,313.0,278.0,,,,,112.0,169.0,64.0,160.0,64.0,278.0,954.0,923.0,954.0,1172.0,1137.0,,,,,971.0,1028.0,1019.0,923.0,458.0,210.0,241.0,210.0,241.0,459.0,424.0,,,,,308.0,315.0,713.0,663.0,146.0,196.0,1137.0,214.0,214.0,48.0,166.0,977
15,Adcetris,brentuximab vedotin,Seattle Genetics,N,Y,N,N,Y,Y,Y,Y,N,01-Jul-18,02-May-19,305.0,CADTH & INESSS,02-Apr-20,post-NOC,New indication,"Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)",Completed,03-Dec-20,Cond'l on Cost,Conditional,22-May-20,post-NOC,New Indication,"Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine, and dacarbazine (AVD)",Completed,05-Nov-20,Inscription - Avec conditions,Conditional,1st,05-Feb-21,28-Apr-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,2021-08-01,2021-07-31,2021-08-01,2022-08-25,2021-11-30,,,,,2021-08-18,31-Jul-21,2021-07-31,2.0,1.0,3.0,6.0,5.0,,,,,4.0,4.50%,24.70%,30.40%,59.00%,91.20%,96.80%,,,,,96.80%,18-Aug-21,30-Nov-21,336.0,386.0,245.0,167.0,64.0,92.0,82.0,95.0,94.0,95.0,484.0,216.0,,,,,112.0,197.0,94.0,183.0,94.0,216.0,822.0,821.0,822.0,1211.0,943.0,,,,,839.0,924.0,910.0,821.0,485.0,240.0,241.0,240.0,241.0,630.0,362.0,,,,,286.0,343.0,581.0,553.0,146.0,174.0,943.0,122.0,122.0,18.0,104.0,886
16,Adcetris (Resubmission),brentuximab vedotin,Seattle Genetics,N,Y,N,Y,Y,Y,Y,Y,N,,01-Feb-13,,CADTH,27-Aug-18,post-NOC,Resubmission,Hodgkin Lymphoma: For the treatment of patients with HL after failure of at least two multi-agent chemotherapy regimens in patients who are not ASCT candidates,Completed,07-Mar-19,Do Not Fund,Negative,,,,,,,,,,17-May-19,,Do Not Negotiate,,Funded,Not funded,Not funded,Under provincial consideration,Funded,Not funded,Under provincial consideration,Not funded,Not funded,NR,2014-06-01,,,,2021-11-30,,,,,,01-Jun-14,2014-06-01,1.0,,,,2.0,,,,,,20.30%,52.50%,,,,,,,,,52.50%,30-Nov-21,,2033.0,,192.0,,71.0,,,,,,,,,,,,,,,,,,485.0,,,,3224.0,,,,,,1855.0,1855.0,485.0,-1548.0,-1740.0,-1740.0,,,,999.0,,,,,,-371.0,2225.0,,,,,,,2739.0,,43531
18,Adempas (PH),riociguat,Bayer ,Y,N,N,Y,N,Y,Y,Y,N,,19-Sep-13,,CADTH & INESSS,30-Sep-13,post-NOC,Initial,"Pulmonary hypertension, chronic thromboembolic (CTEPH)",Completed,17-Jul-14,List with criteria/condition,Conditional,,,New Drug,"Pulmonary hypertension, chronic thromboembolic (CTEPH)",Completed,24-Apr-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,31-Aug-14,23-Jan-15,Negotiation,Completed with Agreements,NR,NR,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,,2015-07-01,2015-04-20,2015-02-11,2015-07-23,2015-06-29,2018-08-01,2015-06-01,2014-04-24,11-Feb-15,2014-04-24,,,6.0,3.0,2.0,7.0,5.0,8.0,4.0,1.0,28.60%,60.80%,66.30%,67.00%,68.30%,74.00%,74.90%,75.30%,,,75.30%,11-Feb-15,,11.0,,290.0,,45.0,129.0,145.0,,,159.0,87.0,19.0,181.0,157.0,1286.0,129.0,-274.0,288.0,19.0,218.0,-274.0,,,,650.0,578.0,510.0,672.0,648.0,1777.0,620.0,217.0,779.0,709.0,510.0,499.0,209.0,,,349.0,277.0,209.0,371.0,347.0,1476.0,319.0,0.0,478.0,301.0,217.0,190.0,274.0,,,,293.0,,41837
19,Adlyxine,lixisenatide,Sanofi-Aventis ,Y,N,N,Y,N,N,N,N,N,01-Jun-16,25-May-17,358.0,CADTH & INESSS,29-May-17,post-NOC,Initial,"Diabetes mellitus, Type 2",Completed,23-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,Diabetes,Completed,01-Feb-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,27-Apr-18,21-Nov-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,FB,SA,EDS,SA,SA,NR,,2020-07-01,2021-01-01,2021-08-05,2019-12-20,2020-05-21,2022-04-19,2022-03-28,2022-05-03,,20-Dec-19,2019-12-20,,3.0,4.0,5.0,1.0,2.0,7.0,6.0,8.0,,32.20%,33.10%,37.60%,43.30%,48.80%,49.20%,50.50%,51.20%,,,51.20%,19-Apr-22,,4.0,,178.0,,155.0,85.0,573.0,,223.0,407.0,623.0,29.0,182.0,880.0,858.0,894.0,,512.0,29.0,512.0,29.0,,,1133.0,1317.0,1533.0,939.0,1092.0,1790.0,1768.0,1804.0,,1422.0,1422.0,939.0,935.0,757.0,,951.0,1135.0,1351.0,757.0,910.0,1608.0,1586.0,1622.0,,1240.0,182.0,252.0,728.0,658.0,,,,851.0,,540
20,Admelog (Cancelled),insulin lispro,sanofi-aventis Canada Inc.,Y,Y,Y,N,N,N,N,N,N,01-Jan-17,16-Nov-17,319.0,CADTH & INESSS,,na,,"Diabetes mellitus, Type 1 & 2",Cancelled,,Cancelled or withdrawn,,,,New Drug,Diabetes,Completed,14-May-20,Inscription,Positive,1st,29-Jan-20,30-Sep-20,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,FB,,FB,FB,FB,2021-11-30,2021-08-01,2021-01-01,2021-04-01,2020-12-18,2020-11-26,,2021-09-27,2022-05-03,2021-03-03,26-Nov-20,2020-11-26,8.0,6.0,3.0,5.0,2.0,1.0,,7.0,9.0,4.0,0.90%,33.10%,38.80%,67.40%,73.00%,77.40%,77.80%,98.00%,98.70%,,98.70%,03-Mar-21,30-Nov-21,,,,,,-106.0,245.0,426.0,305.0,93.0,183.0,79.0,57.0,,362.0,580.0,154.0,261.0,57.0,249.0,57.0,426.0,1475.0,1354.0,1142.0,1232.0,1128.0,1106.0,,1411.0,1629.0,1203.0,1310.0,1298.0,1106.0,,,,,,,,,,,,293.0,,,910.0,,139.0,1475.0,369.0,369.0,97.0,272.0,-42736
23,Aermony RespiClick,fluticasone propionate ,Teva Canada Innovation,N,N,N,N,N,N,N,N,N,01-Oct-16,22-Aug-17,325.0,CADTH & INESSS,04-Oct-17,post-NOC,Initial,Asthma,Completed,19-Dec-18,Reimburse with clinical criteria and/or conditions,Conditional,11-Jan-20,post-NOC,New drug,Asthma,Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,12-Apr-19,31-Jul-19,Negotiation,No agreement reached,FB,FB,FB,FB,FB,FB,FB,FB,FB,FB,2021-08-12,2021-04-01,2021-05-01,2021-08-05,2021-03-29,2021-04-22,2022-02-22,2021-11-22,2021-07-07,2021-03-03,29-Mar-21,2021-03-03,8.0,3.0,5.0,7.0,2.0,4.0,10.0,9.0,6.0,1.0,28.60%,60.80%,65.30%,66.20%,71.90%,72.60%,78.10%,98.30%,98.70%,100.00%,100.00%,29-Mar-21,12-Aug-21,43.0,872.0,441.0,124.0,114.0,-398.0,110.0,743.0,610.0,640.0,736.0,607.0,631.0,937.0,845.0,707.0,581.0,717.0,607.0,704.0,581.0,743.0,1451.0,1318.0,1348.0,1444.0,1315.0,1339.0,1645.0,1553.0,1415.0,1289.0,1425.0,1412.0,1315.0,1272.0,831.0,967.0,834.0,864.0,960.0,831.0,855.0,1161.0,1069.0,931.0,293.0,941.0,484.0,996.0,224.0,-288.0,1451.0,162.0,136.0,26.0,136.0,809
26,Afinitor,everolimus,Novartis,Y,N,N,N,Y,Y,N,Y,N,,17-May-16,,CADTH & INESSS,30-May-16,post-NOC,New indication,"Endocrine, neuroendocrine tumours of GI or lung origin",Completed,01-Dec-16,Cond'l on Cost,Conditional,12-Aug-16,post-NOC,New Indication,Neuroendocrine tumours of Gastrointestinal or Lung origin,Completed,01-Feb-17,Avis de refus dajout dune indication reconnue aux listes des médicaments  Médicament dexception  À moins que certaines conditions soient respectées,Conditional,1st,31-Mar-17,01-Sep-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,,Funded,EM,2018-02-01,2018-09-04,2017-10-01,2018-01-28,2017-11-20,2018-03-20,2021-05-30,,2019-07-29,2017-12-15,01-Oct-17,2017-10-01,5.0,7.0,1.0,4.0,2.0,6.0,9.0,,8.0,3.0,5.70%,38.00%,66.50%,72.10%,92.30%,93.20%,97.70%,98.30%,99.60%,,99.60%,15-Dec-17,01-Feb-18,13.0,87.0,185.0,173.0,120.0,58.0,154.0,153.0,368.0,30.0,149.0,80.0,200.0,1367.0,,696.0,105.0,380.0,30.0,350.0,30.0,153.0,625.0,840.0,502.0,621.0,552.0,672.0,1839.0,,1168.0,577.0,852.0,822.0,502.0,489.0,304.0,427.0,642.0,304.0,423.0,354.0,474.0,1641.0,,970.0,317.0,654.0,198.0,260.0,274.0,212.0,625.0,123.0,123.0,75.0,48.0,42705
29,Ajovy,fremanezumab,Teva Canada Innovation,N,Y,N,Y,N,N,N,N,N,01-Jun-19,09-Apr-20,313.0,CADTH & INESSS,03-Jun-20,post-NOC,Initial,migraine,Completed,24-Mar-21,Reimburse with clinical criteria and/or conditions,Conditional,18-Sep-20,post-NOC,New Drug,Migraine,Completed,31-Mar-21,Refus d'inscription,Negative,1st,16-Jul-21,03-Dec-21,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,FB,SA,EM,2022-03-29,2022-02-01,2022-02-01,2022-06-01,2022-06-09,2022-03-24,2022-03-21,2022-12-28,2022-04-05,2022-02-02,01-Feb-22,2022-02-01,6.0,1.0,2.0,8.0,9.0,5.0,4.0,10.0,7.0,3.0,4.50%,10.20%,38.80%,40.10%,41.00%,61.20%,61.90%,67.40%,99.60%,100.00%,100.00%,29-Mar-22,09-Jun-22,55.0,162.0,294.0,194.0,114.0,107.0,140.0,116.0,60.0,60.0,180.0,188.0,111.0,108.0,390.0,123.0,61.0,148.0,60.0,140.0,60.0,188.0,719.0,663.0,663.0,783.0,791.0,714.0,711.0,993.0,726.0,664.0,751.0,743.0,663.0,608.0,314.0,370.0,314.0,314.0,434.0,442.0,365.0,362.0,644.0,377.0,308.0,402.0,349.0,356.0,254.0,247.0,791.0,128.0,128.0,56.0,72.0,662
30,Akynzeo,netupitant / palonosetron,Purdue Pharma,N,N,N,Y,N,N,N,N,N,01-Dec-16,28-Sep-17,301.0,CADTH & INESSS,08-Dec-17,post-NOC,Initial,Nausea and vomiting (chemotherapy induced) prevention,Completed,20-Jun-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,Nausea and vomiting (chemotherapy induced) prevention,Completed,09-May-18,Avis de refus dinscription aux listes des médicaments (chimiothérapie hautement émétisante) Avis de refus dinscription aux listes des médicaments ? Valeur thérapeutique (chimiothérapie modérément émétisante),Negative,1st,19-Sep-18,24-Apr-19,Negotiation,Completed with Agreements,SA,UR,NR,EDS,LU,SA,EDS,SA,SA,EM,2019-11-26,,,2020-07-16,2019-06-28,2019-11-07,2019-09-01,2019-09-23,2019-07-18,2019-07-04,28-Jun-19,2019-06-28,7.0,,,8.0,1.0,6.0,4.0,5.0,3.0,2.0,32.20%,60.80%,61.50%,62.80%,63.10%,64.00%,84.30%,89.80%,,,89.80%,04-Jul-19,26-Nov-19,71.0,,194.0,,91.0,133.0,217.0,216.0,,,449.0,65.0,197.0,130.0,152.0,85.0,71.0,185.0,65.0,171.0,65.0,216.0,789.0,,,1022.0,638.0,770.0,703.0,725.0,658.0,644.0,758.0,744.0,638.0,567.0,373.0,524.0,,,757.0,373.0,505.0,438.0,460.0,393.0,421.0,493.0,265.0,223.0,308.0,350.0,789.0,151.0,151.0,6.0,145.0,566
33,Alecensaro,alectinib,Hoffman-La Roche ,Y,N,N,N,Y,Y,N,Y,N,01-Feb-16,29-Sep-16,241.0,CADTH & INESSS,18-Aug-17,post-NOC,New indication,Locally advanced or metastatic non-small cell lung cancer (second line),Completed,29-Mar-18,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Locally advanced or metastatic non-small cell lung cancer (second line),Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,07-Sep-18,11-Dec-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2019-05-01,2019-03-01,2019-02-11,2019-05-31,2019-04-17,2019-05-16,2019-10-03,,2019-09-27,2019-02-01,11-Feb-19,2019-02-01,5.0,3.0,2.0,7.0,4.0,6.0,9.0,,8.0,1.0,28.60%,34.30%,38.80%,71.00%,91.20%,92.10%,97.70%,98.30%,99.60%,,99.60%,17-Apr-19,01-May-19,323.0,56.0,223.0,189.0,162.0,463.0,95.0,141.0,80.0,62.0,171.0,127.0,156.0,296.0,,290.0,52.0,165.0,62.0,153.0,52.0,141.0,944.0,883.0,865.0,974.0,930.0,959.0,1099.0,,1093.0,855.0,968.0,956.0,865.0,542.0,319.0,398.0,337.0,319.0,428.0,384.0,413.0,553.0,,547.0,610.0,422.0,546.0,245.0,257.0,558.0,944.0,89.0,79.0,75.0,14.0,787
34,Alecensaro,alectinib,Hoffman-La Roche ,Y,N,N,N,Y,Y,N,Y,N,01-Dec-17,11-Jun-18,192.0,CADTH & INESSS,15-Jan-18,pre-NOC,New indication,Non-Small Cell Lung Cancer (first line),Completed,25-Jul-18,Cond'l on Cost,Conditional,,,New Indication,Locally advanced or metastatic ALK+ NSCLC (first line),Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,07-Sep-18,11-Dec-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2019-05-01,2019-03-01,2019-02-11,2019-05-31,2019-04-17,2019-05-16,2019-10-03,2021-12-06,2019-09-27,2019-02-01,11-Feb-19,2019-02-01,5.0,3.0,2.0,7.0,4.0,6.0,9.0,10.0,8.0,1.0,28.60%,34.30%,38.80%,71.00%,91.20%,92.10%,97.70%,98.30%,99.60%,100.00%,100.00%,17-Apr-19,01-May-19,-147.0,,191.0,,44.0,2.0,95.0,141.0,80.0,62.0,171.0,127.0,156.0,296.0,1091.0,290.0,52.0,268.0,62.0,247.0,52.0,141.0,324.0,263.0,245.0,354.0,310.0,339.0,479.0,1274.0,473.0,235.0,451.0,430.0,245.0,392.0,201.0,280.0,219.0,201.0,310.0,266.0,295.0,435.0,1230.0,429.0,149.0,407.0,44.0,86.0,139.0,97.0,324.0,89.0,79.0,75.0,14.0,236
41,Alunbrig,brigatinib,Takeda ,Y,N,N,N,Y,Y,N,Y,N,01-May-20,03-Mar-21,306.0,CADTH & INESSS,30-Sep-20,pre-NOC,New indication,For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) previously untreated with an ALK inhibitor,Completed,21-Apr-21,Cond'l on Cost,Conditional,02-Oct-20,pre-NOC,New Indication,Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer,Completed,07-May-21,Inscription - Avec conditions,Conditional,1st,29-Oct-21,16-Dec-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2022-06-01,2022-02-28,2022-03-01,2022-06-01,2022-02-28,2022-04-29,2022-07-11,2022-09-26,2022-10-31,2022-02-02,28-Feb-22,2022-02-02,6.0,2.0,4.0,7.0,3.0,5.0,8.0,9.0,10.0,1.0,28.60%,33.00%,65.30%,71.00%,71.90%,92.10%,97.70%,99.00%,99.30%,100.00%,100.00%,28-Feb-22,01-Jun-22,-154.0,-152.0,203.0,217.0,191.0,175.0,48.0,167.0,74.0,75.0,167.0,74.0,134.0,207.0,284.0,319.0,48.0,167.0,74.0,155.0,48.0,167.0,455.0,362.0,363.0,455.0,362.0,422.0,495.0,572.0,607.0,336.0,455.0,443.0,362.0,516.0,313.0,406.0,313.0,314.0,406.0,313.0,373.0,446.0,523.0,558.0,271.0,406.0,49.0,65.0,239.0,223.0,455.0,119.0,93.0,26.0,93.0,355
42,Anoro Ellipta,umeclidinium / vilanterol,GlaxoSmithKline,Y,N,N,Y,N,N,N,N,N,,23-Dec-13,,CADTH & INESSS,26-Feb-14,post-NOC,Initial,COPD (Chronic Obstructive Pulmonary Disease),Completed,15-Jan-15,List with criteria/condition,Conditional,,,New Drug,COPD,Completed,01-Feb-16,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,04-Feb-15,01-May-15,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,2015-08-11,2015-06-01,2015-07-01,2015-07-22,2015-06-29,2015-06-29,2015-09-01,2015-09-21,2015-10-01,2016-03-24,01-Jun-15,2015-06-01,6.0,1.0,4.0,5.0,2.0,3.0,7.0,8.0,9.0,10.0,4.50%,36.70%,37.60%,43.30%,48.80%,69.10%,70.40%,70.70%,71.40%,100.00%,100.00%,11-Aug-15,24-Mar-16,65.0,,323.0,,20.0,-362.0,86.0,102.0,31.0,61.0,82.0,59.0,59.0,123.0,143.0,153.0,328.0,90.0,31.0,114.0,31.0,328.0,596.0,525.0,555.0,576.0,553.0,553.0,617.0,637.0,647.0,822.0,584.0,608.0,525.0,460.0,137.0,208.0,137.0,167.0,188.0,165.0,165.0,229.0,249.0,259.0,52.0,196.0,388.0,770.0,106.0,-276.0,822.0,297.0,297.0,71.0,226.0,42019
43,Aptiom,eslicarbazepine acetate ,Sunovion Pharmaceuticals ,N,N,N,Y,N,N,N,N,N,,08-Jul-14,,CADTH & INESSS,15-Aug-14,post-NOC,Initial,"Epilepsy, partial-onset seizures ",Completed,16-Apr-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,"Epilepsy, partial-onset seizures ",Completed,02-Feb-15,Avis de refus,Negative,1st,15-Jun-15,08-Sep-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2015-11-10,2015-11-01,2016-01-01,2016-01-18,2015-11-26,2016-03-01,2016-03-01,2016-04-25,2015-12-01,2017-03-15,01-Nov-15,2015-11-01,2.0,1.0,5.0,6.0,3.0,7.0,8.0,9.0,4.0,10.0,4.50%,24.70%,56.90%,57.60%,63.30%,68.90%,69.80%,71.10%,71.40%,100.00%,100.00%,26-Nov-15,15-Mar-17,38.0,27.0,244.0,182.0,60.0,133.0,85.0,63.0,54.0,115.0,132.0,79.0,175.0,175.0,230.0,84.0,554.0,123.0,54.0,166.0,54.0,554.0,490.0,481.0,542.0,559.0,506.0,602.0,602.0,657.0,511.0,981.0,550.0,593.0,481.0,443.0,199.0,208.0,199.0,260.0,277.0,224.0,320.0,320.0,375.0,229.0,772.0,268.0,282.0,209.0,145.0,218.0,981.0,500.0,500.0,25.0,475.0,42110
45,Arnuity Ellipta,fluticasone furoate,GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,,21-Sep-15,,CADTH & INESSS,26-Jun-15,pre-NOC,Initial,Asthma,Completed,17-Dec-15,List with criteria/condition,Conditional,22-Mar-16,post-NOC,New Drug,Asthma,Completed,16-Dec-16,Avis d'inscription aux listes des médicaments,Positive,1st,13-Apr-16,08-Aug-16,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,FB,FB,FB,FB,FB,2016-10-12,2017-02-01,2016-10-01,2016-10-20,2016-09-29,2016-09-29,2016-12-01,2017-04-24,2017-04-01,2016-12-16,29-Sep-16,2016-09-29,4.0,8.0,3.0,5.0,1.0,2.0,6.0,10.0,9.0,7.0,32.20%,33.10%,38.80%,59.10%,64.60%,65.90%,94.50%,99.00%,99.60%,100.00%,100.00%,12-Oct-16,16-Dec-16,-87.0,183.0,174.0,269.0,118.0,-247.0,117.0,65.0,177.0,54.0,73.0,52.0,52.0,115.0,259.0,236.0,130.0,120.0,52.0,121.0,52.0,130.0,387.0,499.0,376.0,395.0,374.0,374.0,437.0,581.0,558.0,452.0,442.0,443.0,374.0,461.0,287.0,300.0,412.0,289.0,308.0,287.0,287.0,350.0,494.0,471.0,0.0,355.0,87.0,452.0,235.0,-130.0,452.0,78.0,78.0,13.0,65.0,42355
47,Atectura Breezhaler,indacaterol /mometasone furoate,Novartis Pharmaceuticals Canada Inc.,Y,N,N,N,N,N,N,N,N,01-Jul-19,06-May-20,310.0,CADTH & INESSS,19-May-20,post-NOC,Initial,"Asthma maintenance (adults, children 12 or older)",Completed,24-Nov-20,Reimburse with clinical criteria and/or conditions,Conditional,26-Jun-20,post-NOC,New Drug,Asthma,Completed,02-Dec-20,Inscription - Avec conditions,Conditional,1st,23-Jun-21,30-Sep-21,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,2022-06-14,2021-11-01,2022-03-01,2022-02-24,2022-02-28,2021-12-16,2021-11-30,2022-03-28,2022-05-11,2021-12-15,01-Nov-21,2021-11-01,10.0,1.0,7.0,5.0,6.0,4.0,2.0,8.0,9.0,3.0,4.50%,5.80%,34.30%,35.20%,40.80%,73.00%,78.70%,79.10%,79.70%,100.00%,100.00%,28-Feb-22,14-Jun-22,13.0,51.0,189.0,159.0,211.0,203.0,99.0,257.0,32.0,152.0,147.0,151.0,77.0,61.0,179.0,223.0,76.0,142.0,32.0,136.0,32.0,257.0,769.0,544.0,664.0,659.0,663.0,589.0,573.0,691.0,735.0,588.0,654.0,648.0,544.0,531.0,342.0,567.0,342.0,462.0,457.0,461.0,387.0,371.0,489.0,533.0,378.0,452.0,202.0,210.0,310.0,302.0,769.0,225.0,225.0,119.0,106.0,512
51,Avastin,bevacizumab,Hoffman-La Roche ,Y,Y,N,N,Y,N,N,N,N,,,,CADTH,27-Oct-14,na,New indication,Cervical Cancer,Completed,23-Mar-15,Cond'l on Cost,Conditional,,,,,,,,,1st,30-Apr-15,04-Nov-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,,2014-04-01,2015-12-18,2015-12-28,2015-11-16,2016-01-11,2016-12-15,2016-02-01,2018-08-01,2015-11-05,,01-Apr-14,2014-04-01,1.0,4.0,5.0,3.0,6.0,8.0,7.0,9.0,2.0,,20.30%,20.90%,26.50%,30.90%,36.60%,68.90%,70.20%,71.10%,71.40%,,71.40%,11-Jan-16,,,,147.0,,38.0,,188.0,-582.0,44.0,54.0,12.0,68.0,407.0,89.0,1001.0,1.0,,122.0,-582.0,122.0,-582.0,,,,,,,,,,,,,,,-209.0,-356.0,-356.0,270.0,280.0,238.0,294.0,633.0,315.0,1227.0,227.0,,348.0,,,226.0,,,,,650.0,,42086
52,Avastin,bevacizumab,Hoffman-La Roche ,Y,Y,N,N,Y,Y,N,Y,N,,15-May-15,,CADTH & INESSS,28-Nov-14,pre-NOC,New indication,Ovarian Cancer,Completed,04-Jun-15,Cond'l on Cost,Conditional,,,New Indication,"In combination with paclitaxel and carboplatin for the front-line treatment of epithelial ovarian, fallopian tube or primary peritoneal cancer patients with high risk of relapse (stage III sub-optimally debulked, or stage III unresectable, or stage IV patients",Completed,01-Jun-16,Avis de refus dajout dune indication reconnue à la Liste Établissements  Médicament dexception - À moins que certaines conditions soient respectées,Conditional,1st,30-Jun-15,04-Nov-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-10-01,2015-12-18,2015-12-28,2015-11-16,2016-03-30,2016-12-15,2016-02-01,,2015-11-05,2017-11-15,05-Nov-15,2015-11-05,8.0,3.0,4.0,2.0,6.0,7.0,5.0,,1.0,9.0,0.70%,6.20%,10.70%,16.40%,17.70%,49.90%,50.80%,71.10%,99.60%,,99.60%,15-Dec-16,15-Nov-17,-168.0,,188.0,,26.0,-337.0,127.0,697.0,44.0,54.0,12.0,147.0,407.0,89.0,,1.0,742.0,181.0,1.0,244.0,1.0,742.0,870.0,217.0,227.0,185.0,320.0,580.0,262.0,,174.0,915.0,354.0,417.0,174.0,342.0,154.0,850.0,197.0,207.0,165.0,300.0,560.0,242.0,,154.0,532.0,334.0,20.0,383.0,153.0,-210.0,915.0,741.0,741.0,406.0,335.0,42159
53,Avastin,bevacizumab,Hoffman-La Roche ,Y,Y,N,N,Y,Y,N,Y,N,,28-Sep-15,,CADTH & INESSS,29-Oct-15,post-NOC,New indication,Genitourinany Platinum-Resistant Ovarian Cancer,Completed,05-May-16,Cond'l on Cost,Conditional,24-Nov-15,post-NOC,New Indication,Platinum-Resistant Ovarian Cancer,Completed,19-Aug-16,Avis de refus dajout dune indication reconnue à la Liste Établissements  Médicament dexception - À moins que certaines conditions soient respectées,Conditional,1st,15-Jul-16,21-Aug-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-10-01,2018-05-08,2017-09-01,2017-09-01,2017-10-05,2018-01-09,2018-02-01,,2017-08-11,2017-11-15,11-Aug-17,2017-08-11,4.0,9.0,2.0,3.0,5.0,7.0,8.0,,1.0,6.0,0.70%,6.40%,11.90%,32.20%,64.40%,93.00%,93.90%,95.20%,99.60%,,99.60%,05-Oct-17,15-Nov-17,31.0,57.0,189.0,269.0,71.0,-35.0,402.0,41.0,260.0,11.0,11.0,45.0,141.0,164.0,,-10.0,86.0,83.0,-10.0,83.0,-10.0,86.0,734.0,953.0,704.0,704.0,738.0,834.0,857.0,,683.0,779.0,776.0,776.0,683.0,652.0,463.0,514.0,733.0,484.0,484.0,518.0,614.0,637.0,,463.0,453.0,556.0,220.0,326.0,473.0,367.0,779.0,96.0,96.0,55.0,41.0,42495
55,Baqsimi,glucagon,Eli Lilly ,N,N,N,N,N,N,N,N,Y,01-Nov-18,25-Sep-19,328.0,CADTH & INESSS,24-Jul-19,pre-NOC,Initial,Severe hypoglycemic reactions,Completed,22-Jan-20,Reimburse with clinical criteria and/or conditions,Conditional,19-Jul-19,pre-NOC,New Drug,Hypoglycemia,Completed,05-Feb-20,Inscription - Avec conditions,Conditional,1st,14-Dec-20,22-Nov-21,Negotiation,Completed with Agreements,FB,RB,FB,RB,LU,SA,EDS,SA,SA,EM,2022-04-05,2022-02-01,2022-03-01,2022-06-01,2021-01-31,2022-02-17,2022-06-27,2022-06-01,2022-02-01,2022-02-02,31-Jan-21,2021-01-31,7.0,2.0,6.0,8.0,1.0,5.0,10.0,9.0,3.0,4.0,32.20%,36.70%,37.40%,65.90%,66.80%,72.60%,92.80%,98.30%,98.70%,100.00%,100.00%,02-Feb-22,05-Apr-22,-63.0,-68.0,182.0,201.0,327.0,313.0,343.0,134.0,71.0,99.0,191.0,-295.0,87.0,217.0,191.0,71.0,72.0,85.0,-295.0,84.0,-295.0,134.0,923.0,860.0,888.0,980.0,494.0,876.0,1006.0,980.0,860.0,861.0,874.0,873.0,494.0,557.0,375.0,804.0,741.0,769.0,861.0,375.0,757.0,887.0,861.0,741.0,728.0,755.0,119.0,133.0,670.0,656.0,923.0,429.0,429.0,367.0,62.0,447
56,Basaglar,insulin glargine,Eli Lilly ,N,Y,Y,N,N,N,N,N,N,,01-Sep-15,,CADTH & INESSS,05-Oct-15,post-NOC,Initial,"Diabetes mellitus, Type 1 & 2",Completed,14-Apr-16,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,"Diabetes mellitus, Type 1 & 2",Completed,01-Jun-16,Avis d'inscription aux listes des médicaments-Médicament d'exception,Conditional,1st,15-Jun-16,07-Jul-17,Negotiation,Completed with Agreements,SA,FB,FB,FB,FB,FB,FB,FB,FB,EM,2018-08-21,2017-10-01,2018-01-01,2017-10-19,2019-03-28,2017-10-24,2017-09-01,2017-09-25,2017-10-01,2017-08-18,01-Sep-17,2017-08-18,9.0,4.0,8.0,6.0,10.0,7.0,2.0,3.0,5.0,1.0,28.60%,29.90%,30.20%,34.70%,35.40%,40.90%,41.80%,47.50%,67.80%,100.00%,100.00%,21-Aug-18,28-Mar-19,34.0,84.0,192.0,190.0,62.0,14.0,387.0,410.0,86.0,178.0,104.0,629.0,109.0,56.0,80.0,86.0,42.0,193.0,56.0,178.0,42.0,629.0,1085.0,761.0,853.0,779.0,1304.0,784.0,731.0,755.0,761.0,717.0,868.0,853.0,731.0,697.0,505.0,859.0,535.0,627.0,553.0,1078.0,558.0,505.0,529.0,535.0,443.0,642.0,226.0,274.0,449.0,401.0,1304.0,587.0,573.0,368.0,219.0,42474
57,Bavencio,avelumab,EMD Serono - Pfizer Alliance,Y,Y,N,Y,Y,Y,Y,Y,N,01-Apr-17,18-Dec-17,261.0,CADTH & INESSS,10-Oct-17,pre-NOC,New drug,Metastatic Merkel Cell Carcinoma,Completed,21-Mar-18,Cond'l on Cost,Conditional,,,New Drug,Metastatic Merkel Cell Carcinoma,Completed,06-Jun-18,Avis de refus d'inscription à la Liste Établissements - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,16-Jul-18,17-Jan-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2019-05-01,2019-10-07,2019-05-01,2019-02-14,2019-04-18,2019-06-24,2019-10-03,,2019-08-26,2019-03-07,14-Feb-19,2019-02-14,4.0,9.0,5.0,1.0,3.0,6.0,8.0,,7.0,2.0,5.50%,34.10%,66.30%,86.60%,92.30%,93.20%,93.90%,95.20%,99.60%,,99.60%,18-Apr-19,01-May-19,-69.0,,162.0,,117.0,40.0,185.0,104.0,263.0,104.0,28.0,91.0,158.0,259.0,,221.0,49.0,154.0,28.0,142.0,28.0,104.0,499.0,658.0,499.0,423.0,486.0,553.0,654.0,,616.0,444.0,549.0,537.0,423.0,492.0,330.0,406.0,565.0,406.0,330.0,393.0,460.0,561.0,,523.0,274.0,456.0,93.0,170.0,302.0,225.0,499.0,76.0,76.0,63.0,13.0,354
58,Bavencio,avelumab,EMD Serono - Pfizer Alliance,Y,Y,N,N,Y,N,N,N,N,01-Jun-20,10-Dec-20,192.0,CADTH & INESSS,18-Sep-20,pre-NOC,New indication,First-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.,Completed,23-Mar-21,Cond'l on Cost,Conditional,02-Oct-20,pre-NOC,New Indication,First-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy.,Completed,03-Mar-21,Inscription - Avec conditions,Conditional,1st,22-Jul-21,15-Dec-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2022-06-01,2022-02-28,2022-06-01,2022-12-15,2021-04-30,,,,,2022-02-02,30-Apr-21,2021-04-30,4.0,3.0,5.0,6.0,1.0,,,,,2.0,32.20%,60.80%,65.30%,85.50%,91.20%,96.80%,,,,,96.80%,02-Feb-22,01-Jun-22,-83.0,-69.0,186.0,152.0,121.0,141.0,146.0,168.0,75.0,168.0,365.0,-229.0,,,,,49.0,109.0,-229.0,99.0,-229.0,168.0,538.0,445.0,538.0,735.0,141.0,,,,,419.0,479.0,469.0,141.0,224.0,38.0,435.0,342.0,435.0,632.0,38.0,,,,,336.0,376.0,103.0,83.0,267.0,287.0,538.0,397.0,397.0,278.0,119.0,295
61,Beovu,brolucizumab,Novartis ,Y,Y,N,Y,N,N,N,N,Y,01-May-19,12-Mar-20,316.0,CADTH & INESSS,26-Sep-19,pre-NOC,Initial,"Macular degeneration, age-related",Completed,21-May-20,Reimburse with clinical criteria and/or conditions,Conditional,03-Jan-20,pre-NOC,New Drug,the neovascular (wet) form of age-related macular degeneration,Completed,08-Jul-20,Refus dinscription,Negative,1st,27-Apr-21,31-Aug-21,Negotiation,Completed with Agreements,,RB,EDS,,LU,SA,,SA,,NR,,2022-02-01,2022-03-01,,2021-12-17,2021-12-16,,2022-12-28,,,16-Dec-21,2021-12-16,,3.0,4.0,,2.0,1.0,,5.0,,,0.90%,33.10%,37.60%,43.30%,43.70%,,,,,,43.70%,,,-168.0,-69.0,238.0,187.0,341.0,293.0,126.0,,154.0,182.0,,108.0,107.0,,484.0,,,207.0,107.0,207.0,107.0,,,691.0,719.0,,645.0,644.0,,1021.0,,,744.0,744.0,644.0,812.0,574.0,,621.0,649.0,,575.0,574.0,,951.0,,,674.0,70.0,118.0,467.0,419.0,,,,,,386
63,Besponsa,Inotuzumab Ozogamicin,Pfizer,Y,Y,N,Y,Y,Y,Y,Y,N,01-May-17,15-Mar-18,318.0,CADTH & INESSS,13-Nov-17,pre-NOC,New drug,Acute Lymphoblastic Leukemia (ALL),Completed,06-Jul-18,Cond'l on Cost,Conditional,14-Nov-17,pre-NOC,New Drug,Acute Lymphoblastic Leukemia (ALL),Completed,06-Jun-18,Avis de refus d'inscription à la Liste Établissements - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,07-Sep-18,06-Feb-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,EM,2019-06-01,2022-10-31,2019-09-03,2019-06-26,2019-07-18,2019-11-01,2020-02-01,,,2019-03-07,01-Jun-19,2019-03-07,2.0,8.0,5.0,3.0,4.0,6.0,7.0,,,1.0,28.60%,48.80%,54.40%,86.60%,92.30%,93.20%,94.50%,99.00%,,,99.00%,26-Jun-19,18-Jul-19,-122.0,-121.0,235.0,204.0,63.0,93.0,152.0,115.0,1363.0,209.0,140.0,162.0,268.0,360.0,,,29.0,374.0,115.0,331.0,29.0,162.0,443.0,1691.0,537.0,468.0,490.0,596.0,688.0,,,357.0,702.0,659.0,443.0,565.0,330.0,330.0,1578.0,424.0,355.0,377.0,483.0,575.0,,,274.0,589.0,113.0,83.0,215.0,245.0,490.0,133.0,47.0,111.0,22.0,431
65,Biktarvy,bictegravir/emtricitabine/tenofovir/alafenamide,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,01-Sep-17,10-Jul-18,312.0,CADTH & INESSS,30-Apr-18,pre-NOC,Initial,HIV-1 infection,Completed,25-Oct-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,HIV,Completed,12-Dec-18,Inscription  Avec conditions,Conditional,1st,27-Feb-19,14-Jun-19,Negotiation,Completed with Agreements,HIV,HIV,EDS,EDS,FB,SA,HIV,HIV,SA,FB,,2019-08-22,2019-08-01,2020-03-02,2019-07-31,2019-10-24,2020-02-06,2019-10-28,2019-10-24,2019-08-15,31-Jul-19,2019-07-31,,4.0,2.0,9.0,1.0,5.0,8.0,7.0,6.0,3.0,32.20%,38.00%,66.50%,71.00%,71.90%,72.60%,72.90%,74.20%,79.70%,,79.70%,15-Aug-19,,-71.0,,178.0,,125.0,77.0,107.0,,69.0,48.0,262.0,47.0,132.0,237.0,136.0,132.0,62.0,133.0,47.0,125.0,47.0,,,408.0,387.0,601.0,386.0,471.0,576.0,475.0,471.0,401.0,472.0,464.0,386.0,457.0,279.0,,301.0,280.0,494.0,279.0,364.0,469.0,368.0,364.0,246.0,365.0,107.0,155.0,232.0,184.0,,,,15.0,,419
67,Blincyto,blinatumomab,Amgen ,Y,Y,N,Y,Y,Y,Y,Y,N,01-Apr-15,22-Dec-15,265.0,CADTH & INESSS,24-Aug-15,pre-NOC,New drug,Acute Lymphoblastic Leukemia ,Completed,18-Apr-16,Do Not Fund,Negative,22-Mar-16,post-NOC,New Drug,Acute Lymphoblastic Leukemia ,Completed,18-Aug-17,Avis de refus d'inscription à la Liste Établissements - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,27-Apr-16,09-Jan-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,2017-11-01,2022-10-31,2017-08-02,2017-02-15,2017-04-24,2017-08-24,2018-02-01,,,2019-03-07,15-Feb-17,2017-02-15,5.0,8.0,3.0,1.0,2.0,4.0,6.0,,,7.0,5.50%,37.80%,43.50%,44.40%,64.60%,65.90%,94.50%,99.00%,,,99.00%,01-Nov-17,07-Mar-19,-120.0,91.0,238.0,514.0,9.0,-478.0,257.0,296.0,2121.0,205.0,37.0,105.0,227.0,388.0,,,787.0,483.0,37.0,521.0,37.0,787.0,680.0,2505.0,589.0,421.0,489.0,611.0,772.0,,,1171.0,867.0,905.0,421.0,541.0,303.0,562.0,2387.0,471.0,303.0,371.0,493.0,654.0,,,566.0,749.0,118.0,605.0,266.0,-221.0,1171.0,750.0,750.0,259.0,491.0,383
68,Blincyto,blinatumomab,Amgen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Sep-16,28-Apr-17,239.0,CADTH & INESSS,24-Feb-17,pre-NOC,New indication,Pediatric Acute Lymphoblastic Leukemia (ALL),Completed,23-Aug-17,Cond'l on Cost,Conditional,22-Mar-16,pre-NOC,New Drug,Pediatric Acute Lymphoblastic Leukemia (ALL),Completed,01-Feb-18,Avis d'inscription à la Liste Établissements - Médicament d'exception,Positive,1st,29-Dec-17,15-Jan-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,2019-05-01,2022-10-31,2019-05-01,2019-06-01,2019-06-12,2019-11-01,2019-12-01,,,2019-03-07,01-May-19,2019-03-07,2.0,8.0,3.0,4.0,5.0,6.0,7.0,,,1.0,28.60%,48.80%,54.60%,60.10%,92.30%,93.20%,94.50%,99.00%,,,99.00%,01-May-19,12-Jun-19,-63.0,-402.0,180.0,681.0,128.0,-34.0,382.0,106.0,1385.0,106.0,137.0,148.0,290.0,320.0,,,51.0,356.0,106.0,318.0,51.0,148.0,733.0,2012.0,733.0,764.0,775.0,917.0,947.0,,,678.0,983.0,945.0,733.0,796.0,616.0,616.0,1895.0,616.0,647.0,658.0,800.0,830.0,,,399.0,866.0,117.0,279.0,510.0,348.0,775.0,97.0,42.0,55.0,42.0,356
70,Blincyto,blinatumomab,Amgen ,Y,Y,N,N,Y,Y,Y,Y,N,01-May-17,05-Mar-18,308.0,CADTH & INESSS,31-Aug-18,post-NOC,New indication,Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL),Completed,04-Apr-19,Cond'l on Cost,Conditional,27-Jul-18,post-NOC,New Indication,Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL),Completed,13-Mar-19,Inscription - Avec conditions,Conditional,1st,04-Jul-19,25-Sep-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,EM,2020-05-01,2022-10-31,2020-09-03,2019-11-01,2020-02-25,2019-11-01,2019-12-01,,,2020-12-16,01-Nov-19,2019-11-01,5.0,8.0,6.0,1.0,4.0,2.0,3.0,,,7.0,5.50%,6.40%,7.70%,40.00%,60.20%,65.90%,94.50%,99.00%,,,99.00%,01-May-20,16-Dec-20,179.0,144.0,216.0,229.0,91.0,113.0,83.0,219.0,1132.0,344.0,37.0,153.0,37.0,67.0,,,448.0,284.0,37.0,305.0,37.0,448.0,788.0,1701.0,913.0,606.0,722.0,606.0,636.0,,,1017.0,853.0,874.0,606.0,427.0,211.0,393.0,1306.0,518.0,211.0,327.0,211.0,241.0,,,644.0,458.0,395.0,373.0,174.0,196.0,1017.0,411.0,411.0,182.0,229.0,703
71,Blincyto,blinatumomab,Amgen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Dec-17,19-Dec-19,748.0,CADTH & INESSS,20-Jan-20,post-NOC,Resubmission,Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL),Completed,29-Oct-20,Cond'l on Cost,Conditional,03-Feb-20,post-NOC,New Indication,Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL),Completed,05-Aug-20,Inscription - Avec conditions,Conditional,1st,17-Dec-20,21-May-21,Negotiation,Completed with Agreements,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,2022-11-01,,,,2021-08-30,,,,,2021-07-07,30-Aug-21,2021-07-07,3.0,,,,2.0,,,,,1.0,28.60%,60.80%,81.10%,,,,,,,,81.10%,30-Aug-21,01-Nov-22,32.0,46.0,283.0,184.0,49.0,134.0,155.0,529.0,,,,101.0,,,,,47.0,315.0,101.0,226.0,47.0,529.0,1048.0,,,,620.0,,,,,566.0,834.0,745.0,620.0,588.0,305.0,733.0,,,,305.0,,,,,336.0,519.0,315.0,230.0,204.0,289.0,1048.0,482.0,428.0,54.0,428.0,1063
72,Blincyto (resubmission),blinatumomab,Amgen ,Y,Y,N,Y,Y,Y,Y,Y,N,,22-Dec-15,,CADTH & INESSS,24-Feb-17,post-NOC,Resubmission,"For the treatment of all adult patients with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL), including those who have had one prior line of therapy (i.e., adult patients who are refractory or patients who are in first or later relapse)",Completed,31-Aug-17,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,"For the treatment of all adult patients with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL), including those who have had one prior line of therapy (i.e., adult patients who are refractory or patients who are in first or later relapse)",Completed,18-Aug-17,Notice of Refusal to be Registered in Establishments - Exceptional Drug - With Conditions,Conditional,1st,29-Dec-17,15-Jan-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Under provincial consideration,EM,2019-05-01,2022-10-31,2019-05-01,2019-06-01,2019-06-12,2019-11-01,,,,2019-03-07,01-May-19,2019-03-07,2.0,7.0,3.0,4.0,5.0,6.0,,,,1.0,28.60%,48.80%,54.60%,60.10%,92.30%,93.20%,97.70%,,,,97.70%,01-May-19,12-Jun-19,430.0,91.0,188.0,514.0,120.0,133.0,382.0,106.0,1385.0,106.0,137.0,148.0,290.0,,,,51.0,362.0,106.0,318.0,51.0,148.0,1226.0,2505.0,1226.0,1257.0,1268.0,1410.0,,,,1171.0,1482.0,1438.0,1226.0,796.0,608.0,608.0,1887.0,608.0,639.0,650.0,792.0,,,,566.0,864.0,618.0,605.0,502.0,515.0,1268.0,97.0,42.0,55.0,42.0,42978
73,Bosulif,bosutinib,Pfizer,Y,N,N,Y,Y,Y,Y,Y,N,,07-Mar-14,,CADTH & INESSS,30-May-14,post-NOC,New drug,Chronic Myeloid Leukemia,Completed,21-Apr-15,Cond'l on Cost,Conditional,22-Mar-14,post-NOC,New Drug,Chronic Myeloid Leukemia,Completed,01-Oct-14,Avis de refus - Valeur thérapeutique,Negative,1st,31-May-15,09-Nov-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,NR,2016-12-01,2016-02-03,2015-12-28,2016-04-18,2016-02-26,2016-04-12,2016-05-02,2020-08-18,2016-02-01,,28-Dec-15,2015-12-28,8.0,3.0,1.0,6.0,4.0,5.0,7.0,9.0,2.0,,5.70%,6.40%,10.80%,43.10%,44.00%,49.50%,50.80%,71.10%,71.40%,,71.40%,02-May-16,,84.0,15.0,326.0,193.0,40.0,242.0,162.0,388.0,86.0,49.0,161.0,109.0,155.0,175.0,1744.0,84.0,,328.0,49.0,328.0,49.0,,1000.0,698.0,661.0,773.0,721.0,767.0,787.0,2356.0,696.0,,940.0,940.0,661.0,577.0,251.0,590.0,288.0,251.0,363.0,311.0,357.0,377.0,1946.0,286.0,,530.0,410.0,208.0,202.0,404.0,,,,126.0,,42115
74,Bosulif (RFA),bosutinib,Pfizer,Y,N,N,Y,Y,Y,Y,Y,N,,07-Mar-14,,CADTH & INESSS,08-Apr-19,post-NOC,Request for Advice,Chronic Myeloid Leukemia,Completed,01-Aug-19,Fund,Positive,22-Mar-14,post-NOC,New Drug,Chronic Myeloid Leukemia,Completed,01-Oct-14,Notice of Refusal - Therapeutic Value,Negative,1st,27-Aug-19,19-Feb-20,Negotiation,Completed with Agreements,Under provincial consideration,Funded,Under provincial consideration,Funded,Funded,Funded,Funded,Funded,Funded,NR,,2020-07-30,,2020-07-16,2021-03-31,2020-08-20,2021-03-31,,2021-06-01,,16-Jul-20,2020-07-16,,2.0,,1.0,4.0,3.0,5.0,,6.0,,5.50%,10.00%,10.90%,43.10%,44.40%,45.10%,,,,,45.10%,,,1858.0,15.0,115.0,193.0,26.0,1791.0,176.0,,162.0,,148.0,406.0,183.0,406.0,,468.0,,296.0,148.0,296.0,148.0,,,2337.0,,2323.0,2581.0,2358.0,2581.0,,2643.0,,2471.0,2471.0,2323.0,465.0,350.0,,364.0,,350.0,608.0,385.0,608.0,,670.0,,498.0,1973.0,208.0,202.0,1967.0,,,,,,43678
75,Botox (UI)(OAB),onabotulinumtoxinA,Allergan ,N,Y,N,N,N,N,N,N,N,,10-Oct-13,,CADTH,25-Nov-13,post-NOC,Initial,Urinary incontinence,Completed,12-Nov-14,List with criteria/condition,Conditional,,,,,,,,,none,31-Jan-15,,Negotiation by Province,,SA,FB,EDS,EDS,LU,SA,EDS,NR,NR,,2019-02-26,1993-07-01,2018-08-01,2018-07-19,2015-05-28,2018-07-18,2020-09-10,,,,01-Jul-93,1993-07-01,6.0,1.0,5.0,4.0,2.0,3.0,7.0,,,,4.50%,36.70%,37.60%,43.10%,48.80%,69.10%,70.40%,,,,70.40%,26-Feb-19,,46.0,,352.0,,80.0,,,,,,,,,,,,,,,,,,1965.0,-7406.0,1756.0,1743.0,595.0,1742.0,2527.0,,,,417.0,417.0,-7406.0,-7452.0,-7804.0,1567.0,-7804.0,1358.0,1345.0,197.0,1344.0,2129.0,,,,19.0,398.0,,,,,,,9371.0,,41955
76,Braftovi,encorafenib,Pfizer,Y,N,N,N,Y,N,N,N,Y,01-May-20,31-Mar-21,334.0,CADTH & INESSS,16-Dec-20,pre-NOC,Initial,"In combination with cetuximab, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, after prior therapy.",Completed,26-Jul-21,Cond'l on Cost,Conditional,22-Jan-21,pre-NOC,New Drug,"Metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, after prior therapy",Completed,30-Jun-21,Inscription - Avec conditions,Conditional,1st,03-Nov-21,06-Jul-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,2022-12-01,2022-09-30,2022-12-01,2023-01-24,2022-12-31,2022-11-21,2023-01-01,,2023-01-25,2022-08-17,30-Sep-22,2022-08-17,4.0,2.0,5.0,8.0,6.0,3.0,7.0,,9.0,1.0,28.60%,33.00%,33.90%,54.20%,59.90%,92.10%,93.40%,99.00%,99.60%,,99.60%,01-Dec-22,31-Dec-22,-105.0,-68.0,222.0,159.0,100.0,126.0,245.0,148.0,86.0,148.0,202.0,178.0,138.0,179.0,,203.0,42.0,160.0,86.0,147.0,42.0,178.0,610.0,548.0,610.0,664.0,640.0,600.0,641.0,,665.0,504.0,622.0,609.0,548.0,653.0,431.0,493.0,431.0,493.0,547.0,523.0,483.0,524.0,,548.0,413.0,505.0,117.0,91.0,345.0,371.0,640.0,136.0,92.0,106.0,30.0,451
77,Braftovi and Mektovi,encorafenib,Pfizer,Y,N,N,Y,Y,Y,N,Y,Y,01-Jun-20,02-Mar-21,274.0,CADTH & INESSS,16-Dec-20,pre-NOC,Initial,"Braftovi (encorafenib): In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Mektovi (binimetinib): In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation",Completed,26-Jul-21,Cond'l on Cost,Conditional,22-Jan-21,pre-NOC,New Drug,Unresectable or metastatic melanoma with a BRAF V600 mutation. ,Completed,30-Jun-21,Inscription - Avec conditions,Conditional,1st,03-Nov-21,06-Jul-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,2022-12-01,2022-09-30,2022-12-01,2023-01-24,2023-01-31,2022-11-21,2023-01-01,,2023-01-25,2022-08-17,30-Sep-22,2022-08-17,4.0,2.0,5.0,7.0,9.0,3.0,6.0,,8.0,1.0,28.60%,33.00%,33.90%,54.20%,59.90%,61.20%,66.70%,67.40%,99.60%,,99.60%,01-Dec-22,31-Jan-23,-76.0,-39.0,222.0,159.0,100.0,126.0,245.0,148.0,86.0,148.0,202.0,209.0,138.0,179.0,,203.0,42.0,164.0,86.0,151.0,42.0,209.0,639.0,577.0,639.0,693.0,700.0,629.0,670.0,,694.0,533.0,655.0,642.0,577.0,653.0,431.0,493.0,431.0,493.0,547.0,554.0,483.0,524.0,,548.0,413.0,509.0,146.0,120.0,345.0,371.0,700.0,167.0,123.0,106.0,61.0,420
78,Brenzys (SEB),etanercept,Merck,Y,Y,Y,N,N,N,N,N,N,,31-Aug-16,,CADTH & INESSS,20-Apr-16,pre-NOC,Initial,"Rheumatoid arthritis, Ankylosing spondylitis ",Completed,25-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,pre-NOC,New Drug,Ankylosing spondylitis + Rheumatoid arthritis,Completed,21-Apr-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,14-Nov-16,19-Jun-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2017-07-18,2017-09-01,2017-10-01,2017-10-19,2017-07-31,2017-10-24,2017-10-01,2017-09-25,2018-03-01,2017-08-18,18-Jul-17,2017-07-18,1.0,4.0,6.0,8.0,2.0,9.0,7.0,5.0,10.0,3.0,20.30%,52.50%,81.10%,85.50%,85.90%,91.60%,92.90%,98.40%,99.30%,100.00%,100.00%,31-Jul-17,18-Aug-17,-133.0,-19.0,188.0,252.0,20.0,-158.0,217.0,29.0,74.0,104.0,122.0,42.0,127.0,104.0,98.0,255.0,60.0,106.0,29.0,102.0,29.0,60.0,321.0,366.0,396.0,414.0,334.0,419.0,396.0,390.0,547.0,352.0,398.0,394.0,321.0,454.0,266.0,266.0,311.0,341.0,359.0,279.0,364.0,341.0,335.0,492.0,119.0,343.0,55.0,233.0,237.0,59.0,352.0,31.0,31.0,13.0,18.0,42668
80,Breo Ellipta (Asthma),fluticasone furoate and vilanterol (as trifenatate),GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,,05-Aug-15,,CADTH & INESSS,10-Aug-15,post-NOC,Initial,Asthma,Completed,18-Feb-16,List with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Indication,Asthma,Completed,16-Dec-16,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception,Conditional,1st,13-Apr-16,11-Jul-16,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,2016-09-13,2017-02-01,2016-10-01,2016-10-20,2016-08-30,2016-08-24,2016-09-01,2016-10-24,2016-11-01,2016-12-16,24-Aug-16,2016-08-24,4.0,10.0,5.0,6.0,2.0,1.0,3.0,7.0,8.0,9.0,0.90%,33.10%,34.40%,54.70%,60.40%,65.90%,66.30%,67.00%,95.50%,100.00%,100.00%,13-Sep-16,16-Dec-16,5.0,230.0,192.0,269.0,55.0,-247.0,89.0,64.0,205.0,82.0,101.0,50.0,44.0,52.0,105.0,113.0,158.0,91.0,44.0,97.0,44.0,158.0,405.0,546.0,423.0,442.0,391.0,385.0,393.0,446.0,454.0,499.0,432.0,438.0,385.0,380.0,188.0,208.0,349.0,226.0,245.0,194.0,188.0,196.0,249.0,257.0,0.0,235.0,197.0,499.0,144.0,-158.0,499.0,114.0,114.0,20.0,94.0,42418
82,Breo Ellipta (COPD),fluticasone furoate / vilanterol,GlaxoSmithKline,Y,N,N,Y,N,N,N,N,N,,03-Jul-13,,CADTH & INESSS,29-Oct-13,post-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,18-Aug-14,List with criteria/condition,Conditional,,,New Drug,COPD,Completed,01-Feb-16,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,06-Oct-14,03-Feb-15,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,2015-05-15,2015-06-01,2015-04-01,2015-04-20,2015-03-31,2015-03-06,2015-04-01,2015-05-25,2015-07-01,2016-03-24,06-Mar-15,2015-03-06,6.0,8.0,3.0,5.0,2.0,1.0,4.0,7.0,9.0,10.0,0.90%,33.10%,38.80%,40.20%,45.70%,65.90%,66.30%,70.70%,71.40%,100.00%,100.00%,15-May-15,24-Mar-16,118.0,,293.0,,49.0,-483.0,120.0,101.0,118.0,57.0,76.0,56.0,31.0,57.0,111.0,148.0,415.0,84.0,31.0,117.0,31.0,415.0,681.0,698.0,637.0,656.0,636.0,611.0,637.0,691.0,728.0,995.0,664.0,697.0,611.0,493.0,200.0,270.0,287.0,226.0,245.0,225.0,200.0,226.0,280.0,317.0,52.0,253.0,411.0,943.0,169.0,-363.0,995.0,384.0,384.0,70.0,314.0,41869
84,Breztri Aerosphere,budesonide/ glycopyrronium /formoterol fumarate,AstraZeneca Canada Inc.,Y,N,N,N,N,N,N,N,N,01-Sep-20,15-Jul-21,317.0,CADTH & INESSS,28-Jan-21,pre-NOC,Initial,chronic obstructive pulmonary disease (COPD),Completed,14-Sep-21,Reimburse with clinical criteria and/or conditions,Conditional,18-Jun-21,pre-NOC,New Drug,COPD,Completed,30-Nov-21,Inscription - Avec conditions,Conditional,1st,28-Feb-22,15-Jun-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2022-11-02,2022-11-01,2022-11-01,2022-09-20,2022-10-31,2022-12-19,2022-11-01,2023-03-27,2022-12-07,2022-08-17,20-Sep-22,2022-08-17,7.0,4.0,5.0,2.0,3.0,9.0,6.0,10.0,8.0,1.0,28.60%,34.10%,66.30%,70.80%,76.50%,77.80%,98.10%,98.80%,99.60%,100.00%,100.00%,31-Oct-22,02-Nov-22,-168.0,-27.0,229.0,165.0,167.0,90.0,107.0,140.0,139.0,139.0,97.0,138.0,187.0,139.0,285.0,175.0,63.0,160.0,97.0,150.0,63.0,140.0,475.0,474.0,474.0,432.0,473.0,522.0,474.0,620.0,510.0,398.0,495.0,485.0,432.0,600.0,371.0,414.0,413.0,413.0,371.0,412.0,461.0,413.0,559.0,449.0,260.0,434.0,61.0,138.0,274.0,197.0,475.0,77.0,43.0,75.0,2.0,378
85,Brilinta (atherothrombotic events ),ticagrelor,AstraZeneca ,Y,N,N,N,N,N,N,N,N,,30-May-16,,CADTH & INESSS,18-Feb-16,pre-NOC,Initial,Prevention of atherothrombotic events with history of myocardial infarction,Completed,25-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Indication,Prevention of atherothrombotic events with history of myocardial infarction,Completed,01-Feb-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,04-Aug-17,30-Nov-17,Negotiation,No agreement reached,NR,NR,EDS,NR,NR,NR,NR,NR,NR,NR,,,2019-08-01,,,,,,,,01-Aug-19,2019-08-01,,,1.0,,,,,,,,5.70%,,,,,,,,,,5.70%,,,-102.0,74.0,189.0,173.0,344.0,184.0,118.0,,,609.0,,,,,,,,609.0,609.0,609.0,609.0,,,,1158.0,,,,,,,,1158.0,1158.0,1158.0,1260.0,1071.0,,,1071.0,,,,,,,,1071.0,87.0,247.0,462.0,302.0,,,,,,42607
86,Brineura,cerliponase alfa,BioMarin Pharmaceutical ,N,Y,N,Y,N,Y,Y,Y,N,01-Jun-18,19-Dec-18,201.0,CADTH & INESSS,31-Jul-18,pre-NOC,Initial,Neuronal Ceroid Lipofuscinosis Type 2,Completed,23-May-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Aug-18,pre-NOC,New Drug,Neuronal Ceroid Lipofuscinosis Type 2,Completed,13-Feb-19,Inscription - Avec conditions,Conditional,1st,29-Mar-19,22-Jan-20,Negotiation,Completed with Agreements,EDRD,UR,UR,EDS,EAP,SA,EDF,UR,SA,UR,2020-02-01,,,2020-10-22,2019-11-11,2021-05-13,2020-02-06,,2020-03-05,,11-Nov-19,2019-11-11,2.0,,,5.0,1.0,6.0,3.0,,4.0,,32.20%,52.50%,53.80%,54.50%,60.00%,60.90%,,,,,60.90%,01-Feb-20,,-141.0,-140.0,296.0,196.0,-55.0,44.0,299.0,10.0,,,274.0,-72.0,477.0,15.0,,43.0,,125.0,-72.0,125.0,-72.0,,409.0,,,673.0,327.0,876.0,414.0,,442.0,,524.0,524.0,327.0,468.0,172.0,254.0,,,518.0,172.0,721.0,259.0,,287.0,,369.0,155.0,56.0,244.0,343.0,,,,82.0,,356
87,Brivlera,brivaracetam,UCB ,N,N,N,Y,N,N,N,N,N,01-May-15,09-Mar-16,313.0,CADTH & INESSS,19-Apr-16,post-NOC,Initial,"Epilepsy, partial-onset seizures",Completed,25-Jan-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-16,post-NOC,New Drug,"Epilepsy, partial-onset seizures",Completed,01-Jun-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,29-May-17,22-Oct-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2021-09-03,2018-12-01,2019-01-01,2019-05-31,2018-12-21,2019-02-07,2019-04-01,2019-01-28,2018-12-06,2018-12-13,01-Dec-18,2018-12-01,10.0,1.0,5.0,9.0,4.0,7.0,8.0,6.0,2.0,3.0,4.50%,5.10%,33.70%,65.90%,71.70%,72.00%,72.90%,74.20%,79.70%,100.00%,100.00%,21-Dec-18,03-Sep-21,41.0,260.0,281.0,189.0,124.0,-3.0,511.0,1047.0,40.0,71.0,221.0,60.0,108.0,161.0,98.0,45.0,52.0,206.0,40.0,190.0,40.0,1047.0,2004.0,997.0,1028.0,1178.0,1017.0,1065.0,1118.0,1055.0,1002.0,1009.0,1163.0,1147.0,997.0,956.0,675.0,1682.0,675.0,706.0,856.0,695.0,743.0,796.0,733.0,680.0,560.0,841.0,322.0,449.0,635.0,508.0,2004.0,1007.0,1007.0,20.0,987.0,635
92,"Cabenuva, Vocabria",cabotegravir-rilpivirine cabotegravir sodium,ViiV Healthcare ,N,N,N,Y,N,N,N,N,Y,01-May-19,18-Mar-20,322.0,CADTH & INESSS,19-Aug-19,pre-NOC,Initial,HIV-1 infection,Completed,22-Jul-20,Reimburse with clinical criteria and/or conditions,Conditional,27-Sep-19,pre-NOC,New Drug,HIV Infection,Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,22-Oct-20,07-Sep-21,Negotiation,Completed with Agreements,,,EDS,EDS,FB,SA,NR,HIV,SA,FB,,,2021-12-01,2022-02-24,2021-11-30,2021-12-16,,2022-05-23,2022-07-20,2021-12-15,30-Nov-21,2021-11-30,,,2.0,5.0,1.0,4.0,,6.0,7.0,3.0,32.20%,38.00%,66.50%,67.40%,73.00%,73.30%,74.00%,,,,74.00%,15-Dec-21,,-212.0,-173.0,338.0,230.0,92.0,161.0,320.0,,,85.0,170.0,84.0,100.0,,258.0,316.0,99.0,169.0,84.0,159.0,84.0,,,,623.0,708.0,622.0,638.0,,796.0,854.0,637.0,707.0,697.0,622.0,834.0,496.0,,,497.0,582.0,496.0,512.0,,670.0,728.0,580.0,581.0,126.0,57.0,412.0,481.0,,,,15.0,,448
96,Cabometyx,cabozantinib,Ipsen ,N,N,N,Y,Y,N,N,N,N,01-Jul-17,14-Sep-18,440.0,CADTH & INESSS,17-Sep-18,post-NOC,Resubmission,Renal Cell Carcinoma,Completed,20-Feb-19,Cond'l on Cost,Conditional,,,New Drug,Renal Cell Carcinoma,Completed,08-Nov-18,Inscription  Avec conditions,Conditional,1st,07-Jun-19,05-Nov-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-01-01,2020-04-10,2020-03-01,2020-04-02,2020-05-06,2020-07-16,2020-06-01,2021-12-06,2021-09-30,2019-12-18,01-Jan-20,2019-12-18,2.0,5.0,3.0,4.0,6.0,8.0,7.0,10.0,9.0,1.0,28.60%,48.80%,54.60%,60.10%,64.50%,96.80%,98.10%,99.00%,99.60%,100.00%,100.00%,01-Mar-20,06-May-20,3.0,,156.0,,107.0,211.0,151.0,57.0,157.0,117.0,149.0,183.0,254.0,209.0,762.0,695.0,43.0,287.0,57.0,263.0,43.0,183.0,474.0,574.0,534.0,566.0,600.0,671.0,626.0,1179.0,1112.0,460.0,704.0,680.0,474.0,471.0,315.0,315.0,415.0,375.0,407.0,441.0,512.0,467.0,1020.0,953.0,405.0,545.0,159.0,55.0,258.0,362.0,600.0,140.0,126.0,74.0,66.0,599
97,Cabometyx,cabozantinib,Ipsen ,N,N,N,N,Y,Y,N,Y,Y,01-Jan-19,08-Nov-19,311.0,CADTH & INESSS,16-Oct-19,pre-NOC,New indication,Hepatocelluar Carcinoma:For the treatment of Hepatocellular Carcinoma (HCC) in adults after prior therapy,Completed,22-Apr-20,Cond'l on Cost,Conditional,08-Nov-19,pre-NOC,New Indication,Hepatocellular Carcinoma,Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,24-Nov-20,24-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2022-01-01,2021-11-30,2021-11-01,2021-11-25,2022-03-31,2021-12-16,2021-11-30,2023-01-23,2021-09-30,2021-09-29,30-Sep-21,2021-09-29,8.0,5.0,3.0,4.0,9.0,7.0,6.0,10.0,2.0,1.0,28.60%,29.30%,35.00%,40.50%,45.00%,46.30%,47.20%,67.40%,99.60%,100.00%,100.00%,01-Jan-22,31-Mar-22,-23.0,0.0,189.0,215.0,216.0,167.0,273.0,130.0,98.0,69.0,93.0,219.0,114.0,98.0,517.0,37.0,36.0,153.0,37.0,141.0,36.0,219.0,785.0,753.0,724.0,748.0,874.0,769.0,753.0,1172.0,692.0,691.0,808.0,796.0,692.0,715.0,526.0,619.0,587.0,558.0,582.0,708.0,603.0,587.0,1006.0,526.0,476.0,642.0,166.0,215.0,489.0,440.0,874.0,183.0,182.0,94.0,89.0,477
100,Calquence,acalabrutinib,AstraZeneca,Y,N,N,Y,Y,Y,Y,Y,Y,01-Oct-19,28-Nov-19,58.0,CADTH & INESSS,07-Apr-20,post-NOC,New drug,Chronic Lymphocytic Leukemia (CLL) (previously untreated),Completed,08-Jan-21,Cond'l on Cost,Conditional,08-May-20,post-NOC,New Drug,Chronic Lymphocytic Leukemia (CLL) (previously untreated),Completed,14-Oct-20,Inscription - Avec conditions,Conditional,1st,27-May-21,05-Oct-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2022-02-01,2022-01-31,2022-02-01,2022-02-24,2021-12-31,2022-04-29,2022-06-10,2022-12-12,2022-10-31,2021-12-15,31-Dec-21,2021-12-15,4.0,3.0,5.0,6.0,2.0,7.0,8.0,10.0,9.0,1.0,28.60%,60.80%,65.30%,85.50%,91.20%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,31-Dec-21,01-Feb-22,131.0,162.0,276.0,159.0,139.0,225.0,131.0,119.0,118.0,119.0,142.0,87.0,206.0,248.0,433.0,391.0,71.0,207.0,87.0,193.0,71.0,119.0,796.0,795.0,796.0,819.0,764.0,883.0,925.0,1110.0,1068.0,748.0,884.0,870.0,764.0,633.0,357.0,389.0,388.0,389.0,412.0,357.0,476.0,518.0,703.0,661.0,427.0,477.0,407.0,321.0,270.0,356.0,796.0,48.0,32.0,16.0,32.0,465
101,Calquence,acalabrutinib,AstraZeneca,Y,N,N,Y,Y,Y,Y,Y,Y,01-Oct-19,28-Nov-19,58.0,CADTH & INESSS,07-Apr-20,post-NOC,New drug,Chronic Lymphocytic Leukemia (CLL),Completed,17-Nov-20,Cond'l on Cost,Conditional,08-May-20,post-NOC,New Drug,Chronic Lymphocytic Leukemia (CLL),Completed,14-Oct-20,Inscription - Avec conditions,Conditional,1st,27-May-21,05-Oct-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2022-02-01,2022-01-31,2022-02-01,2022-02-24,2021-12-31,2022-04-29,2022-06-10,2022-12-12,2022-10-31,2021-12-15,31-Dec-21,2021-12-15,4.0,3.0,5.0,6.0,2.0,7.0,8.0,10.0,9.0,1.0,28.60%,60.80%,65.30%,85.50%,91.20%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,31-Dec-21,01-Feb-22,131.0,162.0,224.0,159.0,191.0,225.0,131.0,119.0,118.0,119.0,142.0,87.0,206.0,248.0,433.0,391.0,71.0,207.0,87.0,193.0,71.0,119.0,796.0,795.0,796.0,819.0,764.0,883.0,925.0,1110.0,1068.0,748.0,884.0,870.0,764.0,633.0,409.0,441.0,440.0,441.0,464.0,409.0,528.0,570.0,755.0,713.0,427.0,529.0,355.0,321.0,322.0,356.0,796.0,48.0,32.0,16.0,32.0,413
104,Caprelsa,vandetanib,Sanofi,Y,N,N,Y,Y,Y,N,Y,N,,12-Jan-12,,CADTH,15-Aug-16,post-NOC,New drug,"Endocrine, medullary thyroid cancer",Completed,30-Mar-17,Cond'l on Cost,Conditional,,,,,,,,,2nd,28-Dec-17,01-Jun-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,,2018-12-01,2018-09-04,2018-11-15,2018-10-18,2018-09-13,2018-12-17,2019-12-01,2023-01-23,2021-12-06,,04-Sep-18,2018-09-04,5.0,1.0,4.0,3.0,2.0,6.0,7.0,9.0,8.0,,4.50%,36.70%,42.20%,47.90%,68.20%,69.10%,70.40%,71.10%,71.40%,,71.40%,01-Dec-18,,1677.0,,227.0,,273.0,,155.0,183.0,95.0,167.0,139.0,104.0,199.0,548.0,1697.0,1284.0,,491.0,95.0,491.0,95.0,,2515.0,2427.0,2499.0,2471.0,2436.0,2531.0,2880.0,4029.0,3616.0,,2823.0,2823.0,2427.0,750.0,523.0,611.0,523.0,595.0,567.0,532.0,627.0,976.0,2125.0,1712.0,,919.0,1904.0,,428.0,,,,,88.0,,42824
108,Cimzia (AS),certolizumab pegol ,UCB ,N,Y,N,N,N,N,N,N,N,,15-Jan-14,,CADTH & INESSS,23-Jun-14,post-NOC,Initial,Ankylosing spondylitis,Completed,17-Apr-15,List with criteria/condition,Conditional,,,New Indication,Ankylosing spondylitis,Completed,01-Oct-14,Ajout dune indication reconnue  Médicament dexception  Avis de refus  Valeur thérapeutique,Conditional,1st,05-Oct-15,06-Jan-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2016-02-19,2016-03-01,2016-05-01,2016-04-18,2016-04-26,2016-04-12,2016-02-01,2016-02-22,2016-03-01,2015-02-02,01-Feb-16,2015-02-02,3.0,5.0,10.0,8.0,9.0,7.0,2.0,4.0,6.0,1.0,28.60%,29.90%,50.10%,50.50%,55.00%,55.60%,56.50%,62.00%,94.30%,100.00%,100.00%,19-Feb-16,26-Apr-16,159.0,,298.0,,171.0,369.0,93.0,44.0,55.0,116.0,103.0,111.0,97.0,26.0,47.0,55.0,-338.0,73.0,26.0,32.0,-338.0,111.0,765.0,776.0,837.0,824.0,832.0,818.0,747.0,768.0,776.0,383.0,794.0,753.0,747.0,588.0,290.0,308.0,319.0,380.0,367.0,375.0,361.0,290.0,311.0,319.0,124.0,337.0,457.0,259.0,264.0,462.0,832.0,449.0,85.0,382.0,67.0,42111
109,Cimzia (PsA),certolizumab pegol ,UCB ,N,Y,N,N,N,N,N,N,N,,02-Jan-14,,CADTH & INESSS,02-Sep-14,post-NOC,Initial,"Arthritis, psoriatic ",Completed,17-Apr-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Indication,"Arthritis, psoriatic ",Completed,02-Feb-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,30-Jun-15,31-Jan-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2016-02-19,2016-03-01,2016-05-01,2016-04-18,2016-04-26,2016-04-12,2016-02-01,2016-02-22,2016-03-01,2015-02-02,01-Feb-16,2015-02-02,3.0,5.0,10.0,8.0,9.0,7.0,2.0,4.0,6.0,1.0,28.60%,29.90%,50.10%,50.50%,55.00%,55.60%,56.50%,62.00%,94.30%,100.00%,100.00%,19-Feb-16,26-Apr-16,243.0,214.0,227.0,182.0,74.0,148.0,215.0,19.0,30.0,91.0,78.0,86.0,72.0,1.0,22.0,30.0,-363.0,48.0,1.0,7.0,-363.0,86.0,778.0,789.0,850.0,837.0,845.0,831.0,760.0,781.0,789.0,396.0,807.0,766.0,760.0,517.0,290.0,308.0,319.0,380.0,367.0,375.0,361.0,290.0,311.0,319.0,0.0,337.0,470.0,396.0,289.0,363.0,845.0,449.0,85.0,382.0,67.0,42111
117,Cosentyx (AS),secukinumab,Novartis ,Y,Y,N,N,N,N,N,N,N,,20-Apr-16,,CADTH & INESSS,19-Feb-16,pre-NOC,Initial,Ankylosing spondylitis,Completed,23-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Indication,Ankylosing spondylitis,Completed,01-Feb-17,Avis de refus dajout dune indication reconnue aux listes des médicaments Médicament dexception  Valeur thérapeutique,Negative,1st,13-Apr-17,19-Dec-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,NR,2018-04-24,2018-06-01,2018-04-01,2018-04-19,2018-04-01,2018-05-08,2019-05-01,2018-03-26,2018-03-01,,01-Mar-18,2018-03-01,6.0,8.0,3.0,5.0,4.0,7.0,9.0,2.0,1.0,,0.70%,1.00%,6.70%,39.00%,44.50%,64.80%,65.70%,70.10%,71.40%,,71.40%,24-Apr-18,,-61.0,114.0,186.0,173.0,233.0,71.0,250.0,126.0,164.0,103.0,121.0,103.0,140.0,498.0,97.0,72.0,,158.0,72.0,158.0,72.0,,734.0,772.0,711.0,729.0,711.0,748.0,1106.0,705.0,680.0,,766.0,766.0,680.0,741.0,555.0,609.0,647.0,586.0,604.0,586.0,623.0,981.0,580.0,555.0,,641.0,125.0,287.0,483.0,321.0,,,,54.0,,42605
118,Cosentyx (PsA),secukinumab,Novartis ,Y,Y,N,N,N,N,N,N,N,,20-Apr-16,,CADTH & INESSS,19-Feb-16,pre-NOC,Initial,"Arthritis, psoriatic",Completed,23-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Indication,Psoriatic arthritis,Completed,01-Feb-17,Avis de refus dajout dune indication reconnue aux listes des médicaments Médicament dexception  Valeur thérapeutique,Negative,1st,13-Apr-17,19-Dec-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2018-04-24,2018-06-01,2018-04-01,2018-04-19,2018-04-01,2018-05-08,2019-05-01,2018-03-26,2018-03-01,2018-09-27,01-Mar-18,2018-03-01,6.0,8.0,3.0,5.0,4.0,7.0,10.0,2.0,1.0,9.0,0.70%,1.00%,6.70%,39.00%,44.50%,64.80%,65.70%,70.10%,98.70%,100.00%,100.00%,24-Apr-18,27-Sep-18,-61.0,114.0,186.0,173.0,233.0,71.0,250.0,126.0,164.0,103.0,121.0,103.0,140.0,498.0,97.0,72.0,282.0,158.0,72.0,171.0,72.0,282.0,734.0,772.0,711.0,729.0,711.0,748.0,1106.0,705.0,680.0,890.0,766.0,779.0,680.0,741.0,555.0,609.0,647.0,586.0,604.0,586.0,623.0,981.0,580.0,555.0,603.0,641.0,125.0,287.0,483.0,321.0,890.0,210.0,210.0,54.0,156.0,42605
119,Cosentyx (PsO),secukinumab,Novartis ,Y,Y,N,Y,N,N,N,N,N,,27-Feb-15,,CADTH & INESSS,08-Dec-14,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,28-Oct-15,List with criteria/condition,Conditional,22-Mar-15,post-NOC,New Drug,"Psoriasis, moderate to severe plaque",Completed,01-Oct-15,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,15-Dec-15,08-Jun-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2016-07-28,2016-08-01,2016-04-01,2016-10-20,2016-08-30,2016-07-07,2016-12-01,2016-10-24,2016-11-01,2015-10-01,01-Apr-16,2015-10-01,4.0,5.0,2.0,7.0,6.0,3.0,10.0,8.0,9.0,1.0,28.60%,34.30%,35.20%,55.40%,59.90%,92.10%,97.70%,98.00%,98.70%,100.00%,100.00%,28-Jul-16,30-Aug-16,-81.0,23.0,324.0,193.0,48.0,75.0,176.0,50.0,54.0,-68.0,134.0,83.0,29.0,176.0,138.0,146.0,-251.0,82.0,-68.0,49.0,-251.0,83.0,517.0,521.0,399.0,601.0,550.0,496.0,643.0,605.0,613.0,216.0,549.0,516.0,399.0,480.0,156.0,274.0,278.0,156.0,358.0,307.0,253.0,400.0,362.0,370.0,0.0,306.0,243.0,216.0,224.0,251.0,550.0,334.0,151.0,301.0,33.0,42305
120,Cotellic,cobimetinib,Hoffman-La Roche ,Y,N,N,Y,Y,Y,N,Y,N,01-Apr-15,22-Feb-16,327.0,CADTH & INESSS,11-Dec-15,pre-NOC,New drug,Metastatic Melanoma,Completed,30-Jun-16,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,Metastatic Melanoma,Completed,03-Oct-16,Avis de refus dinscription aux listes des médicaments  Médicament dexception - À moins que certaines conditions soient respectées,Conditional,1st,12-Aug-16,11-May-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-09-01,2017-11-28,2017-09-01,2017-10-19,2017-11-17,2017-09-22,2020-05-01,2018-08-01,2017-06-01,2017-07-19,01-Jun-17,2017-06-01,3.0,8.0,4.0,6.0,7.0,5.0,10.0,9.0,1.0,2.0,0.70%,29.30%,49.50%,55.20%,56.10%,61.60%,93.90%,98.30%,98.70%,100.00%,100.00%,01-Sep-17,17-Nov-17,-73.0,29.0,202.0,195.0,43.0,-52.0,272.0,113.0,201.0,113.0,161.0,190.0,134.0,1086.0,447.0,21.0,69.0,274.0,21.0,254.0,21.0,190.0,557.0,645.0,557.0,605.0,634.0,578.0,1530.0,891.0,465.0,513.0,718.0,698.0,465.0,538.0,336.0,428.0,516.0,428.0,476.0,505.0,449.0,1401.0,762.0,336.0,289.0,589.0,129.0,224.0,315.0,220.0,634.0,169.0,169.0,92.0,77.0,456
121,Cresemba,isavuconazole,AVIR Pharma ,N,N,N,Y,N,Y,Y,Y,Y,01-Feb-18,19-Dec-18,321.0,CADTH & INESSS,02-Nov-18,pre-NOC,Initial,Treatment of invasive aspergillosis and mucormycosis,Completed,15-May-19,Reimburse with clinical criteria and/or conditions,Conditional,04-Sep-18,pre-NOC,New Drug,Aspergillous and mucormycosis ,Completed,13-Mar-19,Inscription  Avec conditions,Conditional,1st,15-Jul-19,25-Nov-19,Negotiation,Completed with Agreements,SA,RB/SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2021-02-23,2020-02-01,2020-03-01,2020-03-02,2020-03-04,2020-03-19,2020-12-14,2023-01-23,2020-11-12,2020-02-05,01-Feb-20,2020-02-01,9.0,1.0,3.0,4.0,5.0,6.0,8.0,10.0,7.0,2.0,4.50%,33.00%,38.80%,44.30%,76.50%,77.40%,78.10%,79.40%,99.60%,100.00%,100.00%,04-Mar-20,23-Feb-21,-47.0,-106.0,194.0,190.0,61.0,124.0,133.0,456.0,68.0,97.0,98.0,100.0,115.0,385.0,1155.0,353.0,72.0,314.0,68.0,290.0,68.0,456.0,797.0,409.0,438.0,439.0,441.0,456.0,726.0,1496.0,694.0,413.0,655.0,631.0,409.0,456.0,262.0,650.0,262.0,291.0,292.0,294.0,309.0,579.0,1349.0,547.0,329.0,508.0,147.0,84.0,194.0,257.0,797.0,388.0,388.0,32.0,356.0,468
122,Crysvita,burosumab,Kyowa Kirin Limited,N,Y,N,Y,N,Y,Y,Y,N,01-Jun-18,05-Dec-18,187.0,CADTH & INESSS,23-Jul-19,post-NOC,Initial,Treatment of X-Linked Hypophosphatemia,Completed,27-May-20,Reimburse with clinical criteria and/or conditions,Conditional,16-Aug-19,post-NOC,New Drug,Hypophosphatemia,Completed,04-Mar-20,Refus d'inscription,Negative,1st,09-Oct-20,10-Sep-21,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,EDS,SA,SA,NR,2021-10-29,2022-02-01,2021-12-01,2022-02-24,2021-12-21,2022-03-24,2022-06-27,2022-07-25,2022-11-21,,29-Oct-21,2021-10-29,1.0,4.0,2.0,5.0,3.0,6.0,7.0,8.0,9.0,,20.30%,26.00%,58.20%,62.70%,68.20%,69.10%,70.40%,70.70%,71.40%,,71.40%,21-Dec-21,,230.0,254.0,309.0,201.0,135.0,219.0,336.0,49.0,144.0,82.0,167.0,102.0,195.0,290.0,318.0,437.0,,198.0,49.0,198.0,49.0,,1059.0,1154.0,1092.0,1177.0,1112.0,1205.0,1300.0,1328.0,1447.0,,1208.0,1208.0,1059.0,829.0,520.0,520.0,615.0,553.0,638.0,573.0,666.0,761.0,789.0,908.0,,669.0,539.0,455.0,471.0,555.0,,,,53.0,,726
123,Cuvposa,glycopyrrolate,MEDEXUS Pharmaceuticals,N,N,N,N,N,Y,N,Y,N,01-Jan-17,30-Oct-17,302.0,CADTH & INESSS,31-May-19,post-NOC,Initial,"Chronic severe drooling, neurologic (pediatric)",Completed,24-Jun-20,Do not reimburse,Negative,10-May-19,post-NOC,New Drug,Sialorrhea,Completed,06-Nov-19,Inscription - Avec conditions,Conditional,1st,24-Oct-22,16-Jan-23,Negotiation,Completed with Agreements,NR,,,,,NR,,,SA,EM,,,,,,,,,2022-12-02,2023-02-01,02-Dec-22,2022-12-02,,,,,,,,,1.0,2.0,0.70%,29.30%,,,,,,,,,29.30%,,,578.0,557.0,390.0,180.0,852.0,1083.0,84.0,,,,,,,,,-45.0,16.0,-45.0,-45.0,-15.0,-45.0,,,,,,,,,,1859.0,1920.0,1859.0,1890.0,1859.0,1281.0,891.0,,,,,,,,,891.0,1183.0,891.0,968.0,737.0,936.0,1167.0,,,,,,1270
125,Cyramza,ramucirumab,Eli Lilly,N,Y,N,Y,Y,Y,Y,Y,N,,16-Jul-15,,CADTH & INESSS,15-Apr-15,pre-NOC,New drug,Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma,Completed,15-Oct-15,Cond'l on Cost,Conditional,04-Aug-15,post-NOC,New Drug,Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma,Completed,01-Feb-16,En monothérapie : Avis de refus dinscription à la Liste Établissements  Médicament dexception -Valeur thérapeutique En association avec le paclitaxel : Avis de refus dinscription à la Liste Établissements  Médicament dexception - À moins que certaines conditions soient respectées,Conditional,1st,12-Nov-15,27-Oct-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-05-01,2017-04-03,2016-12-21,2016-12-12,2017-02-28,2017-08-24,2017-05-30,,2017-08-03,2016-12-16,12-Dec-16,2016-12-12,6.0,5.0,3.0,1.0,4.0,9.0,7.0,,8.0,2.0,5.50%,34.10%,39.80%,72.10%,76.50%,96.80%,98.10%,98.80%,99.60%,,99.60%,28-Feb-17,01-May-17,-92.0,19.0,183.0,181.0,28.0,-81.0,350.0,186.0,158.0,55.0,46.0,124.0,301.0,215.0,,280.0,50.0,171.0,46.0,157.0,46.0,186.0,655.0,627.0,524.0,515.0,593.0,770.0,684.0,,749.0,519.0,640.0,626.0,515.0,607.0,424.0,564.0,536.0,433.0,424.0,502.0,679.0,593.0,,658.0,319.0,549.0,91.0,200.0,378.0,269.0,655.0,140.0,140.0,78.0,62.0,42292
126,Cystadrops,cysteamine,Recordati Rare Diseases Canada Inc.,N,N,N,N,N,N,N,N,N,01-Feb-18,11-Feb-19,375.0,CADTH & INESSS,10-Dec-18,pre-NOC,Initial,Corneal cystine crystal deposits,Completed,18-Jun-19,Reimburse with clinical criteria and/or conditions,Conditional,12-Jul-19,post-NOC,New Drug,Cystine corneal deposits,Completed,08-Apr-20,Refus d'inscription,Negative,1st,26-Jun-19,22-Aug-19,Negotiation,Completed with Agreements,SA,SA,UR,EDS,UR,SA,EDS,UR,SA,EM,2022-02-28,2019-12-01,,2020-03-02,,2020-02-26,2021-01-01,,2021-04-15,2020-07-08,01-Dec-19,2019-12-01,7.0,1.0,,3.0,,2.0,5.0,,6.0,4.0,4.50%,5.30%,10.90%,39.50%,40.80%,41.40%,61.70%,,,,61.70%,28-Feb-22,,-63.0,151.0,190.0,271.0,8.0,-287.0,57.0,921.0,101.0,,193.0,,188.0,498.0,,602.0,321.0,417.0,101.0,403.0,101.0,,1113.0,293.0,,385.0,,380.0,690.0,,794.0,513.0,609.0,595.0,293.0,356.0,166.0,986.0,166.0,,258.0,,253.0,563.0,,667.0,91.0,482.0,127.0,422.0,65.0,-230.0,,,,820.0,,502
127,Daklinza (Drug Plan Submission),daclatasvir,Bristol-Myers Squibb ,Y,N,N,Y,N,N,N,N,N,,13-Aug-15,,CADTH & INESSS,06-Jan-16,post-NOC,Request for Advice,"Hepatitis C, chronic",Completed,19-May-16,Reimburse with clinical criteria and/or conditions,Conditional,04-Aug-15,pre-NOC,New Drug,Hepatitis C,Completed,01-Feb-16,Avis d'inscription aux listes des médicaments-Médicament d'exception,Conditional,2nd,22-Jul-16,17-Feb-17,Negotiation,Completed with Agreements,DL,SA,EDS,EDS,DL,SA,EDS,NR,SA,EM,2017-03-21,2017-04-01,2017-04-01,2017-04-20,2017-02-28,2017-03-29,2017-05-01,,2017-09-01,2017-03-15,28-Feb-17,2017-02-28,3.0,5.0,6.0,7.0,1.0,4.0,8.0,,9.0,2.0,32.20%,60.80%,81.10%,82.00%,86.40%,92.10%,97.70%,99.00%,99.60%,,99.60%,15-Mar-17,21-Mar-17,146.0,-9.0,134.0,181.0,64.0,172.0,210.0,32.0,43.0,43.0,62.0,11.0,40.0,73.0,,196.0,26.0,63.0,11.0,58.0,11.0,32.0,586.0,597.0,597.0,616.0,565.0,594.0,627.0,,750.0,580.0,617.0,612.0,565.0,419.0,285.0,306.0,317.0,317.0,336.0,285.0,314.0,347.0,,470.0,408.0,337.0,280.0,172.0,274.0,382.0,586.0,21.0,21.0,15.0,6.0,42509
128,Daklinza,daclatasvir,Bristol-Myers Squibb ,Y,N,N,Y,N,N,N,N,N,,13-Aug-15,,CADTH & INESSS,13-Feb-15,pre-NOC,Initial,"Hepatitis C, chronic",Completed,21-Sep-15,List with clinical criteria and/or conditions,Conditional,04-Aug-15,pre-NOC,New Drug,Hepatitis C,Completed,01-Feb-16,Avis d'inscription aux listes des médicaments-Médicament d'exception,Conditional,1st,,17-Mar-16,Negotiation,No agreement reached,DL,SA,EDS,EDS,DL,SA,EDS,NR,SA,EM,2017-03-21,2017-04-01,2017-04-01,2017-04-20,2017-02-28,2017-03-29,2017-05-01,,2017-09-01,2017-03-15,28-Feb-17,2017-02-28,3.0,5.0,6.0,7.0,1.0,4.0,8.0,,9.0,2.0,32.20%,60.80%,81.10%,82.00%,86.40%,92.10%,97.70%,99.00%,99.60%,,99.60%,15-Mar-17,21-Mar-17,-181.0,-9.0,220.0,181.0,,,,369.0,380.0,380.0,399.0,348.0,377.0,410.0,,533.0,363.0,400.0,348.0,395.0,348.0,369.0,586.0,597.0,597.0,616.0,565.0,594.0,627.0,,750.0,580.0,617.0,612.0,565.0,746.0,526.0,547.0,558.0,558.0,577.0,526.0,555.0,588.0,,711.0,408.0,578.0,39.0,172.0,178.0,45.0,586.0,21.0,21.0,15.0,6.0,42268
130,Darzalex,daratumumab,Janssen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Oct-16,13-Apr-17,194.0,CADTH & INESSS,03-Mar-17,pre-NOC,New indication,"Multiple Myeloma (second-line or beyond):In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy",Completed,05-Oct-17,Cond'l on Cost,Conditional,,,New Indication,"Multiple Myeloma (second-line or beyond):In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy",Completed,01-Feb-18,,,1st,09-Mar-18,14-Nov-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2019-02-01,2019-01-29,2019-07-15,2019-01-08,2019-03-15,2019-04-26,2019-05-01,2022-07-01,2019-08-16,2018-12-13,08-Jan-19,2018-12-13,4.0,3.0,8.0,2.0,5.0,6.0,7.0,10.0,9.0,1.0,28.60%,34.10%,38.60%,58.80%,91.10%,91.90%,93.30%,99.00%,99.60%,100.00%,100.00%,01-Feb-19,15-Mar-19,-41.0,,216.0,,155.0,36.0,250.0,79.0,76.0,243.0,55.0,121.0,163.0,168.0,1325.0,275.0,29.0,278.0,55.0,253.0,29.0,121.0,659.0,656.0,823.0,635.0,701.0,743.0,748.0,1905.0,855.0,609.0,858.0,833.0,635.0,676.0,460.0,484.0,481.0,648.0,460.0,526.0,568.0,573.0,1730.0,680.0,315.0,683.0,175.0,294.0,405.0,286.0,701.0,92.0,66.0,50.0,42.0,369
131,Darzalex,daratumumab,Janssen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Jan-18,27-Nov-18,330.0,CADTH & INESSS,04-Jan-19,post-NOC,New indication,Multiple Myeloma (newly diagnosed),Completed,29-Aug-19,Cond'l on Cost,Conditional,01-Feb-19,post-NOC,New Indication,"In combination with bortezomib, melphalan and prednisone, for the treatment of patients with newly diagnosed multiple myeloma who are not suitable for autologous stem cell transplant",Completed,07-Aug-19,Refus d'inscription,Negative,1st,29-Nov-19,25-Feb-22,Negotiation,Completed with Agreements,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,NR,2022-06-01,2022-09-30,,2022-05-26,2022-09-30,,,2022-07-01,,,26-May-22,2022-05-26,2.0,4.0,,1.0,5.0,,,3.0,,,5.50%,25.80%,26.10%,30.60%,62.80%,,,,,,62.80%,30-Sep-22,,38.0,66.0,237.0,187.0,92.0,114.0,819.0,96.0,217.0,,90.0,217.0,,,126.0,,,149.0,90.0,149.0,90.0,,1282.0,1403.0,,1276.0,1403.0,,,1312.0,,,1335.0,1335.0,1276.0,1238.0,1001.0,1007.0,1128.0,,1001.0,1128.0,,,1037.0,,,1060.0,275.0,253.0,911.0,933.0,,,,127.0,,605
132,Darzalex,daratumumab,Janssen ,Y,Y,N,N,Y,Y,Y,Y,Y,01-May-19,25-Oct-19,177.0,CADTH & INESSS,17-Jul-19,pre-NOC,New indication,In combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant,Completed,05-Mar-20,Cond'l on Cost,Conditional,09-Aug-19,pre-NOC,New Indication,In combination with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant,Completed,04-Mar-20,Refus d'inscription,Negative,1st,26-Feb-21,25-Feb-22,Negotiation,Completed with Agreements,Funded,Funded,,,Funded,Funded,Under provincial consideration,Funded,Under provincial consideration,EM,2022-06-01,2022-09-30,,,2021-08-31,,,,,2022-04-13,31-Aug-21,2021-08-31,3.0,4.0,,,1.0,,,,,2.0,32.20%,60.80%,81.10%,85.50%,,,,,,,85.50%,13-Apr-22,01-Jun-22,-100.0,-77.0,232.0,208.0,358.0,359.0,364.0,96.0,217.0,,,-178.0,,,,,47.0,45.0,-178.0,46.0,-178.0,96.0,950.0,1071.0,,,676.0,,,,,901.0,899.0,900.0,676.0,776.0,544.0,818.0,939.0,,,544.0,,,,,770.0,767.0,132.0,131.0,722.0,723.0,950.0,274.0,274.0,225.0,49.0,309
133,Darzalex SC,daratumumab,Janssen ,Y,Y,N,N,Y,Y,Y,Y,N,01-Nov-20,12-Apr-21,162.0,CADTH & INESSS,15-Jul-21,post-NOC,Initial,"Darzalex SC in combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis",Completed,28-Jan-22,Cond'l on Cost,Conditional,06-Aug-21,post-NOC,New Indication,"Darzalex SC in combination with bortezomib, cyclophosphamide, and dexamethasone, for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis",Completed,02-Mar-22,Inscription - Avec conditions,Conditional,1st,04-Mar-22,11-Mar-22,Negotiation,Completed with Agreements,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2022-09-01,2022-09-30,,2022-10-19,2022-08-31,,,2022-07-01,,2022-04-13,01-Jul-22,2022-04-13,4.0,5.0,,6.0,3.0,,,2.0,,1.0,28.60%,28.90%,61.20%,81.40%,85.90%,91.40%,,,,,91.40%,31-Aug-22,01-Sep-22,94.0,116.0,197.0,208.0,35.0,2.0,7.0,174.0,203.0,,222.0,173.0,,,112.0,,33.0,177.0,112.0,153.0,33.0,174.0,507.0,536.0,,555.0,506.0,,,445.0,,366.0,510.0,486.0,445.0,351.0,154.0,216.0,245.0,,264.0,215.0,,,154.0,,42.0,219.0,291.0,324.0,42.0,9.0,507.0,141.0,62.0,140.0,1.0,453
136,Delstrigo,doravirine lamuvidine tenofovir disoproxil fumarate,Merck,Y,N,N,N,N,N,N,N,N,01-Jan-18,09-Nov-18,312.0,CADTH & INESSS,16-Nov-18,post-NOC,Initial,HIV-1,Completed,14-May-19,Reimburse with clinical criteria and/or conditions,Conditional,16-Nov-18,post-NOC,New Drug,HIV,Completed,08-May-19,Inscription,Positive,1st,14-Jun-19,15-Oct-19,Negotiation,Completed with Agreements,HIV,UR,UR,EDS,FB,SA,HIV,HIV,SA,FB,,,,2020-03-02,2019-10-31,2020-05-21,2021-03-01,2021-05-31,2020-09-11,2019-11-14,31-Oct-19,2019-10-31,,,,3.0,1.0,4.0,6.0,7.0,5.0,2.0,32.20%,60.80%,66.30%,67.20%,67.90%,69.20%,69.60%,,,,69.60%,14-Nov-19,,7.0,7.0,179.0,173.0,31.0,37.0,123.0,,,,139.0,16.0,219.0,503.0,594.0,332.0,30.0,301.0,16.0,262.0,16.0,,,,,479.0,356.0,559.0,843.0,934.0,672.0,370.0,641.0,602.0,356.0,349.0,170.0,,,,293.0,170.0,373.0,657.0,748.0,486.0,190.0,455.0,186.0,180.0,154.0,160.0,,,,14.0,,498
138,Diacomit,stiripentol,Biocodex,N,N,N,Y,N,Y,N,Y,N,,21-Dec-12,,CADTH & INESSS,30-Oct-13,post-NOC,Initial,"severe myoclonic epilepsy in infancy (as per PCPA), Dravet syndrome (as per CADTH)",Completed,16-Oct-14,List with criteria/condition,Conditional,,,New Drug,Dravet syndrome,Completed,02-Jun-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,30-Nov-14,11-May-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2015-07-07,2015-10-01,2015-07-01,2015-07-22,2015-06-22,2015-11-24,2016-05-01,2018-08-01,2015-10-01,2014-06-02,22-Jun-15,2014-06-02,4.0,6.0,3.0,5.0,2.0,8.0,9.0,10.0,7.0,1.0,28.60%,60.80%,66.50%,86.80%,92.30%,96.80%,97.40%,98.30%,99.60%,100.00%,100.00%,22-Jun-15,07-Jul-15,313.0,,351.0,,45.0,181.0,162.0,57.0,143.0,51.0,72.0,42.0,197.0,356.0,1178.0,143.0,-343.0,249.0,42.0,190.0,-343.0,57.0,928.0,1014.0,922.0,943.0,913.0,1068.0,1227.0,2049.0,1014.0,528.0,1120.0,1061.0,913.0,600.0,249.0,264.0,350.0,258.0,279.0,249.0,404.0,563.0,1385.0,350.0,0.0,456.0,664.0,528.0,207.0,343.0,928.0,400.0,15.0,385.0,15.0,41928
139,Dificid,fidaxomicin,"Optimer Pharmaceuticals Canada, Inc. ",N,N,N,Y,N,N,N,N,N,,07-Jun-12,,CADTH & INESSS,10-Jul-12,post-NOC,Initial,Clostridium difficile infection ,Completed,19-Dec-12,Do not list at the submitted price ,Negative,,,New Drug,Clostridium difficile infection ,Completed,01-Feb-13,Avis de refus,Negative,1st,,13-Nov-13,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2014-02-25,2016-03-01,2015-01-01,2014-07-17,2013-12-16,2014-09-11,2017-05-01,2015-11-23,2015-10-01,2014-06-02,16-Dec-13,2013-12-16,2.0,9.0,6.0,4.0,1.0,5.0,10.0,8.0,7.0,3.0,32.20%,52.50%,81.10%,86.60%,87.50%,93.20%,93.90%,94.20%,98.70%,100.00%,100.00%,25-Feb-14,02-Jun-14,33.0,,162.0,,,,,104.0,839.0,414.0,246.0,33.0,302.0,1265.0,740.0,687.0,201.0,514.0,33.0,483.0,33.0,201.0,628.0,1363.0,938.0,770.0,557.0,826.0,1789.0,1264.0,1211.0,725.0,1038.0,1007.0,557.0,524.0,362.0,433.0,1168.0,743.0,575.0,362.0,631.0,1594.0,1069.0,1016.0,486.0,843.0,195.0,239.0,329.0,285.0,725.0,168.0,168.0,71.0,97.0,41262
142,Dovato,dolutegravir/lamivudine,ViiV Healthcare,N,N,N,N,N,N,N,N,Y,01-Oct-18,22-Aug-19,325.0,CADTH & INESSS,21-Feb-19,pre-NOC,Initial,HIV-1 infection,Completed,30-Sep-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Mar-19,pre-NOC,New drug,HIV Infection,Completed,16-Oct-19,Inscription - Avec conditions,Conditional,1st,04-Oct-19,21-Nov-19,Negotiation,Completed with Agreements,HIV,UR,EDS,EDS,FB,SA,HIV,FB,SA,EM,,,2020-03-01,2020-03-02,2020-01-31,2020-03-19,2020-12-14,2020-12-28,2020-12-16,2019-12-18,31-Jan-20,2019-12-18,,,3.0,4.0,2.0,5.0,6.0,8.0,7.0,1.0,28.60%,60.80%,66.50%,72.10%,73.00%,74.30%,74.90%,75.30%,,,75.30%,31-Jan-20,,-182.0,-174.0,221.0,229.0,4.0,-12.0,48.0,,,101.0,102.0,71.0,119.0,389.0,403.0,391.0,27.0,225.0,71.0,200.0,27.0,,,,192.0,193.0,162.0,210.0,480.0,494.0,482.0,118.0,316.0,291.0,162.0,344.0,123.0,,,153.0,154.0,123.0,171.0,441.0,455.0,443.0,63.0,277.0,39.0,55.0,52.0,36.0,,,,44.0,,364
143,Duaklir Genuair,aclidinium bromide/formoterol fumarate dihydrate,AstraZeneca ,Y,N,N,N,N,N,N,N,N,,02-Apr-15,,CADTH & INESSS,01-Apr-15,pre-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,18-Sep-15,List with clinical criteria and/or conditions,Conditional,04-Aug-15,post-NOC,New Indication,Chronic Obstructive Pulmonary Disease (COPD),Completed,01-Feb-16,Avis de refus d'inscription aux listes de médicaments - Valeur thérapeutique,Negative,1st,23-Oct-15,15-Dec-15,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,NR,2016-04-05,2016-02-01,2016-05-01,2016-04-18,2016-02-25,2015-12-21,2016-03-01,2016-03-28,2016-05-01,,21-Dec-15,2015-12-21,6.0,2.0,8.0,7.0,3.0,1.0,4.0,5.0,9.0,,0.90%,5.30%,37.60%,38.90%,39.20%,59.50%,65.00%,70.70%,71.40%,,71.40%,05-Apr-16,,-1.0,124.0,170.0,181.0,35.0,-101.0,53.0,112.0,48.0,138.0,125.0,72.0,6.0,77.0,104.0,138.0,,91.0,6.0,91.0,6.0,,369.0,305.0,395.0,382.0,329.0,263.0,334.0,361.0,395.0,,348.0,348.0,263.0,264.0,94.0,200.0,136.0,226.0,213.0,160.0,94.0,165.0,192.0,226.0,,179.0,169.0,305.0,88.0,-48.0,,,,106.0,,42265
145,Duobrii,Halobetasol propionate and tazarotene,Bausch Health (Valeant) ,N,N,N,N,N,N,N,N,Y,01-May-18,10-Jun-20,771.0,CADTH & INESSS,24-Jan-20,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,28-Oct-20,Reimburse with clinical criteria and/or conditions,Conditional,13-Mar-20,pre-NOC,New drug,Plaque psoriasis,Completed,09-Sep-20,Refus dinscription,Negative,1st,17-Sep-21,30-Nov-21,Negotiation,Completed with Agreements,NR,SA,FB,FB,FB,FB,EDS,SA,SA,NR,,2022-02-01,2022-03-01,2022-02-24,2021-01-31,2022-02-17,2022-05-16,2022-12-28,2022-07-07,,31-Jan-21,2021-01-31,,2.0,5.0,4.0,1.0,3.0,6.0,8.0,7.0,,32.20%,36.70%,37.60%,43.10%,48.80%,50.10%,50.80%,51.20%,,,51.20%,16-May-22,,-138.0,-89.0,278.0,180.0,324.0,373.0,74.0,,63.0,91.0,86.0,-303.0,79.0,167.0,393.0,219.0,,99.0,-303.0,99.0,-303.0,,,601.0,629.0,624.0,235.0,617.0,705.0,931.0,757.0,,637.0,637.0,235.0,373.0,95.0,,461.0,489.0,484.0,95.0,477.0,565.0,791.0,617.0,,497.0,140.0,91.0,398.0,447.0,,,,470.0,,911
146,Dupixent,dupilumab,Sanofi Genzyme,Y,Y,N,Y,N,N,N,N,N,01-Feb-17,30-Nov-17,302.0,CADTH & INESSS,27-Oct-17,pre-NOC,Initial,atopic dermatitis,Completed,27-Jun-18,Do not reimburse,Negative,,,New Drug,Atopic dermatitis,Completed,09-May-18,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,22-Nov-18,17-Sep-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,,,,,,EM,,2022-07-01,2021-06-01,2021-08-05,,,,,,2019-10-02,01-Jun-21,2019-10-02,,4.0,2.0,3.0,,,,,,1.0,28.60%,34.30%,39.80%,44.30%,,,,,,,44.30%,,,-34.0,,243.0,,148.0,197.0,299.0,,1018.0,623.0,688.0,,,,,,15.0,776.0,623.0,586.0,15.0,,,1674.0,1279.0,1344.0,,,,,,671.0,1432.0,1242.0,1279.0,1313.0,1070.0,,1465.0,1070.0,1135.0,,,,,,511.0,1223.0,209.0,160.0,447.0,496.0,,,,,,511
150,Dupixent (12+),dupilumab,Sanofi Genzyme,Y,Y,N,N,N,N,N,N,N,01-Nov-18,25-Sep-19,328.0,CADTH & INESSS,22-Oct-19,post-NOC,Initial,atopic dermatitis,Completed,22-Apr-20,Reimburse with clinical criteria and/or conditions,Conditional,22-Nov-19,post-NOC,New Indication,"Atopic dermatitis, adolescents",Completed,08-Jul-20,Inscription - Avec conditions,Conditional,1st,28-Jul-20,25-Feb-21,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,2022-07-01,2021-06-01,2021-08-05,2021-05-06,2021-05-13,2021-11-30,2021-11-22,2022-01-17,2021-05-27,06-May-21,2021-05-06,,9.0,4.0,5.0,1.0,2.0,7.0,6.0,8.0,3.0,32.20%,33.10%,61.70%,67.40%,73.00%,73.30%,74.60%,75.30%,79.70%,,79.70%,27-May-21,,27.0,58.0,183.0,229.0,97.0,20.0,212.0,,491.0,96.0,161.0,70.0,77.0,278.0,270.0,326.0,91.0,221.0,70.0,207.0,70.0,,,1010.0,615.0,680.0,589.0,596.0,797.0,789.0,845.0,610.0,740.0,726.0,589.0,562.0,379.0,,800.0,405.0,470.0,379.0,386.0,587.0,579.0,635.0,323.0,530.0,210.0,287.0,309.0,232.0,,,,21.0,,538
152,Dysport Therapeutic,abobotulinumtoxinA,Ipsen Biopharmaceuticals ,N,Y,N,N,N,N,N,N,N,,03-Jan-17,,CADTH & INESSS,24-Apr-17,post-NOC,Initial,Upper limb spasticity,Completed,24-Oct-17,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Treatment of upper limb spasticity,Completed,01-Feb-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,04-May-18,17-Jul-18,Negotiation,Completed with Agreements,SA,FB,EDS,EDS,LU,SA,EDS,UR,UR,EM,2019-02-26,2018-12-01,2018-10-01,2018-10-18,2018-09-27,2018-08-23,2019-08-01,,,2019-04-11,23-Aug-18,2018-08-23,6.0,5.0,3.0,4.0,2.0,1.0,8.0,,,7.0,0.90%,33.10%,38.80%,44.40%,48.80%,69.10%,97.70%,99.00%,,,99.00%,26-Feb-19,11-Apr-19,111.0,,183.0,,192.0,92.0,74.0,224.0,137.0,76.0,93.0,72.0,37.0,380.0,,,268.0,146.0,37.0,161.0,37.0,268.0,784.0,697.0,636.0,653.0,632.0,597.0,940.0,,,828.0,706.0,721.0,597.0,486.0,303.0,490.0,403.0,342.0,359.0,338.0,303.0,646.0,,,434.0,412.0,294.0,394.0,266.0,166.0,828.0,231.0,231.0,187.0,44.0,43032
153,Dysport Therapeutic (cervical),abobotulinumtoxinA,Ipsen Biopharmaceuticals ,N,Y,N,N,N,N,N,N,N,,15-Jun-16,,CADTH & INESSS,31-Jan-17,post-NOC,Initial,Cervical dystonia,Completed,26-Jul-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Treatment of Cervical Dystonia,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,04-May-18,17-Jul-18,Negotiation,Completed with Agreements,SA,FB,EDS,EDS,LU,SA,EDS,UR,UR,EM,2019-02-26,2018-12-01,2018-10-01,2018-10-18,2018-09-27,2018-08-23,2019-08-01,,,2019-04-11,23-Aug-18,2018-08-23,6.0,5.0,3.0,4.0,2.0,1.0,8.0,,,7.0,0.90%,33.10%,38.80%,44.40%,48.80%,69.10%,97.70%,99.00%,,,99.00%,26-Feb-19,11-Apr-19,230.0,282.0,176.0,208.0,282.0,198.0,74.0,224.0,137.0,76.0,93.0,72.0,37.0,380.0,,,268.0,146.0,37.0,161.0,37.0,268.0,986.0,899.0,838.0,855.0,834.0,799.0,1142.0,,,1030.0,908.0,923.0,799.0,569.0,393.0,580.0,493.0,432.0,449.0,428.0,393.0,736.0,,,540.0,502.0,406.0,490.0,356.0,272.0,1030.0,231.0,231.0,187.0,44.0,42942
154,Dysport Therapeutic (lower),abobotulinumtoxinA,Ipsen Biopharmaceuticals ,N,Y,N,N,N,N,N,N,N,,15-Jun-16,,CADTH & INESSS,07-Feb-18,post-NOC,Initial,lower limb spasticity,Completed,23-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,24-Sep-18,post-NOC,New Indication,Treatment of lower limb spasticity in infacts age 2 or older,Completed,13-Feb-19,Inscription  Avec conditions,Conditional,1st,30-Aug-18,30-Aug-18,Negotiation,Completed with Agreements,SA,FB,EDS,EDS,LU,SA,EDS,UR,UR,EM,2019-02-26,2018-12-01,2018-10-01,2019-01-24,2018-09-27,2018-12-17,2019-08-01,,,2019-04-11,27-Sep-18,2018-09-27,6.0,3.0,2.0,5.0,1.0,4.0,8.0,,,7.0,32.20%,38.00%,42.40%,43.30%,48.80%,69.10%,97.70%,99.00%,,,99.00%,26-Feb-19,11-Apr-19,602.0,831.0,197.0,142.0,7.0,-167.0,0.0,180.0,93.0,32.0,147.0,28.0,109.0,336.0,,,224.0,132.0,28.0,144.0,28.0,224.0,986.0,899.0,838.0,953.0,834.0,915.0,1142.0,,,1030.0,938.0,950.0,834.0,232.0,35.0,187.0,100.0,39.0,154.0,35.0,116.0,343.0,,,57.0,139.0,799.0,973.0,7.0,-167.0,1030.0,196.0,196.0,152.0,44.0,43335
159,Elelyso (2nd pCPA),taliglucerase alfa,Pfizer ,Y,Y,N,Y,N,Y,Y,Y,N,,29-May-14,,CADTH & INESSS,15-Aug-14,post-NOC,Initial,Gaucher disease ,Completed,28-Oct-15,Do not list,Negative,24-Nov-14,post-NOC,Resubmission,Gaucher disease ,Completed,15-Jul-15,Avis de refus dinscription  À moins que certaines conditions soient respectées,Conditional,1st,17-Nov-17,17-May-18,Negotiation,Completed with Agreements,UR,SA,UR,EDS,UR,SA,EDS,UR,UR,,,2019-09-01,,2018-10-18,,2019-03-27,2020-07-31,,,,18-Oct-18,2018-10-18,,3.0,,1.0,,2.0,4.0,,,,5.50%,6.40%,10.90%,12.20%,,,,,,,12.20%,,,78.0,179.0,439.0,233.0,751.0,856.0,181.0,,472.0,,154.0,,314.0,806.0,,,,437.0,154.0,437.0,154.0,,,1921.0,,1603.0,,1763.0,2255.0,,,,1886.0,1886.0,1603.0,1525.0,1086.0,,1404.0,,1086.0,,1246.0,1738.0,,,,1369.0,517.0,412.0,932.0,1037.0,,,,,,42305
161,Eliquis (Treat VTE&recurrence),apixaban ,Bristol-Myers Squibb & Pfizer ,Y,N,N,N,N,N,N,N,N,,01-Nov-14,,CADTH & INESSS,18-Sep-14,pre-NOC,Initial,venous thromboembolic events and prevent recurrent deep-vein thrombosis and pulmonary embolism,Completed,07-May-15,List with clinical criteria and/or conditions,Conditional,24-Nov-14,post-NOC,Resubmission,Treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and preventing recurrence,Completed,01-Jun-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,11-Jun-15,09-Jul-15,Negotiation,Completed with Agreements,FB,FB,EDS,EDS,LU,FB,EDS,SA,SA,EM,2016-04-05,2015-11-01,2015-10-01,2015-10-22,2015-09-30,2015-10-14,2016-12-01,2016-04-25,2015-09-01,2015-06-01,01-Sep-15,2015-06-01,8.0,7.0,4.0,6.0,3.0,5.0,10.0,9.0,2.0,1.0,28.60%,29.30%,61.50%,67.20%,68.10%,73.60%,78.10%,98.30%,98.70%,100.00%,100.00%,30-Sep-15,05-Apr-16,-44.0,23.0,231.0,189.0,35.0,10.0,28.0,271.0,115.0,84.0,105.0,83.0,97.0,511.0,291.0,54.0,-38.0,179.0,54.0,157.0,-38.0,271.0,521.0,365.0,334.0,355.0,333.0,347.0,761.0,541.0,304.0,212.0,429.0,407.0,304.0,348.0,117.0,334.0,178.0,147.0,168.0,146.0,160.0,574.0,354.0,117.0,0.0,242.0,187.0,212.0,63.0,38.0,521.0,309.0,217.0,121.0,188.0,42131
162,Emgality,galcanezumab,Eli Lilly Canada Inc. (Lilly),Y,Y,N,Y,N,N,N,N,N,01-Oct-18,30-Jul-19,302.0,CADTH & INESSS,03-Jun-21,post-NOC,Initial,Prevention of migraine,Completed,15-Dec-21,Reimburse with clinical criteria and/or conditions,Conditional,24-Sep-21,post-NOC,New Drug,Prevention of migraine,Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,29-Mar-22,22-Nov-22,Negotiation,Completed with Agreements,,SA,EDS,EDS,EAP,,,,SA,EM,,2023-02-01,2023-02-01,2023-04-01,2022-12-01,,,,2023-03-07,2023-02-01,01-Dec-22,2022-12-01,,2.0,3.0,6.0,1.0,,,,5.0,4.0,32.20%,36.70%,42.40%,71.00%,71.70%,77.20%,,,,,77.20%,01-Feb-23,,674.0,787.0,195.0,187.0,104.0,-1.0,238.0,,71.0,71.0,130.0,9.0,,,,105.0,71.0,77.0,9.0,76.0,9.0,,,1282.0,1282.0,1341.0,1220.0,,,,1316.0,1282.0,1288.0,1287.0,1220.0,546.0,351.0,,413.0,413.0,472.0,351.0,,,,447.0,308.0,419.0,869.0,974.0,342.0,237.0,,,,62.0,,1171
164,Enerzair Breezhaler,indacaterol glycopyrronium mometasone furoate,Novartis Pharmaceuticals Canada Inc.,Y,N,N,N,N,N,N,N,N,01-Sep-19,02-Jul-20,305.0,CADTH & INESSS,19-May-20,pre-NOC,Initial,"Asthma maintenance, adults",Completed,24-Nov-20,Reimburse with clinical criteria and/or conditions,Conditional,26-Jun-20,pre-NOC,New Drug,Asthma,Completed,02-Dec-20,Inscription - Avec conditions,Conditional,1st,23-Jun-21,30-Sep-21,Negotiation,Completed with Agreements,SA,SA,,EDS,LU,SA,EDS,SA,SA,EM,2022-06-14,2021-11-01,,2022-02-24,2022-02-28,2022-01-20,2021-11-30,2022-03-28,2022-05-11,2021-12-15,01-Nov-21,2021-11-01,9.0,1.0,,5.0,6.0,4.0,2.0,7.0,8.0,3.0,4.50%,5.80%,34.30%,35.20%,40.80%,73.00%,73.40%,74.00%,94.30%,,94.30%,28-Feb-22,14-Jun-22,-44.0,-6.0,189.0,159.0,211.0,203.0,99.0,257.0,32.0,,147.0,151.0,112.0,61.0,179.0,223.0,76.0,145.0,32.0,138.0,32.0,257.0,712.0,487.0,,602.0,606.0,567.0,516.0,634.0,678.0,531.0,600.0,593.0,487.0,531.0,342.0,567.0,342.0,,457.0,461.0,422.0,371.0,489.0,533.0,378.0,455.0,145.0,153.0,310.0,302.0,712.0,225.0,225.0,119.0,106.0,450
167,Enspryng,satralizumab,Hoffmann-La Roche Ltd.,Y,Y,N,Y,N,Y,Y,Y,N,01-Dec-19,01-Jun-20,183.0,CADTH & INESSS,22-Oct-20,post-NOC,Initial,Neuromyelitis optica spectrum disorder,Completed,21-Apr-21,Reimburse with clinical criteria and/or conditions,Conditional,13-Nov-20,post-NOC,New Drug,NOSD,Completed,07-May-21,Inscription - Avec conditions,Conditional,1st,30-Jun-21,28-Jun-22,Negotiation,Completed with Agreements,,,EDS,EDS,EAP,SA,EDS,,,EM,,,2022-11-01,2023-01-24,2023-02-03,2022-10-24,2023-02-01,,,2022-08-17,24-Oct-22,2022-08-17,,,3.0,4.0,6.0,2.0,5.0,,,1.0,28.60%,29.50%,35.20%,40.70%,42.00%,74.30%,,,,,74.30%,03-Feb-23,,143.0,165.0,181.0,175.0,70.0,54.0,363.0,,,126.0,210.0,220.0,118.0,218.0,,,50.0,178.0,118.0,157.0,50.0,,,,883.0,967.0,977.0,875.0,975.0,,,807.0,935.0,914.0,875.0,732.0,551.0,,,559.0,643.0,653.0,551.0,651.0,,,467.0,611.0,324.0,340.0,433.0,417.0,,,,170.0,,507
168,Entresto,sacubitril/valsartan,Novartis ,Y,N,N,Y,N,N,N,N,N,,02-Oct-15,,CADTH & INESSS,18-Sep-15,pre-NOC,Initial,"Heart failure, NYHA class II or III",Completed,18-Mar-16,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,"Heart failure, NYHA class II or III",Completed,01-Jun-16,Avis d'inscription aux listes des médicaments-Médicament d'exception-Avec conditions,Conditional,1st,30-Jun-16,06-Mar-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2018-03-06,2017-09-01,2017-04-01,2017-07-19,2017-04-27,2017-09-22,2019-04-01,2019-08-01,2018-06-01,2017-03-15,01-Apr-17,2017-03-15,7.0,5.0,2.0,4.0,3.0,6.0,9.0,10.0,8.0,1.0,28.60%,34.30%,66.50%,72.10%,76.50%,77.40%,97.70%,98.30%,99.60%,100.00%,100.00%,27-Apr-17,06-Mar-18,-14.0,53.0,182.0,190.0,104.0,29.0,249.0,365.0,179.0,26.0,135.0,52.0,200.0,756.0,878.0,452.0,9.0,338.0,26.0,305.0,9.0,365.0,886.0,700.0,547.0,656.0,573.0,721.0,1277.0,1399.0,973.0,530.0,859.0,826.0,547.0,561.0,379.0,718.0,532.0,379.0,488.0,405.0,553.0,1109.0,1231.0,805.0,287.0,691.0,168.0,243.0,353.0,278.0,886.0,356.0,339.0,43.0,313.0,42447
169,Entresto,sacubitril/valsartan,Novartis Pharma Inc.,Y,N,N,Y,N,N,N,N,N,,02-Oct-15,,CADTH & INESSS,22-May-20,post-NOC,Initial,"Heart failure, NYHA class II or III (without prior exposure to ACE or ARB)",Completed,24-Mar-21,Reimburse with clinical criteria and/or conditions,Conditional,03-Jul-20,post-NOC,New Indication,Cardiac insuficiency,Completed,02-Dec-20,Modification dune indication reconnue  Avec conditions,Conditional,1st,17-Aug-22,17-Aug-22,Negotiation,Completed with Agreements,,,,,,,,,,EM,,,,,,,,,,2022-09-28,,2022-09-28,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,1694.0,1736.0,306.0,152.0,511.0,623.0,0.0,,,,,,,,,,42.0,,,42.0,42.0,,,,,,,,,,,2553.0,,2553.0,,,,,,,,,,,,,665.0,,2000.0,1888.0,511.0,623.0,,,,,,44279
170,Entuzity KwikPen,human insulin,Eli Lilly Canada Inc.,Y,Y,N,N,N,N,N,N,N,01-Sep-16,27-Jul-17,329.0,CADTH & INESSS,27-Jan-21,post-NOC,Initial,To improve glycemic control in adults and children with diabetes mellitus requiring more than 200 units of insulin per day,Completed,23-Aug-21,Reimburse with clinical criteria and/or conditions,Conditional,13-Nov-18,post-NOC,New Drug,Diabetes,Completed,10-Apr-19,Inscription,Positive,1st,18-Nov-21,07-Feb-22,Negotiation,Completed with Agreements,FB,SA,FB,FB,FB,FB,EDS,SA,SA,FB,2022-05-31,2022-04-01,2022-04-01,2022-06-01,2022-04-29,2022-04-29,2022-06-27,2023-02-20,2022-07-07,2022-03-02,01-Apr-22,2022-03-02,6.0,2.0,3.0,7.0,4.0,5.0,8.0,10.0,9.0,1.0,28.60%,33.00%,38.80%,71.00%,71.90%,92.10%,97.70%,99.00%,99.60%,100.00%,100.00%,29-Apr-22,31-May-22,1280.0,474.0,208.0,148.0,87.0,953.0,81.0,113.0,53.0,53.0,114.0,81.0,81.0,140.0,378.0,150.0,23.0,129.0,53.0,119.0,23.0,113.0,1769.0,1709.0,1709.0,1770.0,1737.0,1737.0,1796.0,2034.0,1806.0,1679.0,1785.0,1775.0,1709.0,429.0,221.0,281.0,221.0,221.0,282.0,249.0,249.0,308.0,546.0,318.0,1057.0,297.0,1488.0,622.0,168.0,1034.0,1769.0,90.0,60.0,58.0,32.0,1817
171,Entyvio,vedolizumab,Takeda Canada Inc.,Y,Y,N,N,N,N,N,N,N,,19-Nov-20,,CADTH & INESSS,23-Jul-20,pre-NOC,Initial,Crohn's Disease,Completed,21-Jan-21,Reimburse with clinical criteria and/or conditions,Conditional,24-Jan-21,post-NOC,New Drug,Crohn's Disease,Completed,02-Jun-21,Inscription - Avec conditions,Conditional,1st,15-Apr-21,13-Aug-21,Negotiation,Completed with Agreements,SA,SA,,EDS,EAP,SA,EDS,SA,SA,EM,2022-04-12,2022-03-01,,2021-11-25,2022-01-11,2021-10-14,2022-04-29,2021-11-22,2022-02-21,2021-12-15,14-Oct-21,2021-10-14,8.0,7.0,,3.0,5.0,1.0,9.0,2.0,6.0,4.0,0.90%,1.20%,6.80%,35.40%,67.60%,68.30%,72.70%,93.00%,94.30%,,94.30%,11-Jan-22,12-Apr-22,-119.0,66.0,182.0,129.0,84.0,-48.0,120.0,242.0,200.0,,104.0,151.0,62.0,259.0,101.0,192.0,124.0,164.0,62.0,159.0,62.0,242.0,509.0,467.0,,371.0,418.0,329.0,526.0,368.0,459.0,391.0,431.0,426.0,329.0,448.0,266.0,446.0,404.0,,308.0,355.0,266.0,463.0,305.0,396.0,196.0,368.0,63.0,195.0,204.0,72.0,509.0,180.0,180.0,89.0,91.0,44217
172,Entyvio (CD),vedolizumab,Takeda Canada Inc.,Y,Y,N,N,N,N,N,N,N,,22-Mar-16,,CADTH & INESSS,27-Apr-16,post-NOC,Initial,Crohns disease,Completed,31-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Crohn's Disease,Completed,03-Oct-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,08-Nov-16,03-Mar-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2017-05-02,2017-07-01,2017-04-01,2017-07-19,2017-04-18,2017-05-29,2017-05-01,2017-08-07,2017-05-11,2017-04-21,01-Apr-17,2017-04-01,5.0,8.0,1.0,9.0,2.0,7.0,4.0,10.0,6.0,3.0,5.70%,38.00%,66.50%,67.80%,88.10%,88.80%,89.70%,94.10%,99.60%,100.00%,100.00%,21-Apr-17,02-May-17,36.0,,187.0,,8.0,36.0,115.0,60.0,120.0,29.0,138.0,46.0,87.0,59.0,157.0,69.0,49.0,85.0,29.0,81.0,29.0,60.0,406.0,466.0,375.0,484.0,392.0,433.0,405.0,503.0,415.0,395.0,431.0,427.0,375.0,339.0,152.0,183.0,243.0,152.0,261.0,169.0,210.0,182.0,280.0,192.0,200.0,208.0,223.0,195.0,123.0,151.0,406.0,31.0,31.0,20.0,11.0,42674
173,Entyvio (UC),vedolizumab,Takeda Canada Inc.,Y,Y,N,Y,N,N,N,N,N,,29-Jan-15,,CADTH & INESSS,20-Feb-15,post-NOC,Initial,Ulcerative Colitis,Completed,28-Oct-15,List with clinical criteria and/or conditions,Conditional,22-Mar-15,post-NOC,New Drug,Ulcerative Colitis,Completed,01-Oct-15,Avis d'inscription aux listes des médicaments-Médicament d'exception,Conditional,1st,26-May-16,03-Mar-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2017-05-02,2017-07-01,2017-04-01,2017-07-19,2017-04-18,2017-05-29,2017-05-01,2018-08-01,2017-05-11,2017-04-21,01-Apr-17,2017-04-01,5.0,8.0,1.0,9.0,2.0,7.0,4.0,10.0,6.0,3.0,5.70%,38.00%,66.50%,67.80%,88.10%,88.80%,89.70%,94.10%,99.60%,100.00%,100.00%,21-Apr-17,02-May-17,22.0,52.0,250.0,193.0,211.0,238.0,281.0,60.0,120.0,29.0,138.0,46.0,87.0,59.0,516.0,69.0,49.0,125.0,29.0,117.0,29.0,60.0,824.0,884.0,793.0,902.0,810.0,851.0,823.0,1280.0,833.0,813.0,889.0,881.0,793.0,771.0,521.0,552.0,612.0,521.0,630.0,538.0,579.0,551.0,1008.0,561.0,568.0,617.0,272.0,245.0,492.0,519.0,824.0,31.0,31.0,20.0,11.0,42305
174,Entyvio (UC),vedolizumab,Takeda Canada Inc.,Y,Y,N,Y,N,N,N,N,N,,29-Jan-15,,CADTH & INESSS,21-Nov-19,post-NOC,Initial,Ulcerative Colitis,Completed,19-May-20,Reimburse with clinical criteria and/or conditions,Conditional,22-May-20,post-NOC,New Indication,Ulcerative Colitis,Completed,09-Sep-20,Inscription - Avec conditions,Conditional,1st,19-Oct-20,13-Aug-21,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2022-04-12,2022-03-01,2021-12-01,2021-11-25,2022-01-11,2021-10-14,2022-04-29,2021-11-22,2022-02-21,2021-12-15,14-Oct-21,2021-10-14,9.0,8.0,4.0,3.0,6.0,1.0,10.0,2.0,7.0,5.0,0.90%,1.20%,6.80%,12.50%,41.10%,73.30%,74.00%,78.40%,98.70%,100.00%,100.00%,11-Jan-22,12-Apr-22,1757.0,1940.0,180.0,110.0,153.0,40.0,298.0,242.0,200.0,110.0,104.0,151.0,62.0,259.0,101.0,192.0,124.0,158.0,62.0,155.0,62.0,242.0,2630.0,2588.0,2498.0,2492.0,2539.0,2450.0,2647.0,2489.0,2580.0,2512.0,2546.0,2543.0,2450.0,693.0,513.0,693.0,651.0,561.0,555.0,602.0,513.0,710.0,552.0,643.0,462.0,609.0,1937.0,2050.0,451.0,338.0,2630.0,180.0,180.0,89.0,91.0,43970
175,Epclusa,sofosbuvir/ velpatasvir,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,01-Jan-16,11-Jul-16,192.0,CADTH & INESSS,22-Apr-16,pre-NOC,Initial,"Hepatitis C, chronic",Completed,26-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,chronic hepatitis C (CHC),Completed,01-Feb-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,26-Oct-16,17-Feb-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2017-03-21,2017-04-01,2017-04-01,2017-04-20,2017-02-28,2017-04-04,2017-05-01,2017-05-01,2017-08-01,2017-03-15,28-Feb-17,2017-02-28,3.0,4.0,5.0,7.0,1.0,6.0,8.0,9.0,10.0,2.0,32.20%,60.80%,81.10%,85.50%,91.20%,92.10%,97.70%,99.00%,99.30%,100.00%,100.00%,15-Mar-17,21-Mar-17,-80.0,32.0,187.0,173.0,0.0,-98.0,114.0,32.0,43.0,43.0,62.0,11.0,46.0,73.0,73.0,165.0,26.0,61.0,11.0,57.0,11.0,32.0,253.0,264.0,264.0,283.0,232.0,267.0,294.0,294.0,386.0,247.0,282.0,278.0,232.0,312.0,125.0,146.0,157.0,157.0,176.0,125.0,160.0,187.0,187.0,279.0,42.0,175.0,107.0,205.0,114.0,16.0,253.0,21.0,21.0,15.0,6.0,299
177,Erelzi,etanercept,Sandoz Canada Inc.,Y,Y,Y,N,N,N,N,N,N,01-Jun-16,06-Apr-17,309.0,CADTH & INESSS,02-Feb-17,pre-NOC,Initial,"Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis",Completed,25-Jul-17,Reimburse with clinical criteria and/or conditions,Conditional,11-Aug-17,post-NOC,New Drug,"Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis",Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,21-Apr-17,17-Oct-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2017-11-14,2018-03-01,2018-04-01,2018-04-19,2017-12-21,2018-01-22,2018-08-01,2017-11-24,2018-04-01,2018-02-01,14-Nov-17,2017-11-14,1.0,6.0,7.0,9.0,3.0,4.0,10.0,2.0,8.0,5.0,20.30%,20.60%,52.80%,53.70%,82.30%,86.80%,92.50%,93.20%,98.70%,100.00%,100.00%,21-Dec-17,01-Feb-18,-63.0,127.0,173.0,174.0,-95.0,-286.0,179.0,28.0,135.0,166.0,184.0,65.0,97.0,288.0,38.0,166.0,107.0,130.0,28.0,127.0,28.0,107.0,222.0,329.0,360.0,378.0,259.0,291.0,482.0,232.0,360.0,301.0,324.0,321.0,222.0,285.0,112.0,112.0,219.0,250.0,268.0,149.0,181.0,372.0,122.0,250.0,0.0,214.0,110.0,301.0,84.0,-107.0,301.0,79.0,79.0,37.0,42.0,419
178,Erivedge,vismodegib,Hoffman-La Roche ,Y,N,N,Y,Y,N,N,N,N,,12-Jul-13,,CADTH & INESSS,14-Jun-13,pre-NOC,New drug,Advanced Basal Cell Carcinoma,Completed,10-Jan-14,Cond'l on Cost,Conditional,24-Nov-15,post-NOC,New Drug,Carcinome basocellulaire,Completed,19-Aug-16,Avis de refus d'inscription aux listes des médicaments,Negative,1st,21-Jan-14,01-Apr-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2014-10-01,2014-06-20,2014-07-18,2014-07-01,2014-04-16,2014-06-25,2014-12-29,2020-08-18,2014-10-01,2018-05-24,16-Apr-14,2014-04-16,6.0,2.0,5.0,4.0,1.0,3.0,8.0,10.0,7.0,9.0,32.20%,36.70%,37.60%,43.10%,48.80%,69.10%,69.80%,71.10%,99.60%,100.00%,100.00%,01-Oct-14,24-May-18,-28.0,865.0,210.0,269.0,11.0,-941.0,70.0,183.0,80.0,108.0,91.0,15.0,85.0,272.0,2331.0,183.0,1514.0,372.0,15.0,486.0,15.0,1514.0,446.0,343.0,371.0,354.0,278.0,348.0,535.0,2594.0,446.0,1777.0,635.0,749.0,278.0,306.0,96.0,264.0,161.0,189.0,172.0,96.0,166.0,353.0,2412.0,264.0,643.0,453.0,182.0,1134.0,81.0,-871.0,1777.0,1499.0,1499.0,168.0,1331.0,41649
179,Erleada,apalutamide,Janssen ,Y,N,N,Y,Y,N,N,N,N,01-Jan-18,03-Jul-18,183.0,CADTH & INESSS,16-Apr-18,pre-NOC,New drug,Castrate Resistant Prostate Cancer,Completed,01-Nov-18,Cond'l on Cost,Conditional,,,New Drug,Castrate Resistant Prostate Cancer,Completed,17-Oct-18,Inscription  Avec conditions,Conditional,1st,14-Mar-19,09-Jul-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-05-01,2020-04-10,2020-01-01,2020-03-02,2020-01-14,2020-07-16,2020-07-01,2023-02-20,2022-03-31,2019-08-15,01-Jan-20,2019-08-15,6.0,5.0,2.0,4.0,3.0,8.0,7.0,10.0,9.0,1.0,28.60%,34.30%,66.50%,72.10%,76.50%,96.80%,98.10%,99.00%,99.60%,100.00%,100.00%,14-Jan-20,01-May-20,-78.0,,199.0,,133.0,148.0,117.0,297.0,276.0,176.0,237.0,189.0,373.0,358.0,1322.0,996.0,37.0,469.0,176.0,426.0,37.0,297.0,668.0,647.0,547.0,608.0,560.0,744.0,729.0,1693.0,1367.0,408.0,840.0,797.0,547.0,625.0,426.0,547.0,526.0,426.0,487.0,439.0,623.0,608.0,1572.0,1246.0,302.0,719.0,121.0,106.0,250.0,265.0,668.0,260.0,121.0,152.0,108.0,304
180,Erleada,apalutamide,Janssen,Y,N,N,N,Y,N,N,N,N,01-Jun-19,12-Dec-19,194.0,CADTH & INESSS,15-Oct-19,pre-NOC,New indication,Metastatic Castration-Sensitive Prostate Cancer,Completed,22-Apr-20,Cond'l on Cost,Conditional,25-Oct-19,pre-NOC,New Indication,Metastatic Castration-Sensitive Prostate Cancer,Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,09-Oct-20,17-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,EM,2021-12-01,2021-11-30,2021-11-01,2021-11-23,2021-12-31,2022-01-20,,2023-02-20,2022-03-31,2021-09-29,01-Nov-21,2021-09-29,5.0,4.0,2.0,3.0,6.0,7.0,,9.0,8.0,1.0,28.60%,34.30%,39.80%,44.30%,64.50%,96.80%,97.70%,98.30%,98.70%,,98.70%,01-Dec-21,31-Dec-21,-58.0,-48.0,190.0,229.0,170.0,121.0,312.0,106.0,105.0,76.0,98.0,136.0,156.0,,552.0,226.0,43.0,182.0,76.0,166.0,43.0,136.0,720.0,719.0,690.0,712.0,750.0,770.0,,1166.0,840.0,657.0,796.0,780.0,690.0,748.0,558.0,588.0,587.0,558.0,580.0,618.0,638.0,,1034.0,708.0,476.0,664.0,132.0,181.0,482.0,433.0,750.0,93.0,60.0,63.0,30.0,326
183,Esbriet (Resub),pirfenidone,Hoffmann-La Roche Ltd.,Y,N,N,Y,N,Y,Y,Y,N,,01-Oct-12,,CADTH & INESSS,29-Aug-14,post-NOC,Resubmission,"Pulmonary fibrosis (idiopathic, mild to moderate) ",Completed,15-Apr-15,List with criteria/condition,Conditional,,,New Drug,"Pulmonary fibrosis (idiopathic, mild to moderate) ",Completed,02-Feb-15,Avis de refus - Valeur thérapeutique,Negative,2nd,30-Apr-15,11-Sep-16,Negotiation,Completed with Agreements,SA,SA,,,,,,,,EM,2018-02-06,2016-11-01,,,,,,,,2018-04-18,01-Nov-16,2016-11-01,2.0,1.0,,,,,,,,3.0,4.50%,24.70%,53.30%,,,,,,,,53.30%,18-Apr-18,,697.0,,229.0,,15.0,87.0,500.0,513.0,51.0,,,,,,,,584.0,282.0,51.0,383.0,51.0,,1954.0,1492.0,,,,,,,,2025.0,1723.0,1824.0,1492.0,795.0,566.0,1028.0,566.0,,,,,,,,1171.0,797.0,926.0,854.0,515.0,587.0,,,,533.0,,42109
186,Evrysdi,risdiplam,Hoffmann-La Roche Ltd.,Y,N,N,Y,N,Y,Y,Y,N,01-Oct-20,14-Apr-21,195.0,CADTH & INESSS,19-Nov-20,pre-NOC,Initial,Spinal muscular atrophy (SMA),Completed,26-Aug-21,Reimburse with clinical criteria and/or conditions,Conditional,19-Feb-21,pre-NOC,New Drug,Spinal amyotrophy,Completed,28-Jul-21,Inscription - Avec conditions,Conditional,1st,27-Aug-21,19-Jan-22,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,EDS,SA,,EM,2022-02-10,2022-03-01,2022-03-01,2022-06-01,2022-03-28,2022-05-24,2022-10-01,2023-03-27,,2022-02-02,10-Feb-22,2022-02-02,2.0,3.0,4.0,7.0,5.0,6.0,8.0,9.0,,1.0,28.60%,48.80%,53.30%,59.00%,91.20%,92.10%,97.70%,99.00%,99.30%,,99.30%,01-Mar-22,28-Mar-22,-146.0,-54.0,280.0,159.0,1.0,30.0,145.0,22.0,41.0,41.0,133.0,68.0,125.0,255.0,432.0,,14.0,140.0,22.0,126.0,14.0,68.0,302.0,321.0,321.0,413.0,348.0,405.0,535.0,712.0,,294.0,420.0,406.0,302.0,448.0,168.0,168.0,187.0,187.0,279.0,214.0,271.0,401.0,578.0,,189.0,286.0,134.0,105.0,146.0,175.0,348.0,54.0,46.0,27.0,27.0,329
187,Eylea (Macular Edema BRVO),aflibercept,Bayer ,Y,Y,N,N,N,N,N,N,N,,10-Dec-15,,CADTH & INESSS,14-Dec-15,post-NOC,Initial,Macular edema secondary to branch retinal vein occlusion,Completed,27-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-14,pre-NOC,New Indication,Macular edema secondary to branch retinal vein occlusion,Completed,01-Feb-17,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,22-Feb-17,13-Mar-17,Negotiation,Completed with Agreements,BCRDT,RB,EDS,NR,LU,SA,NR,SA,SA,EM,,2017-08-01,2017-07-01,,2017-03-28,2017-10-24,,2018-08-01,2017-05-15,2017-06-01,28-Mar-17,2017-03-28,,5.0,4.0,,1.0,6.0,,7.0,2.0,3.0,32.20%,32.90%,61.50%,67.20%,71.70%,72.60%,72.90%,,,,72.90%,01-Jun-17,,4.0,-381.0,226.0,800.0,210.0,21.0,19.0,,141.0,110.0,,15.0,225.0,,506.0,63.0,80.0,177.0,15.0,163.0,15.0,,,600.0,569.0,,474.0,684.0,,965.0,522.0,539.0,636.0,622.0,474.0,470.0,244.0,,370.0,339.0,,244.0,454.0,,735.0,292.0,120.0,406.0,230.0,419.0,229.0,40.0,,,,65.0,,42578
188,Eylea (Macular Edema CRVO),aflibercept,Bayer ,Y,Y,N,N,N,N,N,N,N,,16-Oct-14,,CADTH & INESSS,17-Oct-14,post-NOC,Initial,Macular edema secondary to central retinal vein occlusion ,Completed,07-May-15,List with clinical criteria and/or conditions,Conditional,24-Nov-14,post-NOC,New Indication,Macular edema secondary to central retinal vein occlusion ,Completed,01-Jun-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,,30-Jun-15,Negotiation,Completed with Agreements,BCRDT,RB,EDS,NR,LU,SA,NR,SA,SA,EM,,2017-08-01,2015-07-01,,2015-07-29,2015-06-29,,2018-08-01,2015-07-01,2015-06-01,29-Jun-15,2015-06-01,,6.0,3.0,,5.0,2.0,,7.0,4.0,1.0,28.60%,29.50%,35.20%,35.90%,68.10%,72.60%,72.90%,,,,72.90%,29-Jul-15,,1.0,39.0,202.0,189.0,,,,,763.0,1.0,,29.0,-1.0,,1128.0,1.0,-29.0,320.0,-1.0,270.0,-29.0,,,1020.0,258.0,,286.0,256.0,,1385.0,258.0,228.0,577.0,527.0,256.0,255.0,53.0,,817.0,55.0,,83.0,53.0,,1182.0,55.0,0.0,374.0,203.0,228.0,54.0,29.0,,,,58.0,,42131
190,Eylea (MDA) pCPA 2nd,aflibercept,Bayer ,Y,Y,N,Y,N,N,N,N,N,,08-Nov-13,,CADTH & INESSS,18-Nov-13,post-NOC,Initial,"Macular degeneration, age-related",Completed,20-Oct-14,List with criteria/condition,Conditional,,,New Drug,nAMD,Completed,24-Apr-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,,27-Mar-15,Negotiation,Completed with Agreements,BCRDT,RB,EDS,NR,LU,SA,NR,SA,SA,,,2017-08-01,2015-07-01,,2015-07-29,2015-06-29,,2015-05-25,2015-07-01,,25-May-15,2015-05-25,,6.0,3.0,,5.0,2.0,,1.0,4.0,,0.40%,1.20%,7.00%,7.60%,39.90%,44.30%,,,,,44.30%,,,10.0,,336.0,,,,,,858.0,96.0,,124.0,94.0,,59.0,96.0,,221.0,59.0,221.0,59.0,,,1362.0,600.0,,628.0,598.0,,563.0,600.0,,725.0,725.0,563.0,553.0,217.0,,1016.0,254.0,,282.0,252.0,,217.0,254.0,,379.0,346.0,167.0,158.0,337.0,,,,,,41932
191,Eylea (MED),aflibercept ,Bayer ,Y,Y,N,N,N,N,N,N,N,,28-Nov-14,,CADTH & INESSS,16-Sep-14,pre-NOC,Initial,"Macular edema, diabetic ",Completed,07-May-15,List with clinical criteria and/or conditions,Conditional,24-Nov-14,pre-NOC,New Indication,"Macular edema, diabetic ",Completed,01-Jun-15,Ajout d'une indication reconnue - Médicament d'exception,Conditional,1st,,30-Jun-15,Negotiation,Completed with Agreements,BCRDT,RB,EDS,NR,LU,SA,NR,SA,SA,EM,,2017-08-01,2015-07-01,,2015-07-29,2015-06-29,,2018-08-01,2015-07-01,2015-06-01,29-Jun-15,2015-06-01,,6.0,3.0,,5.0,2.0,,7.0,4.0,1.0,28.60%,29.50%,35.20%,35.90%,68.10%,72.60%,72.90%,,,,72.90%,29-Jul-15,,-73.0,-4.0,233.0,189.0,,,,,763.0,1.0,,29.0,-1.0,,1128.0,1.0,-29.0,320.0,-1.0,270.0,-29.0,,,977.0,215.0,,243.0,213.0,,1342.0,215.0,185.0,534.0,484.0,213.0,286.0,53.0,,817.0,55.0,,83.0,53.0,,1182.0,55.0,0.0,374.0,160.0,185.0,54.0,29.0,,,,58.0,,42131
194,Fasenra,benralizumab,AstraZeneca ,Y,Y,N,Y,N,N,N,N,N,01-Apr-17,22-Feb-18,327.0,CADTH & INESSS,23-Feb-18,post-NOC,Initial,"Asthma, severe eosinophilic",Completed,21-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New drug,"Asthma, severe eosinophilic",Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,30-Nov-18,03-May-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2020-04-01,2019-08-01,2019-08-01,2020-03-02,2019-06-13,2019-07-04,2019-09-01,2021-03-15,2019-07-19,2019-07-04,13-Jun-19,2019-06-13,9.0,5.0,6.0,8.0,1.0,2.0,7.0,10.0,4.0,3.0,32.20%,33.10%,61.70%,62.40%,66.80%,72.60%,73.90%,79.40%,99.60%,100.00%,100.00%,04-Jul-19,01-Apr-20,1.0,,179.0,,101.0,86.0,154.0,334.0,90.0,90.0,304.0,41.0,62.0,121.0,682.0,77.0,62.0,200.0,41.0,186.0,41.0,334.0,769.0,525.0,525.0,739.0,476.0,497.0,556.0,1117.0,512.0,497.0,635.0,621.0,476.0,475.0,296.0,589.0,345.0,345.0,559.0,296.0,317.0,376.0,937.0,332.0,302.0,455.0,180.0,195.0,255.0,240.0,769.0,293.0,293.0,21.0,272.0,507
196,Faslodex,fulvestrant,AstraZeneca,Y,N,N,Y,Y,N,N,N,N,01-Jan-17,08-Nov-17,311.0,CADTH & INESSS,17-Jul-17,pre-NOC,New drug,"For hormonal treatment of non-visceral locally advanced or metastatic HER2- breast cancer in postmenopausal women, regardless of age, who have not been previously treated with endocrine therapy",Completed,01-Feb-18,Cond'l on Cost,Conditional,,,New Drug,Locally Advanced or Metastatic Breast Cancer,Completed,09-May-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,03-Aug-18,29-Jan-19,Negotiation,No Agreement Reached,Not funded,Funded,Funded,Not funded,Funded,Not funded,Not funded,Not funded,Funded,NR,,2020-09-30,,,2020-11-30,,,,2019-10-22,,22-Oct-19,2019-10-22,,2.0,,,3.0,,,,1.0,,0.70%,5.10%,37.40%,,,,,,,,37.40%,,,-114.0,,199.0,,183.0,86.0,179.0,,610.0,,,671.0,,,,266.0,,516.0,266.0,516.0,266.0,,,1057.0,,,1118.0,,,,713.0,,963.0,963.0,713.0,827.0,628.0,,972.0,,,1033.0,,,,628.0,,878.0,85.0,182.0,362.0,265.0,,,,,,396
198,Ferriprox,deferiprone,ApoPharma ,N,N,N,Y,N,N,N,N,N,,13-Feb-15,,CADTH,24-Sep-15,post-NOC,Initial,Transfusional iron overload,Completed,18-Mar-16,List with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,13-May-16,07-Sep-16,Negotiation,Completed with Agreements,SA,SA,EDS,NR,EAP,SA,EDS,NR,SA,NR,2016-10-25,2017-07-01,2017-01-01,,2016-10-17,2016-12-21,2016-12-01,,2017-05-25,,17-Oct-16,2016-10-17,2.0,7.0,5.0,,1.0,4.0,3.0,,6.0,,32.20%,52.50%,53.80%,54.70%,60.40%,61.10%,65.50%,,,,65.50%,25-Oct-16,,223.0,,176.0,,56.0,,117.0,48.0,297.0,116.0,,40.0,105.0,85.0,,260.0,,136.0,40.0,136.0,40.0,,620.0,869.0,688.0,,612.0,677.0,657.0,,832.0,,708.0,708.0,612.0,389.0,213.0,221.0,470.0,289.0,,213.0,278.0,258.0,,433.0,,309.0,399.0,,173.0,,,,,8.0,,42447
200,Fibristal,ulipristal acetate,Actavis ,N,N,N,Y,N,N,N,N,N,,24-Jun-13,,CADTH & INESSS,17-Apr-13,pre-NOC,Initial,Uterine fibroids (signs and symptoms) ,Completed,15-Nov-13,List with criteria/condition,Conditional,02-Aug-13,post-NOC,New Drug,Uterine fibroids (signs and symptoms) ,Completed,03-Feb-14,Ajout aux listes de médicaments,Positive,1st,28-Feb-14,18-Sep-15,Negotiation,Completed with Agreements,DL,RB,DL,EDS,DL,SA,DL,DL,DL,FB,2018-10-02,2016-01-01,2016-05-01,2016-01-18,2016-01-28,2016-04-12,2017-05-01,2016-06-27,2016-08-01,2014-02-03,01-Jan-16,2014-02-03,10.0,2.0,6.0,3.0,4.0,5.0,9.0,7.0,8.0,1.0,28.60%,33.00%,38.60%,70.80%,71.70%,77.40%,77.80%,78.40%,79.70%,100.00%,100.00%,28-Jan-16,02-Oct-18,-68.0,39.0,212.0,185.0,105.0,25.0,567.0,1110.0,105.0,226.0,122.0,132.0,207.0,591.0,283.0,318.0,-592.0,344.0,105.0,250.0,-592.0,1110.0,1926.0,921.0,1042.0,938.0,948.0,1023.0,1407.0,1099.0,1134.0,224.0,1160.0,1066.0,921.0,989.0,777.0,1782.0,777.0,898.0,794.0,804.0,879.0,1263.0,955.0,990.0,0.0,1016.0,144.0,224.0,672.0,592.0,1926.0,1702.0,1005.0,724.0,978.0,41593
201,Fibristal (Advice) (Ineligible for surgery),ulipristal acetate,Allergan ,N,N,N,N,N,N,N,N,N,,17-Dec-15,,CADTH,28-Mar-19,post-NOC,Request for Advice,Uterine fibroids (signs and symptoms),Completed,24-Jul-19,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,,,,,NR,RB,DL,EDS,DL,SA,DL,,,,,2019-09-01,2019-11-01,2020-03-02,2019-10-31,2020-02-26,2020-07-06,,,,01-Sep-19,2019-09-01,,1.0,3.0,5.0,2.0,4.0,6.0,,,,4.50%,36.70%,42.40%,43.30%,48.80%,50.10%,,,,,50.10%,06-Jul-20,,1197.0,,118.0,,,,,,,,,,,,,,,,,,,,,1354.0,1415.0,1537.0,1414.0,1532.0,1663.0,,,,1486.0,1486.0,1354.0,157.0,39.0,,39.0,100.0,222.0,99.0,217.0,348.0,,,,171.0,1315.0,,,,,,,309.0,,43670
202,Fibristal (Advice) (Intermittent),ulipristal acetate,Allergan ,N,N,N,N,N,N,N,N,N,,17-Dec-15,,CADTH,21-Jun-17,post-NOC,Request for Advice,Uterine fibroids (signs and symptoms),Completed,22-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,28-Sep-18,06-Aug-19,Negotiation,Completed with Agreements,NR,RB,DL,EDS,DL,SA,DL,,,,,2019-09-01,2019-11-01,2020-03-02,2019-10-31,2020-02-26,2020-07-06,,,,01-Sep-19,2019-09-01,,1.0,3.0,5.0,2.0,4.0,6.0,,,,4.50%,36.70%,42.40%,43.30%,48.80%,50.10%,,,,,50.10%,06-Jul-20,,552.0,,154.0,,310.0,,312.0,,26.0,87.0,209.0,86.0,204.0,335.0,,,,158.0,26.0,158.0,26.0,,,1354.0,1415.0,1537.0,1414.0,1532.0,1663.0,,,,1486.0,1486.0,1354.0,802.0,648.0,,648.0,709.0,831.0,708.0,826.0,957.0,,,,780.0,706.0,,622.0,,,,,309.0,,43061
203,Firazyr,icatibant,Shire ,Y,N,N,Y,N,Y,Y,Y,N,,04-Jun-14,,CADTH & INESSS,04-Mar-14,pre-NOC,Initial,"Angioedema, hereditary",Completed,19-Dec-14,List with clinical criteria and/or conditions,Conditional,24-Nov-14,post-NOC,New Drug,"Angioedema, hereditary",Completed,01-Jun-15,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,28-Feb-15,28-Aug-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2018-02-06,2016-01-01,2016-08-01,2016-01-18,2015-11-05,2016-03-01,2016-05-02,2016-06-27,2018-10-01,2015-06-01,05-Nov-15,2015-06-01,9.0,3.0,8.0,4.0,2.0,5.0,6.0,7.0,10.0,1.0,28.60%,60.80%,65.30%,70.80%,71.70%,73.00%,73.40%,79.10%,99.30%,100.00%,100.00%,05-Nov-15,06-Feb-18,-92.0,173.0,290.0,189.0,71.0,-93.0,181.0,893.0,126.0,339.0,143.0,69.0,186.0,248.0,304.0,1130.0,-88.0,382.0,69.0,335.0,-88.0,893.0,1343.0,576.0,789.0,593.0,519.0,636.0,698.0,754.0,1580.0,362.0,832.0,785.0,519.0,611.0,321.0,1145.0,378.0,591.0,395.0,321.0,438.0,500.0,556.0,1382.0,0.0,634.0,198.0,362.0,252.0,88.0,1343.0,981.0,824.0,157.0,824.0,41992
205,Folotyn,pralatrexate,Servier,N,N,N,Y,Y,Y,Y,Y,Y,01-Nov-17,26-Oct-18,359.0,CADTH & INESSS,01-Jun-18,pre-NOC,New drug,Peripheral T-Cell Lymphoma (PTCL): for the treatment of patients with relapsed or refractory PTCL,Completed,04-Apr-19,Cond'l on Cost,Conditional,,,New Drug,Peripheral T-Cell Lymphoma (PTCL): for the treatment of patients with relapsed or refractory PTCL,Completed,13-Feb-19,Refus dinscription,Negative,1st,06-Jun-19,10-Jan-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,NR,2020-04-01,2020-09-15,2020-06-01,2020-07-22,2020-07-17,,2020-07-01,,,,01-Apr-20,2020-04-01,1.0,6.0,2.0,5.0,4.0,,3.0,,,,20.30%,26.00%,27.30%,59.50%,65.00%,69.50%,,,,,69.50%,17-Jul-20,,-147.0,,307.0,,63.0,113.0,218.0,82.0,249.0,143.0,194.0,189.0,,173.0,,,,172.0,82.0,172.0,82.0,,523.0,690.0,584.0,635.0,630.0,,614.0,,,,613.0,613.0,523.0,670.0,363.0,363.0,530.0,424.0,475.0,470.0,,454.0,,,,453.0,160.0,110.0,281.0,331.0,,,,107.0,,519
206,Forxiga,dapagliflozin,AstraZeneca,Y,N,N,N,N,N,N,N,Y,01-Jul-19,02-Apr-20,276.0,CADTH & INESSS,31-Mar-20,pre-NOC,Initial,Heart failure with reduced ejection fraction,Completed,23-Dec-20,Reimburse with clinical criteria and/or conditions,Conditional,08-May-20,post-NOC,New Indication,Chronic cardiac insufficiency,Completed,14-Oct-20,Inscription - Avec conditions,Conditional,1st,17-Jun-21,18-Nov-21,Negotiation,Completed with Agreements,FB,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,2022-01-11,2022-03-01,2022-02-01,2022-02-24,2021-12-17,2022-02-17,2022-06-27,2022-12-12,2022-04-21,2021-12-15,17-Dec-21,2021-12-15,3.0,7.0,4.0,6.0,2.0,5.0,9.0,10.0,8.0,1.0,28.60%,60.80%,81.10%,86.80%,87.70%,93.20%,97.70%,98.30%,99.60%,100.00%,100.00%,17-Dec-21,11-Jan-22,-2.0,36.0,267.0,159.0,176.0,246.0,154.0,54.0,103.0,75.0,98.0,29.0,91.0,221.0,389.0,154.0,27.0,135.0,29.0,124.0,27.0,54.0,649.0,698.0,670.0,693.0,624.0,686.0,816.0,984.0,749.0,622.0,730.0,719.0,624.0,626.0,359.0,384.0,433.0,405.0,428.0,359.0,421.0,551.0,719.0,484.0,427.0,465.0,265.0,195.0,330.0,400.0,649.0,27.0,25.0,2.0,25.0,541
208,"Forxiga (w/ Met OR SU OR insulin+/-Met)
with insulin)",dapagliflozin,AstraZeneca ,Y,N,N,Y,N,N,N,N,N,,12-Dec-14,,CADTH & INESSS,30-Apr-15,post-NOC,Initial,"Diabetes mellitus, Type 2 (with metformin OR sulfonylurea, not both)",Completed,20-Nov-15,List with clinical criteria and/or conditions,Conditional,22-Mar-15,post-NOC,New Drug,Diabetes mellitus (Type 2),Completed,01-Oct-15,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,27-May-16,03-Oct-16,Negotiation,Completed with Agreements,NR,SA,NR,EDS,FB,SA,EDS,NR,NR,EM,,2017-04-01,,2017-01-25,2016-11-30,2016-11-30,2017-08-01,,,2015-10-01,30-Nov-16,2015-10-01,,5.0,,4.0,2.0,3.0,6.0,,,1.0,28.60%,60.80%,61.70%,67.20%,71.70%,73.00%,,,,,73.00%,30-Nov-16,,139.0,100.0,204.0,193.0,189.0,239.0,129.0,,180.0,,114.0,58.0,58.0,302.0,,,-368.0,142.0,58.0,57.0,-368.0,,,841.0,,775.0,719.0,719.0,963.0,,,293.0,803.0,718.0,719.0,580.0,376.0,,498.0,,432.0,376.0,376.0,620.0,,,0.0,460.0,343.0,293.0,318.0,368.0,,,,426.0,,42328
209,"Forxiga (w/Metformin AND SU)
and a sulfonylurea",dapagliflozin,AstraZeneca ,Y,N,N,N,N,N,N,N,N,,02-Dec-15,,CADTH & INESSS,04-Sep-15,pre-NOC,Initial,"Diabetes mellitus, type 2 (in combination with metformin AND sulfonylurea)",Completed,27-Apr-16,Do not list,Negative,,,New Indication,Diabetes mellitus (Type 2),Completed,01-Jun-16,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments-Médicament d'exception,Negative,1st,27-May-16,03-Oct-16,Negotiation,Completed with Agreements,NR,NR,EDS,NR,FB,NR,NR,SA,SA,NR,,,2017-01-01,,2016-11-30,,,2017-04-24,2017-02-01,,30-Nov-16,2016-11-30,,,2.0,,1.0,,,4.0,3.0,,32.20%,38.00%,38.60%,39.00%,,,,,,,39.00%,,,-89.0,,236.0,,30.0,-5.0,129.0,,,90.0,,58.0,,,203.0,121.0,,118.0,58.0,118.0,58.0,,,,396.0,,364.0,,,509.0,427.0,,424.0,424.0,364.0,453.0,217.0,,,249.0,,217.0,,,362.0,280.0,,277.0,147.0,182.0,159.0,124.0,,,,,,42487
210,Fulphila,pegfilgrastim,BGP PHARMA ULC,N,Y,Y,N,N,N,N,N,Y,01-Jan-17,24-Dec-18,722.0,CADTH & INESSS,14-Nov-18,pre-NOC,Initial,Febrile neutropenia in non-myeloid malignancies,Completed,22-Feb-19,Not Applicable: Biosimilar,,06-Nov-18,pre-NOC,New Drug,Neutropenia,Completed,13-Mar-19,Inscription  Avec conditions,Conditional,1st,28-Feb-19,23-Sep-19,Negotiation,Completed with Agreements,NR,SA,UR,UR,FB,SA,EDS,SA,SA,EM,,2020-03-01,,,2020-05-29,2020-06-18,2020-04-22,2021-10-25,2021-02-25,2020-04-29,01-Mar-20,2020-03-01,,1.0,,,4.0,5.0,2.0,7.0,6.0,3.0,4.50%,5.80%,34.30%,66.60%,67.50%,68.10%,68.50%,,,,68.50%,29-May-20,,-40.0,-48.0,100.0,127.0,6.0,-13.0,207.0,,160.0,,,249.0,269.0,212.0,763.0,521.0,219.0,362.0,160.0,342.0,160.0,,,433.0,,,522.0,542.0,485.0,1036.0,794.0,492.0,635.0,615.0,433.0,473.0,373.0,,373.0,,,462.0,482.0,425.0,976.0,734.0,413.0,575.0,60.0,79.0,213.0,194.0,,,,89.0,,782
211,Fycompa (seizures),perampanel ,Eisai Ltd. ,N,N,N,Y,N,N,N,N,N,,04-Apr-13,,CADTH & INESSS,08-Mar-13,pre-NOC,Initial,"Epilepsy, partial onset seizures ",Completed,17-Oct-13,List with criteria/condition,Conditional,02-Aug-13,post-NOC,New Drug,"Epilepsy, partial onset seizures ",Completed,03-Feb-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,31-Jan-14,,Negotiation by Province,,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2014-08-15,2014-05-01,2014-07-01,2014-07-17,2014-02-27,2014-09-11,2014-05-23,2016-04-25,2014-05-20,2014-02-03,27-Feb-14,2014-02-03,8.0,3.0,6.0,7.0,2.0,9.0,5.0,10.0,4.0,1.0,28.60%,60.80%,65.30%,65.90%,67.30%,73.00%,78.50%,98.80%,99.60%,100.00%,100.00%,27-Feb-14,15-Aug-14,-27.0,120.0,223.0,185.0,106.0,-3.0,,,,,,,,,,,,,,,,,498.0,392.0,453.0,469.0,329.0,525.0,414.0,1117.0,411.0,305.0,512.0,491.0,329.0,356.0,133.0,302.0,196.0,257.0,273.0,133.0,329.0,218.0,921.0,215.0,0.0,316.0,196.0,305.0,,,498.0,193.0,169.0,24.0,169.0,41564
212,"Fycompa (seizures, primary)",perampanel,Eisai Ltd. ,N,N,N,N,N,N,N,N,N,,01-Dec-15,,CADTH & INESSS,24-Nov-15,pre-NOC,Initial,"Epilepsy, primary generalized tonic-clonic seizures",Completed,18-May-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Indication,"Epilepsy, primary generalized tonic-clonic seizures",Completed,03-Oct-16,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception,Conditional,1st,15-Aug-16,02-Jul-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,UR,EM,2020-09-24,2019-08-01,2019-11-01,2020-03-02,2019-09-30,2019-12-19,2021-03-01,2021-11-22,,2019-08-15,01-Aug-19,2019-08-01,7.0,1.0,4.0,6.0,3.0,5.0,8.0,9.0,,2.0,4.50%,33.00%,65.30%,71.00%,71.90%,77.40%,97.70%,99.00%,99.30%,,99.30%,30-Sep-19,24-Sep-20,-7.0,112.0,176.0,195.0,89.0,-49.0,1051.0,450.0,30.0,122.0,244.0,90.0,170.0,608.0,874.0,,44.0,324.0,30.0,292.0,30.0,450.0,1759.0,1339.0,1431.0,1553.0,1399.0,1479.0,1917.0,2183.0,,1353.0,1633.0,1601.0,1339.0,1346.0,1170.0,1590.0,1170.0,1262.0,1384.0,1230.0,1310.0,1748.0,2014.0,,1046.0,1464.0,169.0,307.0,1140.0,1002.0,1759.0,420.0,420.0,60.0,360.0,42508
213,Galafold,migalastat,Amicus Therapeutics,N,N,N,Y,N,Y,Y,Y,N,01-Nov-16,05-Sep-17,308.0,CADTH & INESSS,09-Jun-17,pre-NOC,Initial,Fabry Disease,Completed,24-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Jun-18,post-NOC,New Drug,Fabry Disease,Completed,16-Nov-18,Inscription  Avec conditions,Conditional,1st,28-Mar-18,28-Aug-18,Negotiation,Completed with Agreements,UR,SA,UR,UR,EAP,SA,EDS,UR,SA,EM,,2019-10-01,,,2019-05-13,2019-05-16,2019-08-01,,2021-08-19,2019-03-07,13-May-19,2019-03-07,,5.0,,,2.0,3.0,4.0,,6.0,1.0,28.60%,60.80%,61.70%,63.00%,67.50%,68.10%,,,,,68.10%,13-May-19,,-88.0,269.0,229.0,168.0,63.0,-233.0,153.0,,399.0,,,258.0,261.0,338.0,,1087.0,191.0,469.0,258.0,422.0,191.0,,,756.0,,,615.0,618.0,695.0,,1444.0,548.0,826.0,779.0,615.0,703.0,474.0,,615.0,,,474.0,477.0,554.0,,1303.0,111.0,685.0,141.0,437.0,216.0,-80.0,,,,67.0,,449
216,Gazyva,obinutuzumab,Hoffman-La Roche ,Y,Y,N,Y,Y,Y,Y,Y,N,,25-Nov-14,,CADTH & INESSS,11-Aug-14,pre-NOC,New drug,Chronic Lymphocytic Leukemia (CLL),Completed,27-Jan-15,Fund,Positive,24-Nov-14,pre-NOC,New Drug,Chronic Lymphocytic Leukemia (CLL),Completed,01-Jun-15,Ajout à la Liste Établissements - Médicament d'exception,Positive,1st,10-Feb-15,15-May-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2016-05-01,2015-08-06,2015-06-22,2015-06-22,2015-07-17,2016-05-02,2015-10-15,2018-08-01,2018-07-03,2015-06-01,22-Jun-15,2015-06-01,7.0,5.0,2.0,3.0,4.0,8.0,6.0,10.0,9.0,1.0,28.60%,34.30%,39.80%,72.10%,76.50%,77.80%,98.10%,99.00%,99.60%,100.00%,100.00%,17-Jul-15,01-May-16,-106.0,-1.0,169.0,189.0,14.0,-111.0,94.0,352.0,83.0,38.0,38.0,63.0,353.0,153.0,1174.0,1145.0,17.0,378.0,38.0,342.0,17.0,352.0,523.0,254.0,209.0,209.0,234.0,524.0,324.0,1345.0,1316.0,188.0,549.0,513.0,209.0,315.0,146.0,460.0,191.0,146.0,146.0,171.0,461.0,261.0,1282.0,1253.0,0.0,486.0,63.0,188.0,108.0,-17.0,523.0,335.0,314.0,46.0,289.0,42031
217,Gazyva,obinutuzumab,Hoffman-La Roche ,Y,Y,N,N,Y,Y,Y,Y,N,,29-Dec-16,,CADTH & INESSS,04-Nov-16,pre-NOC,New indication,Lymphoma and Myeloma (follicular lymphoma) ,Completed,02-Jun-17,Cond'l on Cost,Conditional,24-Mar-17,post-NOC,New Indication,Relapsed/Refractory Follicular Lymphyoma,Completed,18-Oct-17,Avis d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Positive,1st,10-Oct-17,08-Jan-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-07-01,2018-09-04,2018-08-15,2018-06-01,2018-10-17,2018-10-19,2018-10-15,,2018-07-03,2018-05-24,01-Jun-18,2018-05-24,3.0,6.0,5.0,2.0,8.0,9.0,7.0,,4.0,1.0,28.60%,34.10%,54.40%,55.00%,60.80%,65.20%,66.50%,98.80%,99.60%,,99.60%,01-Jul-18,17-Oct-18,-55.0,85.0,210.0,208.0,130.0,-8.0,90.0,174.0,239.0,219.0,144.0,282.0,284.0,280.0,,176.0,136.0,225.0,144.0,215.0,136.0,282.0,549.0,614.0,594.0,519.0,657.0,659.0,655.0,,551.0,511.0,600.0,590.0,519.0,574.0,364.0,394.0,459.0,439.0,364.0,502.0,504.0,500.0,,396.0,218.0,445.0,155.0,293.0,220.0,82.0,657.0,146.0,138.0,38.0,108.0,42888
222,Genvoya,elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,,27-Nov-15,,CADTH & INESSS,24-Sep-15,pre-NOC,Initial,HIV-1 infection,Completed,18-Mar-16,List,Positive,22-Mar-16,post-NOC,New Drug,HIV-1 infection,Completed,16-Dec-16,Avis de refus d'inscription aux listes des médicaments,Negative,1st,15-Aug-16,13-Mar-17,Negotiation,Completed with Agreements,HIV,HIV,EDS,EDS,FB,SA,HIV,FB,SA,FB,2017-07-12,2017-05-04,2017-07-01,2017-07-19,2017-04-27,2017-08-15,2018-02-01,2019-01-28,2017-08-01,2017-04-21,27-Apr-17,2017-04-21,5.0,3.0,4.0,6.0,2.0,8.0,9.0,10.0,7.0,1.0,28.60%,60.80%,65.30%,71.00%,91.20%,96.80%,97.40%,98.30%,99.60%,100.00%,100.00%,27-Apr-17,12-Jul-17,-64.0,116.0,176.0,269.0,150.0,-123.0,210.0,121.0,52.0,110.0,128.0,45.0,155.0,325.0,686.0,141.0,39.0,196.0,45.0,180.0,39.0,121.0,593.0,524.0,582.0,600.0,517.0,627.0,797.0,1158.0,613.0,511.0,668.0,652.0,517.0,581.0,405.0,481.0,412.0,470.0,488.0,405.0,515.0,685.0,1046.0,501.0,126.0,556.0,112.0,385.0,360.0,87.0,593.0,82.0,76.0,6.0,76.0,42447
223,Giotrif,afatinib,Boehringer Ingelheim,N,N,N,Y,Y,Y,N,Y,N,,01-Nov-13,,CADTH & INESSS,07-Jun-13,pre-NOC,New drug,Advanced Non Small Cell Lung Cancer,Completed,02-May-14,Cond'l on Cost,Conditional,,,New Drug,Advanced Non Small Cell Lung Cancer,Completed,02-Feb-15,Avis de refus,Negative,1st,09-May-14,03-Jul-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2014-10-01,2014-09-30,2014-09-15,2014-10-16,2014-08-19,2014-09-11,2014-12-29,2016-10-24,2015-06-01,2016-05-04,19-Aug-14,2014-08-19,5.0,4.0,3.0,6.0,1.0,2.0,7.0,10.0,8.0,9.0,32.20%,33.10%,38.80%,43.30%,63.60%,69.10%,70.40%,71.10%,99.60%,100.00%,100.00%,01-Oct-14,04-May-16,-147.0,,329.0,,7.0,-269.0,55.0,90.0,89.0,74.0,105.0,47.0,70.0,179.0,844.0,333.0,671.0,203.0,47.0,250.0,47.0,671.0,334.0,333.0,318.0,349.0,291.0,314.0,423.0,1088.0,577.0,915.0,447.0,494.0,291.0,438.0,109.0,152.0,151.0,136.0,167.0,109.0,132.0,241.0,906.0,395.0,457.0,265.0,182.0,458.0,62.0,-214.0,915.0,624.0,624.0,43.0,581.0,41761
226,Glatect,glatiramer acetate,Pendopharm,N,N,N,N,N,N,N,N,N,,17-Jan-17,,CADTH & INESSS,20-Jan-17,post-NOC,Initial,"Multiple Sclerosis, relapsing - remitting",Completed,25-Jul-17,Reimburse with clinical criteria and/or conditions,Conditional,11-Oct-17,post-NOC,New Drug,Multiple sclerosis,Completed,11-Apr-18,Avis dinscription aux listes des médicaments  Médicament dexception,Conditional,1st,08-Sep-17,01-Mar-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,2018-11-27,2018-07-01,2018-07-01,2018-04-19,2018-09-27,2018-06-11,2020-02-01,2021-07-26,2018-08-21,2018-07-05,19-Apr-18,2018-04-19,8.0,3.0,4.0,1.0,7.0,2.0,9.0,10.0,6.0,5.0,5.50%,6.40%,10.90%,16.60%,45.20%,45.80%,78.10%,98.30%,99.60%,100.00%,100.00%,27-Sep-18,27-Nov-18,3.0,267.0,186.0,182.0,45.0,-215.0,174.0,271.0,122.0,122.0,49.0,210.0,102.0,702.0,1243.0,173.0,126.0,333.0,49.0,312.0,49.0,271.0,679.0,530.0,530.0,457.0,618.0,510.0,1110.0,1651.0,581.0,534.0,741.0,720.0,457.0,454.0,268.0,490.0,341.0,341.0,268.0,429.0,321.0,921.0,1462.0,392.0,85.0,552.0,189.0,449.0,219.0,-41.0,679.0,222.0,222.0,161.0,61.0,42941
228,Grastofil (SEB),filgrastim,Apotex ,N,Y,Y,N,N,N,N,N,N,,07-Dec-15,,CADTH & INESSS,11-Sep-15,pre-NOC,Initial,Prevention or treatment of neutropenia in various indications,Completed,18-Mar-16,List with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,Prevention or treatment of neutropenia in various indications,Completed,16-Dec-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,15-Jun-16,12-Dec-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,NR,SA,SA,EM,2017-01-31,2017-04-01,2017-07-01,2017-07-19,2016-12-22,2017-05-29,,2017-08-07,2017-11-01,2018-09-27,22-Dec-16,2016-12-22,2.0,3.0,5.0,6.0,1.0,4.0,,7.0,8.0,9.0,32.20%,52.50%,56.90%,57.80%,63.60%,69.10%,69.40%,70.10%,98.70%,,98.70%,31-Jan-17,27-Sep-18,-87.0,106.0,189.0,269.0,89.0,-184.0,180.0,50.0,110.0,201.0,219.0,10.0,168.0,,238.0,324.0,654.0,165.0,10.0,219.0,10.0,654.0,421.0,481.0,572.0,590.0,381.0,539.0,,609.0,695.0,1025.0,536.0,590.0,381.0,468.0,279.0,319.0,379.0,470.0,488.0,279.0,437.0,,507.0,593.0,650.0,434.0,102.0,375.0,269.0,-4.0,1025.0,644.0,644.0,40.0,604.0,42447
231,Hemangiol,propranolol oral solution,Pierre Fabre Dermo-Cosmétique,N,N,N,N,N,Y,N,Y,N,,23-Sep-16,,CADTH & INESSS,25-Aug-16,pre-NOC,Initial,Infantile hemangioma,Completed,21-Feb-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Proliferating infantile haemangioma requiring systemic therapy,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,04-Aug-17,16-Jul-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2019-01-29,2018-12-01,2019-01-01,2018-10-18,2018-10-29,2018-11-30,2020-09-10,2023-03-27,2019-08-27,2018-09-27,18-Oct-18,2018-09-27,7.0,5.0,6.0,2.0,3.0,4.0,9.0,10.0,8.0,1.0,28.60%,34.10%,66.30%,67.20%,71.70%,77.40%,97.70%,98.30%,99.60%,100.00%,100.00%,29-Oct-18,29-Jan-19,-29.0,182.0,180.0,208.0,164.0,-75.0,346.0,197.0,138.0,169.0,94.0,105.0,137.0,787.0,1715.0,407.0,73.0,417.0,94.0,382.0,73.0,197.0,858.0,799.0,830.0,755.0,766.0,798.0,1448.0,2376.0,1068.0,734.0,1078.0,1043.0,755.0,784.0,604.0,707.0,648.0,679.0,604.0,615.0,647.0,1297.0,2225.0,917.0,344.0,927.0,151.0,390.0,510.0,271.0,858.0,124.0,103.0,32.0,92.0,42787
237,Humira (HS) (2nd pCPA),adalimumab,AbbVie ,Y,Y,N,N,N,Y,N,Y,N,,31-Dec-15,,CADTH & INESSS,03-Nov-15,pre-NOC,Initial,Hidradenitis suppurativa,Completed,19-May-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Indication,Hidradenitis suppurativa,Completed,03-Oct-16,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - Valeur thérapeutique,Negative,1st,24-Jul-17,23-Oct-17,Negotiation,Completed with Agreements,SA,DL,EDS,EDS,EAP,SA,EDS,NR,SA,NR,2018-03-06,2018-04-01,2018-01-01,2018-01-25,,2018-02-12,2018-10-01,,2019-08-26,,01-Jan-18,2018-01-01,4.0,5.0,1.0,2.0,,3.0,6.0,,7.0,,5.70%,11.20%,12.10%,32.40%,36.90%,38.20%,38.80%,,,,38.80%,,,-58.0,82.0,198.0,195.0,431.0,294.0,91.0,134.0,160.0,70.0,94.0,,112.0,343.0,,672.0,,226.0,70.0,226.0,70.0,,796.0,822.0,732.0,756.0,,774.0,1005.0,,1334.0,,888.0,888.0,732.0,790.0,592.0,656.0,682.0,592.0,616.0,,634.0,865.0,,1194.0,,748.0,140.0,277.0,522.0,385.0,,,,,,42509
238,Humira (JIA),adalimumab,AbbVie ,Y,Y,N,N,N,N,N,N,N,,28-Nov-12,,CADTH & INESSS,04-Feb-13,post-NOC,Initial,"Arthritis, Juvenile Idiopathic ",Completed,18-Jul-13,List with clinical criteria and/or conditions,Conditional,,,New Indication,pJIA,Completed,01-Oct-13,Ajout d'une indication reconnue - Médicament d'exception - Avis de refus,Conditional,none,31-Jan-14,,Negotiation by Province,,SA,DL,EDS,EDS,EAP,SA,EDS,SA,SA,NR,2014-02-25,2014-10-01,2014-04-01,2014-01-23,2014-02-18,2015-06-29,2014-05-20,2016-04-25,2015-12-01,,23-Jan-14,2014-01-23,3.0,6.0,4.0,1.0,2.0,7.0,5.0,9.0,8.0,,5.50%,37.80%,58.00%,63.70%,65.00%,69.50%,70.40%,71.10%,71.40%,,71.40%,25-Feb-14,,68.0,,164.0,,197.0,122.0,,,,,,,,,,,,,,,,,454.0,672.0,489.0,421.0,447.0,943.0,538.0,1244.0,1098.0,,701.0,701.0,421.0,353.0,189.0,222.0,440.0,257.0,189.0,215.0,711.0,306.0,1012.0,866.0,,469.0,232.0,307.0,,,,,,33.0,,41473
239,Humira (UC),adalimumab,AbbVie ,Y,Y,N,N,N,N,N,N,N,,21-Nov-13,,CADTH & INESSS,25-Sep-15,post-NOC,Initial,Ulcerative Colitis,Completed,15-Apr-16,Do not list at the submitted price,Negative,,,New Indication,Ulcerative Colitis,Completed,03-Oct-16,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - Valeur thérapeutique,Negative,1st,31-May-16,23-May-17,Negotiation,Completed with Agreements,SA,DL,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2017-07-20,2017-10-01,2017-07-01,2017-10-19,2017-08-01,2017-08-15,2018-10-01,2018-08-01,2017-08-01,2018-03-01,01-Jul-17,2017-07-01,2.0,6.0,1.0,7.0,3.0,5.0,10.0,9.0,4.0,8.0,5.70%,26.00%,58.20%,58.90%,59.80%,64.20%,69.80%,98.30%,98.70%,100.00%,100.00%,01-Aug-17,01-Mar-18,673.0,,203.0,,46.0,-125.0,357.0,58.0,131.0,39.0,149.0,70.0,84.0,496.0,435.0,70.0,282.0,170.0,39.0,181.0,39.0,282.0,1337.0,1410.0,1318.0,1428.0,1349.0,1363.0,1775.0,1714.0,1349.0,1561.0,1449.0,1460.0,1318.0,645.0,442.0,461.0,534.0,442.0,552.0,473.0,487.0,899.0,838.0,473.0,514.0,573.0,876.0,1047.0,403.0,232.0,1561.0,243.0,243.0,31.0,212.0,42475
243,Ibrance (with Faslodex),palbociclib (with fulvestrant),Pfizer,Y,N,N,N,Y,N,N,N,N,01-Jul-16,19-May-17,322.0,CADTH & INESSS,28-Sep-18,post-NOC,New indication,Advanced or Metastatic Breast Cancer,Completed,03-May-19,Cond'l on Cost,Conditional,15-Oct-18,post-NOC,New Indication,Advanced or Metastatic Breast Cancer,Completed,05-Nov-20,Inscription - Avec conditions,Conditional,1st,14-Aug-19,08-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2021-03-01,2020-09-15,2020-08-01,2020-10-22,2021-02-28,2020-09-17,2020-11-01,2022-02-14,2022-02-28,2020-11-11,01-Aug-20,2020-08-01,8.0,2.0,1.0,4.0,7.0,3.0,5.0,9.0,10.0,6.0,5.70%,10.20%,11.10%,16.60%,17.90%,46.50%,78.70%,99.00%,99.30%,100.00%,100.00%,28-Feb-21,01-Mar-21,497.0,514.0,217.0,752.0,103.0,-449.0,238.0,327.0,160.0,115.0,197.0,326.0,162.0,207.0,677.0,691.0,217.0,318.0,115.0,308.0,115.0,327.0,1382.0,1215.0,1170.0,1252.0,1381.0,1217.0,1262.0,1732.0,1746.0,1272.0,1373.0,1363.0,1170.0,673.0,456.0,668.0,501.0,456.0,538.0,667.0,503.0,548.0,1018.0,1032.0,6.0,659.0,714.0,1266.0,341.0,-211.0,1382.0,212.0,212.0,211.0,1.0,1036
244,Ibrance resubmission,palbociclib,Pfizer,Y,N,N,Y,Y,N,N,N,N,,16-Mar-16,,CADTH & INESSS,10-Jun-16,post-NOC,Resubmission,"Breast, advanced breast cancer",Completed,21-Nov-16,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,Advanced Breast Cancer,Completed,15-Mar-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,15-May-17,21-Dec-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-04-01,2018-05-08,2018-02-23,2018-04-19,2018-02-20,2018-02-12,2018-07-31,2019-10-01,2018-05-04,2018-02-01,12-Feb-18,2018-02-01,5.0,8.0,4.0,6.0,3.0,2.0,9.0,10.0,7.0,1.0,28.60%,29.50%,61.70%,67.40%,87.70%,93.20%,93.90%,98.30%,99.60%,100.00%,100.00%,20-Feb-18,01-Apr-18,86.0,6.0,164.0,358.0,175.0,61.0,220.0,101.0,138.0,64.0,119.0,61.0,53.0,222.0,649.0,134.0,42.0,171.0,53.0,158.0,42.0,101.0,746.0,783.0,709.0,764.0,706.0,698.0,867.0,1294.0,779.0,687.0,816.0,803.0,698.0,612.0,448.0,496.0,533.0,459.0,514.0,456.0,448.0,617.0,1044.0,529.0,323.0,566.0,250.0,364.0,395.0,281.0,746.0,59.0,48.0,19.0,40.0,42695
245,Iclusig,ponatinib,Ariad,N,N,N,Y,Y,Y,Y,Y,N,,02-Apr-15,,CADTH & INESSS,13-Mar-15,pre-NOC,New drug,Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia,Completed,01-Oct-15,Cond'l on Cost,Conditional,04-Aug-15,post-NOC,New Drug,Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia,Completed,19-Aug-16,Avis de refus d'inscription aux listes des médicaments-Médicament d'exception- À moins que certaines conditions soient respectées,Conditional,1st,28-Oct-15,04-Jul-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,UR,2016-12-01,2016-10-18,2016-08-08,2017-01-25,2016-08-03,2016-09-29,2016-12-01,,2018-07-01,,03-Aug-16,2016-08-03,5.0,4.0,2.0,7.0,1.0,3.0,6.0,,8.0,,32.20%,38.00%,38.80%,43.30%,63.60%,64.90%,70.40%,71.10%,,,71.10%,01-Dec-16,,-20.0,124.0,202.0,381.0,27.0,-296.0,250.0,150.0,106.0,35.0,205.0,30.0,87.0,150.0,,727.0,,186.0,30.0,186.0,30.0,,609.0,565.0,494.0,664.0,489.0,546.0,609.0,,1186.0,,645.0,645.0,489.0,509.0,307.0,427.0,383.0,312.0,482.0,307.0,364.0,427.0,,1004.0,,463.0,182.0,505.0,277.0,-46.0,,,,120.0,,42278
248,Ilaris (SJIA),canakinumab,Novartis ,Y,Y,N,N,N,N,N,N,N,,12-Dec-13,,CADTH,23-Dec-15,post-NOC,Initial,Systemic juvenile idiopathic arthritis,Completed,17-Jun-16,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,27-Apr-18,19-Nov-18,Negotiation,Completed with Agreements,NR,NR,UR,NR,EAP,SA,EDS,NR,NR,NR,,,,,2018-04-19,2019-06-06,2019-05-01,,,,19-Apr-18,2018-04-19,,,,,1.0,3.0,2.0,,,,32.20%,33.50%,34.40%,,,,,,,,34.40%,,,741.0,,177.0,,679.0,,206.0,,,,,-214.0,199.0,163.0,,,,49.0,-214.0,49.0,-214.0,,,,,,1589.0,2002.0,1966.0,,,,1852.0,1852.0,1589.0,848.0,671.0,,,,,671.0,1084.0,1048.0,,,,934.0,918.0,,885.0,,,,,,,42538
249,Ilumya,tildrakizumab,Sun Pharma,N,Y,N,Y,N,N,N,N,Y,01-Feb-19,19-May-21,838.0,CADTH & INESSS,15-Jul-19,pre-NOC,Initial,Treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Completed,21-Jun-21,Reimburse with clinical criteria and/or conditions,Conditional,09-Aug-19,pre-NOC,New drug,moderate to severe plaque psoriasis,withdrawn,,,,1st,17-Sep-21,20-Dec-21,Negotiation,Completed with Agreements,,SA,EDS,EDS,LU,SA,EDS,SA,SA,,,2021-12-01,2022-04-01,2022-02-24,2022-02-28,2022-03-24,2022-07-13,2023-02-20,2022-07-25,,01-Dec-21,2021-12-01,,1.0,5.0,2.0,3.0,4.0,6.0,8.0,7.0,,4.50%,10.00%,42.20%,43.10%,48.80%,50.10%,50.80%,51.20%,,,51.20%,13-Jul-22,,-674.0,-649.0,707.0,,88.0,,94.0,,-19.0,102.0,66.0,70.0,94.0,205.0,427.0,217.0,,145.0,-19.0,145.0,-19.0,,,196.0,317.0,281.0,285.0,309.0,420.0,642.0,432.0,,360.0,360.0,196.0,870.0,163.0,,163.0,284.0,248.0,252.0,276.0,387.0,609.0,399.0,,327.0,33.0,,182.0,,,,,224.0,,871
252,Imbruvica,ibrutinib,Janssen ,Y,N,N,Y,Y,Y,Y,Y,N,,17-Nov-14,,CADTH & INESSS,15-Aug-14,pre-NOC,New drug,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,Completed,05-Mar-15,Cond'l on Cost,Conditional,24-Nov-14,post-NOC,New Drug,Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma,Completed,15-Jul-15,Avis d'inscription sur les listes de médicaments - Médicament d'exception - Avec conditions,Conditional,1st,06-Mar-15,02-Jun-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2015-12-01,2015-08-06,2015-10-01,2016-01-18,2015-07-14,2022-04-28,2015-11-02,2018-08-01,2015-12-01,2015-10-01,14-Jul-15,2015-07-14,6.0,2.0,3.0,8.0,1.0,10.0,5.0,9.0,7.0,4.0,32.20%,36.70%,42.40%,71.00%,72.30%,92.60%,93.20%,98.80%,99.10%,100.00%,100.00%,01-Oct-15,01-Dec-15,-94.0,7.0,202.0,233.0,1.0,-131.0,88.0,182.0,65.0,121.0,230.0,42.0,2522.0,153.0,1156.0,182.0,121.0,517.0,42.0,477.0,42.0,182.0,379.0,262.0,318.0,427.0,239.0,2719.0,350.0,1353.0,379.0,318.0,714.0,674.0,239.0,333.0,131.0,271.0,154.0,210.0,319.0,131.0,2611.0,242.0,1245.0,271.0,78.0,606.0,108.0,240.0,89.0,-43.0,379.0,140.0,140.0,79.0,61.0,42068
253,Imbruvica,ibrutinib,Janssen ,Y,N,N,N,Y,Y,Y,Y,N,,28-Jul-15,,CADTH & INESSS,29-Jan-16,post-NOC,New indication,Mantle Cell Lymphoma,Completed,19-Jul-16,Cond'l on Cost,Conditional,12-Aug-16,post-NOC,New Indication,Relapsed/refractory mantle cell lymphoma,Completed,01-Feb-17,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament exception,Conditional,1st,12-Aug-16,27-Jun-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-03-01,2018-05-08,2017-10-01,2017-10-19,2017-10-01,2018-06-11,2018-10-15,,2018-05-01,2017-08-18,01-Oct-17,2017-08-18,5.0,7.0,2.0,4.0,3.0,8.0,9.0,,6.0,1.0,28.60%,34.30%,66.50%,72.10%,92.30%,93.00%,97.40%,98.30%,99.60%,,99.60%,01-Oct-17,01-Mar-18,185.0,381.0,172.0,173.0,24.0,-173.0,319.0,247.0,315.0,96.0,114.0,96.0,349.0,475.0,,308.0,52.0,250.0,96.0,228.0,52.0,247.0,947.0,1015.0,796.0,814.0,796.0,1049.0,1175.0,,1008.0,752.0,950.0,928.0,796.0,611.0,439.0,590.0,658.0,439.0,457.0,439.0,692.0,818.0,,651.0,198.0,593.0,357.0,554.0,343.0,146.0,947.0,195.0,151.0,44.0,151.0,42570
255,Imbruvica,ibrutinib,Janssen ,Y,N,N,N,Y,Y,Y,Y,N,,19-Jul-16,,CADTH & INESSS,20-Apr-16,pre-NOC,New indication,Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (previously untreated),Completed,03-Nov-16,Cond'l on Cost,Conditional,12-Aug-16,post-NOC,New Indication,Previously untreated CLL/SLL,Completed,01-Feb-17,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament exception,Negative,1st,20-Dec-16,27-Jun-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2016-10-01,2018-05-08,2017-10-01,2017-10-19,2017-12-28,2018-06-11,2018-10-15,,2018-05-01,2017-08-18,01-Oct-16,2016-10-01,1.0,7.0,3.0,4.0,5.0,8.0,9.0,,6.0,2.0,20.30%,48.80%,54.60%,60.10%,92.30%,93.00%,97.40%,98.30%,99.60%,,99.60%,01-Oct-17,28-Dec-17,-90.0,24.0,197.0,173.0,47.0,-43.0,189.0,-269.0,315.0,96.0,114.0,184.0,349.0,475.0,,308.0,52.0,197.0,-269.0,180.0,-269.0,184.0,74.0,658.0,439.0,457.0,527.0,692.0,818.0,,651.0,395.0,540.0,523.0,74.0,164.0,-33.0,-33.0,551.0,332.0,350.0,420.0,585.0,711.0,,544.0,198.0,433.0,107.0,197.0,236.0,146.0,527.0,453.0,453.0,365.0,88.0,42677
256,Imfinzi,durvalumab,AstraZeneca,Y,Y,N,Y,Y,N,N,N,N,01-Sep-17,04-May-18,245.0,CADTH & INESSS,21-Sep-18,post-NOC,New drug,Non-Small Cell Lung Cancer,Completed,03-May-19,Cond'l on Cost,Conditional,20-Jul-18,post-NOC,New Drug,Non-Small Cell Lung Cancer,Completed,13-Mar-19,Inscription  Avec conditions,Conditional,1st,08-Jul-19,26-Aug-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-02-01,2020-04-10,2020-01-01,2019-12-16,2020-01-22,2020-03-20,2020-02-01,,2020-06-01,2019-10-02,16-Dec-19,2019-10-02,5.0,8.0,3.0,2.0,4.0,7.0,6.0,,9.0,1.0,28.60%,34.10%,39.80%,72.10%,92.30%,93.60%,94.50%,99.00%,99.60%,,99.60%,22-Jan-20,01-Feb-20,140.0,77.0,224.0,236.0,66.0,117.0,49.0,159.0,228.0,128.0,112.0,149.0,207.0,159.0,,280.0,37.0,178.0,112.0,162.0,37.0,159.0,638.0,707.0,607.0,591.0,628.0,686.0,638.0,,759.0,516.0,657.0,641.0,591.0,451.0,227.0,274.0,343.0,243.0,227.0,264.0,322.0,274.0,,395.0,203.0,293.0,364.0,313.0,115.0,166.0,638.0,122.0,47.0,112.0,10.0,609
257,Imfinzi,durvalumab,AstraZeneca,Y,Y,N,N,Y,Y,N,Y,N,01-Nov-19,01-Oct-20,335.0,CADTH & INESSS,01-Dec-20,post-NOC,Initial,In combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC),Completed,27-Jul-21,Cond'l on Cost,Conditional,22-Jan-21,post-NOC,New Indication,In combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC),Completed,30-Jun-21,Refus d'inscription,Negative,1st,21-Oct-21,18-May-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,2022-10-01,2022-06-30,2022-08-01,2022-07-11,2022-07-30,,,,,2022-07-06,30-Jun-22,2022-06-30,6.0,1.0,5.0,3.0,4.0,,,,,2.0,4.50%,33.00%,38.60%,70.80%,76.50%,96.80%,,,,,96.80%,30-Jul-22,01-Oct-22,61.0,113.0,238.0,159.0,86.0,113.0,209.0,136.0,43.0,75.0,54.0,73.0,,,,,49.0,76.0,43.0,72.0,43.0,136.0,730.0,637.0,669.0,648.0,667.0,,,,,643.0,670.0,666.0,637.0,576.0,338.0,431.0,338.0,370.0,349.0,368.0,,,,,371.0,371.0,299.0,272.0,295.0,322.0,730.0,93.0,93.0,30.0,63.0,634
261,Incruse Ellipta,umeclidinium,GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,,16-Apr-14,,CADTH & INESSS,04-Mar-15,post-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,18-Sep-15,List with criteria/condition,Conditional,22-Mar-16,post-NOC,New Indication,Chronic Obstructive Pulmonary Disease (COPD),Completed,03-Oct-16,Avis d'inscription aux listes des médicaments,Positive,1st,23-Oct-15,15-Dec-15,Negotiation,Completed with Agreements,FB,FB,EDS,FB,FB,SA,EDS,SA,SA,FB,2016-03-15,2016-02-01,2016-05-01,2016-04-18,2016-02-25,2016-03-28,2016-03-01,2016-03-28,2016-02-01,2016-10-03,01-Feb-16,2016-02-01,5.0,1.0,9.0,8.0,3.0,6.0,4.0,7.0,2.0,10.0,4.50%,5.10%,37.40%,38.70%,58.90%,59.80%,60.20%,65.70%,71.40%,100.00%,100.00%,15-Mar-16,03-Oct-16,322.0,706.0,198.0,195.0,35.0,-346.0,53.0,91.0,48.0,138.0,125.0,72.0,104.0,77.0,104.0,48.0,293.0,90.0,48.0,110.0,48.0,293.0,699.0,656.0,746.0,733.0,680.0,712.0,685.0,712.0,656.0,901.0,698.0,718.0,656.0,334.0,136.0,179.0,136.0,226.0,213.0,160.0,192.0,165.0,192.0,136.0,0.0,178.0,520.0,901.0,88.0,-293.0,901.0,245.0,245.0,43.0,202.0,42265
262,Inflectra (SEB; Crohn's & UC)),infliximab,"Hospira HealthCare Corporation, a Pfizer Company",Y,Y,Y,N,N,N,N,N,N,,10-Jun-16,,CADTH & INESSS,12-Apr-16,pre-NOC,Initial,"ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohns disease and Ulcerative Colitis",Completed,25-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Indication,Crohn's Disease,Completed,01-Feb-17,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception,Conditional,1st,,31-Oct-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2016-11-01,2016-12-01,2017-01-01,2017-01-25,2016-11-30,2016-11-30,2016-12-01,2018-08-01,2016-12-05,2017-02-01,01-Nov-16,2016-11-01,1.0,4.0,7.0,8.0,2.0,3.0,5.0,10.0,6.0,9.0,20.30%,52.50%,53.40%,57.80%,59.10%,59.80%,65.50%,71.10%,99.60%,100.00%,100.00%,30-Nov-16,01-Feb-17,-59.0,63.0,196.0,173.0,,,,1.0,31.0,62.0,86.0,30.0,30.0,31.0,639.0,35.0,93.0,105.0,1.0,104.0,1.0,93.0,144.0,174.0,205.0,229.0,173.0,173.0,174.0,782.0,178.0,236.0,248.0,247.0,144.0,203.0,7.0,7.0,37.0,68.0,92.0,36.0,36.0,37.0,645.0,41.0,0.0,111.0,137.0,236.0,6.0,-93.0,236.0,92.0,92.0,29.0,63.0,42668
263,Inflectra (SEB; RD),infliximab ,"Hospira HealthCare Corporation, a Pfizer Company",Y,Y,Y,N,N,N,N,N,N,,15-Jan-14,,CADTH & INESSS,17-Jun-14,post-NOC,Initial,"Ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis ",Completed,19-Dec-14,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,"Rheumatoid arthritis , ankylosing spondylitis , psoriatic arthritis and chronic plaque psoriasis",Completed,02-Feb-15,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,14-Jan-15,19-Nov-15,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2016-02-19,2016-04-01,2016-05-01,2016-04-18,2016-02-25,2016-06-01,2016-06-01,2016-06-27,2016-05-01,2015-02-02,19-Feb-16,2015-02-02,2.0,4.0,6.0,5.0,3.0,8.0,9.0,10.0,7.0,1.0,28.60%,48.80%,81.10%,85.50%,91.10%,96.80%,97.40%,98.30%,99.60%,100.00%,100.00%,25-Feb-16,25-Feb-16,153.0,201.0,185.0,182.0,26.0,-19.0,309.0,92.0,134.0,164.0,151.0,98.0,195.0,195.0,221.0,164.0,-290.0,157.0,92.0,112.0,-290.0,98.0,765.0,807.0,837.0,824.0,771.0,868.0,868.0,894.0,837.0,383.0,830.0,785.0,765.0,612.0,427.0,427.0,469.0,499.0,486.0,433.0,530.0,530.0,556.0,499.0,0.0,492.0,338.0,383.0,335.0,290.0,771.0,388.0,6.0,388.0,0.0,41992
264,Inlyta,axitinib,Pfizer,Y,N,N,Y,Y,N,Y,Y,N,,12-Jul-12,,CADTH & INESSS,16-Aug-12,post-NOC,New drug,"For the treatment of patients with metastatic renal cell carcinoma (RCC) of clear histology after failure of prior systemic therapy with either a cytokine or the VEGFR-TKI, sunitinib",Completed,07-Mar-13,Fund,Positive,02-Aug-12,post-NOC,New Drug,Metastatic Renal Cell Carcinoma,Completed,01-Feb-13,Avis de refus à défaut d'un dévelop. preuve et d'une entente de partage de risque financier,Conditional,1st,06-May-13,22-Nov-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2014-03-01,2014-03-05,2013-12-16,2014-04-16,2013-12-17,2014-04-30,2014-10-01,2018-08-01,2014-04-01,2013-02-01,16-Dec-13,2013-02-01,4.0,5.0,2.0,7.0,3.0,8.0,9.0,10.0,6.0,1.0,28.60%,34.30%,66.50%,86.80%,91.20%,91.90%,97.40%,98.30%,99.60%,100.00%,100.00%,17-Dec-13,01-Mar-14,35.0,21.0,203.0,183.0,60.0,94.0,200.0,99.0,103.0,24.0,145.0,25.0,159.0,313.0,1713.0,130.0,-294.0,301.0,24.0,242.0,-294.0,99.0,597.0,601.0,522.0,643.0,523.0,657.0,811.0,2211.0,628.0,204.0,799.0,740.0,522.0,487.0,284.0,359.0,363.0,284.0,405.0,285.0,419.0,573.0,1973.0,390.0,0.0,561.0,238.0,204.0,260.0,294.0,597.0,393.0,75.0,319.0,74.0,41340
266,Inqovi,decitabine-cedazuridine,Taiho Pharma ,N,N,N,Y,Y,Y,Y,Y,N,01-Jan-20,07-Jul-20,188.0,CADTH & INESSS,09-Oct-20,post-NOC,New drug,Myelodysplastic Syndromes (MDS),Completed,22-Sep-21,Cond'l on Cost,Conditional,15-Jan-21,post-NOC,New Drug,Myelodysplastic Syndromes (MDS),Completed,28-Jul-21,Refus d'inscription,Negative,1st,16-Feb-22,22-Apr-22,Negotiation,No Agreement Reached,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,NR,2022-11-01,2022-09-30,2022-12-01,2023-01-24,2023-01-31,2022-11-21,2023-01-01,,,,30-Sep-22,2022-09-30,2.0,1.0,4.0,6.0,7.0,3.0,5.0,,,,4.50%,24.70%,25.60%,31.30%,32.60%,38.20%,70.40%,,,,70.40%,31-Jan-23,,94.0,192.0,348.0,194.0,147.0,203.0,65.0,193.0,161.0,223.0,277.0,284.0,213.0,254.0,,,,229.0,161.0,229.0,161.0,,847.0,815.0,877.0,931.0,938.0,867.0,908.0,,,,883.0,883.0,815.0,721.0,373.0,405.0,373.0,435.0,489.0,496.0,425.0,466.0,,,,441.0,442.0,386.0,212.0,268.0,,,,123.0,,630
268,Inrebic,fedratinib,Celgene,N,N,N,Y,Y,Y,Y,Y,N,01-Oct-19,27-Jul-20,300.0,CADTH & INESSS,05-Nov-20,post-NOC,Initial,"For the treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib",Completed,21-Jun-21,Cond'l on Cost,Conditional,27-Apr-21,post-NOC,New Drug,"For the treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been previously exposed to ruxolitinib",Completed,07-Dec-21,Inscription - Avec conditions,Conditional,1st,21-Dec-21,13-May-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,2022-09-01,2022-09-30,2022-08-01,2022-09-20,2022-09-30,2022-09-26,2022-11-01,,2023-02-08,2022-05-26,01-Aug-22,2022-05-26,3.0,6.0,2.0,4.0,7.0,5.0,8.0,,9.0,1.0,28.60%,34.30%,54.60%,60.10%,61.00%,65.40%,97.70%,99.00%,99.60%,,99.60%,01-Sep-22,30-Sep-22,101.0,274.0,228.0,224.0,183.0,14.0,143.0,111.0,140.0,80.0,130.0,140.0,136.0,172.0,,271.0,13.0,148.0,80.0,133.0,13.0,140.0,766.0,795.0,735.0,785.0,795.0,791.0,827.0,,926.0,668.0,803.0,788.0,735.0,634.0,406.0,437.0,466.0,406.0,456.0,466.0,462.0,498.0,,597.0,170.0,474.0,329.0,498.0,326.0,157.0,795.0,127.0,60.0,98.0,29.0,629
269,Inspiolto Respimat,tiotropium / olodaterol,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,28-May-15,,CADTH & INESSS,04-Jun-15,post-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,17-Dec-15,List with criteria/condition,Conditional,04-Aug-15,post-NOC,New Drug,Chronic Obstructive Pulmonary Disease (COPD),Completed,01-Feb-16,Avis d'inscription aux listes de médicaments - Médicament d'exception,Conditional,1st,22-Feb-16,02-Mar-16,Negotiation,Completed with Agreements,SA,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,2016-04-05,2016-05-01,2016-05-01,2016-07-21,2016-03-30,2016-04-25,2016-05-02,2016-04-25,2016-07-01,2016-03-30,30-Mar-16,2016-03-30,3.0,6.0,7.0,10.0,1.0,4.0,8.0,5.0,9.0,2.0,32.20%,60.80%,81.10%,82.00%,82.30%,86.80%,92.50%,93.80%,94.50%,100.00%,100.00%,30-Mar-16,05-Apr-16,7.0,68.0,196.0,181.0,67.0,21.0,9.0,34.0,60.0,60.0,141.0,28.0,54.0,61.0,54.0,121.0,28.0,68.0,28.0,64.0,28.0,34.0,313.0,339.0,339.0,420.0,307.0,333.0,340.0,333.0,400.0,307.0,347.0,343.0,307.0,300.0,104.0,110.0,136.0,136.0,217.0,104.0,130.0,137.0,130.0,197.0,58.0,144.0,203.0,249.0,76.0,30.0,313.0,6.0,6.0,0.0,6.0,42355
272,Intuniv XR,guanfacine hydrochloride,Shire ,Y,N,N,Y,N,N,N,N,N,,05-Jul-13,,CADTH & INESSS,27-Aug-13,post-NOC,Initial,Attention deficit hyperactivity disorder (ADHD),Completed,24-Sep-14,Do not list ,Negative,,,New Drug,Attention deficit hyperactivity disorder (ADHD),Completed,03-Feb-14,Avis de refus - Valeur thérapeutique (monothérapie) Ajout aux listes de médicaments - Médicament d'exception (traitement d'appoint),Conditional,none,18-Nov-14,,Do Not Negotiate,,NR,NR,NR,NR,LU,NR,NR,NR,NR,EM,,,,,2020-01-31,,,,,2014-02-03,31-Jan-20,2014-02-03,,,,,2.0,,,,,1.0,28.60%,60.80%,,,,,,,,,60.80%,31-Jan-20,,53.0,,393.0,,55.0,288.0,,,,,,,,,,,,,,,,,,,,,2401.0,,,,,213.0,2401.0,1307.0,2401.0,2348.0,1955.0,,,,,1955.0,,,,,0.0,1955.0,446.0,213.0,,,,,,2188.0,,41906
276,Istodax,romidepsin,Celgene ,N,Y,N,Y,Y,Y,Y,Y,N,,16-Oct-13,,CADTH & INESSS,01-Dec-14,post-NOC,New drug,Peripheral T-Cell Lymphoma,Completed,19-May-15,Cond'l on Cost,Conditional,,,New Drug,Peripheral T-Cell lymphoma ,Completed,24-Mar-16,Avis de refus dinscription  À moins que certaines conditions soient respectées,Conditional,1st,02-Jun-15,16-Sep-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,2017-02-01,2015-12-18,2015-10-01,2016-01-01,2016-01-11,2016-07-21,2016-02-01,2019-02-01,,2016-03-24,01-Oct-15,2015-10-01,8.0,2.0,1.0,3.0,4.0,7.0,5.0,9.0,,6.0,5.70%,10.20%,15.70%,47.90%,49.20%,77.80%,78.70%,99.00%,99.30%,,99.30%,24-Mar-16,01-Feb-17,411.0,,169.0,,14.0,-296.0,106.0,504.0,93.0,15.0,107.0,117.0,309.0,138.0,1234.0,,190.0,315.0,15.0,301.0,15.0,504.0,1204.0,793.0,715.0,807.0,817.0,1009.0,838.0,1934.0,,890.0,1015.0,1001.0,715.0,304.0,135.0,624.0,213.0,135.0,227.0,237.0,429.0,258.0,1354.0,,0.0,435.0,580.0,890.0,120.0,-190.0,1204.0,489.0,489.0,175.0,314.0,42143
277,Izba,travoprost ophthalmic solution,Novartis ,Y,N,N,N,N,N,N,N,N,,23-Sep-16,,CADTH & INESSS,01-Mar-17,post-NOC,Initial,open-angle glaucoma,Completed,25-Oct-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Reduction of intraocular pressure in patients with open angle glaucoma or ocular hypertension,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,12-Apr-18,06-Dec-18,Negotiation,Completed with Agreements,NR,FB,FB,FB,LU,NR,FB,SA,FB,NR,,2019-03-01,2019-05-01,2020-03-02,2019-04-30,,2020-06-03,2022-06-27,2021-04-20,,01-Mar-19,2019-03-01,,1.0,3.0,4.0,2.0,,5.0,7.0,6.0,,4.50%,36.70%,42.40%,47.90%,49.20%,49.90%,50.30%,,,,50.30%,27-Jun-22,,159.0,182.0,238.0,208.0,169.0,176.0,238.0,,85.0,146.0,452.0,145.0,,545.0,1299.0,866.0,,505.0,85.0,505.0,85.0,,,889.0,950.0,1256.0,949.0,,1349.0,2103.0,1670.0,,1309.0,1309.0,889.0,730.0,492.0,,492.0,553.0,859.0,552.0,,952.0,1706.0,1273.0,,912.0,397.0,390.0,407.0,414.0,,,,1214.0,,43033
280,Jakavi,ruxolitinib,Novartis,Y,N,N,Y,Y,Y,Y,Y,N,,19-Jun-12,,CADTH & INESSS,25-Jun-12,post-NOC,New drug,Myelofibrosis,Completed,14-Jan-13,Cond'l on Cost,Conditional,,,New Drug,Myelofibrosis,Completed,01-Feb-13,Avis de refus à défaut d'une entente de partage de risque financier,Conditional,1st,01-Feb-13,03-Sep-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2013-11-01,2013-10-31,2013-11-25,2014-04-16,2013-09-20,2013-12-19,2014-10-01,2020-09-01,2014-01-15,2013-03-15,20-Sep-13,2013-03-15,4.0,3.0,5.0,8.0,2.0,6.0,9.0,10.0,7.0,1.0,28.60%,60.80%,65.30%,85.50%,91.20%,92.10%,92.80%,98.30%,99.60%,100.00%,100.00%,20-Sep-13,01-Nov-13,6.0,,203.0,,18.0,0.0,214.0,59.0,58.0,83.0,225.0,17.0,107.0,393.0,2555.0,134.0,-172.0,403.0,17.0,346.0,-172.0,59.0,500.0,499.0,524.0,666.0,458.0,548.0,834.0,2996.0,575.0,269.0,844.0,787.0,458.0,452.0,249.0,291.0,290.0,315.0,457.0,249.0,339.0,625.0,2787.0,366.0,42.0,635.0,209.0,227.0,232.0,214.0,500.0,231.0,42.0,189.0,42.0,41288
281,Jakavi,ruxolitinib,Novartis,Y,N,N,N,Y,Y,Y,Y,N,,24-Nov-15,,CADTH & INESSS,27-Aug-15,pre-NOC,New indication,Polycythemia vera,Completed,03-Mar-16,Cond'l on Cost,Conditional,24-Nov-15,pre-NOC,New Indication,Polycythemia vera,Completed,19-Aug-16,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments-Médicament d'exception-À moins que certaines conditions soient respectées,Conditional,1st,30-Jun-16,08-Aug-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-04-01,2018-05-08,2018-02-23,2017-10-19,2017-11-20,2018-05-08,2019-09-03,,2019-08-01,2017-11-15,19-Oct-17,2017-10-19,5.0,6.0,4.0,1.0,3.0,7.0,9.0,,8.0,2.0,5.50%,34.10%,66.30%,72.10%,92.30%,96.80%,97.70%,98.30%,99.60%,,99.60%,20-Nov-17,01-Apr-18,-89.0,0.0,189.0,269.0,119.0,-50.0,404.0,236.0,273.0,199.0,72.0,104.0,273.0,756.0,,723.0,99.0,330.0,72.0,304.0,72.0,236.0,859.0,896.0,822.0,695.0,727.0,896.0,1379.0,,1346.0,722.0,953.0,927.0,695.0,784.0,595.0,759.0,796.0,722.0,595.0,627.0,796.0,1279.0,,1246.0,453.0,853.0,100.0,269.0,523.0,354.0,859.0,164.0,164.0,32.0,132.0,42432
282,Jardiance,empagliflozin,Boehringer Ingelheim ,N,N,N,Y,N,N,N,N,N,,23-Jul-15,,CADTH & INESSS,23-Apr-15,pre-NOC,Initial,Diabetes mellitus (Type 2),Completed,15-Oct-15,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,Diabetes mellitus (Type 2),Completed,01-Jun-16,Avis d'inscription aux listes des médicaments-Médicament d'exception-Avec conditions,Conditional,1st,03-Mar-16,13-Apr-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,2019-05-27,2016-06-01,2016-05-01,2016-07-21,2016-05-31,2016-07-07,2016-07-01,2016-10-24,2016-05-02,2016-10-03,01-May-16,2016-05-01,10.0,4.0,1.0,7.0,3.0,6.0,5.0,9.0,2.0,8.0,5.70%,6.40%,38.60%,43.10%,44.40%,45.30%,50.80%,79.40%,79.70%,100.00%,100.00%,21-Jul-16,27-May-19,-91.0,124.0,175.0,190.0,140.0,-90.0,41.0,1139.0,49.0,18.0,99.0,48.0,85.0,79.0,194.0,19.0,173.0,192.0,18.0,190.0,18.0,1139.0,1404.0,314.0,283.0,364.0,313.0,350.0,344.0,459.0,284.0,438.0,457.0,455.0,283.0,374.0,199.0,1320.0,230.0,199.0,280.0,229.0,266.0,260.0,375.0,200.0,124.0,373.0,84.0,314.0,181.0,-49.0,1404.0,1121.0,1121.0,81.0,1040.0,42292
284,Jardiance,empagliflozin,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,27-Jul-16,,CADTH & INESSS,27-Apr-16,pre-NOC,Initial,"Diabetes mellitus, type 2 with high cardiovascular risk",Completed,26-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Diabetes mellitus,Completed,03-Oct-16,Avis d'inscription aux listes des médicaments-Médicament d'exception-Avec conditions,Conditional,1st,19-Aug-16,11-Sep-18,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,,2019-01-01,2019-01-01,2019-05-31,2018-10-31,2019-02-27,2019-01-01,2019-08-01,2019-10-22,2018-09-27,31-Oct-18,2018-09-27,,3.0,4.0,7.0,2.0,6.0,5.0,8.0,9.0,1.0,28.60%,60.80%,65.30%,71.00%,72.30%,73.20%,78.70%,79.10%,79.70%,,79.70%,31-Oct-18,,-91.0,,182.0,,-68.0,-45.0,753.0,,112.0,112.0,262.0,50.0,169.0,112.0,324.0,406.0,16.0,193.0,50.0,174.0,16.0,,,888.0,888.0,1038.0,826.0,945.0,888.0,1100.0,1182.0,792.0,969.0,950.0,826.0,917.0,735.0,,797.0,797.0,947.0,735.0,854.0,797.0,1009.0,1091.0,724.0,878.0,91.0,68.0,685.0,708.0,,,,34.0,,42669
287,Jentadueto (2nd pCPA),linagliptin and linagliptin-metformin ,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,07-Mar-13,,CADTH & INESSS,08-Mar-13,post-NOC,Initial,Type 2 diabetes mellitus,Completed,17-Oct-13,List with criteria/condition,Conditional,04-Aug-13,post-NOC,New Drug,Type 2 diabetes mellitus,Completed,01-Oct-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,04-Sep-15,12-Apr-16,Negotiation,Completed with Agreements,,,,,,SA,EDS,,,,,,,,,2016-10-28,2016-05-02,,,,02-May-16,2016-05-02,,,,,,2.0,1.0,,,,1.30%,2.20%,,,,,,,,,2.20%,,,1.0,150.0,223.0,58.0,687.0,703.0,221.0,,,,,,199.0,20.0,,,,110.0,20.0,110.0,20.0,,,,,,,1331.0,1152.0,,,,1242.0,1242.0,1152.0,1151.0,928.0,,,,,,1107.0,928.0,,,,1018.0,224.0,208.0,908.0,924.0,,,,,,41564
293,Juluca,dolutegravir rilpivirine,ViiV Healthcare ,N,N,N,N,N,N,N,N,N,01-Jul-17,18-May-18,321.0,CADTH & INESSS,21-Dec-17,pre-NOC,Initial,HIV infection,Completed,20-Jun-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-18,pre-NOC,New Drug,HIV,Completed,05-Jul-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,03-Aug-18,13-Feb-19,Negotiation,Completed with Agreements,UR,UR,EDS,EDS,FB,SA,HIV,FB,SA,FB,,,2020-03-01,2019-08-22,2019-04-30,2019-11-07,2019-08-01,2019-05-27,2019-10-29,2019-04-11,30-Apr-19,2019-04-11,,,8.0,5.0,2.0,7.0,4.0,3.0,6.0,1.0,28.60%,60.80%,61.20%,62.50%,68.00%,68.70%,69.60%,75.30%,,,75.30%,30-Apr-19,,-148.0,-137.0,181.0,185.0,44.0,29.0,194.0,,,382.0,190.0,76.0,267.0,169.0,103.0,258.0,57.0,206.0,76.0,188.0,57.0,,,,653.0,461.0,347.0,538.0,440.0,374.0,529.0,328.0,477.0,459.0,347.0,495.0,314.0,,,620.0,428.0,314.0,505.0,407.0,341.0,496.0,280.0,444.0,33.0,48.0,238.0,223.0,,,,19.0,,354
295,Kadcyla,trastuzumab emtansine,Hoffman-La Roche ,Y,Y,N,Y,Y,N,N,N,N,,11-Sep-13,,CADTH & INESSS,15-Mar-13,pre-NOC,New drug,Metastatic Breast Cancer,Completed,10-Jan-14,Cond'l on Cost,Conditional,24-Nov-13,post-NOC,New Drug,Metastatic Breast Cancer,Completed,02-Jun-14,Notice of Refusal to be Registered in Establishments - With Conditions,Conditional,1st,31-Jan-14,31-Mar-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2014-05-01,2014-06-20,2014-04-17,2014-05-02,2014-05-28,2014-10-01,2014-11-20,2018-08-01,2014-04-01,2016-06-15,01-Apr-14,2014-04-01,3.0,6.0,2.0,4.0,5.0,7.0,8.0,10.0,1.0,9.0,0.70%,6.40%,26.60%,32.20%,64.40%,68.90%,69.80%,71.10%,99.60%,100.00%,100.00%,28-May-14,15-Jun-16,-180.0,74.0,301.0,190.0,21.0,-122.0,59.0,31.0,81.0,17.0,32.0,58.0,184.0,234.0,1584.0,1.0,807.0,247.0,1.0,303.0,1.0,807.0,232.0,282.0,218.0,233.0,259.0,385.0,435.0,1785.0,202.0,1008.0,448.0,504.0,202.0,382.0,81.0,111.0,161.0,97.0,112.0,138.0,264.0,314.0,1664.0,81.0,744.0,327.0,121.0,264.0,80.0,-63.0,1008.0,806.0,806.0,57.0,749.0,41649
296,Kadcyla,trastuzumab emtansine,Hoffman-La Roche ,Y,Y,N,N,Y,N,N,N,Y,01-May-19,25-Nov-19,208.0,CADTH & INESSS,02-Jul-19,pre-NOC,New indication,"Early Breast Cancer (EBC): For the adjuvant treatment of patients with HER2-positive early breast cancer, who have residual disease, after pre-operative systemic treatment. ",Completed,22-Jan-20,Fund,Positive,19-Jul-19,pre-NOC,New Indication,Early Breast Cancer (EBC),Completed,05-Feb-20,Inscription - Avec conditions,Conditional,1st,21-May-20,05-Nov-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Under provincial consideration,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2021-05-01,2023-01-31,2021-08-01,,2021-02-28,,,2022-04-01,,2020-12-16,28-Feb-21,2020-12-16,3.0,6.0,4.0,,2.0,,,5.0,,1.0,28.60%,60.80%,81.10%,86.80%,87.10%,91.60%,,,,,91.60%,28-Feb-21,01-May-21,-146.0,-129.0,204.0,201.0,120.0,106.0,168.0,177.0,817.0,269.0,,115.0,,,512.0,,41.0,378.0,115.0,322.0,41.0,177.0,523.0,1163.0,615.0,,461.0,,,858.0,,387.0,724.0,668.0,461.0,607.0,403.0,465.0,1105.0,557.0,,403.0,,,800.0,,315.0,666.0,58.0,72.0,288.0,274.0,523.0,136.0,62.0,74.0,62.0,266
297,Kalydeco (CFTR G551D mutation),ivacaftor,Vertex Pharmaceuticals ,N,N,N,Y,N,Y,N,Y,N,,26-Nov-12,,CADTH & INESSS,27-Sep-12,pre-NOC,Initial,Cystic Fibrosis patients (G551D mutation),Completed,22-Mar-13,List with criteria/condition,Conditional,,,New Drug,CFTR G551D,Completed,03-Jun-13,Avis de refus,Negative,1st,31-Jan-14,16-Jun-14,Negotiation,Completed with Agreements,E,SA,EDS,EDS,EAP,SA,CF,SA,SA,EM,2015-03-19,2014-07-01,2014-09-01,2014-10-16,2014-06-20,2014-11-21,2014-10-01,2018-08-01,2015-05-01,2021-09-29,20-Jun-14,2014-06-20,7.0,2.0,3.0,5.0,1.0,6.0,4.0,9.0,8.0,10.0,32.20%,36.70%,42.40%,43.70%,49.20%,50.10%,70.40%,71.10%,71.40%,100.00%,100.00%,21-Nov-14,29-Sep-21,-60.0,,176.0,,315.0,242.0,136.0,276.0,15.0,77.0,122.0,4.0,158.0,107.0,1507.0,319.0,2662.0,287.0,4.0,525.0,4.0,2662.0,843.0,582.0,644.0,689.0,571.0,725.0,674.0,2074.0,886.0,3229.0,854.0,1092.0,571.0,631.0,455.0,727.0,466.0,528.0,573.0,455.0,609.0,558.0,1958.0,770.0,3040.0,738.0,116.0,189.0,451.0,378.0,3229.0,2658.0,2658.0,154.0,2504.0,41355
298,Kalydeco (CFTR gating mutations),ivacaftor,Vertex Pharmaceuticals ,N,N,N,N,N,Y,N,Y,N,,06-Jun-14,,CADTH & INESSS,01-May-14,pre-NOC,Initial,Cystic Fibrosis (CFTR gating mutations),Completed,19-Dec-14,List with criteria/condition,Conditional,,,New Indication,CFTR non-G551D,Completed,01-Jun-15,Avis de refus - Valeur thérapeutique,Negative,1st,27-Jan-15,24-Oct-17,Negotiation,No agreement reached,E,NR,EDS,EDS,EAP,SA,CF,SA,SA,NR,2020-02-13,,2020-07-01,2020-03-02,2019-12-20,2020-01-29,2020-02-06,2021-11-01,2020-09-10,,20-Dec-19,2019-12-20,4.0,,6.0,5.0,1.0,2.0,3.0,8.0,7.0,,32.20%,33.10%,34.40%,54.70%,60.20%,65.90%,66.60%,67.00%,,,67.00%,13-Feb-20,,-36.0,,232.0,,39.0,-125.0,1001.0,842.0,,981.0,860.0,787.0,827.0,835.0,1469.0,1052.0,,957.0,787.0,957.0,787.0,,2078.0,,2217.0,2096.0,2023.0,2063.0,2071.0,2705.0,2288.0,,2193.0,2193.0,2023.0,2059.0,1827.0,1882.0,,2021.0,1900.0,1827.0,1867.0,1875.0,2509.0,2092.0,,1997.0,196.0,360.0,1040.0,876.0,,,,55.0,,41992
299,Kalydeco (R117H CFTR gating mutation),ivacaftor,Vertex Pharmaceuticals ,N,N,N,N,N,Y,N,Y,N,,13-Mar-15,,CADTH,08-May-15,post-NOC,Initial,"Cystic Fibrosis, R117H CFTR gating mutation",Completed,19-Nov-15,List with criteria/condition,Conditional,,,,,,,,,1st,29-Mar-19,17-Jul-19,Negotiation,Completed with Agreements,E,SA,EDS,EDS,EAP,SA,CF,SA,SA,NR,2020-02-13,2020-03-01,2020-07-01,2020-03-02,2019-12-20,2020-01-29,2020-02-06,2021-11-01,2020-09-10,,20-Dec-19,2019-12-20,4.0,5.0,7.0,6.0,1.0,2.0,3.0,9.0,8.0,,32.20%,33.10%,34.40%,54.70%,59.10%,64.70%,70.40%,71.10%,71.40%,,71.40%,13-Feb-20,,56.0,,195.0,,1226.0,,110.0,211.0,228.0,350.0,229.0,156.0,196.0,204.0,838.0,421.0,,315.0,156.0,315.0,156.0,,1798.0,1815.0,1937.0,1816.0,1743.0,1783.0,1791.0,2425.0,2008.0,,1902.0,1902.0,1743.0,1687.0,1492.0,1547.0,1564.0,1686.0,1565.0,1492.0,1532.0,1540.0,2174.0,1757.0,,1651.0,251.0,,1336.0,,,,,55.0,,42327
300,Kanuma,sebelipase alfa,Alexion Pharmaceuticals,N,Y,N,Y,N,Y,Y,Y,N,01-Apr-17,15-Dec-17,258.0,CADTH & INESSS,02-Nov-17,pre-NOC,Initial,Lysosomal acid lipase deficiency,Completed,26-Sep-18,Reimburse with clinical criteria and/or conditions,Conditional,2019-06-07,post-NOC,New Drug,Lysosomal acid lipase deficiency,Completed,08-Jan-20,Refus d'inscription,Negative,1st,30-Nov-18,21-Oct-20,Negotiation,Completed with Agreements,UR,SA,UR,UR,UR,SA,EDS,UR,UR,NR,,2021-08-01,,,,2021-04-22,2021-05-01,,,,22-Apr-21,2021-04-22,,3.0,,,,1.0,2.0,,,,0.90%,2.20%,6.70%,,,,,,,,6.70%,,,-43.0,539.0,328.0,215.0,65.0,-404.0,691.0,,284.0,,,,183.0,192.0,,,,220.0,183.0,220.0,183.0,,,1325.0,,,,1224.0,1233.0,,,,1261.0,1261.0,1224.0,1267.0,939.0,,1040.0,,,,939.0,948.0,,,,976.0,285.0,754.0,756.0,287.0,,,,,,543
303,Kesimpta,ofatumumab,Novartis Pharmaceuticals Canada Inc.,Y,Y,N,N,N,N,N,N,Y,01-May-20,22-Jan-21,266.0,CADTH & INESSS,25-Aug-20,pre-NOC,Initial,"Multiple sclerosis, relapsing",Completed,25-Feb-21,Reimburse with clinical criteria and/or conditions,Conditional,25-Sep-20,pre-NOC,New Drug,Multple Sclerosis,Completed,03-Mar-21,Inscription - Avec conditions,Conditional,1st,27-Aug-21,02-Mar-22,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,2022-05-01,2022-05-01,2022-06-01,2022-03-25,2022-06-20,2022-09-01,2023-03-27,2022-11-28,2022-04-13,25-Mar-22,2022-03-25,,3.0,4.0,5.0,1.0,6.0,7.0,9.0,8.0,2.0,32.20%,60.80%,65.30%,71.00%,76.50%,77.40%,78.70%,79.40%,79.70%,,79.70%,13-Apr-22,,-150.0,-119.0,184.0,159.0,183.0,177.0,187.0,,60.0,60.0,91.0,23.0,110.0,183.0,390.0,271.0,42.0,149.0,23.0,137.0,23.0,,,464.0,464.0,495.0,427.0,514.0,587.0,794.0,675.0,446.0,553.0,541.0,427.0,577.0,393.0,,430.0,430.0,461.0,393.0,480.0,553.0,760.0,641.0,406.0,519.0,34.0,40.0,370.0,364.0,,,,19.0,,300
305,Kevzara (2nd pCPA),sarilumab,Sanofi Genzyme,Y,Y,N,Y,N,N,N,N,N,01-Mar-16,12-Jan-17,317.0,CADTH & INESSS,12-Oct-16,pre-NOC,Initial,"Arthritis, Rheumatoid",Completed,18-Apr-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,rheumatoid arthritis,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments,Negative,2nd,14-Jun-18,26-Feb-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2020-06-30,2019-04-01,2019-06-01,2019-08-22,2019-07-09,2019-08-26,2020-11-12,2019-07-22,2019-12-04,2019-04-11,01-Apr-19,2019-04-01,9.0,1.0,3.0,6.0,4.0,7.0,10.0,5.0,8.0,2.0,4.50%,33.00%,38.80%,71.00%,71.40%,76.90%,77.80%,78.40%,98.70%,100.00%,100.00%,09-Jul-19,30-Jun-20,-92.0,71.0,188.0,208.0,422.0,239.0,257.0,490.0,34.0,95.0,177.0,133.0,181.0,625.0,146.0,281.0,44.0,240.0,34.0,221.0,34.0,490.0,1265.0,809.0,870.0,952.0,908.0,956.0,1400.0,921.0,1056.0,819.0,1015.0,996.0,809.0,901.0,713.0,1169.0,713.0,774.0,856.0,812.0,860.0,1304.0,825.0,960.0,540.0,919.0,96.0,279.0,679.0,496.0,1265.0,456.0,456.0,99.0,357.0,413
306,Keytruda,pembrolizumab,Merck ,Y,Y,N,Y,Y,Y,N,Y,N,,19-May-15,,CADTH & INESSS,16-Apr-15,pre-NOC,New drug,Metastatic melanoma,Completed,16-Nov-15,Cond'l on Cost,Conditional,22-Mar-15,pre-NOC,New Drug,Metastatic Melanom,Completed,19-Aug-16,Avis d'inscription à la Liste Établissements - Médicament d'exception - Avec conditions,Conditional,1st,08-Dec-15,10-Feb-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2016-06-01,2016-07-15,2016-05-20,2016-05-30,2016-06-02,2016-06-02,2016-06-02,2016-09-01,2016-06-02,2015-11-16,20-May-16,2015-11-16,4.0,9.0,2.0,3.0,5.0,6.0,7.0,10.0,8.0,1.0,28.60%,34.30%,39.80%,60.10%,92.30%,93.20%,94.50%,95.20%,99.60%,100.00%,100.00%,01-Jun-16,02-Jun-16,-33.0,-58.0,214.0,516.0,22.0,-255.0,64.0,112.0,156.0,100.0,110.0,113.0,113.0,113.0,204.0,113.0,-86.0,126.0,100.0,105.0,-86.0,113.0,379.0,423.0,367.0,377.0,380.0,380.0,380.0,471.0,380.0,181.0,393.0,372.0,367.0,400.0,186.0,198.0,242.0,186.0,196.0,199.0,199.0,199.0,290.0,199.0,-277.0,212.0,181.0,458.0,86.0,-191.0,380.0,199.0,13.0,198.0,1.0,42324
307,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,,15-Apr-16,,CADTH & INESSS,21-Apr-16,post-NOC,New indication,"Lung, Non-Small Cell Lung Carcinoma (second Line or beyond)",Completed,03-Nov-16,Cond'l on Cost,Conditional,,,New Indication,"Lung, Non-Small Cell Lung Carcinoma (second Line or beyond)",Completed,16-Dec-16,Avis de refus d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Negative,1st,30-Jan-17,01-Nov-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-02-01,2018-02-16,2017-12-15,2017-12-07,2018-01-17,2018-05-02,2018-05-24,2019-08-01,2018-05-30,2017-11-15,07-Dec-17,2017-11-15,5.0,6.0,3.0,2.0,4.0,7.0,8.0,10.0,9.0,1.0,28.60%,34.10%,39.80%,72.10%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,17-Jan-18,01-Feb-18,6.0,,196.0,,88.0,45.0,275.0,92.0,107.0,44.0,36.0,77.0,182.0,204.0,638.0,210.0,14.0,177.0,36.0,160.0,14.0,92.0,657.0,672.0,609.0,601.0,642.0,747.0,769.0,1203.0,775.0,579.0,742.0,725.0,601.0,595.0,399.0,455.0,470.0,407.0,399.0,440.0,545.0,567.0,1001.0,573.0,334.0,540.0,202.0,245.0,363.0,320.0,657.0,78.0,56.0,63.0,15.0,42677
308,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,,12-Jul-17,,CADTH & INESSS,12-Dec-16,pre-NOC,New indication,Non-Small Cell Lung Carcinoma (First Line),Completed,23-Aug-17,Cond'l on Cost,Conditional,24-Mar-17,pre-NOC,New Indication,Non Small cell lung cancer (first line),Completed,18-Aug-17,Avis d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception - Avec conditions,Conditional,1st,08-Sep-17,01-Nov-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-02-01,2018-02-16,2017-12-07,2017-12-15,2018-01-17,2018-05-02,2018-05-24,2019-08-01,2018-05-30,2017-11-15,07-Dec-17,2017-11-15,5.0,6.0,2.0,3.0,4.0,7.0,8.0,10.0,9.0,1.0,28.60%,34.30%,39.80%,72.10%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,17-Jan-18,01-Feb-18,-212.0,-110.0,254.0,147.0,16.0,21.0,54.0,92.0,107.0,36.0,44.0,77.0,182.0,204.0,638.0,210.0,14.0,177.0,36.0,160.0,14.0,92.0,204.0,219.0,148.0,156.0,189.0,294.0,316.0,750.0,322.0,126.0,289.0,272.0,148.0,360.0,106.0,162.0,177.0,106.0,114.0,147.0,252.0,274.0,708.0,280.0,89.0,247.0,42.0,37.0,70.0,75.0,204.0,78.0,56.0,63.0,15.0,42970
309,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,Y,N,Y,N,01-Jan-17,08-Sep-17,250.0,CADTH & INESSS,07-Jul-17,pre-NOC,New indication,As monotherapy is indicated for the treatment of adult patients with refractory or relapsed classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) or who are not ASCT candidates and have failed BV,Completed,05-Jan-18,Cond'l on Cost,Conditional,,,New Indication,Recurrent or refractory classical Hodgkin lymphoma,Completed,01-Feb-18,Avis de refus d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Negative,1st,10-Oct-18,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-06-01,2020-09-15,2020-05-01,2020-05-01,2020-08-04,2020-07-16,2020-05-01,,2020-06-01,2020-04-29,01-May-20,2020-04-29,5.0,9.0,2.0,3.0,8.0,7.0,4.0,,6.0,1.0,28.60%,34.30%,39.80%,41.10%,61.40%,62.10%,63.00%,95.20%,99.60%,,99.60%,01-Jun-20,04-Aug-20,-63.0,,182.0,,278.0,251.0,553.0,47.0,153.0,16.0,16.0,111.0,92.0,16.0,,47.0,14.0,62.0,16.0,57.0,14.0,111.0,997.0,1103.0,966.0,966.0,1061.0,1042.0,966.0,,997.0,964.0,1012.0,1007.0,966.0,1029.0,847.0,878.0,984.0,847.0,847.0,942.0,923.0,847.0,,878.0,818.0,893.0,119.0,146.0,831.0,804.0,1061.0,97.0,95.0,33.0,64.0,369
310,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,01-Mar-17,20-Sep-17,203.0,CADTH & INESSS,24-Jul-17,pre-NOC,New indication,Metastatic Urothelial Carcinoma,Completed,02-Mar-18,Cond'l on Cost,Conditional,,,New Indication,Metastatic Urothelial Carcinoma,Completed,11-Apr-18,Avis de refus dajout dune indication reconnue à la Liste Établissements  Médicament dexception,Negative,1st,27-Aug-18,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-06-01,2020-09-01,2020-05-01,2020-04-22,2020-04-24,2020-07-16,2020-05-01,,2020-06-01,2020-04-29,22-Apr-20,2020-04-22,6.0,9.0,4.0,1.0,2.0,8.0,5.0,,7.0,3.0,5.50%,37.80%,66.30%,72.10%,73.40%,93.60%,94.30%,95.20%,99.60%,,99.60%,29-Apr-20,01-Jun-20,-58.0,,221.0,,178.0,138.0,597.0,47.0,139.0,16.0,7.0,9.0,92.0,16.0,,47.0,14.0,47.0,7.0,43.0,7.0,47.0,985.0,1077.0,954.0,945.0,947.0,1030.0,954.0,,985.0,952.0,985.0,981.0,945.0,1003.0,782.0,822.0,914.0,791.0,782.0,784.0,867.0,791.0,,822.0,749.0,822.0,163.0,203.0,775.0,735.0,985.0,40.0,40.0,7.0,33.0,366
311,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,01-May-18,13-Mar-19,316.0,CADTH & INESSS,14-Sep-18,pre-NOC,New indication,Non-Squamous NSCLC,Completed,31-May-19,Cond'l on Cost,Conditional,20-Sep-18,pre-NOC,New Indication,Non-Squamous NSCLC,Completed,08-May-19,Inscription - Avec conditions,Conditional,1st,13-Aug-19,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-06-01,2020-09-15,2020-05-01,2020-05-01,2020-04-24,2020-07-16,2020-05-01,,2020-06-01,2020-04-29,24-Apr-20,2020-04-24,6.0,9.0,3.0,4.0,1.0,8.0,5.0,,7.0,2.0,32.20%,60.80%,66.50%,72.10%,73.40%,93.60%,94.30%,95.20%,99.60%,,99.60%,29-Apr-20,01-Jun-20,-180.0,-174.0,259.0,230.0,74.0,97.0,246.0,47.0,153.0,16.0,16.0,9.0,92.0,16.0,,47.0,14.0,50.0,9.0,46.0,9.0,47.0,446.0,552.0,415.0,415.0,408.0,491.0,415.0,,446.0,413.0,449.0,445.0,408.0,588.0,329.0,367.0,473.0,336.0,336.0,329.0,412.0,336.0,,367.0,357.0,370.0,79.0,56.0,320.0,343.0,446.0,38.0,38.0,5.0,33.0,395
312,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,Y,N,Y,N,01-Jun-18,02-Apr-19,305.0,CADTH & INESSS,13-Dec-18,pre-NOC,New indication,Melanoma Adjuvant Treatment,Completed,01-Aug-19,Cond'l on Cost,Conditional,05-Dec-18,pre-NOC,New Indication,Melanoma Adjuvant Treatment,Completed,05-Jun-19,Inscription - Avec conditions,Conditional,1st,13-Sep-19,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-06-01,2020-09-15,2020-05-01,2020-05-04,2020-08-04,2020-07-16,2020-05-01,,2020-06-01,2020-04-29,01-May-20,2020-04-29,5.0,9.0,2.0,4.0,8.0,7.0,3.0,,6.0,1.0,28.60%,34.30%,35.60%,41.10%,61.40%,62.10%,63.00%,95.20%,99.60%,,99.60%,01-Jun-20,04-Aug-20,-110.0,-118.0,231.0,182.0,43.0,100.0,215.0,47.0,153.0,16.0,19.0,111.0,92.0,16.0,,47.0,14.0,63.0,16.0,57.0,14.0,111.0,426.0,532.0,395.0,398.0,490.0,471.0,395.0,,426.0,393.0,442.0,436.0,395.0,505.0,274.0,305.0,411.0,274.0,277.0,369.0,350.0,274.0,,305.0,329.0,321.0,121.0,64.0,258.0,315.0,490.0,97.0,95.0,33.0,64.0,426
313,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,01-Oct-18,04-Jul-19,276.0,CADTH & INESSS,08-Feb-19,pre-NOC,New indication,Squamous NSCLC,Completed,03-Jan-20,Cond'l on Cost,Conditional,22-Feb-19,pre-NOC,New Indication,Squamous NSCLC,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,22-Jan-20,15-Apr-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-06-01,2020-09-15,2020-05-01,2020-04-30,2020-06-10,2020-07-16,2022-04-29,,2020-06-01,2020-04-29,30-Apr-20,2020-04-29,4.0,8.0,3.0,2.0,6.0,7.0,9.0,,5.0,1.0,28.60%,34.10%,39.80%,60.10%,60.80%,93.00%,93.90%,98.30%,99.60%,,99.60%,01-Jun-20,10-Jun-20,-146.0,-132.0,329.0,201.0,19.0,133.0,84.0,47.0,153.0,16.0,15.0,56.0,92.0,744.0,,47.0,14.0,146.0,15.0,132.0,14.0,56.0,333.0,439.0,302.0,301.0,342.0,378.0,1030.0,,333.0,300.0,432.0,418.0,301.0,447.0,118.0,150.0,256.0,119.0,118.0,159.0,195.0,847.0,,150.0,231.0,249.0,183.0,69.0,103.0,217.0,342.0,42.0,41.0,33.0,9.0,459
315,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,N,01-Aug-18,16-Dec-19,502.0,CADTH & INESSS,02-Aug-19,pre-NOC,New indication,"For the treatment of patients with advanced renal cell carcinoma (RCC) in combination with axinitib, as first-line treatment.",Completed,02-Apr-20,Cond'l on Cost,Conditional,02-Jul-19,pre-NOC,New Indication,"For the treatment of patients with advanced renal cell carcinoma (RCC) in combination with axinitib, as first-line treatment.",Completed,04-Mar-20,Inscription - Avec conditions,Conditional,1st,11-May-20,01-Dec-20,Negotiation,Completed with Agreements,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,Funded,Funded,Under provincial consideration,EM,2021-03-01,2021-02-28,,2021-01-21,2021-03-31,,2021-03-31,,,2020-12-16,21-Jan-21,2020-12-16,4.0,3.0,,2.0,5.0,,6.0,,,1.0,28.60%,34.10%,38.60%,58.80%,91.10%,92.40%,,,,,92.40%,01-Mar-21,31-Mar-21,-136.0,-167.0,244.0,246.0,39.0,68.0,204.0,90.0,89.0,,51.0,120.0,,120.0,,,15.0,94.0,51.0,81.0,15.0,120.0,441.0,440.0,,402.0,471.0,,471.0,,,366.0,445.0,432.0,402.0,538.0,294.0,333.0,332.0,,294.0,363.0,,363.0,,,287.0,337.0,108.0,79.0,243.0,272.0,471.0,105.0,69.0,75.0,30.0,610
316,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,Y,01-Dec-19,09-Oct-20,313.0,CADTH & INESSS,01-May-20,pre-NOC,New indication,"First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression [Combined Positive Score (CPS) ? 1] as determined by a validated test. First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in combination with platinum and fluorouracil (FU) chemotherapy, in adult patients.",Completed,22-Dec-20,Cond'l on Cost,Conditional,29-May-20,pre-NOC,New Indication,Head and Neck Squamous Cell Carcinoma (HNSCC),Completed,02-Dec-20,Inscription - Avec conditions,Conditional,1st,10-Feb-21,10-Feb-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2021-08-01,2021-07-31,2021-08-01,2023-02-28,2021-09-30,,,,,2021-03-03,31-Jul-21,2021-03-03,3.0,2.0,4.0,6.0,5.0,,,,,1.0,28.60%,33.00%,53.30%,59.00%,91.20%,96.80%,,,,,96.80%,01-Aug-21,30-Sep-21,-161.0,-133.0,235.0,187.0,50.0,70.0,0.0,172.0,171.0,172.0,748.0,232.0,,,,,21.0,299.0,171.0,253.0,21.0,232.0,296.0,295.0,296.0,872.0,356.0,,,,,145.0,423.0,377.0,295.0,456.0,221.0,222.0,221.0,222.0,798.0,282.0,,,,,91.0,349.0,74.0,54.0,50.0,70.0,356.0,211.0,61.0,151.0,60.0,387
317,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,N,N,N,Y,01-Jul-20,03-Mar-21,245.0,CADTH & INESSS,30-Nov-20,pre-NOC,Initial,For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC),Completed,27-Jul-21,Cond'l on Cost,Conditional,01-Jan-21,pre-NOC,New Indication,For the first line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC).,Completed,09-Jun-21,Inscription - Avec conditions,Conditional,1st,11-Aug-21,11-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2022-02-01,2022-02-28,2021-12-01,2022-01-11,2022-02-28,,,,,2021-09-29,01-Dec-21,2021-09-29,4.0,5.0,2.0,3.0,6.0,,,,,1.0,28.60%,34.30%,39.80%,60.10%,64.50%,96.80%,,,,,96.80%,01-Feb-22,28-Feb-22,-93.0,-61.0,239.0,159.0,15.0,63.0,0.0,174.0,201.0,112.0,153.0,201.0,,,,,49.0,168.0,112.0,148.0,49.0,201.0,335.0,362.0,273.0,314.0,362.0,,,,,210.0,329.0,309.0,273.0,366.0,127.0,189.0,216.0,127.0,168.0,216.0,,,,,112.0,183.0,146.0,98.0,15.0,63.0,362.0,152.0,89.0,125.0,27.0,391
318,Keytruda,pembrolizumab,Merck ,Y,Y,N,N,Y,Y,N,Y,N,01-Jun-20,05-Feb-21,249.0,CADTH & INESSS,29-Jan-21,pre-NOC,Initial,"Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT",Completed,01-Nov-21,Cond'l on Cost,Conditional,23-Apr-21,post-NOC,New Indication,"Adult and pediatric patients with refractory or relapsed classical Hodgkin Lymphoma (cHL), as monotherapy, who have failed autologous stem cell transplant (ASCT) or who are not candidates for multi-agent salvage chemotherapy and ASCT.",Completed,03-Nov-21,Inscription - Avec conditions,Conditional,1st,18-Nov-21,18-Nov-21,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,,,,2023-03-01,2023-01-31,,,,,2021-12-15,31-Jan-23,2021-12-15,,,,3.0,2.0,,,,,1.0,28.60%,60.80%,66.30%,,,,,,,,66.30%,31-Jan-23,,-7.0,77.0,276.0,194.0,17.0,15.0,0.0,,,,468.0,439.0,,,,,27.0,454.0,439.0,311.0,27.0,,,,,754.0,725.0,,,,,313.0,740.0,597.0,725.0,732.0,456.0,,,,485.0,456.0,,,,,42.0,471.0,269.0,271.0,17.0,15.0,,,,412.0,,518
319,Keytruda,pembrolizumab,Merck,Y,Y,N,N,Y,Y,N,Y,N,01-Dec-20,04-Jun-21,185.0,CADTH & INESSS,26-May-21,pre-NOC,Initial,"First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients.",Completed,20-Dec-21,Cond'l on Cost,Conditional,20-Aug-21,post-NOC,New Indication,"First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients.",Completed,02-Mar-22,Inscription - Avec conditions,Conditional,1st,11-Feb-22,11-Feb-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,2022-07-01,2022-05-31,2022-06-01,2023-02-28,2022-08-31,,,,,2022-04-13,31-May-22,2022-04-13,4.0,2.0,3.0,6.0,5.0,,,,,1.0,28.60%,33.00%,38.80%,59.00%,91.20%,96.80%,,,,,96.80%,01-Jul-22,31-Aug-22,-9.0,77.0,208.0,194.0,53.0,-19.0,0.0,140.0,109.0,110.0,382.0,201.0,,,,,61.0,188.0,109.0,167.0,61.0,201.0,392.0,361.0,362.0,634.0,453.0,,,,,313.0,440.0,419.0,361.0,370.0,162.0,193.0,162.0,163.0,435.0,254.0,,,,,42.0,241.0,199.0,271.0,53.0,-19.0,453.0,140.0,92.0,79.0,61.0,384
330,Kisqali,ribociclib,Novartis,Y,N,N,Y,Y,N,N,N,N,01-May-17,02-Mar-18,305.0,CADTH & INESSS,17-Oct-17,pre-NOC,New drug,"For the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as an initial endocrine-based therapy",Completed,18-Apr-18,Cond'l on Cost,Conditional,,,New Drug,Advanced or Metastatic Breast Cancer,Completed,06-Jun-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,17-Aug-18,26-Apr-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2019-10-01,2019-11-19,2019-11-04,2020-03-02,2020-08-14,2020-01-20,2019-11-01,,,2019-07-04,01-Oct-19,2019-07-04,2.0,5.0,4.0,7.0,8.0,6.0,3.0,,,1.0,28.60%,48.80%,50.10%,55.90%,60.30%,61.20%,66.70%,99.00%,,,99.00%,01-Nov-19,14-Aug-20,-136.0,,183.0,,121.0,72.0,252.0,158.0,207.0,192.0,311.0,476.0,269.0,189.0,,,69.0,257.0,158.0,234.0,69.0,476.0,578.0,627.0,612.0,731.0,896.0,689.0,609.0,,,489.0,677.0,654.0,578.0,714.0,531.0,531.0,580.0,565.0,684.0,849.0,642.0,562.0,,,393.0,630.0,47.0,96.0,373.0,324.0,896.0,407.0,318.0,120.0,287.0,352
331,Kisqali,ribociclib,Novartis,Y,N,N,N,Y,N,N,N,N,01-Apr-19,07-Feb-20,312.0,CADTH & INESSS,26-Aug-19,pre-NOC,New indication,"In combination with an aromatase inhibitor (AI) and a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of pre/peri- menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy",Completed,04-Jun-20,Cond'l on Cost,Conditional,27-Sep-19,pre-NOC,New Indication,"In combination with an aromatase inhibitor (AI) and a luteinizing hormone releasing hormone (LHRH) agonist for the treatment of pre/peri- menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer, as initial endocrine-based therapy",Completed,14-May-20,Inscription- Avec conditions,Conditional,1st,22-Jun-20,14-Jul-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,EM,2021-02-01,2020-07-31,2020-08-01,2020-10-22,2021-04-30,2020-09-17,,2022-12-12,2023-03-31,2020-08-19,31-Jul-20,2020-07-31,6.0,1.0,2.0,5.0,7.0,4.0,,8.0,9.0,3.0,4.50%,10.20%,38.80%,39.70%,45.20%,65.40%,97.70%,98.00%,98.70%,,98.70%,01-Feb-21,30-Apr-21,-165.0,-133.0,283.0,230.0,18.0,39.0,22.0,202.0,17.0,18.0,100.0,290.0,65.0,,881.0,990.0,36.0,320.0,17.0,289.0,17.0,290.0,360.0,175.0,176.0,258.0,448.0,223.0,,1039.0,1148.0,194.0,478.0,447.0,175.0,340.0,57.0,242.0,57.0,58.0,140.0,330.0,105.0,,921.0,1030.0,97.0,360.0,118.0,97.0,40.0,61.0,448.0,273.0,273.0,185.0,88.0,430
332,Kisqali,ribociclib with fulvestrant,Novartis,Y,N,N,N,Y,N,N,N,N,01-Apr-19,07-Feb-20,312.0,CADTH & INESSS,26-Aug-19,pre-NOC,New indication,"+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer",Completed,22-Apr-20,Cond'l on Cost,Conditional,11-Oct-19,pre-NOC,New Indication,"+Fulvestrant for HR+, HER2- advanced or metastatic breast cancer",Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,11-May-20,14-Jul-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,EM,2021-02-01,2021-04-30,2020-08-01,2020-10-22,2021-04-30,2020-09-17,,2022-12-12,2023-03-31,2020-08-19,01-Aug-20,2020-08-01,5.0,6.0,1.0,4.0,7.0,3.0,,8.0,9.0,2.0,5.70%,34.30%,35.20%,40.70%,61.00%,65.40%,97.70%,98.00%,98.70%,,98.70%,01-Feb-21,30-Apr-21,-165.0,-119.0,240.0,216.0,19.0,-3.0,64.0,202.0,290.0,18.0,100.0,290.0,65.0,,881.0,990.0,36.0,355.0,18.0,319.0,18.0,290.0,360.0,448.0,176.0,258.0,448.0,223.0,,1039.0,1148.0,194.0,513.0,477.0,176.0,341.0,101.0,285.0,373.0,101.0,183.0,373.0,148.0,,964.0,1073.0,97.0,438.0,75.0,97.0,83.0,61.0,448.0,272.0,272.0,184.0,88.0,387
333,Komboglyze,saxagliptin + metformin ,Bristol-Myers Squibb & AstraZeneca ,Y,N,N,N,N,N,N,N,N,,02-Aug-13,,CADTH & INESSS,23-Aug-13,post-NOC,Initial,"Diabetes Mellitus, Type 2 ",Completed,20-Jun-14,List with criteria/condition,Conditional,04-Aug-13,post-NOC,New Drug,"Diabetes Mellitus, Type 2 ",Completed,01-Oct-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,none,30-Sep-14,,Negotiation by Province,,SA,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,2014-08-05,2017-04-01,2015-01-01,2015-01-19,2014-11-27,2015-07-23,2015-04-01,2015-07-27,2015-07-01,2013-10-01,05-Aug-14,2013-10-01,2.0,10.0,4.0,5.0,3.0,8.0,6.0,9.0,7.0,1.0,28.60%,48.80%,81.10%,86.80%,92.30%,93.60%,94.30%,95.20%,95.50%,100.00%,100.00%,27-Nov-14,27-Nov-14,21.0,2.0,301.0,58.0,102.0,364.0,,,,,,,,,,,,,,,,,368.0,1338.0,517.0,535.0,482.0,720.0,607.0,724.0,698.0,60.0,665.0,605.0,368.0,347.0,46.0,46.0,1016.0,195.0,213.0,160.0,398.0,285.0,402.0,376.0,0.0,343.0,322.0,60.0,,,482.0,422.0,114.0,422.0,0.0,41810
337,Kynmobi,apomorphine hydrochloride,Sunovion Pharmaceuticals Canada Inc.,N,N,N,N,N,N,N,N,N,01-Aug-18,12-Jun-20,681.0,CADTH & INESSS,25-Jun-20,post-NOC,Initial,Parkinson's disease,Completed,24-Feb-21,Reimburse with clinical criteria and/or conditions,Conditional,26-Apr-19,pre-NOC,New drug,Parkinsons disease,Completed,30-Dec-20,Inscription - Avec conditions,Conditional,1st,03-Sep-21,04-Apr-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,,SA,EM,2022-06-27,2022-10-01,2022-08-01,2022-09-20,2022-08-15,2022-06-20,2022-11-01,,2022-08-19,2021-05-26,20-Jun-22,2021-05-26,3.0,8.0,4.0,7.0,5.0,2.0,9.0,,6.0,1.0,28.60%,29.50%,49.70%,55.40%,87.70%,88.30%,93.90%,98.30%,99.60%,,99.60%,01-Aug-22,15-Aug-22,13.0,-413.0,244.0,614.0,191.0,247.0,213.0,84.0,180.0,119.0,169.0,133.0,77.0,211.0,,137.0,-313.0,139.0,77.0,89.0,-313.0,133.0,745.0,841.0,780.0,830.0,794.0,738.0,872.0,,798.0,348.0,800.0,750.0,738.0,725.0,481.0,488.0,584.0,523.0,573.0,537.0,481.0,615.0,,541.0,147.0,543.0,257.0,201.0,404.0,460.0,794.0,446.0,56.0,432.0,14.0,938
339,Kyprolis,carfilzomib,Amgen ,Y,N,N,N,Y,Y,Y,Y,N,,22-Nov-16,,CADTH & INESSS,09-Sep-16,pre-NOC,New indication,Multiple myeloma (relapsed),Completed,30-Mar-17,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Multiple Myeloma ((with lenalidomide),Completed,01-Jun-17,Avis de refus d'inscription à la Liste Établissements,Negative,1st,02-Jun-17,08-Dec-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-04-01,2018-10-30,2018-08-15,2018-03-09,2018-05-01,2018-09-27,2018-10-15,,2018-07-03,2018-07-05,09-Mar-18,2018-03-09,2.0,9.0,6.0,1.0,3.0,7.0,8.0,,4.0,5.0,5.50%,25.80%,58.00%,58.70%,87.30%,93.00%,93.90%,95.20%,99.60%,,99.60%,01-May-18,05-Jul-18,-74.0,2.0,202.0,189.0,64.0,1.0,189.0,114.0,326.0,250.0,91.0,144.0,293.0,311.0,,207.0,209.0,217.0,91.0,216.0,91.0,209.0,495.0,707.0,631.0,472.0,525.0,674.0,692.0,,588.0,590.0,598.0,597.0,472.0,546.0,344.0,367.0,579.0,503.0,344.0,397.0,546.0,564.0,,460.0,399.0,470.0,128.0,191.0,253.0,190.0,590.0,118.0,118.0,53.0,65.0,42824
340,Kyprolis (with lenalidomide),carfilzomib (with lenalidomide),Amgen ,Y,N,N,Y,Y,Y,Y,Y,N,01-Jul-15,15-Jan-16,198.0,CADTH & INESSS,11-Dec-15,pre-NOC,New drug,Multiple Myeloma,Completed,11-Nov-16,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,Multiple Myeloma,Completed,03-Oct-16,Avis de refus d'inscription à la Liste Établissements,Negative,1st,14-Oct-16,08-Dec-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-04-01,2018-10-30,2018-08-15,2018-03-09,2018-05-01,2018-09-27,2018-10-15,,2018-07-03,2018-07-05,09-Mar-18,2018-03-09,2.0,9.0,6.0,1.0,3.0,7.0,8.0,,4.0,5.0,5.50%,25.80%,58.00%,58.70%,87.30%,93.00%,93.90%,95.20%,99.60%,,99.60%,01-May-18,05-Jul-18,-35.0,67.0,336.0,195.0,-28.0,11.0,420.0,114.0,326.0,250.0,91.0,144.0,293.0,311.0,,207.0,209.0,217.0,91.0,216.0,91.0,209.0,807.0,1019.0,943.0,784.0,837.0,986.0,1004.0,,900.0,902.0,910.0,909.0,784.0,819.0,483.0,506.0,718.0,642.0,483.0,536.0,685.0,703.0,,599.0,640.0,609.0,301.0,262.0,392.0,431.0,902.0,118.0,118.0,53.0,65.0,499
341,Lancora,ivabradine,Servier,N,N,N,Y,N,N,N,N,N,,23-Dec-16,,CADTH & INESSS,08-Nov-16,pre-NOC,Initial,"Heart failure, NYHA class II or III",Completed,24-May-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,treatment of heart failure,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,08-Dec-17,22-Aug-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2018-10-30,2018-12-01,2018-10-01,2019-01-24,2018-10-31,2018-12-17,2019-01-01,2019-08-01,2018-12-18,2018-09-27,01-Oct-18,2018-09-27,3.0,5.0,2.0,9.0,4.0,6.0,8.0,10.0,7.0,1.0,28.60%,34.30%,54.60%,86.80%,91.20%,92.10%,92.80%,94.10%,99.60%,100.00%,100.00%,30-Oct-18,31-Oct-18,-45.0,91.0,197.0,208.0,198.0,51.0,257.0,69.0,101.0,40.0,155.0,70.0,117.0,132.0,344.0,118.0,36.0,127.0,40.0,118.0,36.0,70.0,676.0,708.0,647.0,762.0,677.0,724.0,739.0,951.0,725.0,643.0,734.0,725.0,647.0,692.0,495.0,524.0,556.0,495.0,610.0,525.0,572.0,587.0,799.0,573.0,344.0,582.0,152.0,299.0,455.0,308.0,677.0,34.0,30.0,33.0,1.0,42879
342,Lapelga,pegfilgrastim,Apobiologix,N,Y,Y,N,N,N,N,N,N,01-Jun-17,05-Apr-18,308.0,CADTH & INESSS,23-Feb-18,pre-NOC,Initial,Febrile neutropenia,Completed,30-Apr-18,Not Applicable: Biosimilar,,01-Feb-18,pre-NOC,New Drug,Neutropenia,Completed,08-Aug-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,10-Oct-18,28-Feb-19,Negotiation,Completed with Agreements,NR,SA,UR,UR,FB,SA,EDS,SA,SA,EM,,2019-06-01,,,2019-08-30,2019-07-04,2020-04-22,2021-12-20,2020-09-09,2020-04-29,01-Jun-19,2019-06-01,,1.0,,,3.0,2.0,4.0,7.0,6.0,5.0,4.50%,5.30%,37.60%,38.90%,67.50%,68.10%,68.50%,,,,68.50%,29-Apr-20,,-41.0,-63.0,66.0,188.0,163.0,63.0,141.0,,93.0,,,183.0,126.0,419.0,1026.0,559.0,426.0,401.0,93.0,405.0,93.0,,,422.0,,,512.0,455.0,748.0,1355.0,888.0,755.0,730.0,734.0,422.0,463.0,397.0,,397.0,,,487.0,430.0,723.0,1330.0,863.0,630.0,705.0,25.0,125.0,304.0,204.0,,,,333.0,,333
346,Ledaga,chlormethine hydrochloride,Recordati Rare Diseases Canada Inc.,N,N,N,Y,Y,N,Y,Y,N,01-Aug-20,08-Jun-21,311.0,CADTH & INESSS,21-Dec-20,pre-NOC,Initial,Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients,Completed,24-Nov-21,Do Not Fund,Negative,23-Apr-21,pre-NOC,New Drug,Topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients,Completed,08-Oct-21,Inscription - Avec conditions,Conditional,1st,21-Oct-22,27-Jan-23,Negotiation,No Agreement Reached,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Not funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,UR,2022-05-01,,,,,,,,,,01-May-22,2022-05-01,1.0,,,,,,,,,,20.30%,,,,,,,,,,20.30%,,,-169.0,-46.0,338.0,168.0,331.0,378.0,98.0,-271.0,,,,,,,,,,-271.0,-271.0,-271.0,-271.0,,327.0,,,,,,,,,,327.0,327.0,327.0,496.0,158.0,158.0,,,,,,,,,,158.0,169.0,122.0,429.0,476.0,,,,,,480
347,Lemtrada,alemtuzumab ,Sanofi Genzyme,Y,Y,N,N,N,N,N,N,N,,12-Dec-13,,CADTH & INESSS,27-Nov-14,post-NOC,Initial,relapsing remitting multiple sclerosis,Completed,18-Jun-15,List with criteria/condition,Conditional,22-Mar-14,post-NOC,New Drug,relapsing remitting multiple sclerosis,Completed,01-Oct-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,28-Jul-15,11-May-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,NR,EM,2018-02-06,2016-09-01,2016-07-01,2016-07-21,2016-07-06,2016-08-24,2016-12-01,2017-08-07,,2014-10-01,01-Jul-16,2014-10-01,9.0,6.0,2.0,4.0,3.0,5.0,7.0,8.0,,1.0,28.60%,34.30%,66.50%,72.10%,73.00%,77.40%,78.70%,79.10%,99.30%,,99.30%,06-Jul-16,06-Feb-18,350.0,100.0,203.0,193.0,40.0,300.0,288.0,636.0,113.0,51.0,71.0,56.0,105.0,204.0,453.0,,-588.0,211.0,51.0,122.0,-588.0,636.0,1517.0,994.0,932.0,952.0,937.0,986.0,1085.0,1334.0,,293.0,1092.0,1003.0,932.0,582.0,379.0,964.0,441.0,379.0,399.0,384.0,433.0,532.0,781.0,,0.0,539.0,553.0,293.0,328.0,588.0,1517.0,1224.0,585.0,644.0,580.0,42173
349,Lenvima,lenvatinib,Eisai Ltd.,N,N,N,Y,Y,Y,Y,Y,N,,22-Dec-15,,CADTH & INESSS,18-Apr-16,post-NOC,New drug,Differentiated Thyroid Cancer,Completed,20-Sep-16,Cond'l on Cost,Conditional,22-Mar-16,post-NOC,New Drug,Differentiated Thyroid Cancer,Completed,03-Oct-16,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions: 10mg & 14mg----Avis de refus d'inscription aux listes des médicaments: 20mg & 24 mg,Conditional,1st,04-Apr-17,16-Jun-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-10-01,2017-11-28,2017-08-02,2017-10-19,2017-09-12,2017-12-15,2018-04-09,2023-02-20,2018-05-10,2017-08-18,02-Aug-17,2017-08-02,4.0,6.0,1.0,5.0,3.0,7.0,8.0,10.0,9.0,2.0,5.70%,34.30%,66.50%,86.80%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,12-Sep-17,01-Oct-17,118.0,91.0,155.0,195.0,196.0,183.0,73.0,107.0,165.0,47.0,125.0,88.0,182.0,297.0,2075.0,328.0,63.0,379.0,47.0,348.0,47.0,107.0,649.0,707.0,589.0,667.0,630.0,724.0,839.0,2617.0,870.0,605.0,921.0,890.0,589.0,471.0,316.0,376.0,434.0,316.0,394.0,357.0,451.0,566.0,2344.0,597.0,319.0,648.0,273.0,286.0,269.0,256.0,649.0,60.0,60.0,41.0,19.0,42633
351,Lenvima,lenvatinib,Eisai Ltd.,N,N,N,N,Y,Y,Y,Y,N,01-Feb-18,19-Dec-18,321.0,CADTH & INESSS,08-Feb-19,post-NOC,New indication,Hepatocellular Carcinoma,Completed,24-Jul-19,Cond'l on Cost,Conditional,15-Mar-19,post-NOC,New Indication,Hepatocellular Carcinoma,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,27-Sep-19,08-Nov-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-07-01,2020-04-10,2020-03-01,2020-04-02,2020-03-05,2020-07-16,2022-04-29,2021-07-12,2020-09-02,2019-12-18,01-Mar-20,2019-12-18,6.0,5.0,2.0,4.0,3.0,7.0,10.0,9.0,8.0,1.0,28.60%,34.30%,66.50%,72.10%,76.50%,96.80%,97.70%,98.30%,98.70%,100.00%,100.00%,05-Mar-20,01-Jul-20,51.0,86.0,166.0,180.0,65.0,16.0,42.0,236.0,154.0,114.0,146.0,118.0,251.0,903.0,612.0,299.0,40.0,315.0,114.0,287.0,40.0,236.0,560.0,478.0,438.0,470.0,442.0,575.0,1227.0,936.0,623.0,364.0,639.0,611.0,438.0,387.0,221.0,343.0,261.0,221.0,253.0,225.0,358.0,1010.0,719.0,406.0,98.0,422.0,217.0,266.0,107.0,58.0,560.0,196.0,122.0,78.0,118.0,538
354,Libtayo,cemiplimab,Sanofi Genzyme,Y,Y,N,Y,Y,N,N,N,N,01-Aug-18,10-Apr-19,252.0,CADTH & INESSS,09-Jul-19,post-NOC,New drug,Cutaneous Squamous Cell Carcinoma,Completed,22-Jan-20,Cond'l on Cost,Conditional,09-Aug-19,post-NOC,New Drug,Cutaneous Squamous Cell Carcinoma,Completed,04-Mar-20,Inscription - Avec conditions,Conditional,1st,08-Jun-20,04-Nov-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,,Under provincial consideration,EM,2021-02-01,2021-04-30,2021-01-01,2021-11-24,2021-02-28,,,,,2020-12-16,01-Jan-21,2020-12-16,3.0,5.0,2.0,6.0,4.0,,,,,1.0,28.60%,34.30%,54.60%,86.80%,91.20%,96.80%,,,,,96.80%,01-Feb-21,28-Feb-21,90.0,121.0,197.0,208.0,138.0,96.0,149.0,89.0,177.0,58.0,385.0,116.0,,,,,42.0,165.0,58.0,145.0,42.0,116.0,663.0,751.0,632.0,959.0,690.0,,,,,616.0,739.0,719.0,632.0,542.0,345.0,376.0,464.0,345.0,672.0,403.0,,,,,287.0,452.0,287.0,329.0,287.0,245.0,690.0,74.0,58.0,47.0,27.0,539
358,Lixiana NVAF,edoxaban,Daiichi Sankyo,N,N,N,Y,N,N,N,N,N,01-Dec-15,04-Nov-16,339.0,CADTH & INESSS,09-Sep-16,pre-NOC,Initial,"Nonvalvular atrial fibrillation, prevention of stroke and systemic embolism",Completed,21-Mar-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Prevention of stroke and the systemic embolic event in people with atrial fibrilation,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,20-Jul-18,05-Feb-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,,2019-03-01,2019-04-01,2019-05-31,2019-04-30,2019-07-04,2019-06-01,2019-07-22,2019-05-01,2019-03-07,01-Mar-19,2019-03-01,,1.0,3.0,6.0,4.0,8.0,7.0,9.0,5.0,2.0,4.50%,33.00%,38.80%,71.00%,71.70%,77.20%,78.50%,79.40%,79.70%,,79.70%,30-Apr-19,,-56.0,140.0,193.0,208.0,486.0,275.0,200.0,,24.0,55.0,115.0,84.0,149.0,116.0,167.0,85.0,30.0,99.0,24.0,92.0,24.0,,,847.0,878.0,938.0,907.0,972.0,939.0,990.0,908.0,853.0,922.0,915.0,847.0,903.0,710.0,,710.0,741.0,801.0,770.0,835.0,802.0,853.0,771.0,505.0,785.0,137.0,348.0,686.0,475.0,,,,60.0,,476
359,Lixiana VTE,edoxaban,Daiichi Sankyo,N,N,N,Y,N,N,N,N,N,01-Dec-15,04-Nov-16,339.0,CADTH & INESSS,09-Sep-16,pre-NOC,Initial,"Venous thromboembolism, treatment and recurrence prevention",Completed,25-May-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Treatment of venous thromboembolism,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,20-Jul-18,05-Feb-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,,2019-03-01,2019-04-01,2019-05-31,2019-04-30,2019-07-04,2019-06-01,2019-07-22,2019-05-01,2019-03-07,01-Mar-19,2019-03-01,,1.0,3.0,6.0,4.0,8.0,7.0,9.0,5.0,2.0,4.50%,33.00%,38.80%,71.00%,71.70%,77.20%,78.50%,79.40%,79.70%,,79.70%,30-Apr-19,,-56.0,140.0,258.0,208.0,421.0,275.0,200.0,,24.0,55.0,115.0,84.0,149.0,116.0,167.0,85.0,30.0,99.0,24.0,92.0,24.0,,,847.0,878.0,938.0,907.0,972.0,939.0,990.0,908.0,853.0,922.0,915.0,847.0,903.0,645.0,,645.0,676.0,736.0,705.0,770.0,737.0,788.0,706.0,505.0,720.0,202.0,348.0,621.0,475.0,,,,60.0,,541
361,Lonsurf,trifluridine and tipiracil,Taiho Pharma,N,N,N,Y,Y,N,N,N,N,01-Jul-17,25-Jan-18,208.0,CADTH & INESSS,06-Nov-17,pre-NOC,New drug,Metastatic Colorectal Cancer,Completed,06-Jul-18,Do Not Fund,Negative,,,New Drug,CRC,Completed,06-Jun-18,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,30-May-19,08-Aug-19,Negotiation,Completed with Agreements,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,EM,,,,,,,,,,2019-08-15,,2019-08-15,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,-80.0,,242.0,,328.0,358.0,70.0,,,,,,,,,,7.0,,,7.0,7.0,,,,,,,,,,,567.0,,567.0,,,,,,,,,,,,,435.0,,162.0,132.0,398.0,428.0,,,,,,370
362,Lonsurf,trifluridine and tipiracil,Taiho Pharma,N,N,N,N,Y,Y,N,Y,N,01-May-19,19-Nov-19,202.0,CADTH & INESSS,03-Sep-19,pre-NOC,New indication,Gastric Cancer,Completed,24-Mar-20,Cond'l on Cost,Conditional,11-Oct-19,pre-NOC,New Indication,Gastric Cancer,Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,07-Jul-20,11-Jan-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,2021-03-01,2021-02-28,2021-02-01,2021-04-01,2021-09-30,2021-02-24,2021-05-30,2023-01-23,,2021-03-03,01-Feb-21,2021-02-01,4.0,3.0,1.0,6.0,8.0,2.0,7.0,9.0,,5.0,5.70%,6.60%,11.10%,31.30%,59.90%,65.40%,66.70%,99.00%,99.30%,,99.30%,03-Mar-21,30-Sep-21,-77.0,-39.0,203.0,216.0,105.0,54.0,188.0,49.0,48.0,21.0,80.0,262.0,44.0,139.0,742.0,,51.0,173.0,21.0,160.0,21.0,262.0,468.0,467.0,440.0,499.0,681.0,463.0,558.0,1161.0,,470.0,592.0,579.0,440.0,517.0,314.0,342.0,341.0,314.0,373.0,555.0,337.0,432.0,1035.0,,293.0,466.0,126.0,177.0,293.0,242.0,681.0,241.0,241.0,30.0,211.0,328
367,Lucentis (myopic CNV),ranibizumab,Novartis ,Y,Y,N,N,N,N,N,N,N,,28-Jan-14,,CADTH & INESSS,28-Feb-14,post-NOC,Initial,"Choroidal neovascularisation, myopic",Completed,19-Feb-15,List with criteria/condition,Conditional,22-Mar-14,post-NOC,New Indication,"Choroidal neovascularisation, myopic",Completed,01-Oct-14,Ajout d'une indication reconnue - Médicament d'exception,Conditional,none,31-May-15,,Negotiation by Province,,BCRDT,NR,EDS,,LU,NR,,SA,NR,EM,,,2015-07-01,,2015-07-29,,,2018-08-01,,2014-10-01,01-Jul-15,2014-10-01,,,2.0,,3.0,,,4.0,,1.0,28.60%,34.30%,66.50%,66.90%,,,,,,,66.90%,29-Jul-15,,31.0,53.0,356.0,193.0,101.0,242.0,,,,,,,,,,,,,,,,,,,519.0,,547.0,,,1646.0,,246.0,904.0,740.0,519.0,488.0,132.0,,,132.0,,160.0,,,1259.0,,0.0,517.0,387.0,246.0,,,,,,301.0,,42054
369,Lutathera,lutetium (177LU) oxodotreotide,Advanced Accelerator Applications,N,N,N,Y,Y,Y,Y,Y,N,01-Jul-18,09-Jan-19,192.0,CADTH,30-Jul-18,pre-NOC,New drug,Gastroenteropancreatic neuroendocrine tumours (GEP-NETs),Completed,01-Aug-19,Cond'l on Cost,Conditional,,,,,,,,,1st,26-Sep-19,30-Dec-19,Negotiation,No Agreement Reached,Funded,Under provincial consideration,Funded,Funded,Funded,Not funded,Funded,Under provincial consideration,Under provincial consideration,EM,2021-03-01,,2021-06-01,2022-02-01,2020-10-08,,2020-08-01,,,2020-09-30,01-Aug-20,2020-08-01,4.0,,5.0,6.0,3.0,,1.0,,,2.0,1.30%,29.90%,62.10%,82.40%,88.10%,93.60%,,,,,93.60%,08-Oct-20,01-Mar-21,-163.0,,367.0,,56.0,,95.0,427.0,,519.0,764.0,283.0,,215.0,,,275.0,442.0,215.0,414.0,215.0,427.0,782.0,,874.0,1119.0,638.0,,570.0,,,630.0,797.0,769.0,570.0,733.0,366.0,578.0,,670.0,915.0,434.0,,366.0,,,,593.0,204.0,,151.0,,782.0,212.0,212.0,68.0,144.0,396
371,Lutathera,lutetium (177LU) oxodotreotide,Advanced Accelerator Applications (AAA),N,N,N,N,Y,Y,Y,Y,Y,01-Jul-18,09-Jan-19,192.0,CADTH & INESSS,23-Mar-22,post-NOC,Initial,"For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease.",Completed,28-Sep-22,Cond'l on Cost,Conditional,,,New Indication,"For the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease.",Completed,13-Feb-19,Inscription - Avec conditions,Conditional,,,,Under consideration for negotiation,,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,,,,,,,,,,2020-09-30,,2020-09-30,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,1169.0,,189.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,630.0,,630.0,,,,,,,,,,,,,595.0,,1358.0,35.0,,,,,,,,1550
372,Luxturna ,voretigene neparvovec,Novartis Pharmaceuticals Canada Inc.,Y,Y,N,Y,N,Y,Y,Y,Y,01-Dec-19,13-Oct-20,317.0,CADTH & INESSS,23-Apr-20,pre-NOC,Initial,"Vision loss, inherited retinal dystrophy",Completed,12-Nov-20,Reimburse with clinical criteria and/or conditions,Conditional,08-May-20,pre-NOC,New Drug,Hereditary Retinal Dystrophy,Completed,02-Dec-20,Inscription - Avec conditions,Conditional,1st,25-Nov-21,16-Sep-22,Negotiation,Completed with Agreements,UR,,,,,,NR,,,EM,,,,,,,,,,2022-09-28,,2022-09-28,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,-173.0,-158.0,203.0,208.0,378.0,358.0,295.0,,,,,,,,,,12.0,,,12.0,12.0,,,,,,,,,,,715.0,,715.0,,,,,,,,,,,,,665.0,,30.0,50.0,673.0,653.0,,,,,,347
373,Lynparza,olaparib,AstraZeneca ,Y,N,N,Y,Y,Y,Y,Y,N,01-Jun-15,29-Apr-16,333.0,CADTH & INESSS,01-Apr-16,pre-NOC,New drug,"Ovarian Cancer:As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy",Completed,29-Sep-16,Do Not Fund,Negative,,,New Drug,"As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy",Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,,30-Nov-16,,Do Not Negotiate,,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,EM,,,,,,,,,,2018-09-27,,2018-09-27,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,-28.0,,181.0,,62.0,-644.0,,,,,,,,,,,,,,,,,,,,,,,,,,881.0,,881.0,,,,,,,,,,,,,22.0,,153.0,859.0,,,,,,,,486
374,Lynparza,olaparib,AstraZeneca ,Y,N,N,N,Y,Y,Y,Y,Y,01-Nov-18,06-May-19,186.0,CADTH & INESSS,18-Apr-19,pre-NOC,New indication,"Newly Diagnosed Ovarian Cancer: As monotherapy for the maintenance treatment of adult patients with newly diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Completed,05-Dec-19,Cond'l on Cost,Conditional,10-May-19,post-NOC,New Indication,"Newly Diagnosed Ovarian Cancer: As monotherapy for the maintenance treatment of adult patients with newly diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer",Completed,06-Nov-19,Inscription - Avec conditions,Conditional,1st,18-Jun-20,21-Oct-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-11-01,2021-02-28,2021-01-01,2021-01-21,2022-10-31,2021-04-22,2021-01-31,2022-12-12,2023-03-01,2020-12-16,01-Nov-20,2020-11-01,1.0,6.0,3.0,4.0,8.0,7.0,5.0,9.0,10.0,2.0,20.30%,48.80%,54.60%,60.10%,61.40%,65.90%,66.70%,99.00%,99.30%,100.00%,100.00%,01-Jan-21,31-Oct-22,-18.0,4.0,231.0,180.0,196.0,225.0,125.0,11.0,130.0,72.0,92.0,740.0,183.0,102.0,782.0,861.0,56.0,330.0,11.0,303.0,11.0,740.0,545.0,664.0,606.0,626.0,1274.0,717.0,636.0,1316.0,1395.0,590.0,864.0,837.0,545.0,563.0,332.0,332.0,451.0,393.0,413.0,1061.0,504.0,423.0,1103.0,1182.0,406.0,651.0,213.0,184.0,321.0,350.0,1274.0,729.0,729.0,61.0,668.0,399
376,Lynparza ,olaparib,AstraZeneca ,Y,N,N,N,Y,N,N,N,N,01-Feb-20,21-Aug-20,202.0,CADTH & INESSS,22-Sep-20,post-NOC,New indication,As monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene mutations (germline and/or somatic) who have progressed following prior treatment with a new hormonal agent (NHA),Completed,21-Apr-21,Cond'l on Cost,Conditional,16-Oct-20,post-NOC,New Indication,Metastatic Castration-Resistant Prostate Cancer (mCRPC),Completed,07-May-21,Inscription - Avec conditions et Refus d'inscription,Conditional,1st,07-Jul-21,17-Jan-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2022-05-01,2022-02-28,2022-05-01,2022-06-01,2021-10-30,2022-07-01,2022-09-01,2022-12-12,2023-02-28,2022-04-13,30-Oct-21,2021-10-30,4.0,2.0,5.0,6.0,1.0,7.0,8.0,9.0,10.0,3.0,32.20%,36.70%,65.30%,85.50%,91.20%,96.80%,97.70%,99.00%,99.30%,100.00%,100.00%,13-Apr-22,01-May-22,32.0,56.0,211.0,203.0,77.0,61.0,194.0,104.0,42.0,104.0,135.0,-79.0,165.0,227.0,329.0,407.0,86.0,159.0,-79.0,152.0,-79.0,104.0,618.0,556.0,618.0,649.0,435.0,679.0,741.0,843.0,921.0,600.0,673.0,666.0,435.0,403.0,192.0,375.0,313.0,375.0,406.0,192.0,436.0,498.0,600.0,678.0,341.0,430.0,243.0,259.0,271.0,255.0,618.0,183.0,183.0,165.0,18.0,445
377,Lynparza (resubmission),olaparib,AstraZeneca ,Y,N,N,Y,Y,Y,Y,Y,N,01-Jun-15,29-Apr-16,333.0,CADTH & INESSS,17-Mar-17,post-NOC,Resubmission,"Ovarian Cancer:As monotherapy maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy",Completed,20-Sep-17,Cond'l on Cost,Conditional,19-Aug-17,post-NOC,New Drug,Ovarian (monotherapy maintenance treatment of patients with platinum-sensitive relapsed BRCA-mutated cancer),Completed,15-Dec-17,Add to Exception drug,Conditional,1st,10-Oct-17,15-May-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-09-01,2018-09-04,2018-11-15,2018-10-18,2018-08-20,2018-12-17,2019-04-01,2022-12-12,2019-08-01,2018-07-05,20-Aug-18,2018-07-05,3.0,4.0,6.0,5.0,2.0,7.0,8.0,10.0,9.0,1.0,28.60%,60.80%,81.10%,85.50%,91.10%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,20-Aug-18,01-Sep-18,322.0,477.0,187.0,118.0,20.0,-66.0,217.0,109.0,112.0,184.0,156.0,97.0,216.0,321.0,1672.0,443.0,51.0,368.0,97.0,336.0,51.0,109.0,855.0,858.0,930.0,902.0,843.0,962.0,1067.0,2418.0,1189.0,797.0,1114.0,1082.0,843.0,521.0,334.0,346.0,349.0,421.0,393.0,334.0,453.0,558.0,1909.0,680.0,202.0,605.0,509.0,595.0,237.0,151.0,855.0,58.0,12.0,46.0,12.0,842
378,MAR-Trientine,Trientine Hydrochloride,Marcan Pharmaceuticals Inc.,N,N,N,N,N,Y,N,Y,N,01-Nov-19,14-Sep-20,318.0,CADTH & INESSS,19-Apr-21,post-NOC,Initial,Wilson's Disease,Completed,11-Nov-21,Reimburse with clinical criteria and/or conditions,Conditional,06-Aug-21,post-NOC,New drug,Wilson's Disease,Completed,29-Dec-21,Inscription - Avec conditions,Conditional,1st,07-Dec-21,25-Mar-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,,,EM,2022-05-17,2022-05-01,2022-05-01,2022-09-20,2022-03-25,2022-07-25,2022-09-01,,,2021-05-26,25-Mar-22,2021-05-26,5.0,3.0,4.0,8.0,2.0,6.0,7.0,,,1.0,28.60%,60.80%,65.30%,71.00%,91.20%,92.10%,93.40%,99.00%,,,99.00%,25-Mar-22,17-May-22,217.0,326.0,206.0,145.0,26.0,-22.0,108.0,53.0,37.0,37.0,179.0,0.0,122.0,160.0,,,-303.0,84.0,0.0,36.0,-303.0,53.0,610.0,594.0,594.0,736.0,557.0,679.0,717.0,,,254.0,641.0,593.0,557.0,340.0,134.0,187.0,171.0,171.0,313.0,134.0,256.0,294.0,,,-217.0,218.0,423.0,471.0,134.0,86.0,610.0,356.0,53.0,303.0,53.0,741
379,Mavenclad,cladribine ,EMD Serono ,N,N,N,N,N,N,N,N,N,01-Feb-17,30-Nov-17,302.0,CADTH & INESSS,01-Dec-17,post-NOC,Initial,"Multiple Sclerosis, relapsing",Completed,24-Oct-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-18,post-NOC,New Drug,Multiple Sclerosis,Completed,05-Jul-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,14-Feb-19,22-Nov-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,NR,2022-01-25,2020-06-01,2020-07-01,2020-10-22,2020-04-28,2020-04-23,2020-07-31,2023-02-20,2020-12-22,,23-Apr-20,2020-04-23,8.0,3.0,4.0,6.0,2.0,1.0,5.0,9.0,7.0,,0.90%,33.10%,37.60%,43.30%,44.60%,50.10%,50.80%,71.10%,71.40%,,71.40%,22-Oct-20,,1.0,32.0,327.0,185.0,113.0,224.0,281.0,795.0,192.0,222.0,335.0,158.0,153.0,252.0,1186.0,396.0,,410.0,153.0,410.0,153.0,,1517.0,914.0,944.0,1057.0,880.0,875.0,974.0,1908.0,1118.0,,1132.0,1132.0,875.0,874.0,547.0,1189.0,586.0,616.0,729.0,552.0,547.0,646.0,1580.0,790.0,,804.0,328.0,217.0,394.0,505.0,,,,182.0,,630
380,Maviret,glecaprevir pibrentasvir,AbbVie ,Y,N,N,Y,N,N,N,N,N,01-Feb-17,16-Aug-17,196.0,CADTH & INESSS,09-Jun-17,pre-NOC,Initial,"Hepatitis C, chronic",Completed,23-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,17-Aug-17,post-NOC,New Drug,Hepatitis C,Completed,01-Mar-18,Avis dinscription aux listes des médicaments  Médicament dexception (Patients naïfs ou expérimentés à un traitement à base dinterféron ou de sofosbuvir) Avis dinscription aux listes des médicaments  Médicament dexception  Avec conditions (Patients expérimentés à un inhibiteur de la protéine NS5A ou un inhibiteur de la protéase NS3/4A),Conditional,1st,29-Jun-18,19-Dec-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,NR,SA,EM,2019-01-29,2019-04-01,2019-04-01,2019-05-31,2019-02-28,2019-05-16,2019-05-01,,2019-12-18,2019-02-01,29-Jan-19,2019-01-29,1.0,4.0,5.0,8.0,3.0,7.0,6.0,,9.0,2.0,20.30%,48.80%,81.10%,85.50%,91.20%,92.60%,93.40%,99.00%,99.60%,,99.60%,28-Feb-19,28-Feb-19,-68.0,1.0,228.0,196.0,157.0,120.0,173.0,41.0,103.0,103.0,163.0,71.0,148.0,133.0,,364.0,44.0,141.0,41.0,130.0,41.0,71.0,531.0,593.0,593.0,653.0,561.0,638.0,623.0,,854.0,534.0,631.0,620.0,531.0,599.0,371.0,371.0,433.0,433.0,493.0,401.0,478.0,463.0,,694.0,337.0,471.0,160.0,197.0,330.0,293.0,561.0,30.0,30.0,30.0,0.0,356
381,Mayzent,siponimod,Novartis ,Y,N,N,Y,N,N,N,N,Y,01-Feb-19,20-Feb-20,384.0,CADTH & INESSS,26-Sep-19,pre-NOC,Initial,Secondary progressive multiple sclerosis,Completed,21-Jul-20,Reimburse with clinical criteria and/or conditions,Conditional,25-Oct-19,pre-NOC,New Drug,Progressive secondary multiple sclerosis,Completed,14-May-20,Inscription - Avec conditions,Conditional,1st,27-Apr-21,22-Oct-21,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2022-01-25,2021-12-01,2022-03-01,2022-02-24,2022-03-25,2022-03-24,2022-06-27,2023-03-27,2022-04-05,2021-12-15,01-Dec-21,2021-12-01,3.0,1.0,5.0,4.0,7.0,6.0,9.0,10.0,8.0,2.0,4.50%,33.00%,53.30%,58.80%,64.50%,65.40%,97.70%,98.30%,99.60%,100.00%,100.00%,25-Jan-22,25-Mar-22,-147.0,-118.0,299.0,202.0,280.0,348.0,178.0,95.0,40.0,130.0,125.0,154.0,153.0,248.0,521.0,165.0,54.0,181.0,40.0,169.0,40.0,154.0,705.0,650.0,740.0,735.0,764.0,763.0,858.0,1131.0,775.0,664.0,791.0,779.0,650.0,797.0,498.0,553.0,498.0,588.0,583.0,612.0,611.0,706.0,979.0,623.0,580.0,639.0,152.0,84.0,458.0,526.0,764.0,114.0,114.0,55.0,59.0,536
382,MDK-nitisinone,nitisinone,MendeliKABS Inc,N,N,N,Y,N,N,N,N,N,01-Mar-16,20-Sep-16,203.0,CADTH & INESSS,29-Sep-17,post-NOC,Initial,Hereditary tyrosinemia type 1,Completed,25-Apr-18,Reimburse with clinical criteria and/or conditions,Conditional,04-Sep-17,post-NOC,New Drug,hereditary Type 1 tyrosinemia,Completed,01-Feb-18,Avis d'inscription à la Liste Établissements - Médicament d'exception - Avec conditions,Conditional,1st,20-Aug-18,28-Nov-18,Negotiation,Completed with Agreements,E,SA,NR,EDS,NR,SA,NR,NR,UR,EM,2019-02-26,2019-02-01,,2019-05-31,,2019-12-19,,,,2018-02-01,01-Feb-19,2018-02-01,3.0,2.0,,4.0,,5.0,,,,1.0,28.60%,33.00%,53.30%,58.80%,59.70%,,,,,,59.70%,26-Feb-19,,374.0,349.0,208.0,150.0,117.0,200.0,100.0,90.0,65.0,,184.0,,386.0,,,,-300.0,181.0,65.0,85.0,-300.0,,889.0,864.0,,983.0,,1185.0,,,,499.0,980.0,884.0,864.0,490.0,282.0,307.0,282.0,,401.0,,603.0,,,,0.0,398.0,582.0,499.0,217.0,300.0,,,,390.0,,785
383,Mekinist,trametinib,GlaxoSmithKline,Y,N,N,Y,Y,Y,N,Y,N,,18-Jul-13,,CADTH & INESSS,06-May-13,pre-NOC,New drug,Metastatic Melanoma,Completed,22-Oct-13,Cond'l on Cost,Conditional,01-Nov-13,post-NOC,New Drug,BRAF+ metastatic melanoma,Completed,03-Feb-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,18-Nov-13,25-Jun-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2016-12-01,2016-10-18,2014-09-15,2014-10-16,2014-08-19,2014-10-03,2016-09-01,2018-10-29,2014-08-01,2014-02-03,01-Aug-14,2014-02-03,9.0,8.0,4.0,6.0,3.0,5.0,7.0,10.0,2.0,1.0,28.60%,29.30%,61.50%,67.20%,68.10%,73.60%,74.90%,79.40%,99.60%,100.00%,100.00%,19-Aug-14,01-Dec-16,-73.0,106.0,169.0,94.0,27.0,-77.0,219.0,890.0,846.0,82.0,113.0,55.0,100.0,799.0,1587.0,37.0,-142.0,501.0,37.0,437.0,-142.0,890.0,1232.0,1188.0,424.0,455.0,397.0,442.0,1141.0,1929.0,379.0,200.0,843.0,779.0,379.0,452.0,283.0,1136.0,1092.0,328.0,359.0,301.0,346.0,1045.0,1833.0,283.0,0.0,747.0,96.0,200.0,246.0,142.0,1232.0,1032.0,853.0,197.0,835.0,41569
385,Mictoryl (ped),propiverine hydrochloride,Duchesnay,N,N,N,Y,N,N,N,N,N,01-Mar-16,05-Jan-17,310.0,CADTH & INESSS,14-Oct-16,pre-NOC,Initial,"Overactive bladder (OAB), pediatric",Completed,19-Apr-17,Reimburse with clinical criteria and/or conditions,Conditional,19-Aug-17,post-NOC,New Drug,"Overactive bladder (OAB), pediatric",Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,30-Aug-17,12-Feb-18,Negotiation,Completed with Agreements,NR,RB,EDS,EDS,LU,SA,EDS,SA,SA,EM,,2018-06-01,2018-07-01,2018-07-19,2018-05-31,2018-06-11,2020-07-31,2021-10-25,2018-09-12,2018-05-24,31-May-18,2018-05-24,,3.0,5.0,6.0,2.0,4.0,8.0,9.0,7.0,1.0,28.60%,60.80%,65.30%,66.20%,71.90%,77.40%,78.10%,79.40%,79.70%,,79.70%,31-May-18,,-83.0,226.0,187.0,166.0,133.0,-155.0,166.0,,109.0,139.0,157.0,108.0,119.0,900.0,1351.0,212.0,101.0,387.0,108.0,355.0,101.0,,,512.0,542.0,560.0,511.0,522.0,1303.0,1754.0,615.0,504.0,790.0,758.0,511.0,594.0,407.0,,408.0,438.0,456.0,407.0,418.0,1199.0,1650.0,511.0,112.0,686.0,104.0,392.0,299.0,11.0,,,,7.0,,414
386,Mifegymiso,mifepristone and misoprostol,Celopharma ,N,N,N,Y,N,N,N,N,N,,29-Jul-15,,CADTH,07-Oct-16,post-NOC,Initial,Medical termination of pregnancy,Completed,18-Apr-17,Reimburse,Positive,,,,,,,,,1st,21-Apr-17,05-Jul-17,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,FB,EDS,FB,FB,FB,2017-07-25,2017-07-24,2017-09-05,2017-07-20,2017-08-10,2017-07-07,2017-11-01,2017-11-08,2018-09-01,2017-12-15,07-Jul-17,2017-07-07,4.0,3.0,6.0,2.0,5.0,1.0,7.0,8.0,10.0,9.0,0.90%,6.40%,10.90%,31.10%,63.40%,69.10%,70.40%,70.70%,99.30%,100.00%,100.00%,10-Aug-17,15-Dec-17,436.0,,193.0,,3.0,,75.0,20.0,19.0,62.0,15.0,36.0,2.0,119.0,126.0,423.0,163.0,91.0,2.0,99.0,2.0,163.0,727.0,726.0,769.0,722.0,743.0,709.0,826.0,833.0,1130.0,870.0,798.0,806.0,709.0,273.0,80.0,98.0,97.0,140.0,93.0,114.0,80.0,197.0,204.0,501.0,,169.0,629.0,,78.0,,870.0,161.0,161.0,34.0,127.0,42843
389,Monoferric,Iron (III) Isomaltoside 1000,Pharmacosmos A/S,N,N,N,Y,N,N,N,N,N,01-Jul-16,22-Jun-18,721.0,CADTH & INESSS,26-Jun-19,post-NOC,Initial,Iron deficiency anemia,Completed,25-Mar-20,Reimburse with clinical criteria and/or conditions,Conditional,20-Apr-18,pre-NOC,New Drug,Iron deficiency anemia,Completed,17-Oct-18,Inscription,Positive,1st,21-Jul-20,02-Feb-21,Negotiation,Completed with Agreements,SA,SA,,EDS,LU,SA,EDS,,SA,FB,2021-10-06,2021-05-01,,2022-06-01,2021-02-26,2021-04-22,2022-03-21,,2021-12-29,2018-11-15,26-Feb-21,2018-11-15,5.0,4.0,,8.0,2.0,3.0,7.0,,6.0,1.0,28.60%,60.80%,61.70%,66.20%,86.40%,87.10%,88.40%,93.90%,,,93.90%,26-Feb-21,06-Oct-21,369.0,-63.0,273.0,180.0,118.0,643.0,196.0,246.0,88.0,,484.0,24.0,79.0,412.0,,330.0,-810.0,238.0,24.0,107.0,-810.0,246.0,1202.0,1044.0,,1440.0,980.0,1035.0,1368.0,,1286.0,146.0,1194.0,1063.0,980.0,611.0,338.0,560.0,402.0,,798.0,338.0,393.0,726.0,,644.0,29.0,552.0,642.0,117.0,314.0,839.0,1202.0,1056.0,222.0,834.0,222.0,1363
392,Movapo,apomorphine hydrochloride,Paladin Labs ,N,N,N,N,N,N,N,N,N,,22-Nov-16,,CADTH & INESSS,06-Jul-17,post-NOC,Initial,Parkinson's disease,Completed,23-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,19-Aug-17,post-NOC,New Drug,Parkinson,Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,29-Jun-18,27-Mar-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,UR,SA,EM,2019-11-26,2019-06-01,2019-05-01,2019-08-22,2019-08-22,2019-08-26,2019-05-01,,2021-01-20,2019-05-23,01-May-19,2019-05-01,8.0,4.0,1.0,5.0,6.0,7.0,2.0,,9.0,3.0,5.70%,7.00%,35.60%,40.10%,45.60%,77.80%,78.70%,99.00%,99.60%,,99.60%,22-Aug-19,26-Nov-19,226.0,270.0,201.0,166.0,157.0,148.0,271.0,244.0,66.0,35.0,148.0,148.0,152.0,35.0,,665.0,57.0,187.0,35.0,172.0,35.0,244.0,1099.0,921.0,890.0,1003.0,1003.0,1007.0,890.0,,1520.0,912.0,1042.0,1027.0,890.0,664.0,463.0,672.0,494.0,463.0,576.0,576.0,580.0,463.0,,1093.0,476.0,615.0,427.0,436.0,428.0,419.0,1099.0,209.0,209.0,113.0,96.0,43123
393,Mvasi,bevacizumab,Amgen ,Y,Y,Y,Y,Y,N,N,N,N,01-Feb-17,30-Apr-18,453.0,CADTH & INESSS,03-Oct-18,post-NOC,New drug,Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar,Completed,14-Jan-19,,,,,New Drug,Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar,Completed,13-Feb-19,Inscription - Avec conditions,Conditional,1st,28-Feb-19,08-Jul-19,Negotiation,Completed with Agreements,Funded,Under provincial consideration,Funded,Under provincial consideration,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2019-11-01,,2020-01-27,,2019-08-19,,,2019-10-01,,2019-11-14,19-Aug-19,2019-08-19,3.0,,5.0,,1.0,,,2.0,,4.0,32.20%,32.60%,52.80%,81.40%,87.10%,,,,,,87.10%,01-Nov-19,14-Nov-19,156.0,,103.0,,45.0,15.0,130.0,116.0,,203.0,,42.0,,,85.0,,129.0,112.0,42.0,115.0,42.0,129.0,550.0,,637.0,,476.0,,,519.0,,563.0,546.0,549.0,476.0,320.0,217.0,291.0,,378.0,,217.0,,,260.0,,274.0,287.0,259.0,289.0,175.0,145.0,563.0,87.0,87.0,74.0,13.0,712
395,Mylotarg,gemtuzumab ozogamicin,Pfizer,Y,Y,N,Y,Y,Y,Y,Y,Y,01-Feb-19,28-Nov-19,300.0,CADTH & INESSS,09-Aug-19,pre-NOC,New drug,"Acute Myeloid Leukemia:In combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of adult patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia",Completed,02-Apr-20,Fund,Positive,27-Sep-19,pre-NOC,New Drug,"Acute Myeloid Leukemia:In combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of adult patients with previously untreated, de novo CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia",Completed,08-Apr-20,Inscription - Avec conditions,Conditional,1st,17-Jun-20,12-Aug-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,2021-02-01,2022-10-31,2021-01-01,2022-09-13,2021-11-30,,,,,2020-09-30,01-Jan-21,2020-09-30,3.0,6.0,2.0,5.0,4.0,,,,,1.0,28.60%,34.30%,54.60%,86.80%,92.30%,96.80%,,,,,96.80%,01-Feb-21,30-Nov-21,-111.0,-62.0,237.0,194.0,76.0,70.0,56.0,173.0,810.0,142.0,762.0,475.0,,,,,49.0,472.0,142.0,402.0,49.0,475.0,431.0,1068.0,400.0,1020.0,733.0,,,,,307.0,730.0,660.0,400.0,511.0,274.0,305.0,942.0,274.0,894.0,607.0,,,,,175.0,604.0,126.0,132.0,132.0,126.0,733.0,426.0,333.0,124.0,302.0,426
396,Myrbetriq,mirabegron,Astellas Pharma,N,N,N,Y,N,N,N,N,N,,06-Mar-13,,CADTH & INESSS,27-Nov-13,post-NOC,Initial,"Bladder, overactive",Completed,12-Nov-14,List with criteria/condition,Conditional,,,New Drug,"Bladder, Overactive ",Completed,03-Feb-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,14-Jan-15,08-Apr-15,Negotiation,Completed with Agreements,NR,SA,EDS,FB,LU,SA,EDS,SA,SA,EM,,2015-09-01,2015-07-01,2015-07-22,2015-05-28,2015-10-14,2015-06-29,2018-03-26,2015-10-01,2014-02-03,28-May-15,2014-02-03,,6.0,4.0,5.0,2.0,8.0,3.0,9.0,7.0,1.0,28.60%,60.80%,62.10%,67.80%,73.40%,77.80%,78.50%,79.40%,79.70%,,79.70%,28-May-15,,266.0,,350.0,,63.0,345.0,84.0,,146.0,84.0,105.0,50.0,189.0,82.0,1083.0,176.0,-429.0,239.0,50.0,165.0,-429.0,,,909.0,847.0,868.0,813.0,952.0,845.0,1846.0,939.0,334.0,1002.0,928.0,813.0,547.0,197.0,,293.0,231.0,252.0,197.0,336.0,229.0,1230.0,323.0,0.0,386.0,616.0,334.0,147.0,429.0,,,,479.0,,41955
405,Neupro (Resub),rotigotine,UCB ,N,N,N,Y,N,N,N,N,N,,21-Mar-13,,CADTH & INESSS,21-May-15,post-NOC,Resubmission,Parkinsons Disease,Completed,19-Nov-15,List with clinical criteria and/or conditions,Conditional,01-Feb-15,post-NOC,Resubmission,Parkinsons Disease,Completed,01-Jun-15,Avis de refus - Valeur thérapeutique,Negative,1st,09-Feb-16,23-Jun-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2018-11-13,2017-10-01,2017-10-01,2017-10-19,2017-09-28,2017-10-24,2017-11-01,2017-11-27,2017-12-01,2017-10-18,28-Sep-17,2017-09-28,10.0,2.0,3.0,5.0,1.0,6.0,7.0,8.0,9.0,4.0,32.20%,36.70%,42.40%,71.00%,76.50%,77.40%,78.70%,79.10%,79.70%,100.00%,100.00%,18-Oct-17,13-Nov-18,791.0,682.0,182.0,120.0,82.0,253.0,500.0,508.0,100.0,100.0,118.0,97.0,123.0,131.0,157.0,161.0,117.0,166.0,97.0,161.0,97.0,508.0,2063.0,1655.0,1655.0,1673.0,1652.0,1678.0,1686.0,1712.0,1716.0,1672.0,1721.0,1716.0,1652.0,861.0,679.0,1090.0,682.0,682.0,700.0,679.0,705.0,713.0,739.0,743.0,870.0,748.0,973.0,802.0,582.0,753.0,2063.0,411.0,411.0,20.0,391.0,42327
408,Nexplanon,etonogestrel,Merck Canada Inc.,Y,N,N,N,N,N,N,N,N,01-May-19,25-May-20,390.0,CADTH & INESSS,03-Jun-20,post-NOC,Initial,Prevention of pregnany,Completed,20-Oct-20,Reimburse with clinical criteria and/or conditions,Conditional,01-Nov-19,pre-NOC,New drug,Prevention of pregnancy,Completed,05-Nov-20,Inscription,Positive,1st,24-Feb-21,20-Sep-21,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,FB,FB,FB,FB,FB,2021-12-07,2021-11-01,2021-11-01,2022-02-24,2021-12-17,2021-11-18,2021-12-11,2021-11-22,2021-12-01,2021-11-10,01-Nov-21,2021-11-01,7.0,1.0,2.0,10.0,9.0,4.0,8.0,5.0,6.0,3.0,4.50%,10.20%,38.80%,39.70%,40.00%,40.70%,60.90%,62.20%,94.50%,100.00%,100.00%,07-Dec-21,17-Dec-21,9.0,-206.0,139.0,370.0,127.0,111.0,208.0,78.0,42.0,42.0,157.0,88.0,59.0,82.0,63.0,72.0,51.0,76.0,42.0,73.0,42.0,88.0,561.0,525.0,525.0,640.0,571.0,542.0,565.0,546.0,555.0,534.0,559.0,556.0,525.0,516.0,377.0,413.0,377.0,377.0,492.0,423.0,394.0,417.0,398.0,407.0,370.0,411.0,148.0,164.0,335.0,319.0,571.0,46.0,46.0,36.0,10.0,538
413,Nitisinone,nitisinone,Cycle Pharmaceuticals Ltd,N,N,N,Y,N,N,N,N,N,01-May-16,04-Nov-16,187.0,CADTH & INESSS,25-Jan-18,post-NOC,Initial,Hereditary tyrosinemia type 1,Completed,23-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,hereditary Type 1 tyrosinemia,Completed,01-Jun-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,21-Aug-18,28-Nov-18,Negotiation,Completed with Agreements,E,SA,NR,NR,NR,NR,EDS,NR,UR,EM,2019-02-26,2019-02-01,,,,,2019-08-01,,,2018-02-01,01-Feb-19,2018-02-01,3.0,2.0,,,,,4.0,,,1.0,28.60%,33.00%,53.30%,54.60%,,,,,,,54.60%,26-Feb-19,,447.0,,210.0,,-2.0,446.0,99.0,90.0,65.0,,,,,246.0,,,-300.0,134.0,65.0,25.0,-300.0,,844.0,819.0,,,,,1000.0,,,454.0,888.0,779.0,819.0,372.0,162.0,187.0,162.0,,,,,343.0,,,245.0,231.0,657.0,209.0,97.0,545.0,,,,390.0,,844
414,Nivestym,filgrastim,Pfizer ,Y,Y,Y,N,N,N,N,N,N,01-Apr-18,16-Apr-20,746.0,CADTH & INESSS,01-Nov-18,pre-NOC,Initial,Prevention or treatment of neutropenia in various indications,Withdrawn,31-May-19,Cancelled or withdrawn,,05-Jun-20,post-NOC,New Drug,Neutropenia,Completed,09-Sep-20,Inscription - Avec conditions,Conditional,1st,27-Apr-20,17-Jun-20,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,UR,SA,SA,EM,2022-03-22,2020-12-01,2020-09-01,2020-10-22,2020-07-31,2020-11-26,,2021-10-25,2021-06-09,2020-09-30,31-Jul-20,2020-07-31,9.0,6.0,2.0,4.0,1.0,5.0,,8.0,7.0,3.0,32.20%,38.00%,66.50%,72.10%,73.00%,77.40%,78.10%,78.40%,98.70%,,98.70%,30-Sep-20,22-Mar-22,-532.0,50.0,211.0,96.0,332.0,-135.0,51.0,643.0,167.0,76.0,127.0,44.0,162.0,,495.0,357.0,105.0,259.0,44.0,242.0,44.0,643.0,705.0,229.0,138.0,189.0,106.0,224.0,,557.0,419.0,167.0,321.0,304.0,106.0,638.0,427.0,1026.0,550.0,459.0,510.0,427.0,545.0,,878.0,740.0,21.0,642.0,-321.0,146.0,383.0,-84.0,705.0,599.0,599.0,61.0,538.0,425
415,Nubeqa,darolutamide,Bayer,Y,N,N,Y,Y,N,N,N,N,01-Apr-19,20-Feb-20,325.0,CADTH & INESSS,27-Aug-19,pre-NOC,New drug,Non-metastatic castration-resistant prostate cancer,Completed,22-Apr-20,Cond'l on Cost,Conditional,06-Sep-19,pre-NOC,New Drug,Non-metastatic castration-resistant prostate cancer,Completed,08-Apr-20,Inscription - Avec conditions,Conditional,1st,23-Oct-20,18-Feb-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2021-08-01,2021-05-31,2021-08-01,2021-08-05,2021-06-08,2021-08-19,2021-05-30,2023-01-23,2021-08-11,2021-04-14,30-May-21,2021-04-14,5.0,3.0,6.0,7.0,4.0,9.0,2.0,10.0,8.0,1.0,28.60%,29.90%,34.30%,66.60%,86.80%,92.60%,98.10%,98.80%,99.60%,100.00%,100.00%,08-Jun-21,01-Aug-21,-177.0,-167.0,239.0,215.0,184.0,198.0,118.0,164.0,102.0,164.0,168.0,110.0,182.0,101.0,704.0,174.0,55.0,208.0,101.0,192.0,55.0,164.0,528.0,466.0,528.0,532.0,474.0,546.0,465.0,1068.0,538.0,419.0,572.0,556.0,465.0,642.0,403.0,466.0,404.0,466.0,470.0,412.0,484.0,403.0,1006.0,476.0,371.0,510.0,62.0,48.0,302.0,316.0,528.0,109.0,63.0,55.0,54.0,387
417,Nucala,mepolizumab,GlaxoSmithKline,Y,Y,N,Y,N,N,N,N,N,,03-Dec-15,,CADTH & INESSS,18-Dec-15,post-NOC,Initial,"Asthma, severe eosinophilic",Completed,16-Jun-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,"Asthma, severe eosinophilic",Completed,03-Oct-16,Avis de refus dinscription aux listes des médicaments  Médicament dexception  À moins que certaines conditions soient respectées,Conditional,1st,21-Oct-16,24-Nov-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2018-11-13,2018-05-01,2018-07-01,2018-04-19,2018-03-15,2018-02-12,2019-02-01,2021-03-15,2018-10-01,2018-02-01,12-Feb-18,2018-02-01,8.0,5.0,6.0,4.0,3.0,2.0,9.0,10.0,7.0,1.0,28.60%,29.50%,61.70%,67.20%,71.70%,77.40%,78.10%,98.30%,99.60%,100.00%,100.00%,15-Mar-18,13-Nov-18,15.0,110.0,181.0,195.0,127.0,18.0,399.0,354.0,158.0,219.0,146.0,111.0,80.0,434.0,1207.0,311.0,69.0,336.0,80.0,309.0,69.0,354.0,1076.0,880.0,941.0,868.0,833.0,802.0,1156.0,1929.0,1033.0,791.0,1058.0,1031.0,802.0,787.0,606.0,880.0,684.0,745.0,672.0,637.0,606.0,960.0,1733.0,837.0,486.0,862.0,196.0,305.0,526.0,417.0,1076.0,285.0,274.0,42.0,243.0,42537
419,Nucala (Advice),mepolizumab,GlaxoSmithKline,Y,Y,N,Y,N,N,N,N,N,,03-Dec-15,,CADTH & INESSS,24-Oct-18,post-NOC,Request for Advice,"Asthma, severe eosinophilic",Completed,27-Mar-19,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,"Asthma, severe eosinophilic",Completed,05-Sep-18,Avis de modification d'une indication reconnue aux listes des médicaments - Médicament d'exception- Avec conditions,Conditional,none,,,,,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2019-10-29,2019-08-01,2019-10-01,2020-03-02,2019-07-23,2019-07-04,2019-09-01,2021-03-15,2020-12-21,2019-07-04,04-Jul-19,2019-07-04,7.0,4.0,6.0,8.0,3.0,1.0,5.0,10.0,9.0,2.0,0.90%,29.50%,61.70%,66.20%,67.50%,73.20%,93.40%,99.00%,99.60%,100.00%,100.00%,23-Jul-19,29-Oct-19,1056.0,,154.0,,,,,,,,,,,,,,,,,,,43767.0,1426.0,1337.0,1398.0,1551.0,1328.0,1309.0,1368.0,1929.0,1845.0,1309.0,1499.0,1480.0,1309.0,253.0,99.0,216.0,127.0,188.0,341.0,118.0,99.0,158.0,719.0,635.0,302.0,289.0,1210.0,1007.0,,,1426.0,117.0,117.0,19.0,98.0,43551
421,Ocaliva,obeticholic acid,Intercept Pharmaceuticals ,N,N,N,Y,N,N,N,N,N,01-Oct-16,24-May-17,235.0,CADTH & INESSS,22-Dec-16,pre-NOC,Initial,Primary biliary cholangitis,Completed,25-Jul-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,pre-NOC,New Drug,Primary biliary cholangitis,Completed,18-Aug-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,08-Dec-17,27-Jun-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2018-10-30,2019-01-01,2018-10-01,2018-10-18,2018-09-13,2018-12-17,2019-02-01,2021-12-20,2019-08-16,2018-08-16,13-Sep-18,2018-08-16,5.0,7.0,3.0,4.0,2.0,6.0,8.0,10.0,9.0,1.0,28.60%,60.80%,66.50%,72.10%,92.30%,93.20%,97.70%,99.00%,99.60%,100.00%,100.00%,13-Sep-18,30-Oct-18,-153.0,-61.0,215.0,147.0,136.0,112.0,201.0,125.0,188.0,96.0,113.0,78.0,173.0,219.0,1272.0,415.0,50.0,298.0,78.0,273.0,50.0,125.0,524.0,587.0,495.0,512.0,477.0,572.0,618.0,1671.0,814.0,449.0,697.0,672.0,477.0,630.0,415.0,462.0,525.0,433.0,450.0,415.0,510.0,556.0,1609.0,752.0,363.0,635.0,62.0,86.0,337.0,313.0,524.0,75.0,47.0,28.0,47.0,297
422,Ocrevus,ocrelizumab,Hoffmann-La Roche Ltd.,Y,Y,N,Y,N,N,N,N,N,01-Oct-16,14-Aug-17,317.0,CADTH & INESSS,16-May-17,pre-NOC,Initial,"Multiple sclerosis, relapsing",Completed,21-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,15-Aug-17,post-NOC,New Drug,RRMS,Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,19-Jul-18,13-Feb-19,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,2019-04-01,2019-05-01,2019-08-22,2019-09-12,2019-11-07,2020-04-22,2022-12-28,2019-10-10,2019-04-11,01-Apr-19,2019-04-01,,1.0,3.0,4.0,5.0,7.0,8.0,9.0,6.0,2.0,4.50%,33.00%,38.80%,44.30%,76.50%,77.20%,78.10%,79.40%,79.70%,,79.70%,12-Sep-19,,-90.0,1.0,189.0,170.0,240.0,168.0,209.0,,47.0,77.0,190.0,211.0,267.0,434.0,1414.0,239.0,57.0,360.0,47.0,326.0,47.0,,,595.0,625.0,738.0,759.0,815.0,982.0,1962.0,787.0,605.0,908.0,874.0,595.0,685.0,496.0,,496.0,526.0,639.0,660.0,716.0,883.0,1863.0,688.0,434.0,809.0,99.0,171.0,449.0,377.0,,,,164.0,,416
423,Ocrevus (Primary),ocrelizumab,Hoffmann-La Roche Ltd.,Y,Y,N,N,N,N,N,N,N,01-Oct-16,14-Feb-18,501.0,CADTH & INESSS,26-Oct-17,pre-NOC,Initial,Primary progressive multiple sclerosis,Completed,26-Apr-18,Reimburse with clinical criteria and/or conditions,Conditional,23-Nov-17,pre-NOC,New Indication,PPMS,Completed,06-Jun-18,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,19-Jul-18,13-Feb-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2020-08-20,2019-04-01,2019-05-01,2019-08-22,2019-09-12,2019-11-07,2020-04-22,2022-12-28,2019-10-10,2019-04-11,01-Apr-19,2019-04-01,9.0,1.0,3.0,4.0,5.0,7.0,8.0,10.0,6.0,2.0,4.50%,33.00%,38.80%,44.30%,76.50%,77.20%,78.10%,79.40%,99.60%,100.00%,100.00%,12-Sep-19,20-Aug-20,-111.0,-83.0,182.0,195.0,84.0,43.0,209.0,554.0,47.0,77.0,190.0,211.0,267.0,434.0,1414.0,239.0,57.0,381.0,47.0,349.0,47.0,554.0,918.0,411.0,441.0,554.0,575.0,631.0,798.0,1778.0,603.0,421.0,745.0,713.0,411.0,522.0,340.0,847.0,340.0,370.0,483.0,504.0,560.0,727.0,1707.0,532.0,309.0,674.0,71.0,112.0,293.0,252.0,918.0,507.0,507.0,164.0,343.0,572
424,Odefsey,emtricitabine/rilpivirine/ tenofovir alafenamide,Gilead Sciences ,Y,N,N,N,N,N,N,N,N,,10-Feb-17,,CADTH & INESSS,24-Nov-16,pre-NOC,Initial,HIV-1 infection,Completed,25-May-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,HIV,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments,Positive,1st,04-Aug-17,06-Jun-18,Negotiation,Completed with Agreements,NR,NR,EDS,EDS,FB,SA,NR,HIV,SA,FB,,,2018-08-01,2018-10-18,2018-08-30,2018-11-30,,2019-11-25,2018-12-01,2018-07-05,01-Aug-18,2018-07-05,,,2.0,4.0,3.0,5.0,,7.0,6.0,1.0,28.60%,34.30%,66.50%,72.10%,73.00%,73.60%,74.00%,,,,74.00%,30-Aug-18,,-78.0,42.0,182.0,208.0,71.0,-75.0,306.0,,,56.0,134.0,85.0,177.0,,537.0,178.0,29.0,195.0,56.0,171.0,29.0,,,,537.0,615.0,566.0,658.0,,1018.0,659.0,510.0,676.0,652.0,537.0,615.0,433.0,,,433.0,511.0,462.0,554.0,,914.0,555.0,260.0,572.0,104.0,250.0,377.0,231.0,,,,56.0,,42880
426,Ofev,nintedanib,Boehringer Ingelheim (Canada) Ltd.,N,N,N,N,N,Y,N,Y,N,01-Nov-19,20-May-20,201.0,CADTH & INESSS,24-Jul-20,post-NOC,Initial,chronic fibrosing interstitial lung diseases,Completed,24-Feb-21,Reimburse with clinical criteria and/or conditions,Conditional,21-Aug-20,post-NOC,New Indication,Pulmonary interstitial disease,Completed,03-Mar-21,Inscription - Avec conditions,Conditional,1st,16-Jul-21,05-Feb-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2022-06-07,2022-04-01,2022-06-01,2022-06-01,2022-04-29,2022-04-29,2022-05-16,2022-07-01,2022-04-22,2022-04-13,01-Apr-22,2022-04-01,9.0,1.0,7.0,8.0,4.0,5.0,6.0,10.0,3.0,2.0,4.50%,33.00%,33.70%,65.90%,66.80%,68.10%,73.90%,79.40%,99.60%,100.00%,100.00%,29-Apr-22,07-Jun-22,65.0,93.0,215.0,194.0,142.0,135.0,204.0,122.0,55.0,116.0,116.0,83.0,83.0,100.0,146.0,76.0,67.0,100.0,55.0,96.0,55.0,122.0,748.0,681.0,742.0,742.0,709.0,709.0,726.0,772.0,702.0,693.0,726.0,722.0,681.0,616.0,401.0,468.0,401.0,462.0,462.0,429.0,429.0,446.0,492.0,422.0,406.0,446.0,280.0,287.0,346.0,339.0,748.0,67.0,67.0,28.0,39.0,481
427,Ofev,nintedanib,Boehringer Ingelheim ,N,N,N,Y,N,Y,N,Y,N,,25-Jun-15,,CADTH & INESSS,23-Apr-15,pre-NOC,Initial,Idiopathic pulmonary fibrosis (IPF),Completed,15-Oct-15,List with clinical criteria and/or conditions,Conditional,01-Dec-15,post-NOC,New Drug,Idiopathic pulmonary fibrosis (IPF),Completed,26-Apr-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,27-Oct-15,29-Aug-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2018-02-06,2016-11-01,2016-10-01,2017-01-25,2016-09-16,2016-11-30,2016-12-01,2017-04-24,2017-02-01,2017-03-15,16-Sep-16,2016-09-16,10.0,3.0,2.0,6.0,1.0,4.0,5.0,9.0,7.0,8.0,32.20%,38.00%,42.40%,43.30%,44.60%,50.10%,50.80%,79.40%,79.70%,100.00%,100.00%,25-Jan-17,06-Feb-18,-63.0,159.0,175.0,147.0,12.0,-182.0,307.0,526.0,64.0,33.0,149.0,18.0,93.0,94.0,238.0,156.0,198.0,152.0,18.0,157.0,18.0,526.0,957.0,495.0,464.0,580.0,449.0,524.0,525.0,669.0,587.0,629.0,583.0,588.0,449.0,512.0,337.0,845.0,383.0,352.0,468.0,337.0,412.0,413.0,557.0,475.0,323.0,471.0,112.0,306.0,319.0,125.0,957.0,508.0,508.0,131.0,377.0,42292
428,Ogivri,trastuzumab,BGP Pharma ULC,N,Y,Y,Y,Y,N,N,N,N,01-Jun-17,05-May-19,703.0,CADTH & INESSS,18-Dec-18,pre-NOC,New drug,Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar,Withdrawn,31-May-19,,,,,New Drug,Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar,Completed,10-Jul-19,Inscription - Avec conditions,Conditional,1st,30-May-19,03-Oct-19,Negotiation,Completed with Agreements,,,,,,,,,,EM,,,,,,,,,,2020-11-11,,2020-11-11,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,-138.0,,164.0,,-1.0,-41.0,126.0,,,,,,,,,,405.0,,,405.0,405.0,,,,,,,,,,,556.0,,556.0,,,,,,,,,,,,,490.0,,26.0,66.0,125.0,85.0,,,,,,729
429,Olumiant,baricitinib,Eli Lilly ,N,N,N,Y,N,N,N,N,N,01-May-16,17-Aug-18,838.0,CADTH & INESSS,20-Dec-18,post-NOC,Initial,"Arthritis, Rheumatoid",Completed,02-Aug-19,Reimburse with clinical criteria and/or conditions,Conditional,26-Nov-18,post-NOC,New Drug,Rheumatoid arthritis,Completed,05-Jun-19,Inscription - Avec conditions,Conditional,1st,20-Sep-19,10-May-21,Negotiation,Completed with Agreements,NR,SA,EDS,RB,LU,SA,,SA,,FB,,2021-07-01,2021-07-01,2021-08-05,2021-08-31,2021-08-19,,2022-02-28,,2021-08-18,01-Jul-21,2021-07-01,,1.0,2.0,3.0,6.0,5.0,,7.0,,4.0,4.50%,10.20%,15.70%,44.30%,45.20%,77.40%,77.80%,,,,77.80%,31-Aug-21,,125.0,101.0,225.0,191.0,49.0,107.0,598.0,,52.0,52.0,87.0,113.0,101.0,,294.0,,100.0,117.0,52.0,114.0,52.0,,,1049.0,1049.0,1084.0,1110.0,1098.0,,1291.0,,1097.0,1114.0,1111.0,1049.0,924.0,699.0,,699.0,699.0,734.0,760.0,748.0,,941.0,,805.0,764.0,350.0,292.0,647.0,705.0,,,,61.0,,1188
433,Onpattro,patisiran,Alnylam Pharmaceuticals,N,N,N,Y,N,Y,Y,Y,Y,01-Dec-18,07-Jun-19,188.0,CADTH & INESSS,25-Jan-19,pre-NOC,Initial,Polyneuropathy in hereditary transthyretin-mediated amyloidosis,Completed,25-Jul-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Mar-19,pre-NOC,New Drug,Polyneuropathy ATTRh,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,15-Nov-19,30-Nov-20,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,EDS,UR,SA,EM,2022-01-01,2021-03-01,2021-03-01,2021-04-01,2021-04-08,2021-02-24,2021-05-01,,2021-10-27,2021-02-03,24-Feb-21,2021-02-03,9.0,3.0,4.0,5.0,6.0,2.0,7.0,,8.0,1.0,28.60%,29.50%,33.90%,39.70%,45.20%,77.40%,78.70%,79.40%,99.60%,,99.60%,08-Apr-21,01-Jan-22,-133.0,-98.0,181.0,194.0,113.0,65.0,381.0,397.0,91.0,91.0,122.0,129.0,86.0,152.0,,331.0,65.0,175.0,86.0,163.0,65.0,397.0,939.0,633.0,633.0,664.0,671.0,628.0,694.0,,873.0,607.0,717.0,705.0,628.0,761.0,580.0,891.0,585.0,585.0,616.0,623.0,580.0,646.0,,825.0,511.0,669.0,48.0,96.0,494.0,446.0,939.0,332.0,311.0,64.0,268.0,236
435,Onureg,azacitidine,Bristol-Myers Squibb ,Y,N,N,Y,Y,Y,N,Y,N,01-Jul-20,05-Jan-21,188.0,CADTH & INESSS,01-Mar-21,post-NOC,Initial,"Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT).",Completed,20-Oct-21,Cond'l on Cost,Conditional,19-Apr-21,post-NOC,New Drug,"Maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment, and who are not eligible for hematopoietic stem cell transplantation (HSCT).",Completed,30-Nov-21,Inscription - Avec conditions,Conditional,1st,27-Jan-22,07-Jun-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,2022-10-01,2022-06-30,2022-09-01,2022-09-20,2022-12-31,2022-12-19,2023-02-01,,2023-02-08,2022-07-06,30-Jun-22,2022-06-30,5.0,1.0,3.0,4.0,7.0,6.0,8.0,,9.0,2.0,4.50%,33.00%,38.80%,44.30%,64.50%,65.40%,97.70%,99.00%,99.60%,,99.60%,01-Oct-22,31-Dec-22,55.0,104.0,233.0,225.0,99.0,58.0,131.0,116.0,23.0,86.0,105.0,207.0,195.0,239.0,,246.0,29.0,152.0,23.0,138.0,23.0,207.0,634.0,541.0,604.0,623.0,725.0,713.0,757.0,,764.0,547.0,670.0,656.0,541.0,486.0,253.0,346.0,253.0,316.0,335.0,437.0,425.0,469.0,,476.0,218.0,382.0,288.0,329.0,230.0,189.0,725.0,184.0,184.0,93.0,91.0,476
436,Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,Y,Y,Y,N,Y,N,,25-Sep-15,,CADTH & INESSS,13-Aug-15,pre-NOC,New drug,Metastatic Melanoma,Completed,01-Apr-16,Cond'l on Cost,Conditional,24-Nov-15,post-NOC,New Drug,Metastatic Melanoma,Completed,19-Aug-16,Avis d'inscritpion à la Liste Établissements-Médicaments d'exception-Avec condition,Conditional,1st,04-May-16,20-Jan-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-03-01,2017-04-03,2017-03-23,2017-03-13,2017-03-21,2017-05-02,2017-04-01,2018-08-01,2017-08-03,2017-03-15,01-Mar-17,2017-03-01,1.0,7.0,5.0,2.0,4.0,8.0,6.0,10.0,9.0,3.0,20.30%,25.80%,54.40%,86.60%,92.30%,93.60%,98.10%,99.00%,99.60%,100.00%,100.00%,15-Mar-17,21-Mar-17,-43.0,60.0,232.0,269.0,33.0,-107.0,261.0,40.0,73.0,62.0,52.0,60.0,102.0,71.0,558.0,195.0,54.0,135.0,40.0,127.0,40.0,60.0,523.0,556.0,545.0,535.0,543.0,585.0,554.0,1041.0,678.0,537.0,618.0,610.0,523.0,566.0,334.0,334.0,367.0,356.0,346.0,354.0,396.0,365.0,852.0,489.0,208.0,429.0,189.0,329.0,294.0,154.0,543.0,20.0,20.0,14.0,6.0,42461
437,Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,,26-Feb-16,,CADTH & INESSS,29-Oct-15,pre-NOC,New indication,Non-Small Cell Lung Cancer,Completed,03-Jun-16,Cond'l on Cost,Conditional,01-Mar-16,post-NOC,New Indication,Non-Small Cell Lung Cancer,Completed,19-Aug-16,Avis de refus d'inscription à la Liste Établissements,Negative,1st,04-Jul-16,20-Jan-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-03-01,2017-04-03,2017-03-23,2017-03-13,2017-03-21,2017-05-02,2017-04-01,2018-08-01,2017-08-03,2017-03-15,01-Mar-17,2017-03-01,1.0,7.0,5.0,2.0,4.0,8.0,6.0,10.0,9.0,3.0,20.30%,25.80%,54.40%,86.60%,92.30%,93.60%,98.10%,99.00%,99.60%,100.00%,100.00%,15-Mar-17,21-Mar-17,-120.0,4.0,218.0,171.0,31.0,-46.0,200.0,40.0,73.0,62.0,52.0,60.0,102.0,71.0,558.0,195.0,54.0,135.0,40.0,127.0,40.0,60.0,369.0,402.0,391.0,381.0,389.0,431.0,400.0,887.0,524.0,383.0,464.0,456.0,369.0,489.0,271.0,271.0,304.0,293.0,283.0,291.0,333.0,302.0,789.0,426.0,208.0,366.0,98.0,175.0,231.0,154.0,389.0,20.0,20.0,14.0,6.0,42524
438,Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,,25-Apr-16,,CADTH & INESSS,24-Feb-16,pre-NOC,New indication,Metastatic Renal Cell Carcinoma,Completed,01-Sep-16,Cond'l on Cost,Conditional,01-Apr-16,pre-NOC,New Indication,Kidney Cancer,Completed,19-Aug-16,Avis de refus d'inscription à la Liste Établissements,Negative,1st,18-Nov-16,20-Jan-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-03-01,2017-04-03,2017-03-23,2017-03-13,2017-03-21,2017-05-02,2017-04-01,2018-08-01,2017-08-03,2017-03-15,01-Mar-17,2017-03-01,1.0,7.0,5.0,2.0,4.0,8.0,6.0,10.0,9.0,3.0,20.30%,25.80%,54.40%,86.60%,92.30%,93.60%,98.10%,99.00%,99.60%,100.00%,100.00%,15-Mar-17,21-Mar-17,-61.0,-24.0,190.0,140.0,78.0,91.0,63.0,40.0,73.0,62.0,52.0,60.0,102.0,71.0,558.0,195.0,54.0,135.0,40.0,127.0,40.0,60.0,310.0,343.0,332.0,322.0,330.0,372.0,341.0,828.0,465.0,324.0,405.0,397.0,310.0,371.0,181.0,181.0,214.0,203.0,193.0,201.0,243.0,212.0,699.0,336.0,208.0,276.0,129.0,116.0,141.0,154.0,330.0,20.0,20.0,14.0,6.0,42614
439,Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,01-Nov-16,12-May-17,192.0,CADTH & INESSS,31-Jan-17,pre-NOC,New indication,Squamous Cell Carcinoma of the Head and Neck (SCCHN),Completed,31-Aug-17,Cond'l on Cost,Conditional,24-Mar-17,pre-NOC,New Indication,Head and Neck Cancer,Completed,18-Aug-17,Avis de refus dajout dune indication reconnue à la Liste Établissements  Médicament dexception  À moins que certaines conditions soient respectées,Conditional,1st,29-Sep-17,20-Nov-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-03-01,2018-05-08,2017-12-07,2017-12-05,2018-01-17,2017-12-18,2018-04-18,,2018-05-30,2018-02-01,05-Dec-17,2017-12-05,6.0,8.0,2.0,1.0,4.0,3.0,7.0,,9.0,5.0,5.50%,11.20%,12.10%,44.40%,73.00%,93.20%,94.50%,99.00%,99.60%,,99.60%,01-Feb-18,01-Mar-18,-101.0,-49.0,212.0,147.0,29.0,42.0,52.0,101.0,169.0,17.0,15.0,58.0,28.0,149.0,,191.0,73.0,91.0,15.0,89.0,15.0,101.0,293.0,361.0,209.0,207.0,250.0,220.0,341.0,,383.0,265.0,283.0,281.0,207.0,308.0,96.0,182.0,250.0,98.0,96.0,139.0,109.0,230.0,,272.0,167.0,172.0,111.0,98.0,81.0,94.0,293.0,86.0,86.0,58.0,28.0,303
440,Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Mar-17,10-Nov-17,254.0,CADTH & INESSS,29-Sep-17,pre-NOC,New indication,Classical Hodgkin Lymphoma after failure of ASCT,Completed,03-May-18,Cond'l on Cost,Conditional,30-Oct-17,pre-NOC,New Indication,Classical Hodgkin Lymphoma after failure of ASCT,Completed,09-May-18,Avis de refus d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Negative,1st,09-Oct-18,04-Oct-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,2019-12-01,2020-04-10,2020-03-01,2020-02-03,2020-01-29,2020-04-06,2020-04-01,,,2019-12-18,01-Dec-19,2019-12-01,1.0,8.0,5.0,4.0,3.0,7.0,6.0,,,2.0,20.30%,48.80%,81.10%,86.60%,92.30%,93.60%,94.50%,99.00%,,,99.00%,29-Jan-20,29-Jan-20,-42.0,-11.0,216.0,191.0,159.0,153.0,360.0,58.0,189.0,149.0,122.0,117.0,185.0,180.0,,,75.0,143.0,58.0,134.0,58.0,117.0,751.0,882.0,842.0,815.0,810.0,878.0,873.0,,,768.0,836.0,827.0,751.0,793.0,577.0,577.0,708.0,668.0,641.0,636.0,704.0,699.0,,,588.0,662.0,174.0,180.0,519.0,513.0,810.0,59.0,59.0,59.0,0.0,428
442,Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Jan-18,15-Nov-18,318.0,CADTH & INESSS,27-Aug-18,pre-NOC,New indication,Melanoma Adjuvant Therapy,Completed,07-Mar-19,Cond'l on Cost,Conditional,01-Feb-19,post-NOC,New Indication,Adjuvant Melanoma,Completed,13-Mar-19,Inscription  Avec conditions,Conditional,1st,26-Jun-19,06-Sep-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,2019-11-01,2020-04-10,2020-01-01,2020-01-15,2020-01-20,2020-04-06,2020-04-01,,,2019-10-02,01-Nov-19,2019-10-02,2.0,8.0,3.0,4.0,5.0,7.0,6.0,,,1.0,28.60%,48.80%,54.60%,60.10%,92.30%,93.60%,94.50%,99.00%,,,99.00%,01-Jan-20,20-Jan-20,-80.0,78.0,192.0,40.0,111.0,105.0,72.0,56.0,217.0,117.0,131.0,136.0,213.0,208.0,,,26.0,154.0,56.0,138.0,26.0,136.0,351.0,512.0,412.0,426.0,431.0,508.0,503.0,,,321.0,449.0,433.0,351.0,431.0,239.0,239.0,400.0,300.0,314.0,319.0,396.0,391.0,,,203.0,337.0,112.0,118.0,183.0,177.0,431.0,110.0,80.0,91.0,19.0,430
443,Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Jan-21,02-Jul-21,182.0,CADTH & INESSS,07-Jul-21,post-NOC,Initial,For the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).,Completed,26-Jan-22,Cond'l on Cost,Conditional,09-Aug-21,post-NOC,New Indication,Opdivo (nivolumab) for the adjuvant treatment of completely resected esophageal or gastroesophageal junction cancer in patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).,Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,28-Jun-22,25-Aug-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2022-11-01,2022-09-30,2022-12-01,2022-10-28,2023-03-31,,,2023-04-03,,2022-09-28,30-Sep-22,2022-09-28,4.0,2.0,5.0,3.0,6.0,,,7.0,,1.0,28.60%,33.00%,38.60%,58.80%,64.50%,96.80%,97.10%,,,,97.10%,01-Nov-22,31-Mar-23,5.0,38.0,203.0,233.0,153.0,90.0,58.0,68.0,36.0,98.0,64.0,218.0,,,221.0,,34.0,118.0,36.0,106.0,34.0,218.0,487.0,455.0,517.0,483.0,637.0,,,640.0,,453.0,537.0,525.0,455.0,450.0,247.0,279.0,247.0,309.0,275.0,429.0,,,432.0,,182.0,329.0,208.0,271.0,211.0,148.0,637.0,184.0,182.0,34.0,150.0,390
444,Opdivo,nivolumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Jan-21,28-Oct-21,300.0,CADTH & INESSS,18-Aug-21,pre-NOC,Initial,"In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.",Completed,04-Mar-22,Cond'l on Cost,Conditional,24-Sep-21,pre-NOC,New Indication,"In combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of adult patients with advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.",Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,28-Jun-22,25-Aug-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2022-11-01,2023-01-31,2022-12-01,2022-10-20,2022-11-30,,,2023-04-03,,2022-09-28,20-Oct-22,2022-09-28,3.0,6.0,5.0,2.0,4.0,,,7.0,,1.0,28.60%,34.10%,54.40%,86.60%,92.30%,96.80%,97.10%,,,,97.10%,01-Nov-22,30-Nov-22,-71.0,-34.0,198.0,187.0,116.0,90.0,58.0,68.0,159.0,98.0,56.0,97.0,,,221.0,,34.0,117.0,56.0,105.0,34.0,97.0,369.0,460.0,399.0,357.0,398.0,,,522.0,,335.0,418.0,406.0,357.0,428.0,230.0,242.0,333.0,272.0,230.0,271.0,,,395.0,,182.0,291.0,127.0,153.0,174.0,148.0,398.0,63.0,41.0,34.0,29.0,427
447,Opdivo & Yervoy in combo,nivolumab & ipilimumab in combo,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,,26-Oct-16,,CADTH & INESSS,30-Nov-16,post-NOC,New indication,Metastatic Melanoma,Completed,30-Nov-17,Cond'l on Cost,Conditional,24-Mar-17,post-NOC,New Indication,Metastatic Melanoma,Completed,18-Oct-17,Avis de refus d'ajout d'une indication reconnue à la Liste Établissements - Médicament d'exception,Negative,1st,13-Jun-18,20-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2019-04-01,2019-07-16,2019-04-15,2019-04-15,2019-04-04,2019-06-28,2019-07-01,,2019-07-16,2019-05-23,01-Apr-19,2019-04-01,1.0,8.0,3.0,4.0,2.0,6.0,7.0,,9.0,5.0,20.30%,52.50%,58.20%,63.70%,92.30%,93.20%,94.50%,99.00%,99.60%,,99.60%,04-Apr-19,23-May-19,35.0,149.0,365.0,208.0,195.0,238.0,280.0,12.0,118.0,26.0,26.0,15.0,100.0,103.0,,118.0,64.0,65.0,12.0,65.0,12.0,64.0,887.0,993.0,901.0,901.0,890.0,975.0,978.0,,993.0,939.0,940.0,940.0,887.0,852.0,487.0,487.0,593.0,501.0,501.0,490.0,575.0,578.0,,593.0,582.0,540.0,400.0,357.0,475.0,518.0,939.0,52.0,52.0,3.0,49.0,43069
448,Opdivo in combination with Yervoy,nivolumab in combination with Ipilimumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,01-Jan-18,06-Jul-18,186.0,CADTH & INESSS,26-Apr-18,pre-NOC,New indication,Renal Cell Carinoma,Completed,01-Nov-18,Cond'l on Cost,Conditional,25-May-18,pre-NOC,New Indication,RCC,Completed,08-Nov-18,Inscription  Avec conditions,Conditional,1st,28-Dec-18,20-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2019-05-01,2019-07-16,2019-06-01,2019-06-05,2019-05-15,2019-06-28,2019-07-01,,2019-07-16,2019-05-23,01-May-19,2019-05-01,1.0,8.0,4.0,5.0,2.0,6.0,7.0,,9.0,3.0,20.30%,52.50%,81.10%,86.80%,92.30%,93.20%,94.50%,99.00%,99.60%,,99.60%,15-May-19,23-May-19,-71.0,-42.0,189.0,167.0,57.0,50.0,82.0,42.0,118.0,73.0,77.0,56.0,100.0,103.0,,118.0,64.0,86.0,42.0,83.0,42.0,64.0,299.0,375.0,330.0,334.0,313.0,357.0,360.0,,375.0,321.0,343.0,340.0,299.0,370.0,181.0,181.0,257.0,212.0,216.0,195.0,239.0,242.0,,257.0,196.0,225.0,118.0,125.0,139.0,132.0,321.0,22.0,22.0,14.0,8.0,304
449,Opdivo in combination with Yervoy,nivolumab in combination with Ipilimumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,N,N,N,N,01-Mar-20,06-Aug-20,158.0,CADTH & INESSS,23-Jun-20,pre-NOC,New indication,"Non-Small Cell Lung Cancer (NSCLC):Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations",Completed,04-Mar-21,Cond'l on Cost,Conditional,,,New Indication,"Non-Small Cell Lung Cancer (NSCLC):Nivolumab, in combination with ipilimumab and 2 cycles of platinum-based chemotherapy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations",Completed,03-Mar-21,Refus d'inscription,Negative,1st,01-Nov-21,18-Jan-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,NR,2022-05-01,2022-03-31,2022-05-01,2022-03-29,2022-06-30,,,,,,29-Mar-22,2022-03-29,3.0,2.0,4.0,1.0,5.0,,,,,,5.50%,10.00%,30.20%,36.00%,68.20%,,,,,,68.20%,30-Jun-22,,-44.0,,254.0,,242.0,243.0,78.0,103.0,72.0,103.0,70.0,163.0,,,,,,102.0,70.0,102.0,70.0,,633.0,602.0,633.0,600.0,693.0,,,,,,632.0,632.0,600.0,644.0,390.0,423.0,392.0,423.0,390.0,483.0,,,,,,422.0,210.0,209.0,320.0,321.0,,,,93.0,,368
450,Opdivo-Yervoy,nivolumab-ipilimumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,01-Sep-20,28-May-21,269.0,CADTH & INESSS,29-Oct-20,pre-NOC,Initial,"in combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",Completed,04-Aug-21,Cond'l on Cost,Conditional,22-Jan-21,pre-NOC,New Indication,"In combination with ipilimumab, is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.",Completed,28-Jul-21,Inscription - Avec conditions,Conditional,1st,29-Oct-21,18-Jan-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2022-05-01,2022-03-31,2022-05-01,2022-04-01,2022-06-30,,,,,2022-03-02,31-Mar-22,2022-03-02,4.0,2.0,5.0,3.0,6.0,,,,,1.0,28.60%,33.00%,38.60%,58.80%,64.50%,96.80%,,,,,96.80%,01-May-22,30-Jun-22,-211.0,-126.0,279.0,187.0,86.0,93.0,81.0,103.0,72.0,103.0,73.0,163.0,,,,,43.0,103.0,72.0,93.0,43.0,163.0,338.0,307.0,338.0,308.0,398.0,,,,,278.0,338.0,328.0,307.0,518.0,239.0,270.0,239.0,270.0,240.0,330.0,,,,,217.0,270.0,68.0,61.0,167.0,174.0,398.0,120.0,91.0,60.0,60.0,337
452,Opsumit pCPA 2nd,macitentan,Actelion,Y,N,N,Y,N,Y,Y,Y,N,,06-Nov-13,,CADTH & INESSS,18-Dec-13,post-NOC,Initial,Pulmonary arterial hypertension,Completed,28-Jan-15,List with clinical criteria and/or conditions,Conditional,,,New Drug,Pulmonary arterial hypertension,Completed,02-Jun-14,Avis de refus,Negative,2nd,31-Jul-19,23-Dec-20,Negotiation,Completed with Agreements,,,EDS,EDS,EAP,SA,EDS,SA,SA,,,,2021-03-01,2021-04-01,2021-04-20,2021-07-15,2022-03-21,2023-01-23,2022-07-07,,01-Mar-21,2021-03-01,,,1.0,2.0,3.0,4.0,5.0,7.0,6.0,,5.70%,11.20%,43.50%,44.40%,45.70%,46.30%,46.70%,,,,46.70%,,,42.0,,406.0,,1645.0,1885.0,511.0,,,68.0,99.0,118.0,204.0,453.0,761.0,561.0,,323.0,68.0,323.0,68.0,,,,2672.0,2703.0,2722.0,2808.0,3057.0,3365.0,3165.0,,2927.0,2927.0,2672.0,2630.0,2224.0,,,2224.0,2255.0,2274.0,2360.0,2609.0,2917.0,2717.0,,2479.0,448.0,208.0,2156.0,2396.0,,,,,,42032
455,Orencia (SC),abatacept ,Bristol-Myers Squibb ,Y,Y,N,N,N,N,N,N,N,,21-Feb-13,,CADTH & INESSS,29-Nov-12,pre-NOC,Initial,"Arthritis, Rheumatoid ",Completed,18-Jul-13,List with clinical criteria and/or conditions,Conditional,04-Aug-13,post-NOC,New Form,Rheumatoid arthritis,Completed,01-Oct-13,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,31-Jan-14,10-Sep-14,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2014-02-25,2013-11-01,2015-04-01,2013-10-17,2013-06-12,2014-11-21,2016-12-01,2015-03-02,2016-11-24,2013-10-01,12-Jun-13,2013-06-12,5.0,4.0,8.0,3.0,1.0,6.0,10.0,7.0,9.0,2.0,32.20%,60.80%,66.30%,70.80%,91.10%,91.90%,92.30%,98.00%,98.70%,100.00%,100.00%,01-Oct-13,25-Feb-14,-84.0,164.0,231.0,58.0,197.0,122.0,222.0,-197.0,-313.0,203.0,-328.0,-455.0,72.0,813.0,173.0,806.0,-344.0,86.0,-455.0,43.0,-455.0,-197.0,369.0,253.0,769.0,238.0,111.0,638.0,1379.0,739.0,1372.0,222.0,652.0,609.0,111.0,195.0,-36.0,222.0,106.0,622.0,91.0,-36.0,491.0,1232.0,592.0,1225.0,0.0,505.0,147.0,222.0,419.0,344.0,369.0,258.0,258.0,111.0,147.0,41473
456,Orfadin,nitisinone,Sobi Canada,N,N,N,Y,N,Y,N,Y,N,01-Jul-16,13-Dec-16,165.0,CADTH & INESSS,29-Aug-17,post-NOC,Initial,Hereditary tyrosinemia type 1,Completed,21-Feb-18,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,hereditary Type 1 tyrosinemia,Completed,18-Aug-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,20-Aug-18,28-Nov-18,Negotiation,Completed with Agreements,SA,SA,UR,EDS,UR,SA,EDS,UR,UR,EM,2021-01-01,2019-02-01,,2019-08-22,,2019-08-26,2019-08-01,,,2018-02-01,01-Feb-19,2018-02-01,6.0,2.0,,4.0,,5.0,3.0,,,1.0,28.60%,33.00%,34.30%,39.90%,40.80%,61.00%,,,,,61.00%,01-Jan-21,,259.0,101.0,176.0,147.0,180.0,367.0,100.0,765.0,65.0,,267.0,,271.0,246.0,,,-300.0,323.0,65.0,219.0,-300.0,,1480.0,780.0,,982.0,,986.0,961.0,,,415.0,1038.0,934.0,780.0,521.0,345.0,1045.0,345.0,,547.0,,551.0,526.0,,,167.0,603.0,435.0,248.0,280.0,467.0,,,,1065.0,,600
458,Orkambi,lumacaftor/ivacaftor,Vertex Pharmaceuticals ,N,N,N,N,N,Y,N,Y,N,01-Nov-16,18-Apr-17,168.0,CADTH & INESSS,22-Feb-18,post-NOC,Initial,"Cystic Fibrosis, F508del CFTR mutation in patients 6 years and older",Completed,26-Sep-18,Do not reimburse,Negative,,,New Indication,Cystic Fibrosis,Completed,17-Oct-18,Refus dinscription,Negative,none,19-Feb-19,,Do Not Negotiate,,UR,SA,EDS,EDS,EAP,UR,CF,SA,UR,NR,,2021-08-01,2021-07-01,2021-10-22,2021-06-25,,2021-11-18,2021-11-01,,,25-Jun-21,2021-06-25,,3.0,2.0,4.0,1.0,,6.0,5.0,,,32.20%,38.00%,42.40%,47.90%,48.30%,49.60%,,,,,49.60%,,,310.0,,216.0,,146.0,125.0,,,,,,,,,,,,,,,,,,1566.0,1535.0,1648.0,1529.0,,1675.0,1658.0,,,1602.0,1602.0,1529.0,1219.0,1003.0,,1040.0,1009.0,1122.0,1003.0,,1149.0,1132.0,,,1076.0,526.0,547.0,,,,,,,,694
467,Ozempic,semaglutide,Novo Nordisk ,Y,Y,N,Y,N,N,N,N,N,01-Mar-17,04-Jan-18,309.0,CADTH & INESSS,23-Nov-18,post-NOC,Initial,"Diabetes mellitus, type 2",Completed,15-May-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-18,pre-NOC,New Drug,Type 2 diabetes,Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,31-Jan-19,26-Jul-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,2020-12-15,2019-09-01,2020-10-01,2021-01-21,2019-09-30,2019-12-19,2020-10-07,2019-09-23,2019-11-27,2019-11-14,01-Sep-19,2019-09-01,9.0,1.0,7.0,10.0,3.0,6.0,8.0,2.0,5.0,4.0,4.50%,4.80%,37.00%,65.60%,66.30%,67.20%,72.90%,74.20%,94.50%,100.00%,100.00%,14-Nov-19,15-Dec-20,323.0,-3.0,173.0,247.0,-104.0,148.0,176.0,508.0,37.0,433.0,545.0,66.0,146.0,439.0,59.0,124.0,111.0,262.0,37.0,247.0,37.0,508.0,1076.0,605.0,1001.0,1113.0,634.0,714.0,1007.0,627.0,692.0,679.0,830.0,815.0,605.0,282.0,109.0,580.0,109.0,505.0,617.0,138.0,218.0,511.0,131.0,196.0,435.0,334.0,496.0,244.0,72.0,324.0,1076.0,471.0,471.0,74.0,397.0,805
468,Ozurdex,dexamethasone ,Allergan ,N,N,N,N,N,N,N,N,N,,16-Apr-15,,CADTH & INESSS,26-Sep-17,post-NOC,Initial,Diabetic macular edema ,Completed,24-Oct-18,Do not reimburse,Negative,,,New Indication,Diabetic macular edema,Completed,01-Feb-16,Avis d'ajout d'une indication reconnue aux listes de médicaments - Médicament d'exception - Avec conditions,Conditional,none,29-Nov-18,,Do Not Negotiate,,NR,NR,NR,NR,NR,NR,NR,NR,NR,EM,,,,,,,,,,2016-07-01,,2016-07-01,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,894.0,,393.0,,36.0,1032.0,,,,,,,,,,,,,,,,,,,,,,,,,,442.0,,442.0,,,,,,,,,,,,,151.0,,1287.0,291.0,,,,,,,,43397
470,Padcev,enfortumab vedotin,SeaGen,N,Y,N,N,Y,N,N,N,Y,01-May-21,29-Oct-21,181.0,CADTH & INESSS,23-Jun-21,pre-NOC,Initial,"For the treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and who: have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or are not eligible for cisplatin-containing chemotherapy",Completed,06-Jan-22,Cond'l on Cost,Conditional,24-Sep-21,pre-NOC,New Indication,"For the treatment of patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and who: have received a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting or are not eligible for cisplatin-containing chemotherapy",Completed,30-Mar-22,Inscription - Avec conditions,Conditional,1st,28-Jun-22,28-Nov-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,2023-03-01,2023-01-31,2023-03-01,,,,,,,2022-12-14,31-Jan-23,2022-12-14,3.0,2.0,4.0,,,,,,,1.0,28.60%,33.00%,53.30%,59.00%,,,,,,,59.00%,01-Mar-23,,-128.0,-35.0,197.0,187.0,173.0,90.0,153.0,93.0,64.0,93.0,,,,,,,16.0,83.0,64.0,67.0,16.0,,488.0,459.0,488.0,,,,,,,411.0,478.0,462.0,459.0,587.0,390.0,419.0,390.0,419.0,,,,,,,259.0,409.0,69.0,152.0,326.0,243.0,,,,77.0,,250
472,pdp-levETIRAcetam,Levetiracetam,"Pendopharm, a division of Pharmascience Inc.",N,N,N,N,N,N,N,N,N,01-Sep-18,11-Jul-19,313.0,CADTH & INESSS,23-Jul-20,post-NOC,Initial,Epilepsy,Completed,03-Feb-21,Reimburse with clinical criteria and/or conditions,Conditional,11-Sep-20,post-NOC,New Drug,Epilepsy,Completed,30-Dec-20,Inscription - Avec conditions,Conditional,1st,23-Nov-21,05-Aug-22,Negotiation,Completed with Agreements,SA,FB,FB,FB,LU,SA,EDS,SA,SA,EM,2022-11-22,2022-10-01,2022-09-01,2023-01-24,2022-12-21,2022-10-24,2022-11-01,2023-03-27,2023-02-01,2022-09-28,01-Sep-22,2022-09-01,6.0,3.0,1.0,8.0,7.0,4.0,5.0,10.0,9.0,2.0,5.70%,34.30%,38.80%,39.70%,41.00%,61.20%,93.40%,99.00%,99.60%,100.00%,100.00%,22-Nov-22,21-Dec-22,378.0,428.0,195.0,110.0,293.0,328.0,255.0,109.0,57.0,27.0,172.0,138.0,80.0,88.0,234.0,180.0,54.0,121.0,27.0,114.0,27.0,138.0,1230.0,1178.0,1148.0,1293.0,1259.0,1201.0,1209.0,1355.0,1301.0,1175.0,1242.0,1235.0,1148.0,770.0,575.0,657.0,605.0,575.0,720.0,686.0,628.0,636.0,782.0,728.0,637.0,669.0,573.0,538.0,548.0,583.0,1259.0,111.0,111.0,82.0,29.0,886
475,Perjeta Herceptin Combo Pack,pertuzumab,Hoffman-La Roche ,Y,Y,N,Y,Y,N,N,N,N,,12-Apr-13,,CADTH & INESSS,02-Nov-12,pre-NOC,New drug,In combination with trastuzumab and a taxane for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease,Completed,01-Aug-13,Cond'l on Cost,Conditional,,,New Drug,In combination with trastuzumab and a taxane for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease,Completed,03-Feb-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,02-Aug-13,18-Oct-13,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2013-11-01,2013-12-19,2013-11-25,2014-03-14,2013-11-25,2014-04-01,2014-06-23,2015-04-27,2014-04-01,2016-03-24,01-Nov-13,2013-11-01,1.0,4.0,2.0,5.0,3.0,6.0,8.0,9.0,7.0,10.0,20.30%,26.00%,58.20%,62.70%,68.20%,69.10%,69.80%,71.10%,71.40%,100.00%,100.00%,25-Nov-13,24-Mar-16,-161.0,,272.0,,1.0,-185.0,77.0,14.0,62.0,38.0,147.0,38.0,165.0,248.0,556.0,165.0,888.0,159.0,14.0,232.0,14.0,888.0,203.0,251.0,227.0,336.0,227.0,354.0,437.0,745.0,354.0,1077.0,348.0,421.0,203.0,364.0,92.0,92.0,140.0,116.0,225.0,116.0,243.0,326.0,634.0,243.0,780.0,237.0,111.0,297.0,78.0,-108.0,1077.0,874.0,874.0,24.0,850.0,41487
479,Pheburane,sodium phenylbutyrate,Médunik Canada,N,N,N,Y,N,Y,N,Y,N,,26-Jan-15,,CADTH & INESSS,20-Oct-15,post-NOC,Initial,Urea cycle disorders,Completed,15-Apr-16,List,Positive,04-Aug-15,post-NOC,New Drug,Urea cycle disorders,Completed,01-Feb-16,Avis de refus d'inscription aux listes de médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,21-Apr-17,20-Nov-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,NR,SA,EDS,NR,SA,NR,2018-01-23,2018-05-01,2018-04-01,2018-04-19,,2018-05-08,2019-04-01,,2018-03-01,,23-Jan-18,2018-01-23,1.0,5.0,3.0,4.0,,6.0,7.0,,2.0,,20.30%,20.90%,26.60%,32.20%,36.60%,37.50%,38.80%,,,,38.80%,,,267.0,190.0,178.0,181.0,371.0,445.0,213.0,64.0,162.0,132.0,150.0,,169.0,497.0,,101.0,,182.0,64.0,182.0,64.0,,1093.0,1191.0,1161.0,1179.0,,1198.0,1526.0,,1130.0,,1211.0,1211.0,1093.0,826.0,648.0,648.0,746.0,716.0,734.0,,753.0,1081.0,,685.0,,766.0,445.0,371.0,584.0,658.0,,,,,,42475
482,Pifeltro,doravirine,Merck,Y,N,N,Y,N,N,N,N,N,01-Dec-17,12-Oct-18,315.0,CADTH & INESSS,16-Nov-18,post-NOC,Initial,HIV-1,Completed,14-May-19,Reimburse with clinical criteria and/or conditions,Conditional,16-Nov-18,post-NOC,New Drug,HIV,Completed,08-May-19,Inscription,Positive,1st,14-Jun-19,15-Oct-19,Negotiation,Completed with Agreements,HIV,UR,UR,EDS,FB,SA,HIV,HIV,SA,FB,,,,2020-03-02,2019-10-31,2020-05-21,2021-03-01,2021-05-31,2020-09-11,2019-11-14,31-Oct-19,2019-10-31,,,,3.0,1.0,4.0,6.0,7.0,5.0,2.0,32.20%,60.80%,66.30%,67.20%,67.90%,69.20%,69.60%,,,,69.60%,14-Nov-19,,35.0,35.0,179.0,173.0,31.0,37.0,123.0,,,,139.0,16.0,219.0,503.0,594.0,332.0,30.0,301.0,16.0,262.0,16.0,,,,,507.0,384.0,587.0,871.0,962.0,700.0,398.0,669.0,630.0,384.0,349.0,170.0,,,,293.0,170.0,373.0,657.0,748.0,486.0,190.0,455.0,214.0,208.0,154.0,160.0,,,,14.0,,529
484,Plegridy,peginterferon beta-1a,Biogen,N,Y,N,Y,N,N,N,N,N,,10-Aug-15,,CADTH & INESSS,26-Jun-15,pre-NOC,Initial,"Multiple Sclerosis, relapsing",Completed,17-Dec-15,List with criteria/condition,Conditional,24-Nov-15,post-NOC,New Drug,"Multiple Sclerosis, relapsing",Completed,01-Jun-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,17-Jun-16,14-Feb-17,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,NR,,2017-07-01,2017-04-01,2017-07-19,2017-03-17,2017-08-15,2017-10-24,2017-04-24,2017-05-26,,17-Mar-17,2017-03-17,,5.0,2.0,6.0,1.0,7.0,8.0,3.0,4.0,,32.20%,38.00%,38.30%,39.00%,43.40%,49.00%,49.90%,51.20%,,,51.20%,24-Oct-17,,-45.0,106.0,174.0,190.0,183.0,16.0,242.0,,137.0,46.0,155.0,31.0,182.0,252.0,69.0,101.0,,122.0,31.0,122.0,31.0,,,691.0,600.0,709.0,585.0,736.0,806.0,623.0,655.0,,676.0,676.0,585.0,630.0,456.0,,562.0,471.0,580.0,456.0,607.0,677.0,494.0,526.0,,547.0,129.0,296.0,425.0,258.0,,,,221.0,,42355
486,Polivy,polatuzumab vedotin,Hoffman-La Roche ,Y,Y,N,Y,Y,Y,Y,Y,N,01-Nov-19,09-Jul-20,251.0,CADTH & INESSS,29-Sep-20,post-NOC,New drug,"Diffuse Large B-Cell Lymphoma (DLBCL): Polatuzumab vedotin, in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who are not eligible for autologous stem cell transplant and have received at least one prior therapy.",Completed,21-Apr-21,Cond'l on Cost,Conditional,06-Nov-20,post-NOC,New Drug,Diffuse Large B-Cell Lymphoma (DLBCL),Completed,02-Jun-21,Refus d'inscription,Negative,1st,21-Jul-21,01-Dec-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,NR,2022-04-01,2022-02-28,2022-01-01,2022-01-04,2022-05-31,,,,,,01-Jan-22,2022-01-01,4.0,3.0,1.0,2.0,5.0,,,,,,5.70%,11.20%,15.70%,36.00%,68.20%,,,,,,68.20%,31-May-22,,82.0,120.0,204.0,208.0,91.0,49.0,133.0,121.0,89.0,31.0,34.0,181.0,,,,,,91.0,31.0,91.0,31.0,,631.0,599.0,541.0,544.0,691.0,,,,,,601.0,601.0,541.0,459.0,255.0,345.0,313.0,255.0,258.0,405.0,,,,,,315.0,286.0,328.0,224.0,182.0,,,,150.0,,537
489,Pomalyst,pomalidomide,Celgene ,N,N,N,Y,Y,Y,Y,Y,N,,20-Jan-14,,CADTH & INESSS,13-Jan-14,pre-NOC,New drug,Multiple Myeloma:In combination with low-dose dexamethasone for patients with multiple myeloma for whom both bortezomib and lenalidomide have failed and who have received at least two prior treatment regimens and have demonstrated disease progression on the last regimen,Completed,31-Jul-14,Cond'l on Cost,Conditional,24-Nov-13,pre-NOC,New Drug,Multiple Myeloma,Completed,16-Jul-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,21-Aug-14,23-Jan-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2015-03-01,2015-04-28,2015-05-01,2015-04-20,2015-02-06,2015-03-23,2015-05-04,2015-11-23,2015-05-01,2016-03-24,06-Feb-15,2015-02-06,2.0,5.0,6.0,4.0,1.0,3.0,8.0,9.0,7.0,10.0,32.20%,52.50%,53.40%,58.90%,63.40%,69.10%,69.80%,71.10%,71.40%,100.00%,100.00%,01-Mar-15,24-Mar-16,-7.0,-57.0,199.0,234.0,21.0,36.0,155.0,37.0,95.0,98.0,87.0,14.0,59.0,101.0,304.0,98.0,426.0,99.0,14.0,132.0,14.0,426.0,405.0,463.0,466.0,455.0,382.0,427.0,469.0,672.0,466.0,794.0,467.0,500.0,382.0,389.0,190.0,213.0,271.0,274.0,263.0,190.0,235.0,277.0,480.0,274.0,617.0,275.0,192.0,177.0,176.0,191.0,794.0,412.0,412.0,23.0,389.0,41851
492,Praluent,alirocumab,Sanofi-Aventis ,Y,Y,N,Y,N,N,N,N,N,01-Jun-15,11-Apr-16,315.0,CADTH & INESSS,12-Jan-16,pre-NOC,Initial,"Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia",Completed,20-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,"Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia",Completed,01-Feb-17,Avis de refus dinscription aux listes des médicaments  Médicament dexception  À moins que certaines conditions soient respectées,Conditional,1st,26-Aug-16,02-Aug-18,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,LU,SA,EDS,SA,SA,NR,,2019-02-01,2018-10-01,2019-05-31,2019-03-28,2018-11-30,2019-05-01,2022-07-25,2022-05-02,,01-Oct-18,2018-10-01,,3.0,1.0,6.0,4.0,2.0,5.0,8.0,7.0,,5.70%,6.60%,11.10%,43.30%,44.60%,50.10%,50.80%,51.20%,,,51.20%,31-May-19,,-90.0,123.0,190.0,173.0,37.0,-159.0,706.0,,183.0,60.0,302.0,238.0,120.0,272.0,1453.0,1369.0,,500.0,60.0,500.0,60.0,,,1026.0,903.0,1145.0,1081.0,963.0,1115.0,2296.0,2212.0,,1343.0,1343.0,903.0,993.0,803.0,,926.0,803.0,1045.0,981.0,863.0,1015.0,2196.0,2112.0,,1243.0,100.0,296.0,743.0,547.0,,,,242.0,,415
494,Prevymis,letermovir,Merck,Y,N,N,Y,N,Y,Y,Y,N,01-May-17,01-Nov-17,184.0,CADTH & INESSS,07-Dec-17,post-NOC,Initial,"Cytomegalovirus infection, prophylaxis",Completed,20-Jun-18,Reimburse with clinical criteria and/or conditions,Conditional,22-Dec-17,post-NOC,New Drug,CMV Prophylaxis,Completed,05-Jul-18,Avis de refus d'inscription aux listes des médicaments,Negative,1st,29-Nov-18,18-Dec-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2021-05-18,2020-04-01,2020-07-01,2020-07-16,2020-01-22,2020-07-16,2021-08-01,2021-12-20,2021-06-08,2020-02-05,22-Jan-20,2020-01-22,7.0,3.0,4.0,5.0,1.0,6.0,9.0,10.0,8.0,2.0,32.20%,60.80%,65.30%,71.00%,76.50%,77.40%,97.70%,98.30%,99.60%,100.00%,100.00%,05-Feb-20,18-May-21,36.0,51.0,195.0,195.0,162.0,147.0,384.0,517.0,105.0,196.0,211.0,35.0,211.0,592.0,733.0,538.0,49.0,349.0,35.0,319.0,35.0,517.0,1294.0,882.0,973.0,988.0,812.0,988.0,1369.0,1510.0,1315.0,826.0,1126.0,1096.0,812.0,776.0,581.0,1063.0,651.0,742.0,757.0,581.0,757.0,1138.0,1279.0,1084.0,580.0,895.0,231.0,246.0,546.0,531.0,1294.0,482.0,482.0,14.0,468.0,415
495,Prezcobix,darunavir/cobicistat,Janssen ,Y,N,N,N,N,N,N,N,N,,19-Jun-14,,CADTH,22-May-14,pre-NOC,Initial,HIV infection,Completed,18-Mar-15,List with criteria/condition,Conditional,,,,,,,,,1st,10-Jun-15,24-Mar-16,Negotiation,Completed with Agreements,HIV,HIV,EDS,EDS,FB,SA,HIV,FB,SA,NR,2015-08-12,,2016-05-01,2016-07-21,2016-06-29,2016-09-29,2016-09-01,2016-11-28,2016-11-01,,12-Aug-15,2015-08-12,1.0,,2.0,4.0,3.0,6.0,5.0,8.0,7.0,,20.30%,26.00%,58.20%,63.70%,65.00%,65.90%,66.60%,67.00%,,,67.00%,29-Jun-16,,-28.0,,300.0,,84.0,,288.0,-225.0,,38.0,119.0,97.0,189.0,161.0,249.0,222.0,,106.0,-225.0,106.0,-225.0,,419.0,,682.0,763.0,741.0,833.0,805.0,893.0,866.0,,750.0,750.0,419.0,447.0,147.0,147.0,,410.0,491.0,469.0,561.0,533.0,621.0,594.0,,478.0,272.0,,372.0,,,,,322.0,,42081
497,Probuphine,buprenorphine hydrochloride,Knight Therapeutics ,N,N,N,N,N,N,N,N,N,01-Jun-17,18-Apr-18,321.0,CADTH & INESSS,21-Dec-17,pre-NOC,Initial,"Opioid drug dependence, treatment",Completed,22-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,17-Apr-18,pre-NOC,New Drug,Opioid Dependency,Completed,17-Oct-18,Inscription  Avec conditions,Conditional,1st,30-Nov-18,03-May-19,Negotiation,Completed with Agreements,NR,SA,EDS,RB,LU,SA,EDS,SA,SA,EM,,2019-07-01,2019-08-01,2020-03-02,2020-04-30,2019-08-26,2020-02-06,2021-05-31,2019-12-04,2019-11-14,01-Jul-19,2019-07-01,,1.0,2.0,7.0,8.0,3.0,6.0,9.0,5.0,4.0,4.50%,10.20%,11.10%,39.70%,40.30%,41.60%,47.20%,79.40%,79.70%,,79.70%,30-Apr-20,,-118.0,-1.0,244.0,183.0,100.0,44.0,154.0,,59.0,90.0,304.0,363.0,115.0,279.0,759.0,215.0,195.0,273.0,59.0,264.0,59.0,,,439.0,470.0,684.0,743.0,495.0,659.0,1139.0,595.0,575.0,653.0,644.0,439.0,557.0,313.0,,313.0,344.0,558.0,617.0,369.0,533.0,1013.0,469.0,393.0,527.0,126.0,182.0,254.0,198.0,,,,304.0,,447
498,Procysbi,cysteamine bitartrate,Horizon Pharma,N,N,N,Y,N,N,Y,Y,N,,13-Jun-17,,CADTH & INESSS,08-Aug-17,post-NOC,Initial,Nephropathic cystinosis,Completed,24-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,05-Mar-18,post-NOC,New Drug,Nephropathic cystinosis,Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,09-Feb-18,20-Jul-18,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,NR,SA,EDS,NR,SA,EM,,2018-09-01,2018-10-01,2018-10-18,,2018-11-30,2019-02-01,,2021-04-20,2018-09-27,01-Sep-18,2018-09-01,,1.0,3.0,4.0,,5.0,6.0,,7.0,2.0,4.50%,33.00%,38.80%,44.30%,45.20%,46.50%,47.20%,,,,47.20%,,,56.0,265.0,169.0,184.0,16.0,-208.0,161.0,,43.0,73.0,90.0,,133.0,196.0,,1005.0,69.0,257.0,43.0,230.0,43.0,,,445.0,475.0,492.0,,535.0,598.0,,1407.0,471.0,659.0,632.0,445.0,389.0,220.0,,220.0,250.0,267.0,,310.0,373.0,,1182.0,22.0,434.0,225.0,449.0,177.0,-47.0,,,,,,43124
499,Proleukin,aldesleukin (IL-2),Novartis,Y,Y,N,N,Y,Y,N,Y,N,,16-Sep-14,,CADTH,30-Jan-15,post-NOC,New indication,In-transit Melanoma,Completed,22-Jun-15,Fund,Positive,,,,,,,,,,,,,,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,,2021-06-01,2015-12-18,2015-09-11,2015-09-09,2016-09-09,2017-12-14,2015-12-01,,,,09-Sep-15,2015-09-09,7.0,4.0,2.0,1.0,5.0,6.0,3.0,,,,5.50%,11.20%,12.60%,17.00%,49.20%,50.10%,70.40%,,,,70.40%,14-Dec-17,,136.0,,143.0,,,,,,,,,,,,,,,,,,,,2450.0,458.0,360.0,358.0,724.0,1185.0,441.0,,,,854.0,854.0,358.0,222.0,79.0,2171.0,179.0,81.0,79.0,445.0,906.0,162.0,,,,575.0,279.0,,,,,,,827.0,,42177
500,Prolia (men Osteo) (Drug Plan Submission),denosumab ,Amgen ,Y,Y,N,N,N,N,N,N,N,,21-Nov-12,,CADTH & INESSS,10-Mar-15,post-NOC,Request for Advice,"Osteoporosis, men",Completed,21-Sep-15,List with clinical criteria and/or conditions,Conditional,31-Jan-18,post-NOC,New Indication,"Osteoporosis, men",Completed,08-Aug-18,Avis de refus d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception,Negative,1st,09-Dec-15,17-Oct-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2017-02-14,2016-02-01,2018-01-01,,2018-01-31,2018-02-12,2019-06-01,2019-11-25,2018-03-16,2018-08-16,01-Feb-16,2016-02-01,2.0,1.0,3.0,,4.0,5.0,8.0,9.0,6.0,7.0,4.50%,24.70%,30.40%,62.70%,63.60%,64.20%,92.80%,94.10%,94.50%,,94.50%,31-Jan-18,16-Aug-18,839.0,1897.0,195.0,189.0,79.0,-973.0,678.0,-245.0,-624.0,76.0,,106.0,118.0,592.0,769.0,150.0,303.0,118.0,-624.0,138.0,-624.0,303.0,1546.0,1167.0,1867.0,,1897.0,1909.0,2383.0,2560.0,1941.0,2094.0,1909.0,1929.0,1167.0,328.0,133.0,512.0,133.0,833.0,,863.0,875.0,1349.0,1526.0,907.0,8.0,875.0,1034.0,2086.0,757.0,-295.0,2094.0,927.0,927.0,730.0,197.0,42268
502,Quinsair,levofloxacin,Raptor Pharmaceuticals Inc.,N,N,N,N,N,N,N,N,N,,09-Jun-15,,CADTH & INESSS,31-May-16,post-NOC,Initial,Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections,Completed,21-Nov-16,Reimburse with clinical criteria and/or conditions,Conditional,,,New drug,Cystic fibrosis with chronic pulmonary Pseudomonas aeruginosa infections,completed,01-Jun-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,29-May-17,11-Oct-18,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,FB,CF,UR,SA,EM,,2018-12-01,2019-01-01,2020-03-02,2019-02-04,2019-03-27,2019-04-01,,2019-03-01,2018-11-15,01-Dec-18,2018-11-15,,2.0,3.0,8.0,4.0,6.0,7.0,,5.0,1.0,28.60%,33.00%,38.80%,71.00%,71.70%,72.60%,73.90%,79.40%,,,79.40%,04-Feb-19,,357.0,,174.0,,189.0,-3.0,500.0,,51.0,82.0,508.0,116.0,167.0,172.0,,141.0,35.0,177.0,51.0,159.0,35.0,,,1271.0,1302.0,1728.0,1336.0,1387.0,1392.0,,1361.0,1255.0,1397.0,1379.0,1271.0,914.0,740.0,,740.0,771.0,1197.0,805.0,856.0,861.0,,830.0,532.0,866.0,531.0,723.0,689.0,497.0,,,,81.0,,42695
504,Radicava,edaravone,Mitsubishi Tanabe Pharma Corporation,N,N,N,Y,N,Y,Y,Y,Y,01-Apr-18,03-Oct-18,185.0,CADTH & INESSS,05-Jul-18,pre-NOC,Initial,amyotrophic lateral sclerosis,Completed,27-Mar-19,Reimburse with clinical criteria and/or conditions,Conditional,11-Jul-18,pre-NOC,New Drug,Amyotropic lateral sclerosis,Completed,13-Feb-19,Inscription  Avec conditions,Conditional,1st,24-Sep-19,15-Apr-20,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2020-08-19,2020-06-01,2020-07-01,2020-07-16,2020-05-11,2020-06-18,2020-07-06,2021-11-22,2021-03-01,2020-04-29,11-May-20,2020-04-29,8.0,3.0,5.0,7.0,2.0,4.0,6.0,10.0,9.0,1.0,28.60%,60.80%,65.30%,66.20%,71.90%,73.20%,78.70%,99.00%,99.60%,100.00%,100.00%,11-May-20,19-Aug-20,-90.0,-84.0,265.0,217.0,181.0,223.0,204.0,126.0,47.0,77.0,92.0,26.0,64.0,82.0,586.0,320.0,14.0,158.0,26.0,143.0,14.0,126.0,686.0,607.0,637.0,652.0,586.0,624.0,642.0,1146.0,880.0,574.0,718.0,703.0,586.0,676.0,411.0,511.0,432.0,462.0,477.0,411.0,449.0,467.0,971.0,705.0,441.0,543.0,175.0,133.0,385.0,427.0,686.0,112.0,100.0,12.0,100.0,360
506,Ravicti,glycerol phenylbutyrate,Horizon Therapeutics Canada/Horizon Pharma Ireland Ltd.,N,N,N,Y,N,Y,Y,Y,N,,18-Mar-16,,CADTH & INESSS,30-Aug-16,post-NOC,Initial,Urea cycle disorders,Completed,21-Mar-17,Reimburse with clinical criteria and/or conditions,Conditional,,,New Drug,Chronic management of adult and pediatric patients two years of age and older with Urea Cycle Disorders (UCDs),Completed,06-Jan-17,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,21-Apr-17,12-Dec-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,UR,SA,EM,2018-01-23,2018-05-01,2018-04-01,2018-04-19,2018-04-09,2018-07-18,2019-02-01,,2019-03-04,2019-05-23,23-Jan-18,2018-01-23,1.0,5.0,2.0,4.0,3.0,6.0,7.0,,8.0,9.0,20.30%,26.00%,58.20%,63.70%,68.20%,69.10%,70.40%,71.10%,99.60%,,99.60%,09-Apr-18,23-May-19,165.0,,203.0,,31.0,105.0,235.0,42.0,140.0,110.0,128.0,118.0,218.0,416.0,,447.0,527.0,202.0,42.0,238.0,42.0,527.0,676.0,774.0,744.0,762.0,752.0,852.0,1050.0,,1081.0,1161.0,836.0,872.0,676.0,511.0,308.0,308.0,406.0,376.0,394.0,384.0,484.0,682.0,,713.0,867.0,468.0,368.0,294.0,266.0,340.0,1161.0,485.0,485.0,76.0,409.0,42815
508,Reblozyl,luspatercept,Celgene Inc./Bristol-Myers Squibb Canada Co.,Y,Y,N,Y,N,Y,Y,Y,N,01-Mar-20,25-Sep-20,208.0,CADTH & INESSS,26-Nov-20,post-NOC,Initial,beta-thalassemia associated anemia,Completed,08-Jun-21,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-21,post-NOC,New Drug,Beta-thalassemia related anemia requiring blood transfusion,Completed,02-Jun-21,Inscription - Avec conditions,Conditional,1st,07-Mar-22,18-Oct-22,Negotiation,Completed with Agreements,,SA,,,EAP,,,,,EM,,2023-02-01,,,2023-02-27,,,,,2022-11-09,01-Feb-23,2022-11-09,,2.0,,,3.0,,,,,1.0,28.60%,33.00%,65.30%,,,,,,,,65.30%,27-Feb-23,,62.0,98.0,194.0,152.0,272.0,278.0,225.0,,106.0,,,132.0,,,,,22.0,119.0,106.0,87.0,22.0,,,859.0,,,885.0,,,,,775.0,872.0,840.0,859.0,797.0,603.0,,603.0,,,629.0,,,,,525.0,616.0,256.0,250.0,497.0,503.0,,,,110.0,,464
509,Reblozyl,luspatercept,"Celgene Inc., a Bristol Myers Squibb company",N,Y,N,Y,N,Y,Y,Y,N,01-Mar-20,11-Feb-21,347.0,CADTH & INESSS,28-Jan-21,pre-NOC,Initial,Myelodysplastic syndromes-associated anemia,Completed,07-Dec-21,Reimburse with clinical criteria and/or conditions,Conditional,23-Apr-21,post-NOC,New Indication,Myelodysplastic syndromes-associated anemia,Completed,08-Oct-21,Inscription - Avec conditions,Conditional,1st,07-Mar-22,18-Oct-22,Negotiation,Completed with Agreements,,,,,EAP,,,,,EM,,,,,2023-02-27,,,,,2022-11-09,27-Feb-23,2022-11-09,,,,,2.0,,,,,1.0,28.60%,60.80%,,,,,,,,,60.80%,27-Feb-23,,-14.0,71.0,313.0,168.0,90.0,150.0,225.0,,,,,132.0,,,,,22.0,132.0,132.0,77.0,22.0,,,,,,746.0,,,,,636.0,746.0,691.0,746.0,760.0,447.0,,,,,447.0,,,,,397.0,447.0,299.0,239.0,315.0,375.0,,,,110.0,,646
512,Renflexis,infliximab,Merck,Y,Y,Y,N,N,N,N,N,N,,01-Dec-17,,CADTH & INESSS,05-Sep-17,pre-NOC,Initial,"rheumatoid arthritis, ankylosing spondylitis, adult Crohns disease, pediatric Crohns disease, fistulising Crohns disease, adult ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, plaque psoriasis ",Completed,20-Feb-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Feb-18,post-NOC,New Drug,Multiple,Completed,14-Jun-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,13-Apr-18,27-Jul-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2018-08-21,2019-01-01,2019-04-01,2018-10-18,2018-09-27,2019-02-07,2019-09-01,2018-11-26,2018-12-01,2018-09-27,21-Aug-18,2018-08-21,1.0,7.0,9.0,4.0,2.0,8.0,10.0,5.0,6.0,3.0,20.30%,52.50%,81.10%,86.60%,87.00%,87.60%,92.10%,93.00%,98.70%,100.00%,100.00%,27-Sep-18,27-Sep-18,-87.0,62.0,168.0,133.0,52.0,-62.0,105.0,25.0,158.0,248.0,83.0,62.0,195.0,401.0,122.0,127.0,62.0,158.0,25.0,148.0,25.0,62.0,263.0,396.0,486.0,321.0,300.0,433.0,639.0,360.0,365.0,300.0,396.0,386.0,263.0,350.0,182.0,182.0,315.0,405.0,240.0,219.0,352.0,558.0,279.0,284.0,105.0,315.0,81.0,195.0,157.0,43.0,300.0,37.0,37.0,37.0,0.0,43151
514,Repatha (HeFH),evolocumab,Amgen ,Y,Y,N,Y,N,N,N,N,N,,10-Sep-15,,CADTH & INESSS,30-Jun-15,pre-NOC,Initial,Primary hyperlipidemia and mixed dyslipidemia,Completed,19-Feb-16,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,Primary hyperlipidemia and mixed dyslipidemia (homo),Completed,01-Jun-16,Avis de refus d'inscription aux listes des médicaments-Médicament d'exception-À moins que certaines conditions soient respectées (hypercholestérolémie familiale hétérozygote),Conditional,1st,26-Aug-16,23-Oct-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2018-12-18,2018-06-01,2018-07-01,2018-01-25,2018-04-30,2018-07-18,2019-05-01,2022-02-28,2020-02-14,2018-02-01,25-Jan-18,2018-01-25,7.0,4.0,5.0,1.0,3.0,6.0,8.0,10.0,9.0,2.0,5.50%,34.10%,66.30%,70.80%,76.50%,77.40%,97.70%,99.00%,99.60%,100.00%,100.00%,30-Apr-18,18-Dec-18,-72.0,75.0,234.0,190.0,189.0,86.0,423.0,421.0,221.0,251.0,94.0,189.0,268.0,555.0,1589.0,844.0,101.0,492.0,94.0,453.0,94.0,421.0,1195.0,995.0,1025.0,868.0,963.0,1042.0,1329.0,2363.0,1618.0,875.0,1266.0,1227.0,868.0,940.0,706.0,1033.0,833.0,863.0,706.0,801.0,880.0,1167.0,2201.0,1456.0,610.0,1104.0,162.0,265.0,612.0,509.0,1195.0,327.0,327.0,95.0,232.0,42419
518,Revestive,teduglutide,Shire,Y,Y,N,Y,N,Y,Y,Y,N,,04-Sep-15,,CADTH & INESSS,26-Nov-15,post-NOC,Initial,Short Bowel Syndrome (SBS),Completed,27-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,Short Bowel Syndrome (SBS),Completed,01-Jun-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,30-Jun-17,07-Aug-18,Negotiation,Completed with Agreements,NR,SA,NR,EDS,EAP,SA,EDS,NR,NR,NR,,2019-01-01,,2019-01-24,2018-12-12,2019-07-04,2019-08-01,,,,12-Dec-18,2018-12-12,,2.0,,3.0,1.0,4.0,5.0,,,,32.20%,36.70%,42.20%,43.10%,44.40%,,,,,,44.40%,,,83.0,81.0,244.0,190.0,338.0,394.0,403.0,,147.0,,170.0,127.0,331.0,359.0,,,,227.0,127.0,227.0,127.0,,,1215.0,,1238.0,1195.0,1399.0,1427.0,,,,1295.0,1295.0,1195.0,1112.0,868.0,,888.0,,911.0,868.0,1072.0,1100.0,,,,968.0,327.0,271.0,741.0,797.0,,,,,,42578
519,Revestive,teduglutide,Shire,Y,Y,N,N,N,Y,Y,Y,N,01-Feb-19,13-Aug-19,193.0,CADTH,29-May-19,pre-NOC,Initial,"Short Bowel Syndrome (SBS), pediatrics",Completed,19-Nov-19,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,2nd,21-Feb-20,28-Oct-20,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,UR,SA,,,2021-05-01,2021-05-01,2021-04-01,2021-04-06,2021-04-22,2021-05-01,,2021-10-27,,01-Apr-21,2021-04-01,,4.0,5.0,1.0,2.0,3.0,6.0,,7.0,,5.50%,37.80%,38.70%,43.10%,48.80%,50.10%,50.80%,,,,50.80%,01-May-21,,-76.0,,174.0,,94.0,,250.0,,185.0,185.0,155.0,160.0,176.0,185.0,,364.0,,201.0,155.0,201.0,155.0,,,627.0,627.0,597.0,602.0,618.0,627.0,,806.0,,643.0,643.0,597.0,673.0,499.0,,529.0,529.0,499.0,504.0,520.0,529.0,,708.0,,545.0,98.0,,344.0,,,,,30.0,,291
521,Revlimid,lenalidomide,Celgene ,N,N,N,N,Y,Y,Y,Y,N,,14-Dec-16,,CADTH & INESSS,04-May-15,pre-NOC,New indication,"In combination with low-dose dexamethasone, for treatment of newly diagnosed multiple myeloma patients who are not candidates for stem cell transplantation",Completed,03-Dec-15,Cond'l on Cost,Conditional,24-Mar-17,post-NOC,New Indication,Multiple myeloma- combination with dexamethasone,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,10-Dec-15,14-Sep-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-04-01,2016-10-18,2016-10-27,2017-04-20,2017-03-14,2016-12-21,2016-12-01,2022-07-11,2016-12-31,2018-07-05,18-Oct-16,2016-10-18,7.0,1.0,2.0,8.0,6.0,4.0,3.0,10.0,5.0,9.0,4.50%,10.20%,11.50%,12.40%,13.00%,45.30%,65.50%,71.10%,99.60%,100.00%,100.00%,01-Apr-17,05-Jul-18,-590.0,100.0,213.0,208.0,7.0,-678.0,279.0,199.0,34.0,43.0,218.0,181.0,98.0,78.0,2126.0,108.0,659.0,343.0,34.0,374.0,34.0,659.0,108.0,-57.0,-48.0,127.0,90.0,7.0,-13.0,2035.0,17.0,568.0,252.0,283.0,-57.0,533.0,320.0,485.0,320.0,329.0,504.0,467.0,384.0,364.0,2412.0,394.0,260.0,629.0,-377.0,308.0,286.0,-399.0,568.0,625.0,625.0,165.0,460.0,42341
522,Revlimid,lenalidomide,Celgene ,N,N,N,N,Y,Y,Y,Y,N,,,,CADTH,14-Jan-19,na,New indication,"The combination of lenalidomide, bortezomib, and low-dose dexamethasone, for the treatment of newly diagnosed multiple myeloma patients in whom stem cell transplantation is not intended",Completed,19-Jun-19,Cond'l on Cost,Conditional,,,,,,,,,1st,24-Sep-19,10-Jun-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,,2021-02-01,2020-12-31,2020-09-01,2020-10-22,2022-06-30,2021-05-13,2021-05-31,,,,01-Sep-20,2020-09-01,4.0,3.0,1.0,2.0,7.0,5.0,6.0,,,,5.70%,11.20%,15.70%,36.00%,36.90%,38.20%,70.40%,,,,70.40%,30-Jun-22,,,,156.0,,97.0,,260.0,236.0,204.0,83.0,134.0,750.0,337.0,355.0,,,,300.0,83.0,300.0,83.0,,,,,,,,,,,,,,,596.0,440.0,593.0,561.0,440.0,491.0,1107.0,694.0,712.0,,,,657.0,,,357.0,,,,,667.0,,43635
524,Rexulti,brexpiprazole,Otsuka-Lundbeck,N,N,N,Y,N,N,N,N,N,01-Apr-16,16-Feb-17,321.0,CADTH & INESSS,03-Feb-17,pre-NOC,Initial,Schizophrenia,Completed,22-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Drug,Schizophrenia,Completed,18-Oct-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,04-Apr-18,14-Dec-18,Negotiation,Completed with Agreements,SA,FB,EDS,FB,FB,FB,FB,FB,FB,NR,2019-12-17,2019-04-01,2019-06-01,2019-05-31,2019-04-30,2019-05-16,2022-08-18,2019-03-25,2019-05-01,,25-Mar-19,2019-03-25,8.0,2.0,7.0,6.0,3.0,5.0,9.0,1.0,4.0,,0.40%,4.80%,37.00%,37.70%,38.60%,44.10%,49.90%,70.10%,71.40%,,71.40%,17-Dec-19,,-13.0,36.0,292.0,208.0,133.0,168.0,254.0,368.0,108.0,169.0,168.0,137.0,153.0,1343.0,101.0,138.0,,298.0,101.0,298.0,101.0,,1034.0,774.0,835.0,834.0,803.0,819.0,2009.0,767.0,804.0,,964.0,964.0,767.0,780.0,488.0,755.0,495.0,556.0,555.0,524.0,540.0,1730.0,488.0,525.0,,685.0,279.0,244.0,387.0,422.0,,,,267.0,,600
525,Rinvoq,upadacitinib,AbbVie,Y,N,N,Y,N,N,N,N,N,01-Mar-19,23-Dec-19,297.0,CADTH & INESSS,04-Jul-19,pre-NOC,Initial,"Arthritis, Rheumatoid",Completed,04-Feb-20,Reimburse with clinical criteria and/or conditions,Conditional,09-Aug-19,pre-NOC,New Drug,Rheumatoid arthritis,Completed,04-Mar-20,Inscription - Avec conditions,Conditional,1st,21-Jan-21,08-Aug-22,Negotiation,Completed with Agreements,NR,SA,EDS,,LU,SA,EDS,,SA,EM,,2022-10-01,2022-10-01,,2022-10-31,2022-11-21,2023-03-01,,2023-01-23,2022-09-28,01-Oct-22,2022-09-28,,2.0,3.0,,4.0,5.0,7.0,,6.0,1.0,28.60%,33.00%,38.80%,71.00%,71.90%,72.60%,73.90%,,,,73.90%,31-Oct-22,,-172.0,-136.0,215.0,208.0,352.0,323.0,564.0,,54.0,54.0,,84.0,105.0,205.0,,168.0,51.0,112.0,54.0,103.0,51.0,,,1013.0,1013.0,,1043.0,1064.0,1164.0,,1127.0,1010.0,1071.0,1062.0,1013.0,1185.0,970.0,,970.0,970.0,,1000.0,1021.0,1121.0,,1084.0,938.0,1028.0,43.0,72.0,916.0,887.0,,,,33.0,,340
526,Rinvoq,upadacitinib,AbbVie,Y,N,N,N,N,N,N,N,N,01-Aug-20,03-Jun-21,306.0,CADTH & INESSS,04-Jan-21,pre-NOC,Initial,"Active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more DMARDs. Rinvoq may be used as monotherapy or in combination with nonbiologic DMARDs",Completed,20-Aug-21,Reimburse with clinical criteria and/or conditions,Conditional,19-Mar-21,pre-NOC,New Indication,Psoriatic arthritis,Completed,01-Sep-21,Inscription - Avec conditions,Conditional,1st,28-Feb-22,08-Aug-22,Negotiation,Completed with Agreements,NR,SA,EDS,,EAP,SA,EDS,,SA,EM,,2022-10-01,2022-10-01,,2022-11-16,2022-11-21,2023-03-01,,2023-01-23,2022-09-28,01-Oct-22,2022-09-28,,2.0,3.0,,4.0,5.0,7.0,,6.0,1.0,28.60%,33.00%,38.80%,71.00%,71.90%,72.60%,73.90%,,,,73.90%,16-Nov-22,,-150.0,-76.0,228.0,166.0,192.0,180.0,161.0,,54.0,54.0,,100.0,105.0,205.0,,168.0,51.0,114.0,54.0,105.0,51.0,,,485.0,485.0,,531.0,536.0,636.0,,599.0,482.0,545.0,536.0,485.0,635.0,407.0,,407.0,407.0,,453.0,458.0,558.0,,521.0,392.0,467.0,78.0,90.0,353.0,341.0,,,,49.0,,384
534,Rozlytrek,entrectinib,Hoffman-La Roche,Y,N,N,N,Y,Y,N,Y,N,01-Jul-19,05-May-20,309.0,CADTH & INESSS,08-Jan-20,pre-NOC,New indication,ROS1-positive Non-Small Cell Lung Cancer: For the first-line treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer,Completed,27-Jan-21,Cond'l on Cost,Conditional,03-Jan-20,pre-NOC,New Indication,ROS1-positive Non-Small Cell Lung Cancer,Completed,05-Nov-20,Inscription - Avec conditions,Conditional,1st,04-May-21,06-Jul-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2022-04-01,2021-11-30,2021-11-01,2021-11-25,2022-01-31,2021-10-14,2021-11-30,2022-12-12,2022-05-24,2021-08-18,14-Oct-21,2021-08-18,8.0,5.0,3.0,4.0,7.0,2.0,6.0,10.0,9.0,1.0,28.60%,29.50%,35.20%,40.70%,45.20%,46.50%,78.70%,99.00%,99.60%,100.00%,100.00%,31-Jan-22,01-Apr-22,-118.0,-123.0,385.0,307.0,97.0,180.0,63.0,269.0,147.0,118.0,142.0,209.0,100.0,147.0,524.0,322.0,43.0,220.0,100.0,202.0,43.0,269.0,696.0,574.0,545.0,569.0,636.0,527.0,574.0,951.0,749.0,470.0,647.0,629.0,527.0,645.0,260.0,429.0,307.0,278.0,302.0,369.0,260.0,307.0,684.0,482.0,286.0,380.0,267.0,184.0,160.0,243.0,696.0,226.0,169.0,166.0,60.0,576
540,Rydapt,midostaurin,Novartis,Y,N,N,Y,Y,Y,Y,Y,N,01-Jul-17,21-Jul-17,20.0,CADTH & INESSS,12-Jun-17,pre-NOC,New drug,Acute Myeloid Leukemia,Completed,19-Dec-17,Fund,Positive,15-Dec-17,post-NOC,New Drug,Acute Myeloid Leukemia,Completed,11-Apr-18,Avis dinscription à la liste Établissements  Médicament dexception,Positive,1st,02-Feb-18,05-Jul-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-12-01,2019-01-29,2018-11-01,2018-10-18,2018-10-11,2019-06-24,2019-09-03,2020-04-01,2019-12-19,2018-08-16,11-Oct-18,2018-08-16,5.0,6.0,4.0,3.0,2.0,7.0,8.0,10.0,9.0,1.0,28.60%,60.80%,66.30%,72.10%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,11-Oct-18,01-Dec-18,-39.0,147.0,190.0,117.0,45.0,-68.0,153.0,149.0,208.0,119.0,105.0,98.0,354.0,425.0,636.0,532.0,42.0,292.0,98.0,267.0,42.0,149.0,498.0,557.0,468.0,454.0,447.0,703.0,774.0,985.0,881.0,391.0,641.0,616.0,447.0,486.0,296.0,347.0,406.0,317.0,303.0,296.0,552.0,623.0,834.0,730.0,127.0,490.0,151.0,264.0,198.0,85.0,498.0,107.0,51.0,56.0,51.0,171
550,Semglee (withdrawn),insulin glargine,BGP PHARMA ULC,N,Y,Y,,N,N,N,N,Y,01-Apr-17,,,CADTH,14-Nov-18,na,Initial,"Diabetes mellitus, Type 1 & 2",Withdrawn,05-Mar-19,Cancelled or withdrawn,,,,,,,,,,1st,17-Aug-22,07-Nov-22,Negotiation,Completed with Agreements,,FB,FB,FB,FB,FB,FB,FB,FB,,,2022-12-01,2023-02-01,2023-01-24,2022-12-21,2023-01-30,2023-02-01,2023-02-20,2023-01-04,,01-Dec-22,2022-12-01,,1.0,6.0,4.0,2.0,5.0,7.0,8.0,3.0,,4.50%,36.70%,37.40%,42.90%,43.80%,49.50%,50.80%,51.20%,,,51.20%,01-Feb-23,,,,111.0,,1261.0,,82.0,,24.0,86.0,78.0,44.0,84.0,86.0,105.0,58.0,,71.0,24.0,71.0,24.0,,,,,,,,,,,,,,,1478.0,1367.0,,1367.0,1429.0,1421.0,1387.0,1427.0,1429.0,1448.0,1401.0,,1414.0,,,1343.0,,,,,62.0,,703
552,Siliq,brodalumab,Bausch Health (Valeant) ,N,Y,N,Y,N,N,N,N,N,01-Jul-16,06-Mar-18,613.0,CADTH & INESSS,14-Dec-17,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,20-Jun-18,Reimburse with clinical criteria and/or conditions,Conditional,01-Jan-18,pre-NOC,New Drug,Plaque psoriasis,Completed,05-Jul-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,05-Oct-18,14-Dec-18,Negotiation,Completed with Agreements,NR,NR,EDS,EDS,LU,SA,EDS,SA,SA,EM,,,2019-06-01,2019-05-31,2019-04-30,2019-06-24,2019-05-01,2019-03-25,2019-05-01,2019-02-01,25-Mar-19,2019-02-01,,,7.0,6.0,3.0,8.0,4.0,2.0,5.0,1.0,28.60%,28.90%,61.20%,62.50%,63.10%,68.70%,74.40%,75.30%,,,75.30%,30-Apr-19,,-82.0,-64.0,188.0,185.0,107.0,92.0,70.0,,,169.0,168.0,137.0,192.0,138.0,101.0,138.0,49.0,149.0,101.0,137.0,49.0,,,,452.0,451.0,420.0,475.0,421.0,384.0,421.0,332.0,432.0,420.0,384.0,466.0,278.0,,,346.0,345.0,314.0,369.0,315.0,278.0,315.0,211.0,326.0,106.0,121.0,177.0,162.0,,,,88.0,,719
553,Simbrinza,brinzolamide / brimonidine,Alcon ,N,N,N,N,N,N,N,N,N,,11-Dec-14,,CADTH & INESSS,03-Nov-14,pre-NOC,Initial,Glaucoma and ocular hypertension,Completed,17-Jun-15,List,Positive,22-Mar-15,post-NOC,New Drug,Glaucoma and ocular hypertension,Completed,01-Oct-15,Avis d'inscription aux listes de médicaments,Positive,1st,06-Aug-15,27-Aug-15,Negotiation,Completed with Agreements,FB,FB,FB,FB,LU,FB,FB,FB,FB,FB,2015-10-27,2015-12-01,2015-10-01,2015-10-22,2015-10-29,2015-11-24,2016-02-01,2015-11-23,2015-10-01,2015-10-01,01-Oct-15,2015-10-01,5.0,9.0,1.0,4.0,6.0,8.0,10.0,7.0,2.0,3.0,5.70%,6.40%,35.00%,40.50%,60.80%,93.00%,93.30%,94.20%,98.70%,100.00%,100.00%,27-Oct-15,29-Oct-15,-38.0,101.0,226.0,193.0,50.0,-56.0,21.0,61.0,96.0,35.0,56.0,63.0,89.0,158.0,88.0,35.0,35.0,76.0,35.0,72.0,35.0,63.0,320.0,355.0,294.0,315.0,322.0,348.0,417.0,347.0,294.0,294.0,335.0,331.0,294.0,332.0,106.0,132.0,167.0,106.0,127.0,134.0,160.0,229.0,159.0,106.0,0.0,147.0,188.0,294.0,71.0,-35.0,322.0,28.0,28.0,26.0,2.0,42172
554,Simponi (IV) (RA),golimumab,Janssen ,Y,Y,N,N,N,N,N,N,N,,28-Nov-13,,CADTH & INESSS,12-Sep-13,pre-NOC,Initial,"Arthritis, rheumatoid",Completed,17-Jul-14,List with criteria/condition,Conditional,24-Nov-13,pre-NOC,New Form,Rheumatoid arthritis,Completed,02-Jun-14,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,06-Oct-14,19-Apr-16,Negotiation,No agreement reached,NR,NR,EDS,EDS,NR,NR,NR,NR,NR,EM,,,2016-09-01,2014-10-16,,,,,,2014-06-02,16-Oct-14,2014-06-02,,,3.0,2.0,,,,,,1.0,28.60%,34.10%,39.80%,,,,,,,,39.80%,,,-77.0,-4.0,308.0,190.0,81.0,126.0,561.0,,,135.0,-551.0,,,,,,-687.0,-208.0,-551.0,-368.0,-687.0,,,,1008.0,322.0,,,,,,186.0,665.0,505.0,322.0,399.0,91.0,,,777.0,91.0,,,,,,0.0,434.0,231.0,186.0,642.0,687.0,,,,,,41837
555,Simponi (UC),golimumab,Janssen ,Y,Y,N,N,N,N,N,N,N,,19-Sep-13,,CADTH & INESSS,12-Jul-13,pre-NOC,Initial,Ulcerative colitis,Completed,19-Mar-14,Do not list at the submitted price,Negative,,,New Indication,ulcerative collitis,Completed,02-Jun-14,Ajout d'une indication reconnue - Médicament d'exception - Avis de refus - Valeur thérapeutique,Conditional,1st,23-May-14,12-Aug-16,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,NR,SA,NR,,2017-05-01,2016-09-01,2017-04-20,2016-09-16,2017-05-29,2017-02-01,,2017-04-12,,01-Sep-16,2016-09-01,,6.0,1.0,5.0,2.0,7.0,3.0,,4.0,,5.70%,38.00%,39.30%,39.90%,45.50%,49.90%,50.80%,,,,50.80%,29-May-17,,-69.0,,250.0,,65.0,-10.0,812.0,,262.0,20.0,251.0,35.0,290.0,173.0,,243.0,,182.0,20.0,182.0,20.0,,,1320.0,1078.0,1309.0,1093.0,1348.0,1231.0,,1301.0,,1240.0,1240.0,1078.0,1147.0,897.0,,1139.0,897.0,1128.0,912.0,1167.0,1050.0,,1120.0,,1059.0,181.0,256.0,877.0,802.0,,,,270.0,,41717
557,Skyrizi,risankizumab,AbbVie ,Y,Y,N,Y,N,N,N,N,N,01-Jun-18,17-Apr-19,320.0,CADTH & INESSS,22-Oct-18,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,28-May-19,Reimburse with clinical criteria and/or conditions,Conditional,08-Oct-18,pre-NOC,New Drug,Plaque psoriasis,Completed,05-Jun-19,Inscription - Avec conditions,Conditional,1st,27-Jun-19,28-Nov-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2020-05-05,2020-02-01,2020-02-01,2020-03-02,2020-01-31,2020-03-19,2020-02-06,2021-02-22,2020-09-16,2020-02-05,31-Jan-20,2020-01-31,8.0,2.0,3.0,6.0,1.0,7.0,5.0,10.0,9.0,4.0,32.20%,36.70%,42.40%,71.00%,72.30%,77.80%,78.70%,99.00%,99.60%,100.00%,100.00%,05-Feb-20,05-May-20,-177.0,-191.0,218.0,240.0,30.0,22.0,154.0,159.0,65.0,65.0,95.0,64.0,112.0,70.0,452.0,293.0,69.0,153.0,64.0,144.0,64.0,159.0,384.0,290.0,290.0,320.0,289.0,337.0,295.0,677.0,518.0,294.0,378.0,369.0,289.0,466.0,248.0,343.0,249.0,249.0,279.0,248.0,296.0,254.0,636.0,477.0,245.0,337.0,41.0,49.0,184.0,176.0,384.0,95.0,95.0,5.0,90.0,361
560,Soliqua,lixisenatide + insulin glargine,Sanofi-Aventis ,Y,N,N,N,N,N,N,N,N,01-Sep-17,06-Jul-18,308.0,CADTH & INESSS,18-May-18,pre-NOC,Initial,"Diabetes mellitus, Type 2",Completed,24-Dec-18,Reimburse with clinical criteria and/or conditions,Conditional,03-Jul-20,post-NOC,New Drug,Type 2 Diabetes,Completed,02-Dec-20,Refus d'inscription,Negative,1st,16-Apr-19,21-Nov-19,Negotiation,Completed with Agreements,NR,UR,EDS,EDS,FB,UR,UR,UR,SA,NR,,,2021-01-01,2021-08-05,2019-12-20,,,,2022-05-03,,20-Dec-19,2019-12-20,,,2.0,3.0,1.0,,,,4.0,,32.20%,38.00%,43.50%,44.20%,,,,,,,44.20%,,,-49.0,728.0,220.0,152.0,113.0,-596.0,219.0,,,407.0,623.0,29.0,,,,894.0,,488.0,29.0,488.0,29.0,,,,910.0,1126.0,532.0,,,,1397.0,,991.0,991.0,532.0,581.0,361.0,,,739.0,955.0,361.0,,,,1226.0,,820.0,171.0,880.0,332.0,-377.0,,,,,,479
563,Soliris (Advice),eculizumab,Alexion Pharmaceuticals,N,Y,N,N,N,Y,Y,Y,N,,01-Mar-13,,CADTH,09-Feb-15,post-NOC,Request for Advice,"Hemolytic Uremic Syndrome, Atypical",Completed,20-May-15,Not Applicable: Request for Advice (Completed),,,,,,,,,,1st,06-Aug-15,16-Feb-16,Negotiation,No agreement reached,E,NR,NR,NR,EAP,NR,NR,NR,NR,NR,2017-11-20,,,,2015-02-01,,,,,,01-Feb-15,2015-02-01,2.0,,,,1.0,,,,,,32.20%,52.50%,,,,,,,,,52.50%,20-Nov-17,,710.0,,100.0,,78.0,,194.0,643.0,,,,-380.0,,,,,,132.0,-380.0,132.0,-380.0,,1725.0,,,,702.0,,,,,,1214.0,1214.0,702.0,-8.0,-108.0,915.0,,,,-108.0,,,,,,404.0,810.0,,272.0,,,,,1023.0,,42144
568,Spinraza,nusinersen,Biogen,N,N,N,Y,N,Y,Y,Y,N,01-Dec-16,29-Jun-17,210.0,CADTH & INESSS,28-Jun-17,pre-NOC,Initial,Spinal Muscular Atrophy,Completed,22-Dec-17,Reimburse with clinical criteria and/or conditions,Conditional,23-Jul-17,post-NOC,New Drug,spinal muscular atrophy,Completed,15-Dec-17,Avis de refus d'inscription à la Liste Établissements,Negative,1st,29-Jan-18,26-Sep-18,Negotiation,Completed with Agreements,UR,SA,EDS,EDS,EAP,SA,EDS,NR,NR,EM,,2018-12-01,2019-05-01,2019-01-24,2018-11-20,2019-02-07,2019-09-01,,,2018-12-18,20-Nov-18,2018-11-20,,2.0,6.0,4.0,1.0,5.0,7.0,,,3.0,32.20%,36.70%,65.30%,70.80%,71.70%,77.40%,78.70%,,,,78.70%,18-Dec-18,,-1.0,24.0,177.0,145.0,38.0,45.0,240.0,,66.0,217.0,120.0,55.0,134.0,340.0,,,83.0,155.0,55.0,145.0,55.0,,,520.0,671.0,574.0,509.0,588.0,794.0,,,537.0,609.0,599.0,509.0,510.0,333.0,,344.0,495.0,398.0,333.0,412.0,618.0,,,368.0,433.0,176.0,169.0,278.0,285.0,,,,28.0,,386
569,Spinraza,nusinersen,Biogen,N,N,N,Y,N,Y,Y,Y,N,01-Dec-16,29-Jun-17,210.0,CADTH & INESSS,24-Jul-18,post-NOC,Initial,Spinal Muscular Atrophy,Completed,27-Feb-19,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,spinal muscular atrophy,Completed,14-Jan-19,Inscription  Avec conditions,Conditional,1st,25-Apr-19,26-Jun-19,Negotiation,Completed with Agreements,EDRD,UR,UR,UR,EAP,SA,EDS,SA,SA,EM,2019-07-01,,,,2019-06-12,2019-08-26,2022-11-01,2022-03-28,2020-02-14,2018-12-18,12-Jun-19,2018-12-18,3.0,,,,2.0,4.0,7.0,6.0,5.0,1.0,28.60%,60.80%,81.10%,82.00%,82.60%,83.00%,84.30%,,,,84.30%,12-Jun-19,01-Jul-19,390.0,,218.0,,57.0,101.0,62.0,5.0,,,,-14.0,61.0,1224.0,1006.0,233.0,-190.0,419.0,-14.0,332.0,-190.0,5.0,732.0,,,,713.0,788.0,1951.0,1733.0,960.0,537.0,1146.0,1059.0,713.0,323.0,105.0,124.0,,,,105.0,180.0,1343.0,1125.0,352.0,-27.0,538.0,608.0,564.0,119.0,163.0,732.0,195.0,19.0,176.0,19.0,818
571,Spiriva Respimat,tiotropium bromide,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,17-Dec-14,,CADTH & INESSS,23-Dec-14,post-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,16-Jul-15,List with clinical criteria and/or conditions,Conditional,04-Aug-15,post-NOC,New Drug,Chronic Obstructive Pulmonary Disease (COPD),Completed,01-Feb-16,Avis d'inscription aux listes de médicaments,Positive,1st,21-Aug-15,02-Mar-16,Negotiation,Completed with Agreements,FB,FB,FB,FB,FB,SA,EDS,SA,SA,FB,2020-07-07,2016-05-01,2016-05-01,2016-07-21,2016-03-30,2016-04-12,2016-05-01,2016-04-25,2016-07-01,2016-05-04,30-Mar-16,2016-03-30,10.0,4.0,5.0,9.0,1.0,2.0,6.0,3.0,8.0,7.0,32.20%,33.10%,33.50%,37.90%,43.70%,45.00%,73.50%,74.20%,79.70%,100.00%,100.00%,04-May-16,07-Jul-20,6.0,230.0,205.0,181.0,36.0,-164.0,194.0,1588.0,60.0,60.0,141.0,28.0,41.0,60.0,54.0,121.0,63.0,239.0,28.0,222.0,28.0,1588.0,2029.0,501.0,501.0,582.0,469.0,482.0,501.0,495.0,562.0,504.0,680.0,663.0,469.0,463.0,258.0,1818.0,290.0,290.0,371.0,258.0,271.0,290.0,284.0,351.0,93.0,469.0,211.0,411.0,230.0,30.0,2029.0,1560.0,1560.0,35.0,1525.0,42201
574,Stelara,ustekinumab,Janssen ,Y,Y,N,N,N,N,N,N,N,,21-Jan-14,,CADTH & INESSS,30-Oct-13,pre-NOC,Initial,"Arthritis, Psoriatic",Completed,20-Oct-14,Do not list at the submitted price,Negative,22-Mar-14,post-NOC,New Indication,"Arthritis, Psoriatic",Completed,01-Oct-14,Ajout d'une indication reconnue - Médicament d'exception,Conditional,none,27-Nov-14,,Do Not Negotiate,,NR,NR,EDS,NR,NR,SA,NR,NR,NR,EM,,,2015-10-01,,,2019-03-27,,,,2014-10-01,01-Oct-15,2014-10-01,,,2.0,,,3.0,,,,1.0,28.60%,34.30%,35.20%,,,,,,,,35.20%,,,-83.0,60.0,355.0,193.0,38.0,57.0,,,,,,,,,,,,,,,,,,,618.0,,,1891.0,,,,253.0,1255.0,921.0,618.0,701.0,346.0,,,346.0,,,1619.0,,,,0.0,983.0,272.0,253.0,,,,,,,,41932
575,Stelara (CD),ustekinumab,Janssen ,Y,Y,N,N,N,N,N,N,N,,12-Dec-16,,CADTH & INESSS,12-Sep-16,pre-NOC,Initial,Crohns disease,Completed,21-Mar-17,Reimburse with clinical criteria and/or conditions,Conditional,24-Mar-17,post-NOC,New Indication,Crohn's Disease,Completed,18-Oct-17,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,09-Feb-18,29-Mar-19,Negotiation,No agreement reached,NR,UR,EDS,NR,NR,NR,NR,NR,NR,UR,,,2018-08-01,,,,,,,,01-Aug-18,2018-08-01,,,1.0,,,,,,,,5.70%,,,,,,,,,,5.70%,,,-91.0,102.0,190.0,208.0,325.0,114.0,413.0,,,-240.0,,,,,,,,-240.0,-240.0,-240.0,-240.0,,,,597.0,,,,,,,,597.0,597.0,597.0,688.0,498.0,,,498.0,,,,,,,,498.0,99.0,310.0,738.0,527.0,,,,,,42815
577,Stivarga,regorafenib,Bayer ,Y,N,N,N,Y,Y,N,Y,N,01-Apr-17,18-Sep-17,170.0,CADTH & INESSS,12-Oct-17,post-NOC,New indication,Unresectable Hepatocellular Carcinoma (HCC),Completed,18-Apr-18,Cond'l on Cost,Conditional,05-Mar-18,post-NOC,New Indication,Unresectable Hepatocellular Carcinoma (HCC),Completed,05-Sep-18,Avis d'ajout d'une indication reconnue aux listes - Médicament d'exception - Avec conditions,Conditional,1st,10-Sep-18,07-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2019-07-01,2019-11-18,2019-09-03,2020-03-02,2020-09-30,2019-11-07,2019-11-01,,,2019-04-11,01-Jul-19,2019-04-11,2.0,6.0,3.0,7.0,8.0,5.0,4.0,,,1.0,28.60%,48.80%,54.60%,55.90%,56.80%,61.20%,66.70%,99.00%,,,99.00%,03-Sep-19,30-Sep-20,24.0,168.0,188.0,184.0,145.0,5.0,178.0,116.0,256.0,180.0,361.0,573.0,245.0,239.0,,,35.0,281.0,116.0,251.0,35.0,573.0,651.0,791.0,715.0,896.0,1108.0,780.0,774.0,,,570.0,816.0,786.0,651.0,627.0,439.0,439.0,579.0,503.0,684.0,896.0,568.0,562.0,,,218.0,604.0,212.0,352.0,323.0,183.0,1108.0,538.0,457.0,145.0,393.0,382
583,Strensiq (2nd pCPA),asfotase alfa,Alexion Pharmaceuticals,N,Y,N,Y,N,Y,Y,Y,Y,,14-Aug-15,,CADTH & INESSS,21-Aug-15,post-NOC,Initial,"Hypophosphatasia, pediatric-onset",Completed,23-Mar-16,List with criteria/condition,Conditional,22-Mar-16,post-NOC,Resubmission,"Hypophosphatasia, pediatric-onset",Completed,16-Dec-16,Avis de refus d'inscription aux listes des médicaments,Negative,2nd,07-Jun-17,09-Jan-18,Negotiation,Completed with Agreements,NR,SA,NR,NR,EAP,SA,EDS,NR,NR,UR,,2018-03-01,,,2018-06-06,2020-01-29,2020-09-10,,,,01-Mar-18,2018-03-01,,1.0,,,2.0,3.0,4.0,,,,4.50%,36.70%,37.60%,38.90%,,,,,,,38.90%,,,7.0,221.0,215.0,269.0,441.0,173.0,216.0,,51.0,,,148.0,750.0,975.0,,,,481.0,51.0,481.0,51.0,,,930.0,,,1027.0,1629.0,1854.0,,,,1360.0,1360.0,930.0,923.0,708.0,,708.0,,,805.0,1407.0,1632.0,,,,1138.0,222.0,490.0,657.0,389.0,,,,,,42452
585,Sublocade,buprenorphine,Indivior Canada Ltd.,N,N,N,N,N,N,N,N,N,01-May-18,21-Nov-18,204.0,CADTH & INESSS,20-Dec-18,post-NOC,Initial,"Opioid use disorder, treatment",Completed,19-Jun-19,Reimburse with clinical criteria and/or conditions,Conditional,01-Mar-19,post-NOC,New Drug,Opioid use disorder,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,09-Jul-19,08-Apr-20,Negotiation,Completed with Agreements,SA,SA,EDS,RB,LU,FB,FB,FB,SA,EM,2020-04-30,2020-06-01,2020-07-01,2020-07-16,2021-04-30,2020-05-21,2020-06-03,2021-07-26,2020-06-15,2020-04-29,30-Apr-20,2020-04-29,2.0,4.0,7.0,8.0,9.0,3.0,5.0,10.0,6.0,1.0,28.60%,48.80%,49.70%,54.20%,55.50%,56.20%,61.90%,67.40%,99.60%,100.00%,100.00%,01-Jun-20,30-Apr-21,29.0,100.0,181.0,194.0,20.0,-64.0,274.0,22.0,54.0,84.0,99.0,387.0,43.0,56.0,474.0,68.0,21.0,143.0,22.0,131.0,21.0,387.0,526.0,558.0,588.0,603.0,891.0,547.0,560.0,978.0,572.0,525.0,647.0,635.0,526.0,497.0,316.0,316.0,348.0,378.0,393.0,681.0,337.0,350.0,768.0,362.0,231.0,437.0,210.0,294.0,294.0,210.0,891.0,366.0,365.0,33.0,333.0,414
586,Sunvepra,asunaprevir,Bristol-Myers Squibb ,Y,N,N,Y,N,N,N,N,N,,09-Mar-16,,CADTH & INESSS,13-Feb-15,pre-NOC,Initial,"Hepatitis C, chronic",Completed,20-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,chronic hepatitis C (CHC),Completed,03-Oct-16,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,20-Jul-16,17-Feb-17,Negotiation,Completed with Agreements,DL,DL,DL,DL,DL,DL,DL,DL,DL,DL,2017-03-21,2017-04-01,2017-04-01,,2017-02-28,2017-03-29,2017-05-01,,2017-09-01,2008-06-01,28-Feb-17,2008-06-01,3.0,5.0,6.0,,2.0,4.0,7.0,,8.0,1.0,28.60%,60.80%,81.10%,82.00%,86.40%,92.10%,93.40%,94.10%,,,94.10%,28-Feb-17,21-Mar-17,-390.0,13.0,523.0,195.0,0.0,-75.0,212.0,32.0,43.0,43.0,,11.0,40.0,73.0,,196.0,-3183.0,63.0,11.0,-343.0,-3183.0,32.0,377.0,388.0,388.0,,356.0,385.0,418.0,,541.0,-2838.0,408.0,2.0,356.0,746.0,223.0,244.0,255.0,255.0,,223.0,252.0,285.0,,408.0,-3046.0,275.0,133.0,208.0,212.0,137.0,377.0,3215.0,21.0,3194.0,21.0,42571
587,Sylvant,siltuximab,Janssen ,Y,Y,N,Y,Y,Y,Y,Y,N,,03-Dec-14,,CADTH,30-Jan-15,post-NOC,New drug,Lymphoma & myeloma: Multicentric Castleman's Disease (MCD),Completed,22-Jun-15,Cond'l on Cost,Conditional,,,,,,,,,1st,08-Aug-15,30-Sep-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Not funded,Funded,,2016-12-01,2018-01-01,2017-08-02,2016-12-05,2016-12-22,2017-07-10,2020-02-01,,2020-02-01,,01-Dec-16,2016-12-01,1.0,6.0,5.0,2.0,3.0,4.0,7.0,,8.0,,20.30%,25.80%,58.00%,58.90%,64.60%,69.10%,70.40%,71.10%,,,71.10%,22-Dec-16,,58.0,,143.0,,47.0,,419.0,62.0,458.0,306.0,66.0,83.0,283.0,1219.0,,1219.0,,462.0,62.0,462.0,62.0,,729.0,1125.0,973.0,733.0,750.0,950.0,1886.0,,1886.0,,1129.0,1129.0,729.0,671.0,528.0,528.0,924.0,772.0,532.0,549.0,749.0,1685.0,,1685.0,,928.0,201.0,,466.0,,,,,21.0,,42177
589,Synjardy,empagliflozin and metformin,Boehringer Ingelheim ,N,N,N,N,N,N,N,N,N,,29-Jul-16,,CADTH & INESSS,29-Apr-16,pre-NOC,Initial,Diabetes mellitus (Type 2),Completed,25-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,Type 2 Diabetes,Completed,15-Mar-17,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,11-Sep-18,11-Sep-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,2019-05-27,2019-01-01,2019-01-01,2019-05-31,2018-10-31,2019-02-27,2019-01-01,2019-08-01,2019-10-22,2018-09-27,31-Oct-18,2018-09-27,7.0,3.0,4.0,8.0,2.0,6.0,5.0,9.0,10.0,1.0,28.60%,60.80%,65.30%,71.00%,72.30%,73.20%,93.40%,99.00%,99.30%,100.00%,100.00%,31-Oct-18,27-May-19,-91.0,14.0,179.0,215.0,686.0,545.0,0.0,258.0,112.0,112.0,262.0,50.0,169.0,112.0,324.0,406.0,16.0,201.0,50.0,182.0,16.0,258.0,1032.0,886.0,886.0,1036.0,824.0,943.0,886.0,1098.0,1180.0,790.0,975.0,956.0,824.0,915.0,736.0,944.0,798.0,798.0,948.0,736.0,855.0,798.0,1010.0,1092.0,561.0,887.0,88.0,229.0,686.0,545.0,1032.0,242.0,208.0,34.0,208.0,42668
590,Tafinlar,dabrafenib,GlaxoSmithKline,Y,N,N,Y,Y,Y,N,Y,N,,16-Jul-13,,CADTH & INESSS,18-Mar-13,pre-NOC,New drug,Metastatic Melanoma,Completed,05-Dec-13,Cond'l on Cost,Conditional,02-Aug-13,post-NOC,New Drug,Metastatic Melanoma,Completed,03-Feb-14,Avis de refus - À moins que le rapport entre le coût et l'efficacité soit modifié pour atteindre un niveau acceptable,Conditional,1st,31-Jan-14,25-Jun-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2014-12-01,2015-03-30,2014-09-15,2014-10-16,2014-08-19,2014-10-03,2016-09-01,2018-10-29,2014-08-01,2014-02-03,01-Aug-14,2014-02-03,7.0,8.0,4.0,6.0,3.0,5.0,9.0,10.0,2.0,1.0,28.60%,29.30%,61.50%,67.20%,68.10%,73.60%,93.90%,98.30%,99.60%,100.00%,100.00%,19-Aug-14,01-Dec-14,-120.0,17.0,262.0,185.0,57.0,-3.0,145.0,159.0,278.0,82.0,113.0,55.0,100.0,799.0,1587.0,37.0,-142.0,357.0,37.0,307.0,-142.0,159.0,503.0,622.0,426.0,457.0,399.0,444.0,1143.0,1931.0,381.0,202.0,701.0,651.0,381.0,501.0,239.0,361.0,480.0,284.0,315.0,257.0,302.0,1001.0,1789.0,239.0,0.0,559.0,142.0,202.0,202.0,142.0,503.0,301.0,122.0,197.0,104.0,41613
591,Tafinlar & Mekinist in combo,dabrafenib & trametinib in combo,GlaxoSmithKline,Y,N,N,N,Y,Y,N,Y,N,,06-Mar-15,,CADTH & INESSS,13-Feb-15,pre-NOC,New indication,Metastatic Melanoma,Completed,21-Jul-15,Cond'l on Cost,Conditional,01-May-15,post-NOC,New Indication,Metastatic Melanoma,Completed,01-Oct-15,Avis de refus dajout dune indication reconnue aux listes de médicaments  Médicament dexception - À moins que certaines conditions soient respectées,Conditional,1st,18-Sep-15,25-May-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2016-08-01,2016-10-18,2016-08-08,2016-07-21,2016-08-10,2017-03-13,2016-09-01,2018-10-29,2017-02-01,2016-07-15,21-Jul-16,2016-07-15,3.0,7.0,4.0,2.0,5.0,9.0,6.0,10.0,8.0,1.0,28.60%,34.10%,54.40%,60.10%,92.30%,93.60%,98.10%,98.80%,99.60%,100.00%,100.00%,01-Aug-16,10-Aug-16,-21.0,56.0,158.0,153.0,59.0,-301.0,250.0,68.0,146.0,75.0,57.0,77.0,292.0,99.0,887.0,252.0,51.0,217.0,57.0,200.0,51.0,77.0,514.0,592.0,521.0,503.0,523.0,738.0,545.0,1333.0,698.0,497.0,663.0,646.0,503.0,524.0,366.0,377.0,455.0,384.0,366.0,386.0,601.0,408.0,1196.0,561.0,0.0,526.0,137.0,497.0,309.0,-51.0,523.0,26.0,20.0,17.0,9.0,42206
593,Tafinlar & Mekinist in combo,dabrafenib & trametinib in combo,Novartis,Y,N,N,N,Y,Y,N,Y,N,01-Mar-18,21-Sep-18,204.0,CADTH & INESSS,21-Sep-18,pre-NOC,New indication,Melanoma Adjuvant Therapy,Completed,03-May-19,Cond'l on Cost,Conditional,17-Sep-18,pre-NOC,New Indication,Melanoma Adjuvant Therapy,Completed,13-Mar-19,Inscription  Avec conditions,Conditional,1st,11-Jun-19,30-Aug-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-11-01,2020-04-10,2020-01-01,2020-03-02,2020-01-07,2020-04-23,2020-04-23,2022-01-10,2021-08-11,2019-10-02,01-Jan-20,2019-10-02,8.0,5.0,2.0,4.0,3.0,6.0,7.0,10.0,9.0,1.0,28.60%,34.30%,66.50%,72.10%,76.50%,77.40%,78.70%,99.00%,99.60%,100.00%,100.00%,07-Jan-20,01-Nov-20,0.0,-4.0,224.0,177.0,39.0,90.0,80.0,429.0,224.0,124.0,185.0,130.0,237.0,237.0,864.0,712.0,33.0,349.0,124.0,318.0,33.0,429.0,772.0,567.0,467.0,528.0,473.0,580.0,580.0,1207.0,1055.0,376.0,692.0,661.0,467.0,467.0,243.0,548.0,343.0,243.0,304.0,249.0,356.0,356.0,983.0,831.0,203.0,468.0,224.0,173.0,119.0,170.0,772.0,396.0,305.0,97.0,299.0,428
595,Tagrisso,osimertinib,AstraZeneca ,Y,N,N,Y,Y,Y,N,Y,N,01-Nov-15,05-Jul-16,247.0,CADTH & INESSS,01-Apr-16,pre-NOC,New drug,"Lung, NSCLC",Completed,04-May-17,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Locally advanced or metastatic non-small cell lung cancer who have progressed on or after EGFR TKI therapy,Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments - Médicament d'exception - À moins que certaines conditions soient respectées,Conditional,1st,29-Sep-17,30-Jul-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-10-01,2018-11-20,2018-11-01,2018-10-18,2018-10-03,2019-02-27,2019-11-01,2020-04-01,2020-02-20,2018-11-15,01-Oct-18,2018-10-01,1.0,6.0,4.0,3.0,2.0,7.0,8.0,10.0,9.0,5.0,20.30%,52.50%,58.00%,63.70%,92.30%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,03-Oct-18,15-Nov-18,-95.0,142.0,398.0,189.0,148.0,120.0,304.0,63.0,113.0,94.0,80.0,65.0,212.0,459.0,611.0,570.0,108.0,252.0,63.0,238.0,63.0,108.0,818.0,868.0,849.0,835.0,820.0,967.0,1214.0,1366.0,1325.0,863.0,1007.0,993.0,818.0,913.0,515.0,515.0,565.0,546.0,532.0,517.0,664.0,911.0,1063.0,1022.0,532.0,704.0,303.0,331.0,452.0,424.0,863.0,45.0,45.0,2.0,43.0,550
596,Tagrisso,osimertinib,AstraZeneca ,Y,N,N,N,Y,Y,N,Y,N,01-Jan-18,10-Jul-18,190.0,CADTH & INESSS,16-May-18,pre-NOC,New indication,Non-Small Cell Lung Cancer (first line),Completed,04-Jan-19,Cond'l on Cost,Conditional,,,New Indication,Non-Small Cell Lung Cancer (first line),Completed,12-Dec-18,Inscription  Avec conditions,Conditional,1st,14-Mar-19,19-Nov-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-01-01,2020-04-10,2020-03-01,2020-04-02,2020-01-10,2020-03-19,2020-05-01,2022-02-14,2020-02-20,2019-12-18,01-Jan-20,2019-12-18,2.0,8.0,5.0,7.0,3.0,6.0,9.0,10.0,4.0,1.0,28.60%,48.80%,81.10%,81.70%,87.50%,88.30%,93.90%,98.30%,99.60%,100.00%,100.00%,10-Jan-20,10-Jan-20,-55.0,,233.0,,69.0,92.0,250.0,43.0,143.0,103.0,135.0,52.0,121.0,164.0,818.0,93.0,29.0,186.0,43.0,170.0,29.0,52.0,540.0,640.0,600.0,632.0,549.0,618.0,661.0,1315.0,590.0,526.0,683.0,667.0,540.0,595.0,362.0,362.0,462.0,422.0,454.0,371.0,440.0,483.0,1137.0,412.0,371.0,505.0,178.0,155.0,319.0,342.0,549.0,23.0,9.0,23.0,0.0,368
597,Tagrisso,osimertinib,AstraZeneca ,Y,N,N,N,Y,Y,N,Y,N,01-Sep-20,18-Jan-21,139.0,CADTH & INESSS,24-Mar-21,post-NOC,Initial,Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.  A validated test is required to identify EGFR mutation-positive status (exon 19 deletions or exon 21 (L858R) substitution mutations) prior to treatment.,Completed,10-Jan-22,Cond'l on Cost,Conditional,18-Jun-21,post-NOC,New Indication,Tagrisso (osimertinib) is indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.  A validated test is required to identify EGFR mutation-positive status (exon 19 deletions or exon 21 (L858R) substitution mutations) prior to treatment.,Completed,30-Nov-21,Inscription - Avec conditions,Conditional,1st,16-May-22,07-Oct-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Under provincial consideration,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,EM,2023-02-01,2023-01-31,2023-02-01,,2022-12-31,2023-02-27,2023-03-01,,,2022-11-09,31-Dec-22,2022-11-09,4.0,3.0,5.0,,2.0,6.0,7.0,,,1.0,28.60%,60.80%,65.30%,85.50%,91.20%,92.10%,93.40%,,,,93.40%,31-Dec-22,01-Feb-23,65.0,151.0,292.0,165.0,126.0,167.0,144.0,117.0,116.0,117.0,,85.0,143.0,145.0,,,33.0,121.0,85.0,108.0,33.0,117.0,744.0,743.0,744.0,,712.0,770.0,772.0,,,660.0,748.0,735.0,712.0,647.0,355.0,387.0,386.0,387.0,,355.0,413.0,415.0,,,344.0,391.0,357.0,316.0,270.0,311.0,744.0,84.0,32.0,52.0,32.0,496
598,Takhzyro,lanadelumab,Shire,Y,Y,N,Y,N,Y,Y,Y,N,01-Mar-18,19-Sep-18,202.0,CADTH,29-May-19,post-NOC,Initial,"Hereditary angioedema, prevention",Completed,19-Nov-19,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,21-Feb-20,30-Oct-20,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,EDS,SA,SA,,2021-03-04,2021-05-01,2021-05-01,2021-04-01,2021-02-12,2021-01-27,2021-08-01,2023-02-20,2021-03-17,,27-Jan-21,2021-01-27,3.0,6.0,7.0,5.0,2.0,1.0,8.0,9.0,4.0,,0.90%,33.10%,53.40%,54.00%,59.60%,64.00%,69.80%,71.10%,71.40%,,71.40%,04-Mar-21,,252.0,,174.0,,94.0,,252.0,125.0,183.0,183.0,153.0,105.0,89.0,275.0,843.0,138.0,,233.0,89.0,233.0,89.0,,897.0,955.0,955.0,925.0,877.0,861.0,1047.0,1615.0,910.0,,1005.0,1005.0,861.0,609.0,435.0,471.0,529.0,529.0,499.0,451.0,435.0,621.0,1189.0,484.0,,579.0,426.0,,346.0,,,,,36.0,,628
599,Taltz,ixekizumab,Eli Lilly ,N,Y,N,Y,N,N,N,N,N,01-Jul-15,25-May-16,329.0,CADTH & INESSS,23-Mar-16,pre-NOC,Initial,"Psoriasis, moderate to severe plaque",Completed,25-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,New Drug,"Psoriasis, moderate to severe plaque",Completed,01-Feb-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,05-May-17,29-Dec-17,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2018-03-06,2018-06-01,2018-04-01,2018-04-19,2018-03-29,2018-05-08,2019-02-01,2018-05-28,2018-03-15,2018-03-01,06-Mar-18,2018-03-01,2.0,9.0,5.0,6.0,4.0,7.0,10.0,8.0,3.0,1.0,28.60%,48.80%,49.50%,81.70%,87.50%,93.00%,93.90%,94.20%,98.70%,100.00%,100.00%,29-Mar-18,29-Mar-18,-63.0,79.0,216.0,173.0,192.0,93.0,238.0,67.0,154.0,93.0,111.0,90.0,130.0,399.0,150.0,76.0,62.0,141.0,67.0,133.0,62.0,90.0,650.0,737.0,676.0,694.0,673.0,713.0,982.0,733.0,659.0,645.0,724.0,716.0,650.0,713.0,497.0,497.0,584.0,523.0,541.0,520.0,560.0,829.0,580.0,506.0,393.0,571.0,153.0,252.0,430.0,331.0,673.0,28.0,23.0,28.0,0.0,482
601,Taltz (PsA),ixekizumab,Eli Lilly ,N,Y,N,N,N,N,N,N,N,01-Jun-17,29-Mar-18,301.0,CADTH & INESSS,20-Feb-18,pre-NOC,Initial,"Arthritis, psoriatic",Completed,21-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Psoriatic arthritis,Completed,05-Sep-18,Avis d'ajout d'une indication reconnue aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,03-Oct-18,08-Nov-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2019-05-27,2019-03-01,2019-01-01,2019-05-31,2019-03-04,2019-02-27,2019-02-01,2019-02-25,2019-01-16,2018-12-13,01-Jan-19,2018-12-13,9.0,7.0,2.0,10.0,8.0,6.0,4.0,5.0,3.0,1.0,28.60%,34.30%,35.00%,36.30%,36.60%,37.50%,42.00%,74.20%,94.50%,100.00%,100.00%,04-Mar-19,27-May-19,-37.0,,182.0,,43.0,28.0,36.0,200.0,113.0,54.0,204.0,116.0,111.0,85.0,109.0,69.0,35.0,118.0,54.0,110.0,35.0,200.0,424.0,337.0,278.0,428.0,340.0,335.0,309.0,333.0,293.0,259.0,342.0,334.0,278.0,315.0,133.0,279.0,192.0,133.0,283.0,195.0,190.0,164.0,188.0,148.0,99.0,197.0,145.0,160.0,79.0,64.0,424.0,165.0,146.0,81.0,84.0,446
615,Tecartus,brexucabtagene autoleucel,Gilead ,Y,N,N,Y,Y,Y,Y,Y,N,01-Dec-20,08-Jun-21,189.0,CADTH & INESSS,18-Dec-20,pre-NOC,Initial,Treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Brutons tyrosine kinase inhibitor (BTKi),Completed,24-Aug-21,Cond'l on Cost,Conditional,22-Jan-21,pre-NOC,New Drug,Treatment of adult patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL) who have received treatment with a Brutons tyrosine kinase inhibitor (BTKi),Completed,28-Jul-21,Inscription - Avec conditions,Conditional,1st,22-Nov-21,10-Nov-22,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,,,,,,,,,,2022-12-14,,2022-12-14,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,-172.0,-137.0,249.0,187.0,90.0,117.0,353.0,,,,,,,,,,34.0,,,34.0,34.0,,,,,,,,,,,554.0,,554.0,,,,,,,,,,,,,504.0,,77.0,50.0,443.0,470.0,,,,,,266
617,Tecentriq,atezolizumab,Hoffman-La Roche ,Y,Y,N,Y,Y,N,N,N,N,01-Jun-17,06-Apr-18,309.0,CADTH & INESSS,15-Dec-17,pre-NOC,New drug,Non-Small Cell Lung Cancer:For the treatment of patients with locally advanced or metastatic non-small cell lung cancer who have progressed on or after systemic chemotherapy until loss of clinical benefit,Completed,20-Jun-18,Cond'l on Cost,Conditional,14-Feb-18,pre-NOC,New Indication,Non-Small Cell Lung Cancer in patients after chemo therapy,Completed,08-Aug-18,Avis de refus d'inscription à la Liste Établissements,Negative,1st,20-Jul-18,29-Nov-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,Under provincial consideration,EM,2019-11-01,2019-10-07,2019-02-11,2019-02-13,2019-12-06,2019-10-30,,,,2019-02-01,11-Feb-19,2019-02-01,6.0,4.0,2.0,3.0,7.0,5.0,,,,1.0,28.60%,34.30%,39.80%,44.30%,45.20%,65.40%,97.70%,,,,97.70%,01-Nov-19,06-Dec-19,-112.0,-51.0,187.0,175.0,30.0,-19.0,132.0,337.0,312.0,74.0,76.0,372.0,335.0,,,,64.0,251.0,74.0,224.0,64.0,372.0,574.0,549.0,311.0,313.0,609.0,572.0,,,,301.0,488.0,461.0,311.0,423.0,236.0,499.0,474.0,236.0,238.0,534.0,497.0,,,,177.0,413.0,75.0,124.0,162.0,113.0,609.0,308.0,298.0,273.0,35.0,384
621,Tecentriq,atezolizumab,Hoffmann-La Roche,Y,Y,N,N,Y,Y,N,Y,N,01-Feb-19,08-Aug-19,188.0,CADTH & INESSS,24-Jan-22,post-NOC,Initial,Tecentriq in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).,Completed,01-Sep-22,Cond'l on Cost,Conditional,22-Mar-19,pre-NOC,New Indication,Tecentriq in combination with carboplatin and etoposide is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).,Completed,16-Oct-19,Refus d'inscription,Negative,,,,,,Under provincial consideration,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,,2022-09-30,2023-03-01,2023-01-12,2023-03-31,,,,,2022-04-13,30-Sep-22,2022-04-13,,2.0,4.0,3.0,5.0,,,,,1.0,28.60%,33.00%,38.60%,44.30%,76.50%,,,,,,76.50%,31-Mar-23,,900.0,-139.0,220.0,208.0,,,,,,,,,,,,,,,,,,,,1149.0,1301.0,1253.0,1331.0,,,,,979.0,1259.0,1203.0,1149.0,249.0,29.0,,29.0,181.0,133.0,211.0,,,,,910.0,139.0,1120.0,69.0,,,,,,352.0,,1308
623,Tecentriq & Avastin,atezolizumab & bevacizumab,Hoffman-La Roche,Y,Y,N,N,Y,Y,N,Y,N,01-Feb-20,07-Aug-20,188.0,CADTH & INESSS,21-May-20,pre-NOC,New indication,"Hepatocellular Carcinoma (HCC): TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.",Completed,17-Nov-20,Cond'l on Cost,Conditional,26-Jun-20,pre-NOC,New Indication,"Hepatocellular Carcinoma (HCC): TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy.",Completed,30-Dec-20,Inscription - Avec conditions,Conditional,1st,26-Mar-21,14-Oct-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Funded,Under provincial consideration,EM,2022-04-01,2022-01-31,2021-11-01,2021-11-24,2022-03-31,,,,,2021-12-15,01-Nov-21,2021-11-01,6.0,4.0,1.0,2.0,5.0,,,,,3.0,5.70%,11.20%,39.80%,44.30%,76.50%,96.80%,,,,,96.80%,31-Mar-22,01-Apr-22,-78.0,-42.0,180.0,187.0,129.0,86.0,202.0,169.0,109.0,18.0,41.0,168.0,,,,,62.0,101.0,18.0,95.0,18.0,169.0,602.0,542.0,451.0,474.0,601.0,,,,,495.0,534.0,528.0,451.0,529.0,349.0,500.0,440.0,349.0,372.0,499.0,,,,,350.0,432.0,102.0,145.0,331.0,288.0,602.0,151.0,151.0,150.0,1.0,290
626,Tegsedi,inotersen,Akcea Therapeutics ,N,N,N,Y,N,Y,Y,Y,Y,01-Apr-18,03-Oct-18,185.0,CADTH & INESSS,22-Feb-19,post-NOC,Initial,hereditary transthyretin amlyoidosis,Completed,18-Dec-19,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-19,post-NOC,New Drug,Polyneuropathy ATTRh,Completed,11-Sep-19,Inscription - Avec conditions,Conditional,1st,29-Nov-19,30-Apr-20,Negotiation,Completed with Agreements,EDRD,UR,EDS,EDS,EAP,SA,EDS,UR,UR,EM,2021-12-01,,2020-10-01,2021-01-21,2021-01-29,2020-08-20,2022-06-27,,,2020-07-08,20-Aug-20,2020-07-08,6.0,,3.0,4.0,5.0,2.0,7.0,,,1.0,28.60%,29.50%,35.20%,40.70%,73.00%,93.20%,94.50%,,,,94.50%,29-Jan-21,01-Dec-21,142.0,170.0,299.0,173.0,-19.0,79.0,153.0,580.0,,154.0,266.0,274.0,112.0,788.0,,,69.0,362.0,112.0,320.0,69.0,580.0,1155.0,,729.0,841.0,849.0,687.0,1363.0,,,644.0,937.0,895.0,687.0,545.0,246.0,714.0,,288.0,400.0,408.0,246.0,922.0,,,301.0,496.0,441.0,343.0,134.0,232.0,1155.0,511.0,468.0,205.0,306.0,626
633,Treanda,bendamustine hydrochloride,Lundbeck,N,N,N,Y,Y,Y,N,Y,N,,24-Aug-12,,CADTH & INESSS,24-Apr-12,pre-NOC,New drug,Chronic lymphocytic leukemia (CLL) (1st Line),Completed,19-Feb-13,Cond'l on Cost,Conditional,24-Nov-12,post-NOC,New Drug,Chronic lymphocytic leukemia (CLL) (1st Line),Completed,03-Jun-13,Ajout à la Liste Établissements - Médicament d'exception,Positive,1st,,31-Jan-14,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-01-01,2013-07-18,2013-04-03,2014-01-21,2013-05-21,2014-02-01,2013-07-10,2018-08-01,2013-01-02,2013-06-03,02-Jan-13,2013-01-02,9.0,6.0,2.0,7.0,3.0,8.0,5.0,10.0,1.0,4.0,0.70%,6.40%,38.60%,67.20%,68.50%,73.00%,78.50%,79.40%,99.60%,100.00%,100.00%,03-Jun-13,01-Jan-17,-122.0,92.0,301.0,191.0,,,,1066.0,-197.0,-303.0,-10.0,-255.0,1.0,-205.0,1643.0,-394.0,-242.0,150.0,-394.0,110.0,-394.0,1066.0,1591.0,328.0,222.0,515.0,270.0,526.0,320.0,2168.0,131.0,283.0,675.0,635.0,131.0,253.0,-48.0,1412.0,149.0,43.0,336.0,91.0,347.0,141.0,1989.0,-48.0,0.0,496.0,179.0,283.0,346.0,242.0,1591.0,1460.0,1460.0,152.0,1308.0,41324
634,Treanda (in combination with rituximab),bendamustine hydrochloride,Lundbeck,N,N,N,N,Y,Y,N,Y,N,,,,CADTH,27-Jun-14,na,New indication,Chronic Lymphocytic Leukemia,Withdrawn,26-Sep-14,,,,,,,,,,,,,,,,Funded,Funded,Funded,Funded,Not funded,Not funded,Funded,Not funded,Not funded,,2017-01-01,2015-10-01,2015-04-01,2015-12-01,,,2017-04-01,,,,01-Apr-15,2015-04-01,4.0,2.0,1.0,3.0,,,5.0,,,,5.70%,10.20%,15.70%,36.00%,37.30%,,,,,,37.30%,,,,,91.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,278.0,187.0,828.0,370.0,187.0,431.0,,,918.0,,,,547.0,,,,,,,,,,41908
636,Trelegy Ellipta,fluticasone furoate umeclidinium vilanterol,GlaxoSmithKline,Y,N,N,N,N,N,N,N,N,01-Jun-17,04-Apr-18,307.0,CADTH & INESSS,01-Mar-18,pre-NOC,Initial,Chronic Obstructive Pulmonary Disease (COPD),Completed,23-Aug-18,Reimburse with clinical criteria and/or conditions,Conditional,05-Mar-18,pre-NOC,New Drug,COPD,Completed,05-Sep-18,Avis d'inscription aux listes des médicaments - Médicament d'exception - Avec conditions,Conditional,1st,30-Nov-18,09-Sep-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,FB,SA,EM,2020-07-07,2020-02-01,2019-11-01,2020-03-02,2019-09-30,2019-10-01,2019-12-01,2019-11-25,2020-01-03,2019-11-14,30-Sep-19,2019-09-30,10.0,8.0,3.0,9.0,1.0,2.0,6.0,5.0,7.0,4.0,32.20%,33.10%,38.80%,67.40%,67.80%,69.10%,69.80%,74.20%,79.70%,100.00%,100.00%,14-Nov-19,07-Jul-20,-34.0,-30.0,175.0,184.0,99.0,86.0,283.0,302.0,145.0,53.0,175.0,21.0,22.0,83.0,77.0,116.0,66.0,110.0,21.0,106.0,21.0,302.0,825.0,668.0,576.0,698.0,544.0,545.0,606.0,600.0,639.0,589.0,633.0,629.0,544.0,578.0,403.0,684.0,527.0,435.0,557.0,403.0,404.0,465.0,459.0,498.0,435.0,492.0,141.0,154.0,382.0,369.0,825.0,281.0,281.0,45.0,236.0,448
639,Tresiba,insulin degludec,Novo Nordisk ,Y,Y,N,Y,N,N,N,N,N,01-Oct-16,25-Aug-17,328.0,CADTH & INESSS,31-May-17,pre-NOC,Initial,"Diabetes mellitus, Type 1 & 2",Completed,20-Nov-17,Reimburse with clinical criteria and/or conditions,Conditional,01-Aug-17,pre-NOC,New Drug,Diabetes,Completed,11-Apr-18,Avis dinscription aux listes des médicaments  Médicament dexception (diabète de type 1) Avis de refus dinscription aux listes des médicaments (diabète de type 2),Conditional,1st,30-Apr-18,26-Jul-18,Negotiation,Completed with Agreements,NR,FB,FB,FB,FB,FB,FB,FB,FB,EM,,2018-12-01,2018-10-01,2018-10-18,2018-09-27,2018-11-30,2019-05-01,2018-11-26,2019-01-31,2018-09-27,27-Sep-18,2018-09-27,,7.0,3.0,4.0,1.0,6.0,9.0,5.0,8.0,2.0,32.20%,60.80%,66.50%,72.10%,72.40%,73.30%,77.80%,78.40%,79.70%,,79.70%,27-Sep-18,,-86.0,-24.0,173.0,253.0,161.0,19.0,87.0,,128.0,67.0,84.0,63.0,127.0,279.0,123.0,189.0,63.0,133.0,63.0,125.0,63.0,,,463.0,402.0,419.0,398.0,462.0,614.0,458.0,524.0,398.0,468.0,460.0,398.0,484.0,311.0,,376.0,315.0,332.0,311.0,375.0,527.0,371.0,437.0,169.0,381.0,87.0,229.0,248.0,106.0,,,,0.0,,415
640,Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,Vertex Pharmaceuticals (Canada) Incorporated,N,N,N,Y,N,Y,Y,Y,Y,01-Dec-20,18-Jun-21,199.0,CADTH & INESSS,22-Jan-21,pre-NOC,Initial,Triple Combination Therapy (elexacaftor/tezacaftor/ivacaftor and ivacaftor) tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene,Completed,16-Sep-21,Reimburse with clinical criteria and/or conditions,Conditional,05-Mar-21,pre-NOC,New Drug,Cystic fibrosis children over 12 with CFTR F508del mutation,Completed,01-Sep-21,Inscription - Avec conditions,Conditional,1st,17-Sep-21,17-Sep-21,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,CF,SA,SA,EM,2021-10-05,2021-09-24,2021-10-01,2021-10-22,2021-09-22,2021-10-14,2021-11-18,2021-11-01,2021-11-19,2021-09-29,22-Sep-21,2021-09-22,5.0,2.0,4.0,7.0,1.0,6.0,9.0,8.0,10.0,3.0,32.20%,36.70%,65.30%,71.00%,91.20%,92.10%,97.70%,98.00%,99.30%,100.00%,100.00%,29-Sep-21,05-Oct-21,-147.0,-105.0,237.0,180.0,1.0,16.0,0.0,18.0,7.0,14.0,35.0,5.0,27.0,62.0,45.0,63.0,12.0,31.0,5.0,29.0,5.0,18.0,109.0,98.0,105.0,126.0,96.0,118.0,153.0,136.0,154.0,103.0,122.0,120.0,96.0,243.0,6.0,19.0,8.0,15.0,36.0,6.0,28.0,63.0,46.0,64.0,28.0,32.0,90.0,75.0,1.0,16.0,109.0,13.0,13.0,7.0,6.0,289
641,Trikafta,elexacaftor/tezacaftor/ivacaftor and ivacaftor,Vertex Pharmaceuticals (Canada) Incorporated,N,N,N,Y,N,Y,Y,Y,Y,01-Dec-20,20-Apr-22,505.0,CADTH & INESSS,05-Nov-21,pre-NOC,Initial,"Cystic fibrosis, F508del CFTR mutation, 6 years and olde",Completed,17-Jun-22,Reimburse with clinical criteria and/or conditions,Conditional,22-Apr-22,post-NOC,New Indication,Cystic fibrosis children over 6 with CFTR F508del mutation,Completed,04-Aug-22,Inscription - Avec conditions,Conditional,1st,07-Jul-22,07-Jul-22,Negotiation,Completed with Agreements,EDRD,SA,EDS,EDS,EAP,SA,CF,SA,SA,EM,2022-09-13,2022-08-01,2022-08-01,2022-08-17,2022-07-08,2022-07-25,2022-07-18,2022-08-08,2022-08-08,2022-08-04,08-Jul-22,2022-07-08,10.0,4.0,5.0,9.0,1.0,3.0,2.0,7.0,8.0,6.0,32.20%,33.50%,34.40%,38.90%,44.60%,73.20%,73.50%,74.20%,79.70%,100.00%,100.00%,04-Aug-22,13-Sep-22,-166.0,2.0,224.0,104.0,20.0,-28.0,0.0,68.0,25.0,25.0,41.0,1.0,18.0,11.0,32.0,32.0,28.0,28.0,1.0,28.0,1.0,68.0,146.0,103.0,103.0,119.0,79.0,96.0,89.0,110.0,110.0,106.0,106.0,106.0,79.0,245.0,21.0,88.0,45.0,45.0,61.0,21.0,38.0,31.0,52.0,52.0,0.0,48.0,58.0,106.0,20.0,-28.0,146.0,67.0,67.0,27.0,40.0,563
642,Trintellix,vortioxetine,Lundbeck ,N,N,N,Y,N,N,N,N,N,,22-Oct-14,,CADTH & INESSS,01-May-19,post-NOC,Initial,"Major depressive disorder (MDD), adults",Completed,12-Feb-20,Reimburse with clinical criteria and/or conditions,Conditional,10-May-19,post-NOC,New Drug,Major depressive disorder,Completed,06-Nov-19,Refus d'inscription,Negative,1st,06-Jul-20,03-Dec-20,Negotiation,Completed with Agreements,SA,UR,FB,FB,FB,FB,FB,FB,FB,FB,2021-07-06,,2021-02-01,2021-04-01,2021-01-29,2021-04-22,2021-11-30,2021-12-20,2021-04-20,2021-02-03,29-Jan-21,2021-01-29,7.0,,2.0,4.0,1.0,6.0,8.0,9.0,5.0,3.0,32.20%,38.00%,66.50%,72.10%,72.70%,73.60%,93.90%,95.20%,95.50%,,95.50%,03-Feb-21,06-Jul-21,1652.0,1661.0,287.0,180.0,145.0,243.0,150.0,215.0,,60.0,119.0,57.0,140.0,362.0,382.0,138.0,62.0,184.0,57.0,171.0,57.0,215.0,2449.0,,2294.0,2353.0,2291.0,2374.0,2596.0,2616.0,2372.0,2296.0,2418.0,2405.0,2291.0,639.0,352.0,510.0,,355.0,414.0,352.0,435.0,657.0,677.0,433.0,455.0,479.0,1939.0,1841.0,295.0,393.0,2449.0,158.0,158.0,5.0,153.0,43873
647,Trulicity,dulaglutide,Eli Lilly ,N,Y,N,Y,N,N,N,N,N,,10-Nov-15,,CADTH & INESSS,22-Dec-15,post-NOC,Initial,"Diabetes mellitus, Type 2",Completed,16-Jun-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Drug,"Diabetes mellitus, Type 2",Completed,01-Jun-16,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,07-Jul-17,27-Sep-19,Negotiation,No agreement reached,NR,UR,NR,UR,UR,NR,UR,UR,UR,EM,,,,,,,,,,2016-06-01,,2016-06-01,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,42.0,14.0,177.0,190.0,386.0,401.0,812.0,,,,,,,,,,-1213.0,,,-1213.0,-1213.0,,,,,,,,,,,204.0,,204.0,,,,,,,,,,,,,0.0,,219.0,204.0,1198.0,1213.0,,,,,,42537
648,Truvada (HIV pre-exposure prophylaxis),emtricitabine/tenofovir disoproxil fumarate,Gilead Sciences ,Y,N,N,N,N,N,N,N,N,,26-Feb-16,,CADTH,03-Mar-16,post-NOC,Initial,"HIV-1 infection, pre-exposure prophylaxis",Completed,24-Aug-16,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,none,08-Sep-17,,Do Not Negotiate,,NR,NR,FB,FB,FB,FB,EDS,HIV,SA,FB,,,2018-01-01,2018-04-19,2007-09-04,2009-06-29,2018-07-23,2009-03-01,2018-09-12,2006-10-01,04-Sep-07,2006-10-01,,,5.0,6.0,2.0,4.0,7.0,3.0,8.0,1.0,28.60%,60.80%,61.20%,62.10%,67.80%,73.30%,74.60%,75.30%,,,75.30%,04-Sep-07,,6.0,,174.0,,380.0,,,,,,,,,,,,,,,,,,,,675.0,783.0,-3097.0,-2433.0,878.0,-2553.0,929.0,-3435.0,-688.0,-1032.0,-3097.0,-3103.0,-3277.0,,,495.0,603.0,-3277.0,-2613.0,698.0,-2733.0,749.0,,-868.0,180.0,,,,,,,338.0,,42606
649,Truxima,rituximab,Teva Canada Innovation,N,Y,Y,Y,Y,Y,N,Y,N,01-Sep-17,04-Apr-19,580.0,CADTH,,na,New drug,Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia Biosimilar,File-Closed Not Submitted,,,,,,,,,,,,1st,13-Sep-19,12-Feb-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,,,,EM,2020-08-20,2020-06-01,2021-01-01,2020-07-16,2020-03-31,2020-09-17,,,,2020-12-16,31-Mar-20,2020-03-31,4.0,2.0,7.0,3.0,1.0,5.0,,,,6.0,32.20%,36.70%,42.20%,62.50%,63.40%,91.90%,97.70%,,,,97.70%,20-Aug-20,16-Dec-20,,,,,,,152.0,190.0,110.0,324.0,155.0,48.0,218.0,,,,308.0,174.0,48.0,193.0,48.0,308.0,504.0,424.0,638.0,469.0,362.0,532.0,,,,622.0,488.0,507.0,362.0,,,,,,,,,,,,,,,,,,622.0,260.0,260.0,142.0,118.0,-42979
651,Tukysa,tucatinib,Seagen,N,N,N,Y,Y,N,N,N,N,01-Feb-20,05-Jun-20,125.0,CADTH & INESSS,26-Mar-21,post-NOC,Initial,"Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination",Completed,17-Nov-21,Cond'l on Cost,Conditional,23-Apr-21,post-NOC,New Drug,"Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination",Completed,08-Sep-21,Inscription - Avec conditions,Conditional,1st,18-May-22,14-Sep-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,EM,2022-12-01,2022-09-30,2023-02-01,2023-01-24,2023-02-28,2023-03-27,2023-04-01,,,2022-11-09,30-Sep-22,2022-09-30,3.0,1.0,5.0,4.0,6.0,7.0,8.0,,,2.0,4.50%,33.00%,53.30%,58.80%,64.50%,96.80%,97.70%,99.00%,,,99.00%,01-Dec-22,28-Feb-23,294.0,322.0,236.0,138.0,182.0,252.0,119.0,78.0,16.0,140.0,132.0,167.0,194.0,199.0,,,56.0,132.0,16.0,123.0,16.0,167.0,909.0,847.0,971.0,963.0,998.0,1025.0,1030.0,,,887.0,963.0,954.0,847.0,553.0,317.0,379.0,317.0,441.0,433.0,468.0,495.0,500.0,,,427.0,433.0,530.0,460.0,301.0,371.0,998.0,151.0,151.0,62.0,89.0,655
657,Unituxin,dinutuximab,United Therapeutics Corp.,N,Y,N,Y,Y,Y,Y,Y,N,01-Feb-18,28-Nov-18,300.0,CADTH & INESSS,01-Oct-18,pre-NOC,New drug,Neuroblastoma,Completed,26-Mar-19,Cond'l on Cost,Conditional,26-Apr-19,post-NOC,New Drug,Neuroblastoma,Completed,16-Oct-19,Inscription - Avec conditions,Conditional,1st,08-May-19,30-Aug-19,Negotiation,Completed with Agreements,Funded,Under provincial consideration,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,2019-11-01,,2020-03-01,2020-02-11,2020-01-29,,,,,2020-03-04,01-Nov-19,2019-11-01,1.0,,4.0,3.0,2.0,,,,,5.0,20.30%,52.50%,58.00%,63.70%,92.30%,,,,,,92.30%,29-Jan-20,04-Mar-20,-58.0,149.0,176.0,173.0,43.0,-161.0,114.0,63.0,,184.0,165.0,152.0,,,,,187.0,141.0,63.0,150.0,63.0,187.0,338.0,,459.0,440.0,427.0,,,,,462.0,416.0,425.0,338.0,396.0,220.0,220.0,,341.0,322.0,309.0,,,,,140.0,298.0,118.0,322.0,157.0,-47.0,462.0,124.0,124.0,89.0,35.0,418
659,Uptravi,selexipag,Actelion,Y,N,N,Y,N,Y,N,Y,N,,20-Jan-16,,CADTH & INESSS,31-Mar-16,post-NOC,Initial,Pulmonary arterial hypertension (WHO class II and III),Completed,28-Oct-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,Pulmonary arterial hypertension (WHO class II and III),Completed,03-Oct-16,Avis de refus dinscription aux listes des médicaments  Médicament dexception  À moins que certaines conditions soient respectées,Conditional,1st,13-Apr-17,12-Dec-17,Negotiation,Completed with Agreements,SA,F,EDS,EDS,EAP,SA,EDS,SA,SA,EM,2018-10-30,2018-06-12,2018-04-01,2018-04-19,2018-04-18,2018-09-06,2018-10-29,2018-12-24,2018-03-28,2018-03-01,28-Mar-18,2018-03-01,9.0,6.0,3.0,5.0,4.0,7.0,8.0,10.0,2.0,1.0,28.60%,29.30%,35.00%,67.20%,72.70%,77.20%,78.10%,79.40%,99.60%,100.00%,100.00%,18-Apr-18,30-Oct-18,71.0,62.0,211.0,195.0,167.0,192.0,243.0,322.0,182.0,110.0,128.0,127.0,268.0,321.0,377.0,106.0,79.0,216.0,106.0,202.0,79.0,322.0,1014.0,874.0,802.0,820.0,819.0,960.0,1013.0,1069.0,798.0,771.0,908.0,894.0,798.0,727.0,516.0,732.0,592.0,520.0,538.0,537.0,678.0,731.0,787.0,516.0,514.0,626.0,282.0,257.0,410.0,435.0,1014.0,243.0,216.0,48.0,195.0,42671
662,Vascepa,icosapent ethyl,HLS Therapeutics,N,N,N,Y,N,N,N,N,N,01-Jul-19,30-Dec-19,182.0,CADTH & INESSS,17-Jun-19,pre-NOC,Initial,Ischemic events in statin-treated patients,Completed,16-Jul-20,Reimburse with clinical criteria and/or conditions,Conditional,12-Jul-19,pre-NOC,New drug,Prevention of cardiovascular events,Completed,05-Feb-20,Refus d'inscription,Negative,1st,29-Jan-21,25-Apr-22,Negotiation,Completed with Agreements,,,EDS,EDS,EAP,SA,,,,EM,,,2022-08-01,2022-09-20,2022-07-21,2022-06-20,,,,2021-05-26,20-Jun-22,2021-05-26,,,4.0,5.0,3.0,2.0,,,,1.0,28.60%,29.50%,61.70%,67.40%,73.00%,,,,,,73.00%,21-Jul-22,,-196.0,-171.0,395.0,208.0,197.0,359.0,451.0,,,98.0,148.0,87.0,56.0,,,,-334.0,97.0,56.0,11.0,-334.0,,,,945.0,995.0,934.0,903.0,,,,513.0,944.0,858.0,903.0,1099.0,704.0,,,746.0,796.0,735.0,704.0,,,,476.0,745.0,199.0,37.0,648.0,810.0,,,,421.0,,381
663,Vectibix,panitumumab,Amgen ,Y,Y,N,N,Y,N,N,N,N,,31-Aug-15,,CADTH & INESSS,15-Apr-15,pre-NOC,New indication,Metastatic Colorectal Cancer,Completed,03-Dec-15,Cond'l on Cost,Conditional,24-Nov-15,post-NOC,New Indication,Metastatic Colorectal Cancer,Completed,01-Jun-16,Avis dajout dune indication reconnue à la Liste Établissements  Médicament dexception  Avec conditions (contre-indication ou intolérance au bevacizumab) Avis de refus dajout dune indication reconnue à la Liste Établissements  Médicament dexception  À moins que certaines conditions soient respectées (ensemble des patients),Conditional,1st,23-Dec-15,22-May-17,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2017-11-01,2022-09-30,2017-08-02,2017-11-01,2017-09-01,2017-12-20,2018-02-01,2018-08-01,2017-08-03,2017-07-19,02-Aug-17,2017-07-19,5.0,10.0,2.0,6.0,4.0,7.0,8.0,9.0,3.0,1.0,28.60%,34.30%,35.00%,67.20%,87.50%,93.00%,93.90%,95.20%,95.50%,100.00%,100.00%,01-Sep-17,01-Nov-17,-138.0,85.0,232.0,190.0,20.0,-161.0,516.0,163.0,1957.0,72.0,163.0,102.0,212.0,255.0,436.0,73.0,58.0,381.0,72.0,349.0,58.0,163.0,793.0,2587.0,702.0,793.0,732.0,842.0,885.0,1066.0,703.0,688.0,1011.0,979.0,702.0,840.0,608.0,699.0,2493.0,608.0,699.0,638.0,748.0,791.0,972.0,609.0,413.0,917.0,94.0,275.0,536.0,355.0,793.0,105.0,91.0,44.0,61.0,42341
666,Velphoro,sucroferric oxyhydride,Vifor Fresnius Medical Care Renal Pharma,N,N,N,Y,N,N,N,N,N,01-Feb-17,05-Jan-18,338.0,CADTH & INESSS,12-Jun-18,post-NOC,Initial,"Hyperphosphatemia, end-stage renal disease",Completed,02-Jan-19,Reimburse with clinical criteria and/or conditions,Conditional,11-Jul-18,post-NOC,New Drug,Hyperphosphatemia,Completed,09-Jan-19,Inscription  Avec conditions,Conditional,1st,12-Apr-19,17-Sep-19,Negotiation,Completed with Agreements,UR,UR,EDS,EDS,EAP,SA,EDS,UR,SA,EM,,,2020-11-01,2020-07-16,2020-02-26,2020-06-18,2020-10-07,,2020-09-14,2019-10-02,26-Feb-20,2019-10-02,,,7.0,4.0,2.0,3.0,6.0,,5.0,1.0,28.60%,60.80%,61.70%,67.20%,67.90%,69.20%,74.90%,,,,74.90%,26-Feb-20,,158.0,187.0,204.0,182.0,100.0,93.0,158.0,,,411.0,303.0,162.0,275.0,386.0,,363.0,15.0,317.0,162.0,274.0,15.0,,,,1031.0,923.0,782.0,895.0,1006.0,,983.0,635.0,937.0,894.0,782.0,624.0,420.0,,,669.0,561.0,420.0,533.0,644.0,,621.0,266.0,575.0,362.0,369.0,258.0,251.0,,,,147.0,,700
670,Venclexta,venetoclax,AbbVie ,Y,N,N,Y,Y,Y,Y,Y,N,01-Feb-16,30-Sep-16,242.0,CADTH & INESSS,10-Jul-17,post-NOC,New indication,Chronic Lymphocytic Leukemia,Completed,02-Mar-18,Cond'l on Cost,Conditional,23-Jul-17,post-NOC,New Drug,chronic lymphocytic leukemia,Completed,01-Feb-18,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,21-Jun-18,06-Mar-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,NR,2019-09-01,2019-07-26,2019-09-03,2019-08-22,2019-05-13,2019-10-24,2019-10-03,2021-05-10,2019-09-10,,13-May-19,2019-05-13,4.0,2.0,5.0,3.0,1.0,8.0,7.0,9.0,6.0,,32.20%,36.70%,42.20%,62.50%,68.20%,68.90%,70.20%,71.10%,71.40%,,71.40%,01-Sep-19,,283.0,296.0,235.0,193.0,111.0,140.0,258.0,179.0,142.0,181.0,169.0,68.0,232.0,211.0,796.0,188.0,,241.0,68.0,241.0,68.0,,1066.0,1029.0,1068.0,1056.0,955.0,1119.0,1098.0,1683.0,1075.0,,1128.0,1128.0,955.0,672.0,437.0,548.0,511.0,550.0,538.0,437.0,601.0,580.0,1165.0,557.0,,610.0,518.0,489.0,369.0,398.0,,,,111.0,,760
671,Venclexta,venetoclax with obinutuzumab,AbbVie ,Y,N,N,N,Y,Y,Y,Y,N,01-Jul-19,28-Apr-20,302.0,CADTH & INESSS,17-Apr-20,pre-NOC,New indication,Chronic Lymphocytic Leukemia (CLL):Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible.,Completed,17-Nov-20,Cond'l on Cost,Conditional,22-May-20,post-NOC,New Indication,Venetoclax (VENCLEXTA) in combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) who are fludarabine ineligible,Completed,05-Nov-20,Inscription - Avec conditions,Conditional,1st,23-Feb-21,13-Oct-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2022-02-01,2022-01-31,2022-02-01,2022-02-24,2022-05-31,2022-04-29,2022-06-10,2022-12-12,2022-10-31,2021-11-10,31-Jan-22,2021-11-10,3.0,2.0,4.0,5.0,7.0,6.0,8.0,10.0,9.0,1.0,28.60%,33.00%,53.30%,59.00%,64.50%,65.40%,97.70%,99.00%,99.60%,100.00%,100.00%,01-Feb-22,31-May-22,-11.0,24.0,214.0,167.0,98.0,110.0,232.0,111.0,110.0,111.0,134.0,230.0,198.0,240.0,425.0,383.0,28.0,216.0,110.0,197.0,28.0,230.0,644.0,643.0,644.0,667.0,763.0,731.0,773.0,958.0,916.0,561.0,749.0,730.0,643.0,654.0,440.0,441.0,440.0,441.0,464.0,560.0,528.0,570.0,755.0,713.0,370.0,546.0,203.0,191.0,330.0,342.0,763.0,202.0,120.0,83.0,119.0,505
672,Venclexta,venetoclax with azacitidine,AbbVie ,Y,N,N,N,Y,Y,Y,Y,Y,01-Jun-20,04-Dec-20,186.0,CADTH & INESSS,08-Jan-21,post-NOC,Initial,"In combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",Completed,20-Aug-21,Cond'l on Cost,Conditional,19-Feb-21,post-NOC,New Indication,"In combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.",Completed,15-Aug-21,Inscription - Avec conditions,Conditional,1st,29-Sep-21,06-Dec-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2022-05-01,2022-02-28,2022-02-01,2022-02-24,2022-08-31,2022-04-29,2022-06-10,2022-12-12,2022-10-31,2022-02-02,01-Feb-22,2022-02-01,6.0,4.0,1.0,3.0,8.0,5.0,7.0,10.0,9.0,2.0,5.70%,34.30%,39.80%,44.30%,45.20%,65.40%,66.70%,99.00%,99.60%,100.00%,100.00%,01-May-22,31-Aug-22,35.0,77.0,224.0,177.0,40.0,45.0,68.0,146.0,84.0,57.0,80.0,268.0,144.0,186.0,371.0,329.0,58.0,185.0,57.0,172.0,57.0,268.0,513.0,451.0,424.0,447.0,635.0,511.0,553.0,738.0,696.0,425.0,552.0,539.0,424.0,389.0,165.0,254.0,192.0,165.0,188.0,376.0,252.0,294.0,479.0,437.0,171.0,293.0,259.0,254.0,108.0,113.0,635.0,211.0,211.0,89.0,122.0,445
674,Venclexta in combo Rituximab,venetoclax,AbbVie ,Y,N,N,N,Y,Y,Y,Y,N,01-Mar-18,21-Sep-18,204.0,CADTH & INESSS,24-Oct-18,post-NOC,New indication,Chronic Lymphocytic Leukemia (CLL) -2L+,Completed,31-May-19,Cond'l on Cost,Conditional,22-Oct-18,post-NOC,New Indication,In combination with rituximab (V+R) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy,Completed,05-Jun-19,Inscription - Avec conditions,Conditional,1st,26-Jun-19,28-Oct-19,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-01-01,2020-04-10,2020-03-01,2020-04-02,2020-03-31,2020-07-16,2020-07-01,2021-05-10,2020-09-02,2019-12-18,01-Jan-20,2019-12-18,2.0,6.0,3.0,5.0,4.0,8.0,7.0,10.0,9.0,1.0,28.60%,48.80%,54.60%,86.80%,92.30%,96.80%,98.10%,99.00%,99.60%,100.00%,100.00%,01-Mar-20,31-Mar-20,33.0,31.0,219.0,226.0,26.0,21.0,124.0,65.0,165.0,125.0,157.0,155.0,262.0,247.0,560.0,310.0,51.0,227.0,65.0,210.0,51.0,155.0,467.0,567.0,527.0,559.0,557.0,664.0,649.0,962.0,712.0,453.0,629.0,612.0,467.0,434.0,215.0,215.0,315.0,275.0,307.0,305.0,412.0,397.0,710.0,460.0,196.0,377.0,252.0,257.0,150.0,145.0,557.0,104.0,90.0,74.0,30.0,456
675,Verkazia,cyclosporine,Santen,N,N,N,N,N,Y,Y,Y,N,01-Jul-18,24-Dec-18,176.0,CADTH & INESSS,22-May-19,post-NOC,Initial,"Severe vernal keratoconjunctivitis, pediatric (?4 years)",Completed,18-Nov-19,Reimburse with clinical criteria and/or conditions,Conditional,14-Jun-19,post-NOC,New Drug,Vernal keratoconjunctivitis,Completed,08-Jan-20,Inscription - Avec conditions,Conditional,1st,27-Feb-20,20-Nov-20,Negotiation,Completed with Agreements,NR,UR,EDS,UR,EAP,SA,EDS,SA,UR,EM,,,2021-11-01,,2021-03-03,2021-06-17,2022-06-27,2023-01-23,,2021-03-03,03-Mar-21,2021-03-03,,,4.0,,1.0,3.0,5.0,6.0,,2.0,32.20%,60.80%,61.70%,67.40%,68.70%,69.10%,,,,,69.10%,03-Mar-21,,149.0,172.0,180.0,208.0,101.0,50.0,267.0,,,346.0,,103.0,209.0,584.0,794.0,,103.0,407.0,103.0,357.0,103.0,,,,1043.0,,800.0,906.0,1281.0,1491.0,,800.0,1104.0,1054.0,800.0,651.0,471.0,,,714.0,,471.0,577.0,952.0,1162.0,,420.0,775.0,329.0,380.0,368.0,317.0,,,,0.0,,505
684,Vimizim (resub),elosulfase alfa,BioMarin Pharmaceutical ,N,Y,N,Y,N,Y,Y,Y,N,,02-Jul-14,,CADTH & INESSS,10-Nov-15,post-NOC,Resubmission,Mucopolysaccharidosis IVA (Morquio A syndrome),Completed,20-May-16,Reimburse with clinical criteria and/or conditions,Conditional,12-Aug-16,post-NOC,Resubmission,Mucopolysaccharidosis IVA (Morquio A syndrome) ,Completed,01-Feb-17,Avis de refus d'inscription aux listes des médicaments - Valeur thérapeutique,Negative,1st,28-Oct-16,29-Nov-18,Negotiation,Completed with Agreements,UR,UR,UR,UR,EAP,UR,UR,UR,UR,NR,,,,,2019-05-13,,,,,,13-May-19,2019-05-13,,,,,1.0,,,,,,32.20%,,,,,,,,,,32.20%,,,496.0,772.0,192.0,173.0,161.0,-96.0,762.0,,,,,165.0,,,,,,165.0,165.0,165.0,165.0,,,,,,1776.0,,,,,,1776.0,1776.0,1776.0,1280.0,1088.0,,,,,1088.0,,,,,,1088.0,688.0,945.0,923.0,666.0,,,,,,42510
686,Vitrakvi,larotrectinib,Bayer ,Y,N,N,Y,Y,Y,Y,Y,Y,01-Nov-18,10-Jul-19,251.0,CADTH & INESSS,16-Nov-20,post-NOC,Resubmission,"For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.",Completed,13-Sep-21,Cond'l on Cost,Conditional,01-Jan-21,post-NOC,Resubmission,"For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.",Completed,09-Jun-21,Inscription - Avec conditions,Conditional,1st,31-Mar-22,07-Nov-22,Negotiation,Completed with Agreements,Under provincial consideration,Under provincial consideration,Funded,Funded,Funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,EM,,,2022-12-01,2023-04-01,2023-02-24,,,,,2022-12-14,01-Dec-22,2022-12-01,,,1.0,4.0,3.0,,,,,2.0,5.70%,34.30%,66.50%,72.10%,,,,,,,72.10%,24-Feb-23,,495.0,541.0,301.0,159.0,199.0,295.0,221.0,,,24.0,145.0,109.0,,,,,37.0,93.0,24.0,79.0,24.0,,,,1240.0,1361.0,1325.0,,,,,1253.0,1309.0,1295.0,1240.0,745.0,444.0,,,444.0,565.0,529.0,,,,,553.0,513.0,796.0,700.0,420.0,516.0,,,,85.0,,1047
689,Vosevi,sofosbuvir velpatasvir voxilaprevir,Gilead Sciences ,Y,N,N,Y,N,N,N,N,N,01-Feb-17,16-Aug-17,196.0,CADTH & INESSS,28-Jul-17,pre-NOC,Initial,"Hepatitis C, chronic",Completed,23-Jan-18,Reimburse with clinical criteria and/or conditions,Conditional,04-Aug-17,pre-NOC,New Drug,"Hepatitis C, chronic",Completed,01-Feb-18,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,14-Feb-18,14-Feb-18,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,UR,SA,EM,2018-03-13,2018-05-01,2018-04-01,2018-07-19,2018-02-28,2018-05-08,2018-10-01,,2018-09-20,2018-03-01,28-Feb-18,2018-02-28,3.0,5.0,4.0,7.0,1.0,6.0,9.0,,8.0,2.0,32.20%,60.80%,81.10%,86.80%,91.20%,92.10%,97.70%,98.30%,99.60%,,99.60%,01-Mar-18,13-Mar-18,-19.0,-12.0,179.0,181.0,22.0,13.0,0.0,27.0,76.0,46.0,155.0,14.0,83.0,229.0,,218.0,15.0,106.0,14.0,96.0,14.0,27.0,209.0,258.0,228.0,337.0,196.0,265.0,411.0,,400.0,197.0,288.0,278.0,196.0,215.0,36.0,49.0,98.0,68.0,177.0,36.0,105.0,251.0,,240.0,28.0,128.0,160.0,169.0,22.0,13.0,209.0,13.0,13.0,1.0,12.0,356
694,Vyndaqel,tafamidis,Pfizer ,Y,N,N,Y,N,N,N,N,N,01-Jul-19,20-Jan-20,203.0,CADTH & INESSS,04-Jul-19,pre-NOC,Initial,Transthyretin-mediated amyloidosis,Completed,19-Feb-20,Reimburse with clinical criteria and/or conditions,Conditional,12-Jul-19,pre-NOC,New Drug,Cardiomyopathy ATTR,Completed,08-Apr-20,Refus d'inscription,Negative,1st,10-Jun-20,04-Feb-21,Negotiation,Completed with Agreements,,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,2021-05-01,2021-06-01,2021-08-05,2021-05-12,2021-05-13,2022-09-01,2021-11-22,2021-08-20,2021-03-03,01-May-21,2021-03-03,,2.0,5.0,6.0,3.0,4.0,9.0,8.0,7.0,1.0,28.60%,33.00%,65.30%,66.20%,71.90%,77.40%,78.10%,78.40%,79.70%,,79.70%,12-May-21,,-200.0,-192.0,230.0,271.0,112.0,63.0,239.0,,86.0,117.0,182.0,97.0,98.0,574.0,291.0,197.0,27.0,205.0,86.0,185.0,27.0,,,467.0,498.0,563.0,478.0,479.0,955.0,672.0,578.0,408.0,586.0,566.0,467.0,667.0,437.0,,437.0,468.0,533.0,448.0,449.0,925.0,642.0,548.0,329.0,556.0,30.0,79.0,351.0,302.0,,,,70.0,,233
695,Vyndaqel,tafamidis,Pfizer ,Y,N,N,Y,N,N,N,N,N,01-Jul-19,20-Jan-20,203.0,CADTH,14-Dec-21,post-NOC,Request for Advice,Transthyretin-mediated amyloidosis,Completed,17-Jun-22,Reimburse with clinical criteria and/or conditions,Conditional,,,,,,,,,1st,07-Sep-22,07-Sep-22,Negotiation,Completed with Agreements,,,EDS,EDS,EAP,,EDS,,SA,,,,2022-12-01,2023-01-24,2022-09-15,,2022-11-01,,2023-01-05,,15-Sep-22,2022-09-15,,,3.0,5.0,1.0,,2.0,,4.0,,32.20%,33.50%,39.30%,39.90%,45.50%,,,,,,45.50%,,,694.0,,185.0,,82.0,,0.0,,,85.0,139.0,8.0,,55.0,,120.0,,81.0,8.0,81.0,8.0,,,,1046.0,1100.0,969.0,,1016.0,,1081.0,,1042.0,1042.0,969.0,275.0,90.0,,,167.0,221.0,90.0,,137.0,,202.0,,163.0,879.0,,82.0,,,,,,,1082
696,Vyxeos,daunorubicin and cytarabine,Jazz Pharmaceuticals,N,N,N,Y,Y,Y,Y,Y,N,01-Nov-20,29-Apr-21,179.0,CADTH & INESSS,22-Jan-21,pre-NOC,Initial,For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). For the treatment of relapsed or refractory AML in pediatric and young adult patients aged 1 to 21 years old.,Completed,24-Aug-21,Cond'l on Cost,Conditional,19-Feb-21,pre-NOC,New Drug,For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). For the treatment of relapsed or refractory AML in pediatric and young adult patients aged 1 to 21 years old.,Completed,01-Sep-21,Inscription - Avec conditions,Conditional,1st,13-Jan-22,27-Apr-22,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,Funded,EM,2022-10-01,2022-09-30,2022-08-01,2022-07-14,2022-10-31,,,,,2022-05-26,14-Jul-22,2022-05-26,5.0,4.0,3.0,2.0,6.0,,,,,1.0,28.60%,34.10%,39.80%,44.30%,64.50%,96.80%,,,,,96.80%,01-Oct-22,31-Oct-22,-97.0,-69.0,214.0,194.0,142.0,134.0,104.0,157.0,156.0,96.0,78.0,187.0,,,,,29.0,135.0,78.0,117.0,29.0,187.0,520.0,519.0,459.0,441.0,550.0,,,,,392.0,498.0,480.0,441.0,538.0,324.0,403.0,402.0,342.0,324.0,433.0,,,,,267.0,381.0,117.0,125.0,246.0,238.0,550.0,158.0,109.0,128.0,30.0,296
697,Vyzulta,latanoprostene bunod,Bausch & Lomb ,N,N,N,Y,N,N,N,N,Y,01-Mar-18,27-Dec-18,301.0,CADTH & INESSS,23-Nov-18,pre-NOC,Initial,Open-angle glaucoma or ocular hypertension,Completed,24-Jul-19,Reimburse with clinical criteria and/or conditions,Conditional,20-Dec-18,pre-NOC,New Drug,Glaucoma or ocular hypertension,Completed,07-Aug-19,Refus d'inscription,Negative,1st,30-Aug-19,20-Nov-19,Negotiation,Completed with Agreements,FB,FB,FB,FB,LU,FB,FB,FB,FB,NR,2020-10-30,2020-03-01,2020-02-01,2020-03-02,2019-12-20,2020-04-23,2020-07-31,2020-12-28,2020-06-15,,20-Dec-19,2019-12-20,8.0,3.0,2.0,4.0,1.0,5.0,7.0,9.0,6.0,,32.20%,38.00%,42.40%,47.90%,48.80%,49.50%,50.80%,71.10%,71.40%,,71.40%,31-Jul-20,,-34.0,-7.0,243.0,230.0,37.0,23.0,82.0,345.0,102.0,73.0,103.0,30.0,155.0,254.0,404.0,208.0,,186.0,30.0,186.0,30.0,,673.0,430.0,401.0,431.0,358.0,483.0,582.0,732.0,536.0,,514.0,514.0,358.0,392.0,149.0,464.0,221.0,192.0,222.0,149.0,274.0,373.0,523.0,327.0,,305.0,209.0,223.0,119.0,105.0,,,,224.0,,510
699,Waymade-Trientine,trientine hydrochloride,Waymade PLC,N,N,N,N,N,N,N,N,N,01-Jun-20,20-Apr-21,323.0,CADTH & INESSS,21-Jul-21,post-NOC,Initial,Wilson's Disease,Completed,08-Feb-22,Reimburse with clinical criteria and/or conditions,Conditional,10-Dec-21,post-NOC,New Drug,Wilson's Disease,Completed,29-Dec-21,Inscription - Avec conditions,Conditional,1st,13-Apr-22,11-Aug-22,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,EAP,,EDS,,,EM,2022-10-25,2022-10-01,2022-11-01,2023-01-24,2022-08-11,,2022-11-01,,,2022-12-14,11-Aug-22,2022-08-11,3.0,2.0,4.0,7.0,1.0,,5.0,,,6.0,32.20%,36.70%,56.90%,62.70%,64.00%,92.60%,98.10%,,,,98.10%,25-Oct-22,14-Dec-22,92.0,234.0,202.0,19.0,64.0,105.0,120.0,75.0,51.0,82.0,166.0,0.0,,82.0,,,125.0,76.0,0.0,83.0,0.0,125.0,553.0,529.0,560.0,644.0,478.0,,560.0,,,603.0,554.0,561.0,478.0,386.0,184.0,259.0,235.0,266.0,350.0,184.0,,266.0,,,350.0,260.0,294.0,253.0,184.0,225.0,603.0,125.0,125.0,75.0,50.0,617
703,Xalkori,crizotinib,Pfizer ,Y,N,N,Y,Y,Y,N,Y,N,,25-Apr-12,,CADTH & INESSS,17-Feb-15,post-NOC,Resubmission,First Line ALK Positive Advanced NSCLC,Completed,21-Jul-15,Cond'l on Cost,Conditional,04-Aug-15,post-NOC,New Indication,First Line ALK Positive Advanced NSCLC,Completed,01-Feb-16,Avis dajout dune indication reconnue aux listes de médicaments  Médicament dexception  Avec conditions,Conditional,1st,17-Jul-15,08-Oct-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2015-12-01,2015-12-18,2015-12-28,2016-01-18,2015-12-04,2016-04-12,2016-05-02,2018-08-01,2016-02-01,2014-07-16,01-Dec-15,2014-07-16,2.0,4.0,5.0,6.0,3.0,8.0,9.0,10.0,7.0,1.0,28.60%,48.80%,81.10%,85.50%,91.20%,96.80%,97.40%,98.30%,99.60%,100.00%,100.00%,04-Dec-15,04-Dec-15,1028.0,1196.0,154.0,181.0,-4.0,-199.0,83.0,54.0,71.0,81.0,102.0,57.0,187.0,207.0,1028.0,116.0,-449.0,211.0,54.0,145.0,-449.0,57.0,1315.0,1332.0,1342.0,1363.0,1318.0,1448.0,1468.0,2289.0,1377.0,812.0,1472.0,1406.0,1315.0,287.0,133.0,133.0,150.0,160.0,181.0,136.0,266.0,286.0,1107.0,195.0,-565.0,290.0,1182.0,1377.0,79.0,-116.0,1318.0,506.0,3.0,506.0,0.0,42206
704,Xalkori,crizotinib,Pfizer ,Y,N,N,N,Y,Y,N,Y,N,01-Nov-16,28-Aug-17,300.0,CADTH & INESSS,30-Oct-18,post-NOC,Request for Advice,ROS1-positive advanced Non-Small Cell Lung Cancer,Completed,23-May-19,Cond'l on Cost,Conditional,26-Apr-19,post-NOC,New Indication,ROS1-positive advanced Non-Small Cell Lung Cancer,Completed,16-Oct-19,Inscription - Avec conditions,Conditional,1st,27-Aug-19,20-Mar-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-07-01,2020-07-30,2020-08-01,2021-01-21,2021-03-31,2020-07-16,2021-01-31,2023-01-23,2020-05-01,2020-04-29,01-May-20,2020-04-29,3.0,5.0,6.0,7.0,9.0,4.0,8.0,10.0,2.0,1.0,28.60%,29.30%,49.50%,50.40%,54.90%,60.60%,66.10%,67.40%,99.60%,100.00%,100.00%,16-Jul-20,31-Mar-21,428.0,606.0,205.0,173.0,96.0,-50.0,206.0,103.0,132.0,134.0,307.0,376.0,118.0,317.0,1039.0,42.0,40.0,285.0,42.0,261.0,40.0,376.0,1038.0,1067.0,1069.0,1242.0,1311.0,1053.0,1252.0,1974.0,977.0,975.0,1220.0,1196.0,977.0,549.0,344.0,405.0,434.0,436.0,609.0,678.0,420.0,619.0,1341.0,344.0,196.0,587.0,633.0,779.0,302.0,156.0,1311.0,336.0,334.0,78.0,258.0,933
706,Xarelto (2.5mg),rivaroxaban,Bayer ,Y,N,N,N,N,N,N,N,N,01-Jan-18,14-Sep-18,256.0,CADTH & INESSS,24-May-18,pre-NOC,Initial,Prevention of stroke and cardiovascular events in coronary and peripheral artery disease,Completed,20-Nov-18,Reimburse with clinical criteria and/or conditions,Conditional,,,New Indication,Prevention of cardiovascular events,Completed,09-Jan-19,Inscription  Avec conditions,Conditional,1st,29-Mar-19,15-Nov-19,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,FB,EDS,SA,SA,EM,2020-04-01,2020-06-01,2020-03-01,2020-03-02,2019-12-20,2020-06-18,2020-12-14,2021-11-22,2020-09-01,2019-12-18,20-Dec-19,2019-12-18,5.0,6.0,3.0,4.0,2.0,7.0,9.0,10.0,8.0,1.0,28.60%,60.80%,66.50%,72.10%,92.30%,96.80%,97.70%,98.30%,99.60%,100.00%,100.00%,20-Dec-19,01-Apr-20,-113.0,,180.0,,129.0,79.0,231.0,138.0,199.0,107.0,108.0,35.0,216.0,395.0,738.0,291.0,33.0,247.0,35.0,226.0,33.0,138.0,565.0,626.0,534.0,535.0,462.0,643.0,822.0,1165.0,718.0,460.0,674.0,653.0,462.0,575.0,395.0,498.0,559.0,467.0,468.0,395.0,576.0,755.0,1098.0,651.0,343.0,607.0,67.0,117.0,360.0,310.0,565.0,105.0,103.0,2.0,103.0,323
712,Xeljanz,tofacitinib ,Pfizer ,Y,N,N,Y,N,N,N,N,N,,17-Apr-14,,CADTH & INESSS,05-May-14,post-NOC,Initial,"Arthritis, Rheumatoid",Completed,17-Apr-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,"Arthritis, Rheumatoid",Completed,02-Feb-15,Avis de refus - Valeur thérapeutique,Negative,1st,21-Jul-15,26-Apr-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2017-01-31,2016-08-01,2016-05-01,2016-07-21,2016-12-22,2016-08-24,2016-12-01,2018-12-24,2017-04-01,2015-06-01,01-May-16,2015-06-01,8.0,4.0,2.0,3.0,7.0,5.0,6.0,10.0,9.0,1.0,28.60%,34.30%,39.80%,44.30%,45.20%,46.50%,78.70%,99.00%,99.60%,100.00%,100.00%,22-Dec-16,31-Jan-17,18.0,109.0,347.0,182.0,95.0,169.0,280.0,280.0,97.0,5.0,86.0,240.0,120.0,219.0,972.0,340.0,-330.0,262.0,5.0,203.0,-330.0,280.0,1020.0,837.0,745.0,826.0,980.0,860.0,959.0,1712.0,1080.0,410.0,1002.0,943.0,745.0,727.0,380.0,655.0,472.0,380.0,461.0,615.0,495.0,594.0,1347.0,715.0,119.0,637.0,365.0,291.0,375.0,449.0,1020.0,610.0,275.0,570.0,40.0,42111
713,Xeljanz,tofacitinib ,Pfizer ,Y,N,N,N,N,N,N,N,N,01-Nov-17,11-Sep-18,314.0,CADTH & INESSS,27-Jun-18,pre-NOC,Initial,Ulcerative Colitis,Completed,27-Feb-19,Reimburse with clinical criteria and/or conditions,Conditional,18-Jul-18,pre-NOC,New Indication,Ulcerative Colitis,Completed,09-Jan-19,Inscription  Avec conditions,Conditional,1st,05-Jul-19,24-Jul-20,Negotiation,Completed with Agreements,SA,UR,EDS,RB,LU,SA,EDS,SA,SA,EM,2020-11-17,,2020-10-01,2020-10-22,2020-09-30,2020-10-22,2021-01-01,2022-03-28,2021-12-29,2020-09-30,30-Sep-20,2020-09-30,6.0,,3.0,4.0,1.0,5.0,7.0,9.0,8.0,2.0,32.20%,60.80%,66.50%,72.10%,73.00%,93.20%,94.50%,95.20%,95.50%,,95.50%,30-Sep-20,17-Nov-20,-76.0,-55.0,245.0,175.0,128.0,177.0,385.0,116.0,,69.0,90.0,68.0,90.0,161.0,612.0,523.0,68.0,216.0,68.0,200.0,68.0,116.0,798.0,,751.0,772.0,750.0,772.0,843.0,1294.0,1205.0,750.0,898.0,882.0,750.0,826.0,581.0,629.0,,582.0,603.0,581.0,603.0,674.0,1125.0,1036.0,630.0,729.0,169.0,120.0,513.0,562.0,798.0,48.0,48.0,0.0,48.0,483
718,XigDuo,dapagliflozin/metformin hydrochloride,AstraZeneca ,Y,N,N,N,N,N,N,N,N,,10-Dec-15,,CADTH & INESSS,07-Jan-16,post-NOC,Initial,"Diabetes Mellitus, Type 2",Completed,20-Jul-16,Reimburse with clinical criteria and/or conditions,Conditional,22-Mar-16,post-NOC,New Drug,Type 2 diabetes,Completed,16-Dec-16,Avis d'inscription aux listes des médicaments - Médicament d'exception,Conditional,1st,13-Apr-17,13-Jun-17,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,FB,SA,EDS,SA,SA,EM,,2017-10-01,2017-07-01,2017-10-19,2017-07-31,2017-10-24,2017-08-01,2018-03-26,2017-09-01,2017-11-15,01-Jul-17,2017-07-01,,5.0,1.0,6.0,2.0,7.0,3.0,9.0,4.0,8.0,5.70%,38.00%,39.30%,39.90%,44.40%,49.90%,50.80%,79.40%,79.70%,,79.70%,24-Oct-17,,28.0,103.0,195.0,269.0,267.0,118.0,61.0,,110.0,18.0,128.0,48.0,133.0,49.0,286.0,80.0,155.0,107.0,18.0,112.0,18.0,,,661.0,569.0,679.0,599.0,684.0,600.0,837.0,631.0,706.0,658.0,663.0,569.0,541.0,346.0,,438.0,346.0,456.0,376.0,461.0,377.0,614.0,408.0,334.0,435.0,223.0,372.0,328.0,179.0,,,,115.0,,42571
719,Xolair (CIU),omalizumab ,Novartis ,Y,Y,N,N,N,N,N,N,N,,26-Aug-14,,CADTH & INESSS,22-Sep-14,post-NOC,Initial,"Urticaria, chronic idiopathic ",Completed,07-May-15,List with clinical criteria and/or conditions,Conditional,24-Nov-15,post-NOC,New Indication,"Urticaria, chronic idiopathic ",Completed,01-Jun-16,Avis de refus dinscription aux listes des médicaments  Médicament dexception  À moins que certaines conditions soient respectées,Conditional,1st,17-Jul-15,28-Nov-16,Negotiation,Completed with Agreements,NR,SA,EDS,EDS,EAP,SA,EDS,SA,SA,EM,,2018-04-01,2017-01-01,2017-04-20,2017-04-27,2017-06-28,2016-12-01,2021-03-15,2017-07-19,2017-06-01,01-Dec-16,2016-12-01,,8.0,2.0,3.0,4.0,6.0,1.0,9.0,7.0,5.0,1.30%,7.00%,12.60%,44.80%,73.40%,74.30%,74.90%,79.40%,79.70%,,79.70%,01-Jun-17,,27.0,455.0,227.0,190.0,71.0,-320.0,500.0,,489.0,34.0,143.0,150.0,212.0,3.0,1568.0,233.0,185.0,354.0,3.0,335.0,3.0,,,1314.0,859.0,968.0,975.0,1037.0,828.0,2393.0,1058.0,1010.0,1179.0,1160.0,828.0,801.0,574.0,,1060.0,605.0,714.0,721.0,783.0,574.0,2139.0,804.0,365.0,925.0,254.0,645.0,571.0,180.0,,,,182.0,,42131
720,Xospata,gilteritinib,Astellas,N,N,N,N,Y,Y,Y,Y,Y,01-Jun-19,23-Dec-19,205.0,CADTH & INESSS,28-Oct-19,pre-NOC,New indication,Acute Myeloid Leukemia (AML):For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by a validated test.,Completed,20-May-20,Cond'l on Cost,Conditional,22-Nov-19,pre-NOC,New Indication,Acute Myeloid Leukemia (AML):For the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by a validated test.,Completed,10-Jun-20,Inscription - Avec conditions,Conditional,1st,17-Aug-20,15-Mar-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2021-09-01,2021-05-31,2021-08-01,2021-08-05,2021-12-31,2021-09-16,2021-10-31,2022-12-12,2021-12-01,2021-05-27,31-May-21,2021-05-27,5.0,2.0,3.0,4.0,9.0,6.0,7.0,10.0,8.0,1.0,28.60%,33.00%,38.80%,44.30%,64.50%,65.40%,66.70%,67.40%,99.60%,100.00%,100.00%,01-Sep-21,31-Dec-21,-56.0,-31.0,205.0,201.0,89.0,68.0,210.0,170.0,77.0,139.0,143.0,291.0,185.0,230.0,637.0,261.0,73.0,237.0,77.0,221.0,73.0,291.0,618.0,525.0,587.0,591.0,739.0,633.0,678.0,1085.0,709.0,521.0,685.0,669.0,525.0,581.0,376.0,469.0,376.0,438.0,442.0,590.0,484.0,529.0,936.0,560.0,351.0,536.0,149.0,170.0,299.0,278.0,739.0,218.0,214.0,97.0,121.0,354
723,Xtandi,enzalutamide,Astellas,N,N,N,N,Y,N,N,N,N,,15-Apr-15,,CADTH & INESSS,02-Oct-14,pre-NOC,New indication,Genitourinary: First Line Metastatic Castration-Resistant Prostate Cancer,Completed,22-Jun-15,Cond'l on Cost,Conditional,04-Aug-15,post-NOC,Resubmission,First Line Metastatic Castration-Resistant Prostate Cancer,Completed,01-Feb-16,Notice of Approval to Add an Approved Indication to the List - Exception Drug - With Conditions,Conditional,1st,24-Jun-15,22-Jul-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2015-10-01,2015-12-18,2015-07-29,2016-01-18,2015-08-31,2015-10-14,2015-11-02,2016-02-22,2015-10-01,2016-03-24,29-Jul-15,2015-07-29,3.0,7.0,1.0,8.0,2.0,5.0,6.0,9.0,4.0,10.0,5.70%,38.00%,58.20%,58.90%,59.80%,61.10%,65.50%,71.10%,71.40%,100.00%,100.00%,01-Oct-15,24-Mar-16,-195.0,111.0,263.0,181.0,2.0,-222.0,28.0,71.0,149.0,7.0,180.0,40.0,84.0,103.0,215.0,71.0,246.0,102.0,7.0,117.0,7.0,246.0,169.0,247.0,105.0,278.0,138.0,182.0,201.0,313.0,169.0,344.0,200.0,215.0,105.0,300.0,37.0,101.0,179.0,37.0,210.0,70.0,114.0,133.0,245.0,101.0,52.0,132.0,68.0,292.0,30.0,-194.0,344.0,239.0,239.0,64.0,175.0,42177
724,Xtandi,enzalutamide,Astellas,N,N,N,N,Y,N,N,N,N,01-Jun-18,20-Dec-18,202.0,CADTH & INESSS,24-Sep-18,pre-NOC,New indication,Non-metastatic castration-resistant prostate cancer,Completed,26-Mar-19,Cond'l on Cost,Conditional,,,New Indication,Non-metastatic castration-resistant prostate cancer,Completed,10-Apr-19,Inscription - Avec conditions,Conditional,1st,31-Jul-19,26-Feb-20,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2020-10-01,2020-07-30,2020-06-01,2020-07-16,2020-06-01,2020-11-26,2020-12-01,2022-12-12,2021-12-01,2020-04-29,01-Jun-20,2020-04-29,6.0,5.0,2.0,4.0,3.0,7.0,8.0,10.0,9.0,1.0,28.60%,34.30%,66.50%,72.10%,76.50%,96.80%,97.70%,99.00%,99.60%,100.00%,100.00%,01-Jun-20,01-Oct-20,-87.0,,183.0,,127.0,112.0,210.0,218.0,155.0,96.0,141.0,96.0,274.0,279.0,1020.0,644.0,63.0,325.0,96.0,299.0,63.0,218.0,651.0,588.0,529.0,574.0,529.0,707.0,712.0,1453.0,1077.0,496.0,758.0,732.0,529.0,616.0,433.0,555.0,492.0,433.0,478.0,433.0,611.0,616.0,1357.0,981.0,385.0,662.0,96.0,111.0,337.0,322.0,651.0,155.0,122.0,33.0,122.0,298
725,Xtandi,enzalutamide,Astellas,N,N,N,N,Y,N,N,N,N,01-Feb-19,02-Jun-20,487.0,CADTH & INESSS,24-Feb-20,pre-NOC,New indication,Metastatic Castration Sensitive Prostate Cancer (mCSPC),Completed,23-Sep-20,Cond'l on Cost,Conditional,13-Mar-20,pre-NOC,New Indication,Metastatic Castration Sensitive Prostate Cancer (mCSPC),Completed,09-Sep-20,Inscription - Avec conditions,Conditional,1st,30-Oct-20,30-Jul-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2021-12-01,2021-11-30,2021-11-01,2021-11-25,2021-12-31,2022-01-20,2022-02-28,2022-12-28,2021-12-01,2021-09-29,01-Nov-21,2021-09-29,5.0,4.0,2.0,3.0,7.0,8.0,9.0,10.0,6.0,1.0,28.60%,34.30%,39.80%,44.30%,64.50%,65.20%,97.40%,98.30%,99.60%,100.00%,100.00%,01-Dec-21,31-Dec-21,-99.0,-81.0,212.0,180.0,37.0,51.0,273.0,124.0,123.0,94.0,118.0,154.0,174.0,213.0,516.0,124.0,61.0,182.0,94.0,170.0,61.0,154.0,547.0,546.0,517.0,541.0,577.0,597.0,636.0,939.0,547.0,484.0,605.0,593.0,517.0,616.0,404.0,434.0,433.0,404.0,428.0,464.0,484.0,523.0,826.0,434.0,385.0,492.0,113.0,99.0,310.0,324.0,577.0,93.0,60.0,63.0,30.0,600
729,Yervoy,ipilimumab,Bristol-Myers Squibb ,Y,Y,N,N,Y,Y,N,Y,N,,10-Sep-14,,CADTH & INESSS,15-Aug-14,pre-NOC,New indication,1st Line (unresectable or metastatic) Advanced Melanoma ,Completed,22-Dec-14,Cond'l on Cost,Conditional,24-Nov-14,post-NOC,New Indication,1st Line (unresectable or metastatic) Advanced Melanoma ,Completed,02-Feb-15,Ajout dune indication reconnue à la Liste Établissements  Médicament dexception  Avis de refus  À moins que le rapport entre le coût et lefficacité soit modifié pour atteindre un niveau acceptable et quun suivi soit instauré,Conditional,1st,31-Jan-15,02-Mar-15,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Under provincial consideration,EM,2015-07-01,2015-03-30,2015-05-01,2015-03-05,2015-04-01,2015-07-15,2015-04-01,2016-06-30,,2016-03-24,05-Mar-15,2015-03-05,6.0,2.0,5.0,1.0,3.0,7.0,4.0,9.0,,8.0,5.50%,10.00%,42.20%,43.50%,49.20%,69.50%,70.40%,99.00%,99.30%,,99.30%,01-Jul-15,24-Mar-16,-26.0,75.0,129.0,70.0,40.0,-2.0,30.0,121.0,28.0,60.0,3.0,30.0,135.0,30.0,486.0,,388.0,112.0,3.0,142.0,3.0,388.0,294.0,201.0,233.0,176.0,203.0,308.0,203.0,659.0,,561.0,285.0,315.0,176.0,202.0,73.0,191.0,98.0,130.0,73.0,100.0,205.0,100.0,556.0,,416.0,182.0,103.0,145.0,70.0,28.0,561.0,385.0,385.0,118.0,267.0,41995
732,Zaxine,rifaximin ,Salix Pharmaceuticals Inc. ,N,N,N,Y,N,N,N,N,N,,13-Aug-13,,CADTH & INESSS,05-Aug-14,post-NOC,Initial,"Encephalopathy, Hepatic ",Completed,16-Apr-15,List with criteria/condition,Conditional,04-Aug-14,post-NOC,New Drug,"Encephalopathy, Hepatic ",Completed,02-Feb-15,Ajout aux listes de médicaments - Médicament d'exception,Conditional,1st,30-Jun-15,02-Mar-16,Negotiation,Completed with Agreements,SA,SA,EDS,EDS,LU,SA,EDS,SA,SA,EM,2018-02-06,2016-09-01,2016-05-01,2016-07-21,2016-06-29,2016-07-07,2016-06-01,2018-08-01,2016-04-01,2015-02-02,01-Apr-16,2015-02-02,9.0,8.0,3.0,7.0,5.0,6.0,4.0,10.0,2.0,1.0,28.60%,29.30%,35.00%,36.30%,68.50%,69.40%,74.90%,79.40%,99.60%,100.00%,100.00%,29-Jun-16,06-Feb-18,357.0,356.0,254.0,182.0,75.0,148.0,246.0,706.0,183.0,60.0,141.0,119.0,127.0,91.0,882.0,30.0,-394.0,260.0,30.0,195.0,-394.0,706.0,1638.0,1115.0,992.0,1073.0,1051.0,1059.0,1023.0,1814.0,962.0,538.0,1192.0,1127.0,962.0,605.0,351.0,1027.0,504.0,381.0,462.0,440.0,448.0,412.0,1203.0,351.0,0.0,581.0,611.0,538.0,321.0,394.0,1638.0,1100.0,676.0,513.0,587.0,42110
733,Zejula,niraparib,GlaxoSmithKline,N,N,N,Y,Y,Y,Y,Y,N,01-Sep-18,27-Jun-19,299.0,CADTH & INESSS,07-Feb-20,post-NOC,New drug,"Ovarian Cancer (recurrent): as monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",Completed,03-Sep-20,Cond'l on Cost,Conditional,13-Mar-20,post-NOC,New Drug,"Ovarian Cancer (recurrent): as monotherapy for the maintenance treatment of female adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",Completed,09-Sep-20,Inscription - Avec conditions,Conditional,1st,13-Nov-20,11-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2021-12-01,2021-11-30,2021-12-01,2021-11-25,2022-02-28,2022-02-17,2022-04-29,2022-12-12,2022-01-14,2021-09-29,25-Nov-21,2021-09-29,4.0,3.0,5.0,2.0,8.0,7.0,9.0,10.0,6.0,1.0,28.60%,34.10%,38.60%,58.80%,64.50%,65.20%,66.10%,98.30%,99.60%,100.00%,100.00%,01-Dec-21,28-Feb-22,225.0,260.0,209.0,180.0,71.0,65.0,271.0,112.0,111.0,112.0,106.0,201.0,190.0,261.0,488.0,156.0,49.0,193.0,106.0,179.0,49.0,201.0,888.0,887.0,888.0,882.0,977.0,966.0,1037.0,1264.0,932.0,825.0,969.0,955.0,882.0,657.0,448.0,454.0,453.0,454.0,448.0,543.0,532.0,603.0,830.0,498.0,385.0,535.0,434.0,440.0,342.0,336.0,977.0,152.0,95.0,63.0,89.0,733
734,Zejula,niraparib,GlaxoSmithKline,N,N,N,N,Y,Y,Y,Y,Y,01-Apr-20,02-Oct-20,184.0,CADTH & INESSS,21-Sep-20,pre-NOC,New indication,First line Ovarian Cancer,Completed,29-Apr-21,Cond'l on Cost,Conditional,02-Oct-20,pre-NOC,New Indication,"Maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy",Completed,31-Mar-21,Inscription - Avec conditions,Conditional,1st,01-Jun-21,11-Aug-21,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2021-12-01,2021-11-30,2021-12-01,2021-11-25,2022-02-28,2022-02-17,2022-04-30,2022-12-12,2022-01-14,2021-09-29,25-Nov-21,2021-09-29,4.0,3.0,5.0,2.0,8.0,7.0,9.0,10.0,6.0,1.0,28.60%,34.10%,38.60%,58.80%,64.50%,65.20%,66.10%,98.30%,99.60%,100.00%,100.00%,01-Dec-21,28-Feb-22,-11.0,0.0,220.0,180.0,33.0,62.0,71.0,112.0,111.0,112.0,106.0,201.0,190.0,262.0,488.0,156.0,49.0,193.0,106.0,179.0,49.0,201.0,425.0,424.0,425.0,419.0,514.0,503.0,575.0,801.0,469.0,362.0,506.0,492.0,419.0,430.0,210.0,216.0,215.0,216.0,210.0,305.0,294.0,366.0,592.0,260.0,182.0,297.0,209.0,180.0,104.0,133.0,514.0,152.0,95.0,63.0,89.0,393
737,Zepatier,grazoprevir/elbasvir,Merck,Y,N,N,Y,N,N,N,N,N,01-Jul-15,19-Jan-16,202.0,CADTH & INESSS,27-Oct-15,pre-NOC,Initial,"Hepatitis C, chronic",Completed,19-May-16,Reimburse with clinical criteria and/or conditions,Conditional,24-Nov-15,pre-NOC,New Drug,"Hepatitis C, chronic",Completed,15-Jul-16,Avis dinscription aux listes des médicaments  Médicament dexception  Avec conditions (Hépatite C chronique de génotypes 1 et 4) Avis de refus dinscription aux listes des médicaments  Valeur thérapeutique (Hépatite C chronique de génotype 3),Conditional,1st,14-Apr-16,17-Feb-17,Negotiation,Completed with Agreements,DL,SA,EDS,EDS,LU,SA,EDS,NR,SA,EM,2017-03-21,2017-04-01,2017-04-01,2017-04-20,2017-02-28,2017-04-13,2017-05-01,,2017-08-01,2017-03-15,28-Feb-17,2017-02-28,3.0,4.0,5.0,7.0,1.0,6.0,8.0,,9.0,2.0,32.20%,60.80%,81.10%,85.50%,91.20%,92.10%,97.70%,99.00%,99.60%,,99.60%,15-Mar-17,21-Mar-17,-84.0,-56.0,205.0,234.0,-35.0,-92.0,309.0,32.0,43.0,43.0,62.0,11.0,55.0,73.0,,165.0,26.0,61.0,11.0,57.0,11.0,32.0,427.0,438.0,438.0,457.0,406.0,450.0,468.0,,560.0,421.0,456.0,452.0,406.0,490.0,285.0,306.0,317.0,317.0,336.0,285.0,329.0,347.0,,439.0,243.0,335.0,121.0,178.0,274.0,217.0,427.0,21.0,21.0,15.0,6.0,323
742,Zirabev,bevacizumab,Pfizer,Y,Y,Y,Y,Y,N,N,N,N,01-Aug-18,14-Jun-19,317.0,CADTH & INESSS,14-Mar-19,pre-NOC,New drug,Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,File-Closed Not Submitted,,,,,,New Drug,Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer,Completed,07-Aug-19,Inscription- Avec conditions,Conditional,1st,12-Mar-19,28-Aug-19,Negotiation,Completed with Agreements,,,,,,,,,,EM,,,,,,,,,,2019-11-14,,2019-11-14,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,-92.0,,,,,-148.0,169.0,,,,,,,,,,78.0,,,78.0,78.0,,,,,,,,,,,153.0,,153.0,,,,,,,,,,,,,99.0,,,54.0,,21.0,,,,,,-43313
743,Zolgensma,onasemnogene abeparvovec,Novartis Pharmaceuticals Canada Inc.,Y,Y,N,Y,N,Y,Y,Y,Y,01-Jun-20,15-Dec-20,197.0,CADTH & INESSS,26-May-20,pre-NOC,Initial,"Spinal muscular atrophy (SMA), pediatrics",Completed,24-Mar-21,Reimburse with clinical criteria and/or conditions,Conditional,14-Aug-20,pre-NOC,New Drug,spinal muscular atrophy,Completed,18-Jan-21,Inscription - Avec conditions,Conditional,1st,19-Feb-21,08-Oct-21,Negotiation,Completed with Agreements,EDRD,,,EDS,EAP,SA,EDF,,,EM,2021-11-19,,,2022-06-01,2021-10-29,2022-07-25,2022-10-01,,,2021-10-20,29-Oct-21,2021-10-20,3.0,,,4.0,2.0,5.0,6.0,,,1.0,28.60%,60.80%,81.10%,86.60%,87.50%,88.80%,,,,,88.80%,29-Oct-21,19-Nov-21,-203.0,-123.0,302.0,157.0,-33.0,32.0,231.0,42.0,,,236.0,21.0,290.0,358.0,,,12.0,189.0,21.0,160.0,12.0,42.0,339.0,,,533.0,318.0,587.0,655.0,,,309.0,486.0,457.0,318.0,521.0,219.0,240.0,,,434.0,219.0,488.0,556.0,,,275.0,387.0,99.0,34.0,198.0,263.0,339.0,30.0,21.0,9.0,21.0,296
745,Zydelig,idelalisib,Gilead,Y,N,N,Y,Y,Y,N,Y,N,,27-Mar-15,,CADTH & INESSS,07-Apr-15,post-NOC,New drug,In combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL),Completed,18-Aug-15,Cond'l on Cost,Conditional,22-Mar-15,pre-NOC,New Drug,In combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL),Completed,19-Aug-16,Avis de refus dinscription aux listes des médicaments  À moins que certaines conditions soient respectées,Conditional,1st,24-Sep-15,03-Jun-16,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Not funded,Funded,EM,2017-08-01,2016-10-18,2016-08-08,2016-10-20,2016-10-19,2016-12-21,2017-05-01,,2017-01-01,2016-11-15,08-Aug-16,2016-08-08,9.0,2.0,1.0,4.0,3.0,6.0,8.0,,7.0,5.0,5.70%,10.20%,42.40%,47.90%,76.50%,77.40%,78.10%,79.40%,99.60%,,99.60%,15-Nov-16,01-Aug-17,11.0,-5.0,133.0,516.0,37.0,-330.0,253.0,424.0,137.0,66.0,139.0,138.0,201.0,332.0,,212.0,165.0,206.0,66.0,202.0,66.0,424.0,858.0,571.0,500.0,573.0,572.0,635.0,766.0,,646.0,599.0,640.0,636.0,500.0,489.0,356.0,714.0,427.0,356.0,429.0,428.0,491.0,622.0,,502.0,88.0,496.0,144.0,511.0,290.0,-77.0,858.0,358.0,358.0,99.0,259.0,42234
747,Zykadia,ceritinib,Novartis,Y,N,N,Y,Y,Y,N,Y,N,,27-Mar-15,,CADTH & INESSS,05-Jun-15,post-NOC,New drug,ALK+ non-small cell lung cancer: For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to crizotinib.,Completed,03-Dec-15,Do Not Fund,Negative,24-Nov-16,post-NOC,New Drug,Metastatic Non-Small Cell Lung Cancer,Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments,Negative,,05-Feb-16,,Do Not Negotiate,,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,Not funded,EM,,,,,,,,,,2018-07-05,,2018-07-05,,,,,,,,,,1.0,28.60%,,,,,,,,,,28.60%,,,70.0,608.0,181.0,189.0,64.0,-482.0,,,,,,,,,,,,,,,,,,,,,,,,,,1196.0,,1196.0,,,,,,,,,,,,,399.0,,251.0,797.0,,,,,,,,42341
748,Zykadia (resubmission),ceritinib,Novartis,Y,N,N,Y,Y,Y,N,Y,N,,27-Mar-15,,CADTH & INESSS,19-Oct-16,post-NOC,Resubmission,Non-small cell lung cancer: For treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have progressed on or who were intolerant to crizotinib,Completed,21-Mar-17,Cond'l on Cost,Conditional,24-Nov-16,post-NOC,New Drug,Metastatic Non-Small Cell Lung Cancer,Completed,01-Jun-17,Avis de refus d'inscription aux listes des médicaments,Negative,1st,13-Jul-17,20-Mar-18,Negotiation,Completed with Agreements,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,Funded,EM,2018-09-01,2018-10-30,2018-08-15,2018-07-19,2018-10-11,2018-11-30,2019-10-03,2022-09-26,,2018-07-05,19-Jul-18,2018-07-05,4.0,6.0,3.0,2.0,5.0,7.0,8.0,9.0,,1.0,28.60%,34.10%,39.80%,60.10%,92.30%,96.80%,97.70%,99.00%,99.30%,,99.30%,01-Sep-18,11-Oct-18,572.0,608.0,153.0,189.0,114.0,42.0,250.0,165.0,224.0,148.0,121.0,205.0,255.0,562.0,1651.0,,107.0,416.0,121.0,382.0,107.0,205.0,1254.0,1313.0,1237.0,1210.0,1294.0,1344.0,1651.0,2740.0,,1196.0,1505.0,1471.0,1210.0,638.0,485.0,529.0,588.0,512.0,485.0,569.0,619.0,926.0,2015.0,,399.0,780.0,725.0,797.0,364.0,292.0,1294.0,98.0,84.0,58.0,40.0,42815
751,Zytiga,abiraterone,Janssen,Y,N,N,N,Y,N,N,N,N,01-Aug-17,13-Feb-18,196.0,CADTH,25-Feb-19,post-NOC,New indication,Newly diagnosed high-risk metastatic castration sensitive prostate cancer without small-cell histologic features.,Withdrawn,03-May-19,,,,,,,,,,,,,,,,Funded,Funded,Funded,Under provincial consideration,Not funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,2021-09-01,2021-11-30,2021-11-01,,,,,,,,01-Sep-21,2021-09-01,1.0,3.0,2.0,,,,,,,,20.30%,26.00%,30.40%,,,,,,,,30.40%,,,377.0,,67.0,,,,,,,,,,,,,,,,,,,,1296.0,1386.0,1357.0,,,,,,,,1346.0,1346.0,1296.0,919.0,852.0,852.0,942.0,913.0,,,,,,,,902.0,444.0,,,,,,,,,640
752,Zytiga (Resubmission),abiraterone,Janssen,Y,N,N,N,Y,N,N,N,N,01-Aug-17,13-Feb-18,196.0,CADTH,29-Jul-19,post-NOC,Resubmission,Newly diagnosed high-risk metastatic castration sensitive prostate cancer without small-cell histologic features,Withdrawn,06-Apr-21,,,,,,,,,,,,,,,,Funded,Funded,Under provincial consideration,Under provincial consideration,Not funded,Under provincial consideration,Under provincial consideration,Under provincial consideration,Under provincial consideration,,2021-09-01,2021-11-30,,,,,,,,,01-Sep-21,2021-09-01,1.0,2.0,,,,,,,,,20.30%,24.70%,,,,,,,,,24.70%,,,531.0,,617.0,,,,,,,,,,,,,,,,,,,,1296.0,1386.0,,,,,,,,,1341.0,1341.0,1296.0,765.0,148.0,148.0,238.0,,,,,,,,,193.0,1148.0,,,,,,,,,1344
